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Body fluids such as blood are amongst the most important biological evidence 
recovered from crime scenes. Identification of the donor can be achieved through STR 
profiling; however, extracting additional information regarding the tissue type or the 
donor’s physical appearance such as age could prove very useful in police 
investigations. Firstly, the performance of existing tissue-specific mRNA-based 
systems was assessed via collaborative exercises. All proposed methods have shown to 
be highly sensitive; however, issues regarding markers’ specificity, especially for the 
vaginal detection, were observed. Analysing complex casework samples revealed the 
need for interpretation guidelines and the use of a scoring system when implementing 
mRNA profiling in casework. It was understood that developing DNA-based testing 
would overcome the limitations of existing methods so the main aim of this study was 
to evaluate the applicability of DNA methylation profiling in forensics.  
Using three approaches various tissue-specific differentially methylated CpG sites in 
18 different loci were evaluated by analysing various forensically relevant body fluids 
and tissues. As a result, a set of suitable blood- and semen-specific markers were 
validated using aged and mock casework samples; however, the identification of other 
tissues like saliva, vaginal fluid and menstrual blood seemed to be challenging. 
Regarding age prediction, a set of age-associated CpG sites were selected from 
genome-wide DNA methylation studies and the correlation of their blood methylation 
levels with age was assessed on two sequencing platforms. Using a subset of 16 CpG 
sites and taking advantage of artificial neural networks’ capabilities, age could be 
accurately predicted in 1,156 blood samples (mean error of 4.1 years). The 
applicability of the proposed prediction model was also tested by means of next 
generation sequencing. Although further research is required prior to implementing 
these results in casework, it can be concluded that epigenetics could shed light on the 
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Body fluids such as blood and saliva are amongst the most important biological 
evidence found at crime scenes. In the field of forensic biology, scientists analyse body 
fluid stains in order to identify the donor and potentially incriminate or exclude 
suspects. It is known that DNA profiling is one of the most powerful tools of forensic 
scientists. Although 99.9% of human DNA sequences are the same amongst 
individuals, there are regions that vary and these can be used to distinguish one person 
from another (unless they are monozygotic twins). Scientific developments over the 
last few years have extended the amount of information that can be extracted even 
from minute amounts of evidence. These days hundreds of different loci can be 
successfully amplified using picogram or nanogram of starting DNA material and this 
information can be applied in criminal investigations. DNA profiling is employed for 
almost every type of body fluid stain or swab that is submitted as part of a criminal 
investigation. In cases where there is a suspect, the DNA profile obtained from a crime 
scene sample is compared against the suspect’s DNA profile. However, in cases where 
there is no match or there is no suspect, the obtained DNA profile is uploaded to the 
DNA database in order to search for a potential match with previously stored profiles.  
According to the Home Office’s 2013 annual report, there is a 61% chance that the 
database will produce a possible match every time a DNA profile derived from a crime 
scene is searched against the National DNA Database (NDNAD), and of these, 40% 
are integral to solving the case (National DNA Database Strategy Board, 2012-2013). 
This is one of the highest detection rates in Europe, however most of these crimes refer 
to burglaries and vehicle crimes and there are still a large number of homicides and 
rape cases that remain undetected, unsolved, or there is simply not enough evidence 
for conviction. In cases where a DNA profile is obtained from a crime scene but there 
is no match to profiles on the NDNAD, police officers reach a dead end in their 
investigation.  
DNA profiles notwithstanding the examination of recovered biological material can 
shed light on the identity of the donor and help investigators develop a more detailed 
and clear picture of the crime. It would be very advantageous if forensic scientists were 
able to support DNA findings either by linking a DNA profile with its tissue source or 
by extracting additional information that could assist criminal investigations. Firstly, 
the presence of a specific body fluid could potentially indicate a particular crime; for 
example, the detection of semen could indicate sexual assault. Current testing does 
[26] 
 
allow for the identification of the cellular tissue of origin; however, these methods are 
mostly protein-based and are used in a presumptive manner (Virkler & Lednev, 2009). 
They are presumptive because they lack specificity and sensitivity and there are some 
body fluids such as menstrual blood that have no such tests. Secondly, researchers 
have already determined genetic variations associated with ethnicity or hair, skin and 
eye colour and since these markers are of an individual’s physical characteristics they 
could prove useful in police investigations (Bouakaze et al., 2009; Spichenok et al., 
2011; Walsh et al., 2013). However, there are traits that have not been studied to any 
great depth such as chronological age and such information has been highlighted as 
important in criminal investigations.   
The aim of this research is to investigate genetic and epigenetic differences in 
forensically relevant body fluids and to devise accurate methods to not only identify 
the tissue source of a stain but also estimate the chronological age of the donor. 
Towards achieving these goals, it is believed that methods based on the analysis of 
nucleic acids surpass protein tests as they are more sensitive and have a higher 
discriminatory power. Furthermore, since DNA is more robust than proteins, this 
approach will be applicable to aged and degraded material. Current forensic DNA 
tests used for applications such as identification of an individual or for ethnicity 
prediction are based on differences in DNA sequence, such as short tandem repeats 
(STRs) and single nucleotide polymorphisms (SNPs) (Bouakaze et al., 2009; Butler, 
2012). Since all cells throughout an individual’s lifetime contain the same DNA (apart 
from random mutations), methods based on these variations would not be suitable in 
this project.  
In this study, emphasis will be given to one of the known chemical modifications of 
DNA that occurs naturally, known as DNA methylation; others include histone 
acetylation and chromatin modelling. These modifications have been implicated in the 
regulation of transcription and translation and jointly come under the umbrella term of 
‘epigenetics’.  Thus, this chapter will present an overview of epigenetics with an 
emphasis on DNA methylation and also shed light on existing forensic applications of 
DNA methylation profiling. Later, the state of recent research in the area of tissue 




The character of each cell is determined by its protein components, which are the 
product of specific gene expression patterns; these patterns are determined during cell 
differentiation and carefully controlled. Critical determinants are DNA-binding 
transcription factors that manage a gene’s activation or repression by interacting with 
specific DNA sequences in its promoter region (Svingen & Tonissen, 2006). This 
interaction between transcription factors and DNA generates a sequence of events 
which involves modification of chromatin structure leading to the construction of an 
active transcription complex (Cosma et al., 1999). However, transcription factors are 
not themselves sufficient to control gene expression, other mechanisms are required to 
make those recognition sequences available or not for binding. It is known that DNA 
is not ‘naked’ but exhibits various chemical modifications; these chemical groups 
together with the way DNA is packaged are the ones that control the access to 
regulatory molecules.  
1.1.1 The epigenome 
Epigenetics refers to the study of heritable alterations in gene function or cellular 
phenotype caused by mechanisms other than changes in the DNA sequence itself 
[Figure 1-1]. It involves functionally relevant modifications, such as DNA methylation 
and histone modifications, both of which play a significant role in regulating gene 
expression without altering the DNA sequence.  The molecular basis of epigenetics is 
complex and primarily involves alterations in the activation of particular genes. Also, 
the chromatin proteins associated with DNA may be activated or silenced and 
therefore ensure that each cell expresses only the genes that are necessary for an 
activity (Bird, 2007; Reik, 2007). The term ‘epigenome’ is a parallel to the word 
‘genome’ and refers to the overall epigenetic status of a cell. 
Epigenetic patterns are preserved during cell division just as the DNA sequence is 
inherited from one generation to the next; however, they change over an individual’s 
lifetime (Bird, 2002). Epigenetic changes have been observed to occur in response to 
environmental exposure and can be affected by various factors such as diet and 
smoking (Rando & Verstrepen, 2007). Imprinting, gene silencing, X chromosome 
inactivation, reprogramming and carcinogenesis are all examples of epigenetic 
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processes. A very important cell function that is regulated by epigenetic mechanisms in 
mammals is cell differentiation, where stem cells become fully differentiated cells 
during embryogenesis (Rando & Verstrepen, 2007). 
 
Figure 1-1. Epigenetic mechanisms (Vidaki et al., 2013) 
The field of epigenetics involves various mechanisms including DNA methylation and histone 
modifications; each mechanism can further involve different chemical alterations, such as methylation 
and hydroxymethylation indicated with arrows. 
 
 
1.1.2 DNA methylation and gene regulation 
In the human genome, DNA methylation is a vital biochemical process for normal 
development. It involves the addition of a methyl group (-CH3) at the 5’ position of 
cytosine residues in CpG dinucleotides [Figure 1-2a]. The absence of CpG 
methylation has only been observed in embryonic stem cells (Dogde et al., 2002). 
Considering the genome as a whole it can be seen that most CpGs (60-90%) are 
methylated, whereas the unmethylated CpGs are often found grouped in areas known 
as “CpG islands” (300-3000 bp long, >55% GC content) usually located around the 








Figure 1-2. DNA methylation and gene regulation (Vidaki et al., 2013) 
(a) DNA methylation on cytosine, (b) schematic representation of a typical gene containing a CpG 
island; in most cases, when a CpG island is unmethylated allows for gene expression, while when it is 
methylated the gene becomes inactive. 
 
DNA methylation occurs via DNA methyltransferases, which have two enzymatic 
activities: maintenance of methylation after every cellular DNA replication cycle and 
de novo methylation to set up new DNA methylation patterns early in development 
(Fernandez et al., 2012). It is generally believed that DNA methylation found in the 
promoter regions of genes is associated with condensed nuclease-resistant 
heterochromatin and silencing of gene expression (Newell-Price et al., 2000) [Figure 
1-2b]. Methylation of DNA is followed by subsequent recruitment of binding proteins 
that preferentially recognize methylated DNA. As a result, histone deacetylase and 
chromatin remodelling complexes further stabilize the condensed chromatin. 
 Conversely, the opposite is also possible (Newell-Price et al., 2000).  There have been 
cases in which DNA methylation in gene promoter areas has been associated with 
gene activation (Straussman et al., 2009). Straussman and co-workers identified at 
least 50 loci where host genes are expressed exclusively in the same cell-type only 
when their promoters or gene bodies are methylated. This is mainly observed in non-
CpG-island DNA and it is believed to be a result of a process of selective 





1.1.3 DNA methylation and the environment 
Recent studies support the hypothesis that DNA methylation acts as an interphace 
between the fixed genome and the dynamic environment. Changes in DNA 
methylation patterns in response to environmental stress in early life or subsequently 
serve as a mechanism of life-long genome adaptation, enabling the same genome to 
express different phenotypes (Szyf, 2010). Several studies examining monozygotic 
twins have established a link between environment or ageing and long-lasting 
epigenetic impressions on phenotype (Fraga et al., 2005; Wong et al., 2005). 
Monozygotic twins serve as the ideal system to investigate epigenetics as they share 
the same genetic basis. It has been reported that twins at a young age show similar 
amounts of DNA methylation, whereas as they grow older they differ significantly not 
only in the amount but also in the patterns of DNA methylation (Fraga et al., 2005) 
[Figure 1-3]. Scientists have hypothesized that these non-genetic age-dependent 
differences in ‘gene marking’ could explain differences in a broad range of physical 




Figure 1-3. Mapping chromosomal regions with differential DNA methylation in two pairs 
of monozygotic twins of different ages (Fraga et al., 2005) 
Competitive genomic hybridization for methylated DNA onto normal metaphase chromosomes 1 was 
generated from 3- and 50-year-old twin pairs. Green signals indicate hypermethylation, whereas red 
signals show hypomethylation events.  On the other hand, the yellow colour is obtained by equal 
amounts of the green and red dyes. Therefore, the 50-year-old twin pair shows plentiful changes in the 
pattern of DNA methylation whereas the 3-year-old twins have a very similar distribution of DNA 
methylation.  
3-year-old twins                   50-year-old twins 
[31] 
 
1.1.4 DNA methylation as a biomarker 
As mentioned above, it has been demonstrated that genes with high DNA methylation 
levels in their promoter regions are usually transcriptionally silent, and that DNA 
methylation gradually accumulates upon long-term gene silencing. Epigenetic mis-
programming leading to aberrant DNA methylation patterns (hyper/hypo-
methylation) is a significant observation in several human diseases and malignancies. 
Hypermethylation occurring at CpG islands in the promoter region of cancer-
associated genes results in gene inactivation, however genome-wide hypomethylation 
has been associated with cancer progress and metastasis (Wild & Flanagan, 2010). 
Interestingly, there is evidence to support two competing hypotheses of how 
hypomethylation might occur; one includes a ‘passive’ loss of the maintenance of 
DNA methylation over cell divisions and the other involves an ‘active’, DNA 
replication-independent loss of methylation, which could potentially occur faster.  
1.1.5 DNA methylation analysis 
Determination of DNA methylation patterns either at single CpG sites, or the entire 
methylome has become increasingly important in medical diagnoses and different 
methods of detecting methylation have been developed. These are based on the a) 
chemical modification of the unmethylated cytosine residues, b) protein interaction 
with 5-methyl cytosine and c) digestion by methylation-sensitive restriction enzymes. 
In certain cases, depending on the scientific aim, a combination of these techniques 
may be employed (Ammerpohl et al., 2009; Oakeley, 1999). 
1.1.5.1 Chemical modification of cytosine residues 
The methylation profile of a target DNA sequence can be established through 
treatment with sodium bisulphite (NaHSO3) (Fraga & Esteller, 2002). During this 
process unmethylated cytosine residues are converted into uracil, while methylated 
cytosines remain unchanged.  Thus, bisulphite treatment results in different DNA 
sequences for the methylated and unmethylated DNA [Figure 1-4]. Correct 
determination of a specific methylation pattern is highly dependent on the complete 
conversion of unmethylated cytosines. This procedure suffers, to a degree, from DNA 
fragmentation/loss (Tanaka & Okamoto, 2007), but is probably needed in order to 
obtain high conversion rates of the unmethylated cytosines. 
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Conversion of DNA using sodium bisulphite allows for both qualitative and 
quantitative analysis of individual CpG sites. However, the possibility of incomplete 
conversion of cytosines has to be taken into account as it could result in an 
overestimation of methylation. Following bisulphite treatment it is necessary to 
amplify the DNA using the polymerase chain reaction (PCR) prior to sequencing and 
assuming that all non-CpG cytosines have been converted into uracil, the DNA will 
mainly consist of three bases (DNA polymerase does not recognise uracil, therefore it 
is treated as thymine). Due to this reduced complexity, the options in primer design 
are limited and can result in low yields of PCR products or non-specific products due 
to mis-priming events. Also, differences in methylated and unmethylated DNA 
sequences may affect amplification efficiency by introducing PCR bias (Moskalev et 
al., 2011; Warnecke et al., 1997).   
 
Figure 1-4. Bisulphite conversion of DNA 
After treatment with sodium bisulphite only non-methylated cytosines are converted into uracil, while 
the methylated ones remain unchanged.  
 
1.1.5.2 Protein interaction with 5-methyl cytosine 
In contrast with bisulphite treatment, methods based on protein precipitation of DNA 
maintain the structure of DNA bases (Jacinto et al., 2008); however, they lack high 
specificity and sensitivity. For instance, methylated DNA immunoprecipitation is a 
large-scale purification technique that is used to enrich for methylated DNA 
sequences. It mainly consists of isolating methylated DNA fragments via a monoclonal 
antibody raised against 5-methyl cytosine. To obtain the fragments, DNA is usually 
subjected to sonication and denaturation. The short length of these fragments is crucial 
in achieving sufficient resolution, improving the efficiency of downstream analysis as 
well as reducing fragment-length effects or bias. Such techniques can be combined 
with PCR or array based methods; nevertheless, caution must be taken as limited 
amounts of DNA could also result in PCR bias. 
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1.1.5.3 Methylation-sensitive restriction enzymes 
Restriction enzymes whose cleavage activity depends on the methylation of a CpG 
site in their target sequence can also be used for methylation analysis (Hua et al., 2011) 
[Figure 1-5]. These enzymes, also known as methylation sensitive endonucleases 
usually cut unmethylated DNA only. This approach is simple and robust but 
incomplete digestion or differences in enzyme activity can hinder the analysis and 
affect interpretation.  A main drawback associated with the use of restriction enzymes 
is the dependence on the availability of specific recognition sequences that flank the 
CpG site of interest. 
 
Figure 1-5. Methylation-sensitive restriction enzymes 
Genomic DNA containing unmethylated (white circle) and methylated (black circle) CpG sites is 
restricted using a methylation-sensitive endonuclease. DNA is cleaved only when it is not ‘protected’ 
by a methyl group resulting in no PCR product after amplification with primers flanking the site in 
question (arrows). However, when DNA is methylated, the endonuclease cannot cut the recognition 
site leading to the generation of a PCR product. Note that the PCR product is shown as being 
unmethylated (white circle) since the incorporated nucleotides during PCR are always unmethylated; 
therefore, all methyl groups are lost after the first PCR cycle. 
 
In the context of forensic analysis, it is believed that methods based on bisulphite 
treatment are the most appropriate as the integrity of DNA is maintained and the 
quantity of starting DNA material needed is relatively low. Alternative procedures 
may also be sensitive to external inhibitory compounds, commonly found in forensic 
casework. This is very important as forensic samples are frequently of low quality and 
quantity, aged or degraded. There have been various reported methods based on 
bisulphite treatment of DNA and will be discussed in Chapter 5. 
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1.2 Forensic Epigenetics 
Various cellular decisions including survival, growth and differentiation are controlled 
by particular gene expression patterns, which are further regulated by changes in the 
epigenetic state of ‘key’ genes. The possibility of quantifying the DNA methylation 
levels of specific genes is of interest in a broad range of scientific and medical 
disciplines. As mentioned above, the epigenome acts as an interphace between the 
genome and the environment, and can change according to the specific needs of a cell. 
Therefore, DNA methylation patterns could reveal the activities of genes within a 
certain tissue at a certain point in time. From a forensic standpoint the analysis of 
DNA methylation patterns may give hints on pathological states (Das & Singal, 2004) 
or circumstances leading to death (Fragou et al., 2011). Some of the main forensic 
applications of epigenetic analysis will be discussed below. 
Although DNA methylation is a relatively new approach for gene expression studies, it 
has been previously reported in forensic research. Naito and his colleagues were the 
first to introduce DNA methylation in forensic genetics and proposed a method for 
epigenetic female sex typing (Naito et al., 1993). The method was based on differential 
methylation pattern of an X chromosome-specific repetitive sequence, DXZ4 region, 
which was found highly methylated on the active X, whereas it was hypomethylated 
on the inactive X chromosome. This novel protocol for positively determining female 
sex was shown to be very sensitive as only 50 pg of DNA was required for successful 
sex typing, and the method had been proposed as a complementary technique in cases 
of sex-reversed individuals. 
1.2.1 Determination of the parental origin of alleles 
In paternity testing, the alleged father is usually excluded when he does not have the 
obligatory gene (OG), which can be determined from the child’s genotype when the 
maternal gene is known. However, in motherless cases, the OG cannot be determined 
resulting in a reduced exclusion probability. Consequently, the determination of the 
parental origin of alleles without genealogical analysis could serve as a solution. We all 
inherit two copies (alleles) of each autosomal gene, one from our mother and one from 
our father. In most cases both alleles are active and functional; however, for a small 
group of genes one copy is turned off in a parent-of-origin dependent manner (Li et al., 
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1993; Reik & Walter, 2001). The epigenetic mark of a gene based on its parental 
origin is called genomic imprinting and results in monoallelic expression. Maternal and 
paternal alleles are differentially methylated; therefore the parental origin of an allele 
could be determined by analysing its DNA methylation status. Imprinted expression 
can vary among tissues and developmental stages, while aberrant imprinting is the 
cause of various disease syndromes (Reik & Walter, 2001). 
Zhao and his colleagues studied the methylation status at the imprinted SNP locus 
rs220028 and were able to determine the parental origin of alleles in all tissues tested 
(Zhao et al., 2005). Their methodology involved a combination of digestion with 
methylation-sensitive restriction enzyme and post-digestion PCR using allele-specific 
primers thus allowing for the simultaneous analysis of the polymorphism and the 
methylation marker in one PCR reaction [Figure 1-7]. The authors advised that using 
too much DNA could lead to false methylation detection through incomplete digestion 
by the methylation-sensitive restriction enzyme. This technique is feasible for 
relationship testing but may prove a drawback for forensic samples.  
 
Figure 1-6. Strategy for determining the parental origin of an allele (Zhao et al., 2005) 
The structure of the imprinted SNP locus rs220028 is shown; the locus is found methylated (black 
circle) when inherited from the mother and unmethylated (white circle) when inherited from the father. 
Black boxes represent the recognition sites for enzymes Not I (5’- GC|GGCCGC -3’) and Hpa II (5’-
C|CGG -3’) (also SNP site A/G). The primers used in the study are indicated as straight lines. The 
parental origin of an allele is determined by post-digestion methylation-specific PCR (MS-PCR). 
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Another study includes parentally-imprinted allele (PIA) typing of a variable number 
tandem repeat (VNTR) locus at the 5’-end of the H19 imprinted gene, in blood 
samples and in a range of post-mortem tissues (Sumi et al., 2005). Their protocol 
involved separate PCR for genotyping and PIA typing and showed no tissue-
dependent methylation differences. The potential of H19 gene in high-resolution 
paternity testing has also been investigated by other research groups (Huang et al., 
2008; Naito et al., 2003) who reported two parentally imprinted H19FRs haplotype 
polymorphisms.  
Furthermore, Nakayashiki and his team performed a more comprehensive study 
analysing a set of several SNPs in five imprinted genes using bisulphite sequencing in a 
range of tissues (Nakayashiki et al., 2009a; Nakayashiki et al., 2008; Nakayashiki et al., 
2009b). The maternal allele could be detected from the maternally-expressed gene 
(H19), and the paternal allele from the paternally-expressed ones: the hydrogenase 
subunit HymA (HYMA1), small nuclear ribonucleoprotein polypeptide N (SNRPN) 
and paternally expressed 3 (PEG3) gene (Nakayashiki et al., 2008). However, 
unpredicted DNA methylation levels were detected in a few tissues, such as nails, hair 
and sperm as well as in samples exposed in higher temperatures or longer preservation 
periods (Nakayashiki et al., 2009a; Nakayashiki et al., 2009b). 
In conclusion, the parental discrimination of a polymorphic allele in imprinted genes 
could be very promising for autosomal heritage analysis in difficult paternity cases 
although further research on tissue specificity and DNA methylation stability is 
required. Recent systematic, large-scale efforts to study these effects and to profile 
both tissue-shared and tissue-specific imprinting levels in humans have highlighted 
that there is indeed variation in imprinting not only between genes, but also between 
tissues and individuals (Baran et al., 2015). 
1.2.2 Authentication of DNA samples 
DNA evidence has become an invaluable tool for forensic testing and personal 
identification. The use of DNA recovered from the crime scene and presented as 
evidence in court relies on the assumption that it is genuine, meaning originating from 
natural biological material. However, using well-established methods (Lasken & 
Egholm, 2003) DNA can be artificially produced and it is conceivable that DNA with 
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any desired genetic profile can be synthesized in vitro and planted in crime scenes 
(Frumkin et al., 2010). Conventional genotyping techniques would fail to distinguish 
between natural and artificial DNA samples. Frumkin et al proposed a method of 
identifying artificial DNA based on differential DNA methylation patterns.  
The authors synthesised DNA in vitro using three different methods which all 
produced unmethylated DNA. On the other hand, in vivo generated DNA contains 
both unmethylated and methylated loci. For the purpose of this study, two loci that 
are consistently methylated and two loci that are consistently unmethylated were 
chosen. Moreover, analysing some mock casework samples and natural/artificial DNA 
mixtures, it was shown that in vitro synthesized DNA could be detected, even in cases 
where it represented a minor component (Frumkin et al., 2010).  
Since synthesising DNA in vitro would require knowledge of molecular biology as 
well as dedicated instrumentation, planting someone else’s biological material at a 
crime scene would definitely be an easier option. Furthermore, authors did not take 
into account that following its synthesis artificial DNA can be selectively methylated if 
desired by the use of specially engineered methyltransferases (Chaikind et al., 2012). 
However, in cases where the presence of artificial DNA is suspected, the above 
method could be employed. 
1.2.3 Discrimination of monozygotic twins 
Individual identification of monozygotic twins in forensic casework has always been a 
challenge. Conventional forensic DNA typing cannot be performed, as monozygotic 
twins are expected to have the same DNA sequence. To further highlight how 
genetically identical twins are, a recent study performed ultra-deep next generation 
sequencing in a pair of twins to explore possible differences (Weber-Lehmann et al., 
2014). Researchers revealed only five extremely rare mutations in the whole genome; 
these results were also confirmed by classical Sanger sequencing. Although these 
results are interesting and quite promising, it is impractical to apply this approach in 
forensic casework due to the high cost and often, to the quality and quantity of the 
DNA available. 
Twins do show various degrees of phenotypic difference (Fraga et al., 2005; Wong et 
al., 2005), which are presumably due to environmental differences acting on the 
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genome through epigenetic processes. Support for this theory comes from human 
disease studies, where evidence has been gathered that (apart from other mechanisms 
such as copy-number variation (CNV) in somatic cells) (Bruder et al., 2008), 
epigenetic modifications are the ones that are responsible for these differences (Sahin et 
al., 2011). For a forensic application  of epigenetics to discriminate between identical 
twins, a high throughput DNA methylation microarray was employed to select 
suitable CpG sites (Li et al., 2011). Li et al tested blood DNA samples from 22 pairs of 
adult monozygotic twins, which were bisulphite treated and analysed with Illumina’s 
Human Methylation 27K Beadchip, which allows for the measurement of methylation 
levels of more than 27,000 CpG sites. The results were very promising, revealing 
significant DNA methylation differences in a total of 377 CpG sites; however, further 
investigation is needed regarding the stability of CpG methylation and potential age-, 
tissue- or population-specific influence on DNA methylation. 
1.2.4 Cause of death determination 
The essential duties of the forensic pathologist include the investigation of the cause 
and manner of death, especially in sudden, unexpected or unwitnessed deaths. The 
main purpose of using post-mortem biochemistry and molecular biology is to examine 
the general pathophysiological changes involved in the death that cannot be 
established by morphological and functional changes of cells and organs (Maeda et al., 
2011; Zhao et al., 2009).  
Several studies aimed to use messenger RNA (mRNA) profiling in post-mortem 
human tissues to find clues on events that happened at the time point of death (Maeda 
et al., 2010; Partemi et al., 2010; Zhu et al., 2008). The composition of different RNA 
transcripts within the cells of a tissue is not stable, but can change according to the 
specific needs of cells in response to environmental conditions. Thus, each type of 
death would activate different molecular mechanisms that could be detected through 
different gene expression patterns (Vennemann & Koppelkamm, 2010; Zhao et al., 
2009). However, mRNA instability could be an issue when working with human post-
mortem tissues; gene transcripts are usually degraded by in vivo ubiquitous RNases 
shortly after death. This process might also be accelerated by several factors such as 
high humidity and temperature during post-mortem interval (PMI). Furthermore, it is 
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known that the integrity of RNA may differ between tissue types or different donors 
(Vennemann & Koppelkamm, 2010). 
As mentioned earlier, DNA methylation is an epigenetic mechanism that changes gene 
expression. Recent studies have demonstrated that various diseases and cancer are 
associated with abnormal alterations in DNA methylation levels (Szyf, 2010); 
therefore, it would be interesting to determine whether DNA methylation status in the 
promoter regions of certain genes could change as a response to various acquired 
diathesis and/or causes of death. The methylation status of the promoter region of p16 
gene (also known as cyclin-dependent kinase inhibitor 2A, multiple tumour suppressor 
1, CDKN2A) was investigated in blood of individuals who had been exposed to lead 
(Kovatsi et al., 2010). One of the main symptoms of lead poisoning is the development 
of neurological disorders, closely related to DNA methylation changes (Fragou et al., 
2011). In this study, methylation levels were detected through methylation-specific 
PCR followed by thermal denaturation. p16 methylation was indeed frequent and 
extensive among lead-overexposed individuals and dependant on blood lead 
concentration. Highly exposed individuals (blood Pb2+ concentration: 51-100 µg/dL) 
showed complete methylation, whereas those with low blood Pb2+ concentration (6-11 
µg/dL) demonstrated partial methylation (Kovatsi et al., 2010).  
Moreover, the methylation status of circadian clock gene promoters has been 
examined using forensic autopsy specimens (Nakatome et al., 2011). Circadian clock 
genes play a vital role in the formation of the biological clock and aberrant methylation 
of these genes contributes to several diseases such as lifestyle-related or heart diseases. 
Pathomorphological changes are difficult to be detected in cases of sudden unexpected 
death caused by cardiac arrhythmia or certain long-term medication. The majority of 
patients who are liable to sudden death lose the balance of a range of biological 
functions related to circadian clock genes (Nakatome et al., 2011). The authors 
analysed nine circadian clock genes - period circadian protein homologs 1-3 (Per1, 
Per2, Per3), cryptochrome circadian clock 1 and 2 (Cry1, Cry2), timeless (Tim), casein 
kinase 1 (Ck1e) and the clock component Bmal1 - by employing bisulphite treatment 
followed by methylation-specific PCR. Tissues were obtained from several cadavers 
with known or unknown cause of death (asphyxia, lethal arrhythmia, head injury, fire 
fatality). The methylation status of these promoter regions was found to vary 
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significantly between individuals and among tissues in the same individual. Even 
though it has previously reported that circadian dysregulation is relevant with drug 
addiction or alcohol abuse (Li et al., 2010), this study failed to demonstrate a link 
between methylation pattern and cause of death (Nakatome et al., 2011).  As with the 
other studies there are some interesting links of methylation patterns and cause of 
death but it is too early to draw any definite conclusions. 
1.2.5 Challenges and practical considerations 
DNA-based testing is favoured in forensic analysis as DNA is considered to be among 
the most stable molecules present in cells. Assays based on the use of epigenetic 
markers that by default use the same starting material for downstream profiling have 
obvious advantages. However, caution is needed regarding the selection of CpG sites 
as well as the interpretation of the observed DNA methylation profiles.  
The first step for a successful epigenetic assay is the identification of suitable DNA 
methylation markers. There are two different approaches in selecting CpG sites; the 
first involves screening well-known candidate regions such as CpG islands and gene 
promoters, while the second employs high-throughput analysis for the epigenetic 
biomarker discovery on a truly genome-wide scale (Bock, 2009).  
Regarding the first approach and as discussed earlier in this chapter, it is generally 
believed that DNA methylation is associated with silencing of gene expression 
(Newell-Price et al., 2000), perhaps by blocking the gene promoters at which 
transcription activators should bind. As discussed by Suzuki and Bird, evidence of this 
has been highlighted in studies showing that DNA methylation patterns near gene 
promoters considerably varies depending on the cell-type, with higher levels of 
methylation correlating with very low or no transcription (Suzuki & Bird, 2008). 
Therefore, DNA methylation is known to play a role in cell differentiation and 
adaptation to different cell environments, mainly by regulating the expression of 
selected genes. Depending on the forensic application investigating well-known 
candidate genomic regions would potentially reveal suitable epigenetic markers. On 
the other hand, a genome-wide DNA methylation analysis is very likely to uncover 
many new genomic regions that exhibit epigenetic variations, including those that are 
located outside gene promoters, which would be otherwise missed following the first 
approach. However, this increase in the scale of the search brings about major 
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bioinformatics and statistical challenges; however, these challenges can be resolved 
utilising computational methods. The proposed methods are only used for a first 
screening and identification of a pool of CpG sites; whereas the validation of the 
selected markers needs to be achieved using highly-targeted assays (Bock, 2009). 
As mentioned earlier, DNA methylation as an epigenetic mechanism is responsible for 
a range of activities inside the cell, therefore external factors such as ageing, 
environmental stress, human diseases, cancer and cigarette smoking could interfere by 
altering DNA methylation patterns (Bocklandt et al., 2011; Christensen et al., 2009; 
Koch & Wagner, 2011; Wild & Flanagan, 2010). Thus, following verification of the 
specific DNA methylation pattern of a given CpG site, it is necessary to analyse a large 
number of DNA samples and ensure that this particular CpG site does not display high 
variation in its methylation levels (low inter-individual variation). Moreover, for each 
forensic application all aforementioned external factors need to be tested. For example, 
in order to propose that a particular CpG site demonstrates body-fluid specific DNA 
methylation pattern, it needs to be confirmed that it is not also age-dependent or 
influenced by environmental factors (Christensen et al., 2009). 
In cases where the levels of DNA methylation can be quantified, it is essential to 
choose CpG sites that clearly show a high degree of methylation difference; the larger 
this margin the better the discrimination achieved. For instance, in order to correlate a 
specific CpG site with a particular cause of death, such as drug abuse, it needs to 
demonstrate a minimum of 60-70% difference compared to the normal tissue. This 
would also prevent false estimation due to inter-individual variation.  
After selecting the right candidate CpG sites, the assay has to be carefully designed so 
that it can be applicable for forensic analysis. Forensic specimens are often of low 
quantity and quality, so it is important that a proposed method is tested on low levels 
and/or degraded DNA. Both bisulphite conversion protocols and assays using 
methylation-sensitive restriction enzymes show high degrees of sensitivity (LaRue et 
al., 2013; Madi et al., 2012). In both cases, appropriate controls are necessary 
(bisulphite conversion controls and enzyme digestion controls respectively).  
Other very important steps of assay design are the PCR amplification and primer 
design. When sodium bisulphite is employed, the primers need to be designed to 
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contain some normally converted non-CpG cytosines, so that only the bisulphite-
converted DNA is amplified. Also, primer sequences should not contain any CpG 
sites, except for the cases where methylation-specific PCR is chosen. Differences in 
the DNA sequence between methylated and unmethylated amplicons could introduce 
preferential PCR amplification; therefore, DNA methylation controls with known 
DNA methylation levels can be used to normalise the data (Moskalev et al., 2011; 
Warnecke et al., 1997).  
As for any forensic testing, more stringent validation criteria have to be met for each 
selected epigenetic marker.  All markers have to show high sensitivity and specificity, 



















The field of epigenetics is still considered relatively new, having gathered scientists’ 
attention only the past few decades. There are many fundamental questions that are 
yet to be answered, and even more so when applying epigenetic models in forensic 
investigations. As the epigenetic code is adjustable and dynamic, changing with age 
and environment, forensic scientists need to keep up with new discoveries in scientific 
research. The promise of forensic epigenetics demands not only overcoming challenges 
regarding the design and interpretation of epigenetic profiles, but also exploring 
innovative strategies that could cope with the nature of forensic specimens. More 
comprehensive analyses of Forensic Epigenetics would allow for further identification 
of suitable epigenetic markers, more conclusive links between cell differentiation and 

















This investigation aims to explore novel uses of epigenetics in forensic science by 
analysing various tissue-specific or age-associated differentially methylated CpG sites. 
Since this study looked into two distinct forensic applications, the thesis has been 
divided into two parts.  
Part 1 includes findings regarding the detection of body fluids and tissues; in order to 
meet these aims, the objectives were: 
- To evaluate the performance of existing multiplex mRNA-based PCR assays 
including assessing the sensitivity, specificity and applicability of proposed 
tissue-specific mRNA markers (Chapter 4) 
 
- To identify novel and validate existing tissue-specific differentially methylated 
CpG sites via the development of bisulphite Pyrosequencing® assays (Chapter 
5) 
 
Part 2 includes findings regarding the estimation of an individual’s age from blood 
where aims were met by the following objectives: 
- To investigate a set of age-associated CpG sites proposed in the literature via 
bisulphite Pyrosequencing® and regression analysis and build an age prediction 
model through Artificial Neural Networks (ANN) (Chapter 7) 
 
- To develop a next-generation sequencing protocol that could accurately 




































This chapter will describe all methods and materials used throughout the whole course 
of this research. More specific experimental and assay design will be discussed in detail 
in each of the following results chapters. 
2.1 Samples 
Biological samples included in this study were collected either for the purpose of 
paternity or relationship testing by the fully accredited ‘DNA analysis at King’s’ 
laboratory in the Department of Pharmacy and Forensic Science (UKAS ISO17025, 
UK Ministry of Justice) or as part of this study following obtaining full ethical approval 
by the Biomedical Sciences, Dentistry, Medicine and Natural & Mathematical 
Sciences Research Ethics Subcommittee (BDM RESC 13/14-30, Appendix I). 
Samples were collected and stored in accordance with the Human Tissue Act Code of 
Practice on Consent (HTA, 2014) and according to the Human Genetics Commission 
documents relating to Genetic Testing Services (2010). Full informed consent for the 
testing performed was obtained from the donors or their parents in case of under-aged 
individuals prior to collection. For certain joint European projects, the collaborating 
laboratory obtained ethical approval. Lastly, stains from casework were collected after 
successful DNA analysis was already completed and according to the laboratory’s 
instructions. 
Individuals had the choice to donate one or more of the following body fluids/tissues: 
whole blood, saliva, buccal cells in the form of a mouth swab, seminal fluid, vaginal 
secretion, menstrual blood, urine, skin and/or nasal fluid. Up to 20 ml of whole blood 
were collected by a trained phlebotomist in a sterile location designed for blood 
sampling and collection. All other body fluid samples were collected either using a 
cotton swab or a suitable receptacle by the participants in the privacy of their own 
homes. Information such as subject’s gender, ethnicity and age were also recorded if 
possible. Each sample was anonymised soon after collection; therefore, no genetic 
information obtained can be linked back or relate to an individual. All samples were 




2.2 DNA analysis 
Genomic DNA was extracted and analysed either for the purpose of DNA profiling or 
to investigate DNA methylation patterns. 
2.2.1 DNA extraction 
Body fluid samples were either in a liquid form, deposited on a swab or on a surface 
(fabric, glass). Part of these swabs or stains was used to extract and purify DNA from 
cellular material. The method to be used for DNA extraction was dependent on the 
sample type. For buccal swabs or samples where high quantities of DNA were likely to 
be present (like whole blood), manually performed extraction using Chelex™ beads 
(Sigma) or automated DNA purification system using an EZ1 instrument (QIAGEN) 
was performed. In cases where body fluid samples were suspected of being of low 
quality or quantity, the QIAamp DNA Investigator kit (QIAGEN) was employed, as 
it was possible to adjust the final elution volume for more concentrated DNA samples. 
2.2.1.1 Chelex™ beads (Sigma) 
Chelex™ is a chelating resin in the form of small beads that are capable of binding 
polyvalent metal ions such as magnesium (Mg2+) and removing them from the solution. 
The Chelex™ resin is composed of styrene divinylbenzene copolymers containing 
paired iminodiacetate ions, which act as chelating groups (Singer-Sam et al., 1989). 
The presence of these beads facilitates the inactivation of potentially harmful nucleases 
that could degrade the DNA during boiling in low ionic strength solutions. However, 
the resulting DNA is single-stranded and possible contaminants might not be entirely 
removed. The procedures used in this study were adapted and adjusted from the 
original published protocol (Walsh et al., 1991). 
Lysis of the cellular material was achieved by firstly incubating the samples in 1 ml of 
DNA- and nuclease-free water (Severn Biotech) at room temperature for 20 minutes. 
Samples are in the form of either 4 µl/1.2 mm dried spot of whole blood or the tip (3 
mm) of a mouth swab. Following incubation, the tubes were spun down at 14,000 rpm 
for 5 minutes using a centrifuge (Biofuge pico), after which all liquid was removed 
except for 20 µl at the bottom of the tube. Afterwards, 180 µl of 5% w/v Chelex™ 100 
in H2O suspension were added to the tubes, which were then incubated on a heated 
shaker (ThermoStat Plus) at 56 ºC and 1,000 rpm for 20 minutes. They were then 
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incubated at 100 ºC for exactly 8 minutes and spun down at 14,000 rpm for 5 minutes. 
The piece of mouth swab was not removed from the tube throughout the whole 
procedure in order to avoid any DNA loss. DNA samples were now ready for use and 
stored at 4 ºC for up to 6 months. 
2.2.1.2 QIAamp DNA Investigator (QIAGEN) 
The QIAmp DNA Investigator kit uses an entrenched technology for the isolation of 
both genomic and mitochondrial DNA from small sample volumes and stain sizes. The 
protocol combines the selective binding properties of a silica-based membrane with 
flexible elution volumes (20-100 µl). This ability makes this kit suitable for analysing a 
broad range of forensic samples. The procedure is simple, quick and yields high-
quality DNA. The method mainly comprises four steps including lysis, DNA binding 
to the membrane, removal of contaminants through wash steps and finally elution of 
pure and concentrated DNA. The protocol can be adjusted depending on the type of 
starting material and more information can be found in the QIAamp DNA Investigator 
Handbook (Qiagen, 2010b). 
In this study, a combination of the protocol for ‘body fluid stains’, ‘surface swabs’ and 
‘small volumes of blood or saliva’ was employed. In more detail, 50-100 µl of a body 
fluid, a whole stained cotton swab or a casework stain were placed into a labelled 1.5 
ml tube. 100 to 400 µl of tissue lysis buffer (Buffer ATL) were then added together 
with 20 µl of proteinase K (both provided in the kit). If processing semen swabs, 20 µl 
of 1 M dithiothreitol (C4H10O2S2, DTT) (Thermo Scientific) were also added to the 
samples, as DTT is needed to break the sulphur bonds of various proteins on the 
surface of spermatozoa. The solutions were then incubated on a heated shaker at 56 oC 
and 1,000 rpm for at least 1 hour. When processing casework samples, the solutions 
were incubated for up to 3 hours to ensure sufficient lysis.  
Following the incubation, another 300 to 600 µl of lysis buffer (Buffer AL) was added 
and the solutions were vortexed for at least 15 seconds. The tubes were again placed 
on a heated shaker at 70 oC and 1,000 rpm for 10 minutes. The samples were briefly 
centrifuged to remove any remaining drops from the inside of the lids. To enhance the 
binding of DNA to the silica membrane, 50 to 300 µl of absolute ethanol (96-100%) 
(VWA Chemicals) were added and the solutions were thoroughly mixed by vortexing 
for 15 seconds. The entire lysate was then transferred from the tubes to the QIAamp 
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MinElute columns, which are stored at 4 oC. The columns were centrifuged at 8,000 
rpm for 1 minute and the flow through was discarded since DNA is expected to bind 
to the membrane. The first washing step was performed by adding 500 µl of Buffer 
AW1 followed by centrifugation at 8,000 rpm for 1 minute. The flow through was 
then discarded again and the process was repeated with both 700 µl Buffer AW2 and 
700 µl of absolute ethanol. Both washing buffers were included in the kit.  
The columns were then placed into new collection tubes and were centrifuged at full 
speed (14,000 rpm) for 3 minutes to completely dry the membrane. This step is 
necessary since ethanol carryover may interfere with downstream analysis. To ensure 
successful ethanol removal, the columns were also incubated with the lid open either at 
room temperature for 10 minutes or at 56 oC for 3 minutes. They were then placed 
into new, labelled 1.5 ml collection tubed and were ready for the elution step. Finally, 
20-100 µl of elution buffer or nuclease-free water were added to the centre of the silica 
membrane and samples were incubated at room temperature for 1 minute in order to 
increase DNA yield. DNA was eluted after centrifuging the samples at full speed 
(14,000 rpm) for 1 minute. The last step was usually repeated by loading the eluate 
back to the membrane for maximum yield. DNA samples were stored at -20 oC. 
2.2.1.3 BioRobotEZ1® DNA extraction (QIAGEN) 
The EZ1® instrument offers reproducibly automated DNA extraction and purification 
employing a magnetic-particle technology. This method combines the speed and 
efficiency of silica-based DNA purification together with the expedient handling of 
magnetic beads. Firstly, DNA is isolated from the lysates during its binding to the 
silica surface of the particles in the presence of a chaotropic salt. Applying a magnet, 
the particles are separated from the solution and DNA can be efficiently eluted after it 
has been washed. This process is illustrated in Figure 2-1. 
The protocols for DNA extraction from mouth swabs and whole blood were slightly 
different; therefore, there is a specific kit for each sample type. For blood samples, the 
EZ1® DNA blood kit together with the EZ1® DNA blood card were used; for mouth 
swabs, the EZ1® DNA tissue kit together with the EZ1® DNA tissue card were 
employed. Manufacturer’s instructions can be found in the EZ1® handbooks (Qiagen, 
2009b; Qiagen, 2011). Briefly, up to 6 samples can be extracted at the same time and 
the amount of starting blood material could vary, but usually 50-200 µl was used. The 
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methods are very similar; however for the mouth swabs there is an initial incubation 
step that facilitates cell lysis not present in the extraction protocol for blood. This 
preliminary step included placing the end 3 mm of the buccal swabs into a 2 ml sample 
tubes containing 190 µl of lysis buffer and 10 µl of proteinase K (both supplied with the 
kit). The solutions were incubated on a heating shaker at 56 oC and 1,000 rpm for 20 
minutes. 
 
Figure 2-1. Principle and procedure of DNA extraction technology using EZ1® instruments 
(Qiagen, 2009b) 
This diagram shows the magnetic bead technology employed in the BioRobot EZ1® protocols including 
cell lysis, DNA binding to the magnetic particles, magnetic particle removal, sample washes and elution 
of pure, high-quality DNA. 
[51] 
 
The blood or the pre-treated buccal cells were then put in the correct place and the 
appropriate card was inserted into the EZ1® robot. Following the on-screen 
instructions, reagent cartridges, tip holders with tips and 1.5 ml elution tubes (all 
supplied with the kit) were also placed in the specified positions. The elution volume 
could be selected depending on the starting volume (50-250 µl). The whole process 
lasts for about 20 minutes and purified DNA samples were stored at -20 oC until 
analysis. There is a chance that magnetic particles might still remain in the DNA 
solution; however, this does not affect downstream analysis. 
2.2.2 DNA quantification 
It was necessary to determine the concentration of DNA samples before proceeding to 
further analysis. A method that can accurately evaluate the quality and quantity in a 
DNA sample in a human-specific manner was preferred since it is very likely that some 
of the tissues involved in this research, such as saliva and vaginal fluid, are highly 
contaminated with bacterial DNA. 
2.2.2.1 Quantifiler® Human DNA Quantification (Applied Biosystems) 
This real-time PCR-based system is designed for the accurate quantification of human 
DNA present in a solution and has been widely used in the forensic field. DNA from 
any human tissue source can be quantified and possible PCR inhibitors can be also 
detected with the use of a pre-formulated internal PCR control (IPC), which monitors 
the amplification success of each sample. The IPC is a synthetic template DNA not 
found in nature that is co-amplified in the reaction. The chemistry used is compatible 
with commonly used extraction technologies and currently has the widest dynamic 
range of DNA detection (0.23 to 50 ng/µl) allowing for true quantification of low-level 
samples. 
The Quantifiler® Human DNA Quantification kit takes advantage of the TaqMan® 
technology, which is used to detect and amplify a 62 bp long sequence in a non-
translated region (introns) of the human telomerase reverse transcriptase gene 
(hTERT) at the chromosomal location 5p15.33. The method involves a TaqMan® 
probe which contains a reporter dye (FAM™ or VIC™) linked to its 5’ end, a minor 
groove binder (MGB) at its 3’ end together with a non-fluorescent quencher (NFQ). 
During PCR, the TaqMan® MGB probe specifically anneals to a complementary 
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sequence between the forward and the reverse primer sites. When the probe is intact, 
the proximity of the reporter dye to the quencher dye leads to repression of the 
reporter fluorescence. However, cleavage by the AmpliTaq Gold® DNA polymerase 
during polymerisation results in separation of the reporter dye from the quencher dye, 
which causes fluorescence [Figure 2-2]. The increase in fluorescent signal takes place 
only when the target sequence is complementary to the probe and is amplified during 
PCR. Therefore, it is exponential and proportional to the amount of starting DNA 
present in the sample and can be easily determined with the aid of DNA standards of 
known concentration. The ABI PRISM® 7000 Sequence Detection System was used 
to monitor the fluorescent signal. More details on the technology can be found in the 
manufacturer’s recommendations (ABI, 2014). 
 
Figure 2-2. TaqMan® technology used in the Quantifiler® Human DNA Quantification kit 
(ABI, 2014) 
The TaqMan® MGB probe binds specifically to a complementary sequence between the forward and 
the reverse primer sites. When the probe is intact, the proximity of the reporter dye to the quencher dye 
leads to suppression of the reporter fluorescence. However, when the AmpliTaq Gold® DNA 
polymerase synthesises the DNA during PCR it removes the reporter dye from the quencher dye 
resulting in fluorescence. 
Firstly, the DNA standards were prepared by mixing the standard stock solution (200 
ng/µl) that is provided with the kit with nuclease-free water as shown in Table 2-1. It 
is important that the stock solution is thoroughly defrosted and that all standards are 
vortexed very well during preparation. Quantification was carried out in 25 µl 
reactions and in duplicate for both standards and samples; negative control (H2O) was 
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also included in each experiment. For each reaction, 10.5 µl of the Quantifiler® 
Human Primer mix were added to 12.5 µl of Quantifiler® PCR reaction mix (both 
supplied with the kit) along with 2 µl of DNA standard, DNA sample or water in a 96-
well plate. To avoid contamination, only filter tips were used when handling the 
samples. The plate was sealed, vortexed and briefly centrifuged to remove any 
bubbles. The plate was then loaded in the ABI PRISM® 7000 instrument for analysis. 
The thermal cycling conditions used were 95 oC for 10 minutes followed by 40 cycles 
of 95 oC for 15 seconds and 60 oC for 1 minute. The whole method lasts for about 2 
hours. After the run is complete, it is analysed according to the analysis parameters 
suggested by the manufacturer. The R2 value of the standard curve needs to always be 
>0.985 with a slope of 2.7<s<3.3. In case of a lower R2 value, up to two standards 
could be omitted from the standard curve; if it was still <0.985, the run was repeated. 
Table 2-1. DNA standards dilution series 
Standard Concentration (ng/µl) Dilutions Dilution factor 
Std. 1 50.000 10 µl stock + 30 µl H2O 4X 
Std. 2 16.700 10 µl Std. 1 + 20 µl H2O 3X 
Std. 3 5.560 10 µl Std. 2 + 20 µl H2O 3X 
Std. 4 1.850 10 µl Std. 3 + 20 µl H2O 3X 
Std. 5 0.620 10 µl Std. 4 + 20 µl H2O 3X 
Std. 6 0.210 10 µl Std. 5 + 20 µl H2O 3X 
Std. 7 0.068 10 µl Std. 6 + 20 µl H2O 3X 
Std. 8 0.023 10 µl Std. 7 + 20 µl H2O 3X 
 
2.2.3 DNA treatment with sodium bisulphite 
In order to convert differences in DNA methylation to differences in DNA sequence, 
DNA samples are treated with sodium bisulphite, which converts unmethylated 
cytosines into uracil, while the methylated ones remain unchanged. Once converted, 
the methylation profile of DNA regarding any locus can be determined by PCR 
amplification followed by DNA sequencing. In this research, three commercially 
available bisulphite conversion methods were tested for their efficacy and accuracy, 
including the Epitect® Bisulphite kit (QIAGEN), the EZ DNA Methylation™ kit 
(ZymoResearch) and the MethylEdge™ Bisulphite Conversion system (Promega). All 




Figure 2-3. Main steps of bisulphite conversion protocols 
2.2.3.1 Epitect® Bisulphite (QIAGEN) 
The EpiTect® Bisulphite kit provides a fast and streamlined 6-hour procedure for 
complete conversion and purification of as little as 1 ng of starting DNA material. The 
use of a DNA Protect Buffer (supplied with the kit) prevents DNA fragmentation and 
loss due to high temperatures and low pH values as it includes a control pH-indicator 
dye that allows for verification of the correct pH for cytosine conversion. Additionally, 
the kit allows for the analysis of difficult samples such as small amounts of fragmented 
DNA with adjusted protocols including an additional step that enhances binding of 
DNA and considers starting DNA amounts of less than 500 pg (Qiagen, 2009a).  
The standard protocol allows for complete conversion of 1 ng – 2 µg DNA in a volume 
of up to 20 µl. Each aliquot of Bisulphite mix was diluted with 800 µl of RNase-free 
water (provided in the kit) and vortexed for 5 minutes. Each bisulphite reaction 
consisted of 20 µl of DNA solution (DNA was diluted with water if necessary), 85 µl 
of dissolved Bisulphite mix and 35 µl of DNA Protect Buffer for a total volume of 140 
µl. The bisulphite DNA conversion was performed using a Veriti® thermal cycler (Life 
Technologies) using the program shown in Table 2-2. Following this 5-hour long 
process, the clean-up of bisulphite converted DNA was carried out.  
The complete bisulphite reactions were transferred to new 1.5 ml tubes and 560 µl of 
freshly prepared Buffer BL (containing 10 µg/ml carrier RNA if <100 ng DNA were 
used) were added. The solutions were mixed by vortexing and transferred to the 
EpiTect® spin columns, which were then centrifuged at 14,000 rpm for 1 minute. The 
Step 1
•Sodium bisulphite-mediated conversion of unmethylated cytosines
Step 2
•Binding of converted single-stranded DNA to the membrane 
Step 3
•First wash step to remove any conversion reagent left in the membrane
Step 4
•Desulphonation of membrane-bound DNA
Step 5
•Two additional wash steps to remove any residual reagent
Step 6
•Elution of pure, bisulphite-converted DNA
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flow through was discarded and the first wash step was performed by adding 500 µl of 
wash buffer (Buffer BW) and centrifuging at 14,000 rpm for 1 minute. Next, 500 µl of 
desulphonation buffer (Buffer BD) was added to each column and left at room 
temperature for 15 minutes. The spin columns were then centrifuged, the flow through 
was discarded and two more washing step using 500 µl of Buffer BW were carried out. 
To enable removal or evaporation of any remaining liquid, the columns were 
centrifuged at maximum speed for 1 minute and also incubated in a heating block at 56 
oC for 5 minutes. The bisulphite-converted DNA strands were now ready to be eluted 
by dispensing 20-40 µl of elution buffer (Buffer EB) onto the centre of each membrane 
and centrifuging at 12,000 rpm for 1 minute. To increase the yield of DNA in the 
eluate, the columns were incubated at room temperature for 1 minute prior to the 
centrifugation step. The purified DNA samples could be stored at 4 oC for up to 24 
hours or at -20 oC for long-term storage. 
Table 2-2. Bisulphite conversion thermal cycler conditions (Epitect®, QIAGEN) 
Step Time Temperature 
Denaturation 5 min 95 oC 
Incubation 25 min 60 oC 
Denaturation 5 min 95 oC 
Incubation 85 min (1 h 25 min) 60 oC 
Denaturation 5 min 95 oC 
Incubation 175 min (2 h 55 min) 60 oC 
Hold ∞ 20 oC 
 
2.2.3.2 EZ DNA methylation™ (ZymoResearch) 
In a very similar way, the EZ DNA methylation™ kit is based on a three-step reaction 
where unmethylated cytosine is converted to uracil. In-column desulphonation 
technology is designed to reduce destructive precipitations and at the same time 
eliminate any DNA fragmentation. The kit specifies that the method can be used for 
500 pg to 2 µg starting DNA material, but for optimal results, the input DNA should 
be from 200 to 500 ng, since the final DNA recovery has been calculated to be around 
80% (ZymoResearch, 2013a). 
For the purpose of this research, modified conversion conditions were applied as 
explained in this paragraph. All reagents and buffers are supplied with the kit. The CT 
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conversion reagent was a solid mixture, therefore was diluted with 750 µl of distilled 
water and 185 µl of dilution buffer and left at room temperature for at least 20 minutes 
with frequent vortexing to ensure adequate dissolving. 7.5 µl of dilution buffer was also 
added to the DNA samples and the final volume was adjusted to 50 µl with water. The 
solutions were then incubated at 42 oC for 30 minutes followed by the addition of 97.5 
µl of prepared conversion reagent. The samples were left at 50 oC for 12-16 hours 
(usually overnight) before the clean-up took place. 400 µl of binding buffer was added 
to the Zymo-Spin™ IC columns together with the samples and the mix was inverted 
several times. In order for the bisulphite-converted DNA to bind onto the membrane, 
the samples were centrifuged at 14,000 rpm for 30 seconds and the flow through was 
discarded. A first washing step was performed with 100 µl of wash buffer and the 
desulphonation procedure took place using 200 µl of desulphonation buffer at room 
temperature for 20 minutes. Samples were centrifuged at full speed for 30 seconds and 
then two extra washing steps were carried out as before. Bisulphite-treated DNA 
samples were eluted using 10-20 µl of elution buffer and were stored at -20 oC. 
2.2.3.3 MethylEdge™ bisulphite conversion (Promega) 
As shown above, a bisulphite conversion protocol can last between 6-20 hours, 
therefore it would be very beneficial to have a method that is quick but offers complete 
conversion at the same time. The MethylEdge™ Bisulphite Conversion system by 
Promega offers a novel and efficient method that can be completed in less than 2 hours 
and it can convert 100 pg - 2 µg of DNA (optimal range 200-500 ng). It is suggested 
that prolonged incubation times under harsh conditions can degrade DNA molecules 
emphasising the advantages of a quicker protocol. The protocol was followed as it is 
explained in the manufacturer’s technical manual (Promega, 2013).  
20 µl of aliquots of extracted DNA (volume adjusted with distilled water) were mixed 
with 130 µl of ready-to-use ME Conversion reagent and the solutions were mixed by 
pipetting. The DNA solutions were placed in a thermocycler and incubated at 98 oC 
for 8 minutes and 54 oC for 60 minutes. The clean-up process was very similar with 
the previously described methods, including adding 600 µl of binding buffer, one wash 
step (100 µl wash buffer), adding 200 µl desulphonation buffer and incubating at room 
temperature for 15 minutes, two additional wash steps (200 µl wash buffer) and finally, 
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eluting using 10-20 µl of elution buffer. Samples were stored at 4 oC for use within one 
week and at -20 oC for long-term use. 
2.2.3.4 DNA methylation standards (QIAGEN, ZymoResearch, EpigenDx) 
In DNA methylation analysis, it is important that appropriate methylation controls are 
used. These are DNA standards of known methylation status (0-100%) that are 
employed to assess assay performance. They not only confirm that the bisulphite 
conversion is complete, but also evaluate the accuracy and reproducibility of the 
chosen methylation quantification procedure. For this study, several commercially 
available DNA methylation standards were used: the EpiTect® PCR Control DNA kit 
(QIAGEN), the Human Methylated and Non-Methylated DNA set (ZymoResearch) 
and the Human Premixed Calibration Methylation standards (EpiGenDx).The 
EpiTect® PCR Control DNA kit contains three different types of human DNA – the 
methylated bisulphite-converted, the unmethylated bisulphite-converted and the 
unmethylated non-converted control. All solutions have a concentration of 10 ng/µl in 
Buffer EB (QIAGEN) and a total volume of 100 µl. Complete in vitro methylation of 
the control DNA was achieved using the enzyme CpG methyltransferase, M.SssI and 
bisulphite conversion was completed using the EpiTect® Bisulphite kit. 
The Human Methylated and Non-Methylated DNA set consists of purified, non-
methylated and methylated human DKO DNA (5 µg/20 µl) as well as specifically 
designed control primers (20 µl) that are intended to assess the effectiveness of 
bisulphite conversion. They are designed to amplify non-methylated, methylated, and 
varied methylation copies of the death-associated protein kinase 1 gene (DAPK1) 
following bisulphite treatment. The human non-methylated control is isolated from 
cells that contain genetic knockouts of both DNA methyltransferases (DNMT1 and 
DNMT3b); therefore it has a low level of DNA methylation in all CpG sites across the 
genome. On the other hand, the methylated control DNA has been enzymatically 
methylated at all CpG sites with the M.SssI methyltransferase. Finally, the Human 
Premixed Calibration Methylation standards are manufactured known methylation 
DNA controls (0%, 5%, 10%, 25%, 50%, 75%, 100%) (50 ng/µl). They are made as 
a result of mixing a high-methylated DNA (>85%) and a low-methylated DNA (<5%) 
(both enzymatically made) in the right ratio. 
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2.2.4 DNA amplification 
PCR is one of the most commonly used techniques in the field of molecular biology 
and genetics. It revolutionised the way we analyse DNA variation since it allows for 
the amplification of small DNA regions in an exponential manner. Therefore, it 
facilitates the analysis of the areas of interest from minute amounts of starting material, 
which is particularly important when the samples are aged or degraded. The process is 
simple and resembles the DNA replication that occurs inside the cells.  
Regardless of the application, genome or area of interest, a standard PCR is composed 
of a few fundamental components. Firstly, the template DNA is denatured and the two 
strands are separated. Following denaturation, primers, which are small synthetic 
DNA oligonucleotides (18-35 bp long), recognise and specifically bind to DNA 
regions surrounding the area of interest. Since DNA is double-stranded, two primers - 
forward and reverse - are needed to copy the DNA, one strand each. The 
primer/DNA complex then acts as a starting point for the DNA polymerase.  The 
enzyme used in PCR is the Taq polymerase that comes from the bacterium Thermus 
aquaticus. This type of bacteria lives in hot springs, therefore, the enzyme is 
thermostable and can ‘survive’ the hot temperatures (95 oC) needed for DNA 
denaturation. Using DNA as a template, the enzyme then adds deoxyribonucleotide 
triphosphates (dNTPs) in a complementary manner and extends the DNA strand. The 
nucleotides, also known as building blocks, are needed to generate the DNA copies of 
the area that the primers span. However, as with all enzymes, DNA polymerase can 
reach its maximum activity only in certain environment. Thus, a reaction buffer is 
needed to control the pH and the salt concentration of the solution. Also, the divalent 
cation magnesium chloride (MgCl2) is needed as it promotes DNA annealing and 
serves as a co-factor for DNA polymerase activity. Once the first copy has been 
created, the DNA strands are denatured again and the whole procedure is repeated.  
Consequently, DNA amplification happens during three main steps, denaturation, 
annealing and extension. These steps require different temperatures; therefore a 
thermal cycler is employed. To start with, the denaturation step involves a high 
temperature of 94-95 oC so that the two strands completely break apart. Secondly, the 
annealing process is primer-specific but usually temperatures between 45-65 oC are 
required; the primer length and sequence are the main factors that determine the 
[59] 
 
annealing temperature. Lastly, the extension step where DNA polymerase adds the 
nucleotides is typically performed at 72 oC, the enzyme’s optimum temperature. By 
repeating these steps again and again, a small number of DNA copies can result in 
millions after 20 or 30 cycles. A final extension step is also added following the cycles 
to ensure complete adenylation of the PCR products. Taq polymerase tends to add an 
additional base (adenosine) to the end of each product; therefore incomplete 
adenylation has to be avoided as it results in products that differ by a base (Butler, 
2012). In conclusion, using the method of PCR, researchers are able to amplify any 
part of a genome, either human or bacterial, or bisulphite-converted DNA.  
2.2.4.1 Primer design 
As expected, primers are very important for the success of a PCR reaction, and careful 
design is necessary for a successful amplification with no non-specific signal. In this 
study, primers had to be designed in order to amplify bisulphite-treated DNA, 
therefore specific design parameters needed to be adjusted as bisulphite PCR is 
generally known to be of low efficiency. Mis-priming events as well as non-specific 
amplification are more likely to occur due to the T-richness of the bisulphite-treated 
DNA sequences (all non-CpG cytosines have been converted to thymines). There are 
currently various primer design software specifically designed for methylation analysis; 
however, the online-tool BiSearch was considered as most suitable and selected for 
assay design (Tusnady et al., 2005). This software has the distinctive property of 
applying an algorithm and therefore, suggests potential mis-priming sites for the 
designed primer pair as well as determining possible non-specific amplicons. It can be 
applied in both treated and untreated genomes, however it is suggested that its new 
PCR primer design strategy increases the amplification efficiency of treated templates 
(Tusnady et al., 2005). 
BiSearch allowed for flexible primer design as parameters like primer length, melting 
temperature and PCR length could be manually adjusted. In general, PCR primers 
needed to flank the CpGs of interest but contain no CpG site in their sequence. They 
were designed to be 18-30 bp long; longer primers were preferred since they would be 
more specific, however when amplifying CpG-rich DNA regions designing primers 
longer than 18 bp was sometimes impossible. The PCR products were aimed to be as 
short as possible (100-300 bp) so that the designed assays could be applied in degraded 
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or casework samples. The optimal GC content of the primers (for bisulphite-treated 
DNA) was chosen to be 30% and the melting temperature (Tm) between 45 oC and 65 
oC. Higher temperatures would result in minimising the presence of non-specific PCR 
products. Also, the forward and reverse primers should share a similar melting 
temperature (maximum Tm difference ~3 oC), as the PCR optimisation could be 
difficult otherwise. Furthermore, the software took into account melting differences 
between the methylated and unmethylated ‘versions’ of the PCR product. A 
maximum Tm difference of 2.5 oC was applied so that potential amplification bias was 
eliminated. A summary of these parameters is presented in Table 2-3 and an example 
of bisulphite PCR assay design in illustrated in Appendix II. 
Table 2-3. General primer design parameters applied in BiSearch software (Tusnady et al., 
2005) 
Parameters Minimum Optimal Maximum 
Primer length (bp) 17 23 30 
Primer GC content (original) (%) 40 50 60 
Primer GC content (bisulphite) (%) 0 30 60 
Primer melting temperature (Tm) (oC) 45 55 65 
Tm difference between primers (oC) 0 0 5 
PCR length (bp) 100 200 300 
 
The secondary structure of primers is also important; therefore, the design parameters 
regarding primer self- or pair- annealing had to be strictly controlled. Wherever 
possible, long runs of the same base (-TTTTTTT-) were avoided as this causes the 
primer to twist or curve. Self end-annealing was also considered in order to avoid the 
formation of hairpin structures. To further check for interaction between primers or 
between primers and the PCR product, an additional program called AutoDimer was 
also employed (Vallone & Butler, 2004).  
When PCR products were to be sequenced by Pyrosequencing®, the reverse primers 
had to be biotin-labelled (5’ end). Also, the design of sequencing primers was much 
easier since they just needed to bind to the biotinylated strand within 2-5 bases before 
the CpG of interest. Sequencing primers were chosen to be at least 22 bp long. Since 
the sequencing reaction is run at 28 oC, it was especially important to check the 
primers for self-annealing, in particular at the 3’ end.  
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Moreover, as mentioned above BiSearch allowed for screening the entire bisulphite 
transformed genome and detection of possible mis-priming events of both the forward 
and reverse primers. Possible non-specific products were avoided but in cases where 
the number of potential primer pairs suggested by the software was limited, they were 
chosen not to be of the same length with the desired amplicon so that appropriate PCR 
optimisation could potentially eliminate them. Moreover, it is important that the 
primers bind specifically to bisulphite-converted DNA and not genomic DNA, 
therefore primers with no converted non-CpG cytosines were excluded. To check for 
possible mis-priming events to genomic DNA, the NCBI BLAST algorithm 
(www.ncbi.nlm.nih.gov/blast) was also used. All primers were ordered from 
biomers.net and were HPLC-purified. 
2.2.4.2 Bisulphite PCR optimisation 
PCR optimisation is the procedure by which the PCR product yield is maximised 
through applying optimal PCR reaction conditions. The primer design software 
usually provides suggested PCR conditions, however these are not always the most 
favourable. Optimising the PCR reaction can be achieved by adjusting not only the 
PCR reaction parameters such as primer or magnesium chloride (MgCl2) 
concentration but also the thermal cycling conditions like annealing temperature and 
duration of each different cycle step. In general, regarding MgCl2, optimisation can be 
challenging. Increased concentration usually causes higher incorporation rate and 
efficiency for the DNA polymerase but can also make the enzyme a little less specific 
increasing the risk of incorporation errors. Also, it can further stabilise dimer formation 
allowing for mis-priming or secondary structures in the DNA template. On the other 
hand, reduced concentration can make the PCR reaction more specific, but at the 
same time less efficient producing lower yields. 
2.2.4.3 PyroMark PCR (QIAGEN) 
The PyroMark PCR kit is specifically designed and optimised for Pyrosequencing® 
analysis that promises highly specific and unbiased amplification of template DNA for 
any Pyrosequencing® application such as methylation analysis (Qiagen, 2009d). The 
unique master mix solution guarantees that the primers only bind their specific targets 
with no mis-priming possibilities because of the balanced salt combination (KCl and 
(NH4)2SO4). It also inhibits the build-up of biotinylated reverse primer excess enabling 
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reliable sequencing results. Also, the DNA polymerase used in the kit is a HotStarTaq, 
which is a modified version of the recombinant 94 kDa Taq DNA polymerase. The kit 
is provided with a novel PCR additive called Q Solution that facilitates amplification 
of difficult templates such as bisulphite-converted DNA sequences through modifying 
how DNA melts. Lastly, the kit is supplied with CoralLoad Concentrate, which not 
only assists in producing a high yield of amplified DNA, but also allows for direct 
loading onto an agarose gel without loading buffer because of its bright colour. 
The 25 µl PCR reactions were set up using either thin-walled microtubes (Anachem) 
or 96-well plates (Starlab) and consisted of 12.5 µl of PyroMark PCR Master Mix 
(2x), 2.5 µl CoralLoad Concentrate (10X), 1 µl of each primer (10 µM) (forward and 
biotinylated reverse), 5 µl of Q Solution (5X), 2 µl of DNase-free water and 1 µl of 
DNA template. No additional Mg2+ was added; therefore the final concentration was 
1.5 mM. The samples were then placed in a Veriti® thermal cycler (Life 
Technologies), which was programmed as follows: 95 oC for 15 minutes followed by 
45 cycles of 94 oC for 30 seconds, 55 oC for 30 seconds and 72 oC for 30 seconds as 
well as a final extension step of 72 oC for 10 minutes. PCR products were stored at 4 
oC prior to sequencing analysis. 
2.2.4.4 ZymoTaq™ Premix (ZymoResearch) 
Similarly, the ZymoTaq™ Premix is optimised for the amplification of bisulphite-
treated DNA for methylation detection (ZymoResearch, 2013b). A hot-start DNA 
polymerase included in the ‘master mix’ allows robust product formation by reducing 
the presence of non-specific products. The set-up of the PCR reactions is very simple 
as all required components are included in the mix apart from the primers and DNA 
template. In this study, 25 µl reactions were proposed including 12.5 µl of ZymoTaq™ 
Premix (2X), 1 µl of each primer (10 µM) for a final concentration of 0.4 µM, 1 µl of 
25 mM MgCl2 solution for a final concentration of 2.75 mM (since the ZymoTaq™ 
Premix also contains 1.75 mM MgCl2), 1 µl of DNA template and 8.5 µl of DNase-
free water. The suggested PCR cycling conditions were: 95 oC for 10 minutes 
followed by 30-45 cycles of 94 oC for 30 seconds, Tm (50-60 oC) for 30-40 seconds 
and 72 oC for 30-60 seconds as well as a final extension step of 72 oC for 7-15 minutes. 
PCR products were stored at 4 oC until sequencing analysis. 
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2.2.4.5 PowerPlex® ESI 16 (Promega) 
In this research, DNA profiling was performed in cases where the unique DNA profile 
of an individual needed to be obtained or as a proof that the body fluid samples 
originated only from one source. For example, it was particularly important to avoid 
contamination of seminal fluid in vaginal secretion swabs. For this purpose, the 
PowerPlex® ESI 16 system was chosen which allows for the co-amplification and 
four-colour detection of 16 loci (15 STRs and amelogenin), including D22S1045, 
D2S1338, D19S433, D3S1358, Amelogenin, D2S441, D10S1248, D1S1656, 
D18S51, D16S539, D12S391, D21S11, vWA, TH01, FGA and D8S1179 (Promega, 
2014). All materials necessary are included in the kit, including the hot-start Taq DNA 
polymerase, which is a built-in component of the PowerPlex® ESI 5X Master mix. In 
this study, an adjusted protocol with reduced volumes was employed. Each PCR 
reaction consisted of 2 µl of PowerPlex® ESI 5X Master mix, 1 µl of PowerPlex® ESI 
16 10X Primer Pair mix, 1 µl of template DNA (~1 ng) and 6 µl of nuclease-free water 
up to a final volume of 10 µl. For every experiment, a positive (Control DNA 007, 
Applied Biosystems) and a negative control (distilled water) were also included for 
assay assessment. The samples were then sealed and placed in a Veriti® thermal cycler 
(Life Technologies) with the following program: 96 oC for 2 minutes followed by 28 
cycles of 94 oC for 30 seconds, 59 oC for 2 minutes and 72 oC for 90 seconds as well as 
a final extension step of 60 oC for 45 minutes. PCR products were stored at 4 oC until 
fragment analysis. 
2.2.5 DNA fragment analysis 
The amplified PCR products could be detected with various techniques. In the case of 
bisulphite PCRs, a confirmation of successful amplification was needed through 
agarose gel electrophoresis. Possible non-specific amplicons could also be detected. On 
the other hand, in cases of DNA profiling, the STR amplicons could be analysed by 
capillary electrophoresis. 
2.2.5.1 Agarose gel electrophoresis 
Agarose gel electrophoresis is a very common and effective technique for the 
separation and detection of DNA fragments of varying sizes (50 bp – 25 kb) (Lee et al., 
2012b). During the gel formation, agarose polymers create a network of pores of 
[64] 
 
various sizes, which determine a gel’s properties. DNA samples are loaded in pre-cast 
wells in the gel and a current is applied. Since the phosphate backbone of DNA is 
negatively charged, the DNA fragments migrate to the positively charged anode in an 
electric field. Due to DNA’s distinctive mass-to-charge ratio, the fragments are also 
separated by size in a way that smaller molecules travel faster and more easily through 
the agarose gel pores. Dyes such as ethidium bromide or GelRed® interact with DNA 
and stain it so that it can be seen under UV light. The band intensity on the gel is 
proportional to the DNA amount, so agarose gel can also be used for quantification 
(Lee et al., 2012b). 
In this study, 3.4 g of analytical grade agarose powder (Promega) were mixed with 
170 ml of 0.5X TBE buffer (Sigma) and 17 µl of GelRed® stain (VWR) to obtain a 2% 
agarose gel. 5 µl of each PCR product were mixed with 1 µl of loading buffer (Bioline) 
and were then loaded into a well on the gel. The gel was left to run for 1 hour at 100 V 
in 0.5X TBE buffer. A size ladder of various fragments (25-500 bp) (Hyperladder™ 
25bp, Bioline) was also applied as a size reference. Once the electrophoresis was 
complete, the gel was visualised under UV light in an AlphaImager® gel 
documentation system (Alpha Innotech Corporation). The presence of a bright, dense 
single band of the expected size suggests that a PCR was successful [Figure 2-4]. 
 
Figure 2-4. Example of agarose gel electrophoresis 
This is a picture obtained by exposing a stained agarose gel under UV light. The first column 
corresponds to the DNA marker (M) consisting of various DNA fragments of known length (25-500 
bp). Columns 2-4 contain amplified DNA from various tissue sources (Blood-BL, Semen-SE, Saliva-
SA) of a particular genomic region, which is 147 bp long. As shown, all bands give a quite strong signal 
with no non-specific PCR products present. 
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2.2.5.2 Capillary electrophoresis (CE) 
As mentioned above, the STR amplicons are each labelled with a fluorescent dye that 
allows for their detection and separation. The determination of the amplicon size is 
also very important in DNA profiling as it corresponds to the number of repeats in 
each analysed STR. STR amplicons are now usually separated by capillary 
electrophoresis, which is much more sensitive than the agarose gel electrophoresis. 
PCR products can be separated firstly due to DNA’s negative charge, secondly due to 
their size (shorter PCR products are eluted first) and lastly, by their different coloured 
dye. In this project, an ABI-Prism-3130xl genetic analyser (Life Technologies) was 
used. The instrument has the ability to analyse up to 96 samples by running each 
sample through a polymer-filled (POP-7™, Life Technologies) capillary; it has 16 
capillaries so it can process 16 samples at a time. PCR products of up to 500 bp long 
can be separated within approximately 40 minutes. A laser excites the different dyes, 
whilst a charge coupled device (CCD) camera detects the emitted fluorescence. 
DNA samples are prepared in 10 µl reactions as follows: 1 µl of PCR product is mixed 
together with 8.6 µl of ultra-pure deionised formamide Hi-Di™ (Life Technologies) 
and 0.4 µl of GeneScan™ 500 LIZ® internal size standard (Life Technologies) in a 96-
well plate (Life Technologies). As a size reference, 1 µl of PowerPlex ESI 16 Allelic 
Ladder Mix (Promega) was used. The plate was capped with a septum (Life 
Technologies) and then heated for 3 minutes at 96 oC in order to denature the DNA. 
Formamide also helps in keeping DNA single-stranded. The plate was left at room 
temperature for 5 minutes before loading to the genetic analyser.  
Regarding the instrument, the instructions regarding cleaning, installing the capillary 
array, performing a spatial calibration and adding polymer were followed according to 
the manufacturer (Life Technologies, 2014). The dye set G5 (Life Technologies) was 
selected which contains five dyes that emit fluorescence at different wavelengths (blue 
6-FAM™, green VIC®, yellow NED™, red PET®, orange LIZ®). Standard injection 
and running conditions were used as shown in Table 2-4. DNA profiles were analysed 




Table 2-4. Injection and running conditions in 'FragmentAnalysis36_POP7' 
Parameters Value Range 
Oven temperature (oC) 60 18-65 
Polymer filling volume (steps) 6,500 6,500-38,000 
Current stability (uAmps) 5 0-2,000 
Pre-run voltage (kVolts) 15 0-15 
Pre-run time (sec) 180 1-1,000 
Injection voltage (kVolts) 1.2 1-15 
Injection time (sec) 23 1-600 
Voltage number of steps (nk) 20 1-100 
Voltage step interval (sec) 15 1-60 
Data delay time (sec) 60 1-3,600 
Run voltage (kVolts) 15 0-15 
Run time (sec) 1,200 300-14,000 
 
2.2.6 DNA sequencing 
Once the PCR products were checked through agarose gel electrophoresis to ensure 
successful amplification with no artefacts, they were ready for sequencing. After 
amplification, unmethylated cytosines have been transformed to thymines, while the 
methylated ones remained unchanged. This C/T variation can be treated as equivalent 
to SNP variation and be analysed with methods that are traditionally used in SNP 
analysis. Firstly, the main selected method was Pyrosequencing® technology 
(QIAGEN) as it is very sensitive and allows for successful sequencing of short 
sequences (~100bp) of the genome and secondly, next generation sequencing using 
Illumina’s MiSeq® platform was employed for multiplex sequencing. 
2.2.6.1 Pyrosequencing® 
Pyrosequencing® is a real-time DNA sequencing technology based on a luciferase 
reaction cascade (Ronaghi, 2001). Firstly, the biotin-labelled PCR product, which 
serves as the Pyrosequencing® template needs to be isolated and denatured in order for 
the sequencing primer to bind. The solution is then incubated with the enzymes 
(DNA polymerase, ATP sulfurylase, luciferase and apyrase) and the substrates 
(adenosine 5’ phosphosulfate (APS) and luciferin). Once the 
deoxynucleotidetriphospate (dNTP) complementary to the base in the template is 
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dispensed, DNA polymerase facilitates its incorporation into the DNA strand. Every 
addition is followed by the release of pyrophosphate (PPi), which is proportional to the 
amount of incorporated nucleotides [Figure 2-5a]. Subsequently, the ATP sulfurylase 
is able to convert PPi to ATP in the presence of adenosine 5’ phosphosulfate, which 
then initiates the conversion of luciferin to oxyluciferin by luciferase. This conversion 
generates visible light, which is proportional to the amount of ATP present. The light 
can be detected by a CCD camera and translated as a peak in the pyrogram™ [Figure 
2-5b]. As a result, the height of each peak is directly proportional to the number of 
nucleotides incorporated, which is proportional to the single-stranded DNA strands in 
the solution. Lastly, the nucleotide-degrading enzyme, apyrase, continuously degrades 
ATP and any unincorporated dNTPs before the next dNTP is added. As the 
sequencing process continues, the complementary DNA strand is created, whose 
nucleotide sequence can be determined from the pyrogram™ peaks [Figure 2-5c]. 
 













 Figure 2-5. The Pyrosequencing
® cascade reaction (Qiagen, 2010a) 
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2.2.6.1.1 Assay design 
Pyrosequencing® has the ability to sequence up to 100 bp; however, careful assay 
design is necessary to minimise artefacts due to events like biotinylated primer 
interference, non-specific sequencing primer binding or hairpin formation of the 
single-stranded PCR amplified template. DNA methylation assays were designed in-
house including the sequence to analyse and nucleoside dispensation order. All assays 
were up to 50 bp long as longer reactions were found to be challenging (lower peak 
signal over time). The CpG of interest and any other adjacent CpG sites were 
analysed using a sequencing primer that binds up to 5 nucleotides before the first site. 
Occasionally (especially just before the CpG site of interest), a nucleotide that is not 
expected to be incorporated was dispensed (also known as dead injection) to ensure 
that no background interactions take place. Also, at least one bisulphite-treatment 
control (non-CpG cytosine) was included in the dispensation order; however, a higher 
number of these controls are preferred to ensure complete conversion of DNA. Figure 
2-6 illustrates an example pyrogram™. 
 
Figure 2-6. Example pyrogram™ 
The picture illustrates an example pyrogram™ of HBA1 CpG assay that analyses the following 
bisulphite converted sequence: TTYGYGTTGTAGGYGTYG including four CpG sites in total 
(marked with yellow). The peak height corresponds to the number of nucleotides that are being 
incorporated at each injection (for example, if the next bases in the sequence are three Ts – quite 
common in bisulphite-converted sequences – the peak height will be three times as high as the one 
produced by only one T). Therefore, the peak heights of the reference peaks (indicated with the red 
arrows) can reveal the sequence being analysed. Green arrows indicate dead injections – nucleotides 
being dispensed but not incorporated. Also, the blue box illustrates the bisulphite-treatment control 
which is a non-CpG cytosine that is expected to be converted during bisulphite treatment. Therefore, a 
peak for the ‘C’ dispensation could indicate incomplete conversion (<5% is accepted by the software’s 
settings). Lastly, for each CpG site, both thymine and cytosine are released and peak heights are 
compared allowing for absolute quantification of methylation.  
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2.2.6.1.2 Performance assessment 
For every new assay that was designed, a few carefully selected controls were run in 
order to check for any undesirable interaction between the Pyrosequencing® 
components. These controls were extra Pyrosequencing® reactions that were added to 
the first run and consisted of annealing buffer and the following: (a) the biotinylated 
primer (reverse) only, (b) the template only (PCR product), (c) the sequencing primer 
only and lastly, (d) the biotinylated primer together with the sequencing primer to 
assess for any primer-primer interactions. If there was background signal, the 
Pyrosequencing® assay was optimised by either adding less biotinylated primer or 
adding more PCR product. In cases where optimising the above parameters still 
resulted in unwanted reactions, the assay was redesigned. 
2.2.6.1.3 Pyrosequencing® reaction preparation 
In order for the sequencing primer to bind onto the template DNA, the latter has to be 
single-stranded. This can be achieved via biotin-streptavidin selective binding; 10 µl of 
PCR products were mixed with 3 µl of Streptavidin Sepharose High Performance 
Beads (GE Healthcare) and 37 µl of PyroMark Binding Buffer (QIAGEN) as well as 
30 µl of distilled water for a total volume of 80 µl. The solutions were then vortexed at 
1,000 rpm for 30 minutes using a clear non-skirted 96-well plate (Starlab) to allow for 
efficient binding of the PCR products to the beads. Afterwards, the beads were 
isolated and captured utilising a Vacuum Prep Workstation (QIAGEN). This is a 
simple, specifically-designed preparation tool and consists of a hand-held vacuum prep 
tool and a vacuum prep worktable with five solution trays connected to a vacuum 
source.  
The principle underlying this bench-top workflow is that the suction caused by the 
applied vacuum picks up the immobilised PCR products while the rest of the solution 
is aspirated. While the beads are kept attached to the end of the filter probes of the 
hand-held tool, they can be cleaned up and denatured in a few steps. The first tray was 
filled up with 70% ethanol and the probes were washed for 5 seconds in order to 
remove any undesired leftovers. The second wash was performed using 0.2 M sodium 
hydroxide (NaOH) for 5 seconds to denature the PCR products and filter out the non-
biotinylated amplicon strands. Lastly, the third step involved rinsing the probes with 
PyroMark Wash buffer for 10 seconds. The single-stranded templates were now ready 
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so they were transferred to a previously prepared Pyrosequencing® plate (QIAGEN) 
containing 11.5 µl of PyroMark Annealing buffer (QIAGEN) and 0.5 µl of the 
appropriate 10 µM sequencing primer. This was achieved by placing the device above 
the plate, turning the vacuum off and gently shaking the probes until all beads were 
released into the relevant wells. To ensure complete denaturation of the DNA 
templates, the plate was also heated at 80 oC for 3 minutes. It was then left at room 
temperature for 5 minutes in order for the sequencing primer to bind; the plate was 
then ready to be analysed using a PyroMark MD Pyrosequencer (QIAGEN). All four 
nucleotides together with the enzymes and substrates (PyroMark Gold Q96 reagents, 
QIAGEN) were placed into the instrument before analysis following the 
manufacturer’s instructions (Qiagen, 2009c). 
2.2.6.2 Next generation sequencing using Illumina MiSeq® platform 
Although the potential of Sanger sequencing and Pyrosequencing® has been widely 
exploited by many laboratories worldwide, it has yet always been hampered by certain 
limitations in throughput, scalability, speed and resolution. To overcome these barriers 
and explore its capabilities, a recently developed and fundamentally new technology 
known as next generation sequencing (NGS) was employed (Illumina, 2013a). In 
principle, the NGS technology utilises a similar concept, where small DNA fragments 
are being identified from signals released while they are being re-synthesised using a 
DNA template. However, scientists are able to extend the sequencing process across 
millions of reactions in a massively parallel way allowing for rapid sequencing of DNA 
fragments spanning the entire genome.  
For this study, a targeted sequencing approach was chosen, where a subset of selected 
genomic regions was sequenced in order to further validate reported DNA 
methylation sites. The ability to pool together multiple samples and obtain high 
sequence coverage in one single run allowed for simultaneous analysis of up to 
hundreds of genomic loci. Although various genome-wide DNA methylation studies 
using Illumina’s Infinium HumanMethylation 27K/450K BeadChip arrays have been 
published, there is only one study that explored the potential of Illumina MiSeq® next 
generation sequencing system for locus-specific DNA methylation analysis (Masser et 
al., 2013). Authors reported that they could rapidly and accurately quantify absolute 
CpG methylation levels from as low as 1 ng of starting DNA material. 
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2.2.6.2.1 Assay design 
For this project, an adjusted version of a protocol that is still at the development stage 
(not commercially available) was employed (TruSeq Forensic Amplicon, Illumina). 
The proposed protocol allows for simultaneous sequencing by synthesis of up to 24 
DNA libraries in a single reaction. The input DNA is in the form of PCR amplicons 
(70-300 bp long) that have been previously amplified using ~1 ng of genomic DNA 
and highly specific, unlabelled PCR primers. The aim is to attach adapter sequences to 
these PCR amplicons for subsequent cluster generation and sequencing. An overview 
of sample preparation is illustrated in Figure 2-7. Even though this protocol has been 
designed to mainly investigate genetic variations (SNPs) that are of forensic interest, in 
this study it was used to quantify age-associated CpG sites (C/T variation). By 
integrating six-base sample indexes into the protocol, both loci and samples can be 
multiplexed. Standard assay design parameters such as the addition of built-in 
bisulphite conversion controls were followed as described earlier in the chapter. 
2.2.6.2.2 PCR input and quantification 
It is important to quantify the input PCR product and assess the DNA quality before 
sample preparation as too much or too little input could result in library preparation 
failure. 1-100 ng amplified DNA is generally recommended using fluoremetric-based 
(and not UV spectrophotometric-based) quantification methods like Qubit™ or 
PicoGreen. Quantification methods that rely on intercalating fluorescent dyes measure 
only double-stranded DNA (PCR products) and can be less subject to the presence of 
common contaminants present in the solution such as salts, free nucleotides or 
proteins. PCR products used in this protocol were prepared as described in section 
2.2.4.4 (ZymoTaq™ Premix, ZymoResearch) by amplifying 1 ng of bisulphite-treated 
DNA. The different PCR products were pooled together before analysis. 
Qubit™ dsDNA HS Assay (Life Technologies) 
The Qubit™ dsDNA High Sensitivity assay kit (Invitrogen, 2010) allows easy and 
accurate DNA quantification at room temperature by employing an assay reagent and 
two pre-diluted DNA standards. DNA concentrations are read by a Qubit™ 2.0 




Figure 2-7. TruSeq Forensic Amplicon sample preparation workflow 
Firstly, the Qubit™ working solution was prepared by diluting the Qubit™ dsDNA HS 
reagent 1:200 in Qubit™ dsDNA HS buffer. The final volume of each tube was 200 µl 
by mixing 190 µl of Qubit™ working solution and 10 µl of each Qubit™ standard or 199 
µl of Qubit™ working solution and 1 µl of PCR product. All tubes were mixed by 
vortexing for 2-3 seconds and left at room temperature for at least 2 minutes. A 
standard calibration curve was created using the two standards and all measurements 
for the samples were performed in duplicate. The Qubit™2.0 Fluorometer gives a 
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concentration value in ng/ml considering the dilution of the assay tube by using the 
following formula: 
Concentration = QF value * (200/x), where 
QF value is the value given by the Qubit™ 2.0 Fluorometer and x is the number of 
microliters of sample added to the assay tube (1 µl). PCR products were normalised to 
a final volume of 50 µl at 20-2,000 pg/µl (optimum amount for library preparation) 
and solution were transferred to the wells of a new 96-well 0.3 ml PCR plate. 
2.2.6.2.3 Repair of 5’ ends 
This step converts the 5’ overhangs caused by incomplete polymerisation during PCR 
into blunt ends and phosphorylates 5’ ends using an End-Repair mix. For this step, 
reagents from the TruSeq ChIP Sample Prep kit (Illumina) were used. Briefly, 10 µl of 
Resuspension buffer (Illumina) were added to each sample containing 50 µl PCR 
DNA (1-100 ng). 40 µl of End-Repair mix (Illumina) were then added to each well 
and pipetting of the entire volume up and down ten times was performed to mix 
thoroughly. The PCR plate was sealed and incubated on a pre-heated Veriti® thermal 
cycler (Life Technologies) at 30 oC for 30 minutes. Following incubation, 180 µl of 
well-dispersed AMPure XP Beads (Beckman Coulter Genomics) were added to each 
well containing 100 µl of End-Repair mix. The solutions were thoroughly mixed by 
pipetting and incubated at room temperature for 5 minutes. 
In order to separate the magnetic beads, the PCR plate was placed on a magnetic stand 
at room temperature for 15 minutes until the liquid was clear. Then, the supernatant 
was discarded and some wash steps were performed. While the PCR plate is still on 
the magnetic stand, 200 µl of freshly-prepared 80% absolute ethanol (Sigma-Aldrich) 
were added to each well without disturbing the beads. The solutions were left at room 
temperature for 30 seconds before the supernatant was removed. The wash step was 
repeated once more for a total of two 80% absolute ethanol washes. It is important that 
the PCR plate is completely dry before it is taken off the magnetic stand, so it was left 
for at least 10 minutes at room temperature. Lastly, to resuspend the dried pellets, 17.5 
µl of Resuspension buffer was added and the solutions were homogenised by pipetting 
up and down ten times. Following a 2 minute-incubation at room temperature, the 
PCR plate was placed back on the magnetic stand until the liquid was clear again. A 
[74] 
 
total of 15 µl of the clear supernatant from each well was transferred to a new 96-well 
0.3 ml PCR plate. The plate could then be stored at -20 oC for up to 7 days before 
proceeding to the next stage.  
2.2.6.2.4 Adenylation of 3’ ends 
During this process, a single adenine (-A-) nucleotide is added to the 3’ ends of the 
generated blunt fragments in order to prevent them from ligating to each other during 
the adapter ligation reaction. Also, a corresponding single thymine (-T-) nucleotide on 
the 3’ end of the adapter provides a complementary overhang for ligating the adapter 
to the fragment. For this step, reagents from the TruSeq ChIP Sample Prep kit 
(Illumina) were used. In brief, 2.5 µl of Resuspension buffer (Illumina) and 12.5 µl of 
thawed A-Tailing mix (Illumina) were added to each well of the PCR plate and mixed 
by pipetting. The plate was sealed and placed on a Veriti® thermal cycler (Life 
Technologies) for a total of two incubations; 37 oC for 30 minutes followed by 70 oC 
for 50 minutes. It is essential that the next step is immediately followed. 
2.2.6.2.5 Ligation with multiple indexing adapters 
This step ensures that multiple indexing adapters are ligated to the ends of the DNA 
fragments, preparing them for hybridisation on a flow cell. For this step, reagents from 
the TruSeq ChIP Sample Prep kit (Illumina) were used; it should be noted that there 
are two sets of RNA Adapter Indexes available shown in Table 5. Before starting the 
procedure, it is important to completely thaw and centrifuge the RNA adapters. 
Table 2-5. Set A and B Indexed adapter sequences (Illumina) 
RNA adapter Indexes A Sequence RNA adapter Indexes B Sequence 
A002 CGATGT A001 ATCACG 
A004 TGACCA A003 TTAGGC 
A005 ACAGTG A008 ACTTGA 
A006 GCCAAT A009 GATCAG 
A007 CAGATC A010 TAGCTT 
A012 CTTGTA A011 GGCTAC 
A013 AGTCAA A020 GTGGCC 
A014 AGTTCC A021 GTTTCG 
A015 ATGTCA A022 CGTACG 
A016 CCGTCC A023 GAGTGG 
A018 GTCCGC A025 ACTGAT 




Briefly, 2.5 µl of Resuspension buffer (Illumina) together with 2.5 µl of Ligation mix 
(Illumina) were added to each well of the PCR plate. It is important that the ligation 
mix is returned to -20 oC immediately after use. Afterwards, 2.5 µl of each RNA 
Adapter Index was added to the corresponding well and mixed with pipetting. The 
plate was sealed and centrifuged at 280 g for 1 minute to collect any drops on the walls 
of the tubes. The solutions were then incubated at 30 oC for 10 minutes and the 
ligation process was inactivated by adding 5 µl of Stop Ligation buffer. 
The second part of this step includes the clean-up and resuspension using the magnetic 
beads. 59.5 µl of well-dispersed AMPure XP Beads (Beckman Coulter Genomics) 
were added to each well of the PCR plate, which was then left at room temperature for 
at least 5 minutes. In order to separate the magnetic beads, the PCR plate was placed 
on a magnetic stand at room temperature for 5 minutes until the liquid was clear. 
Then, the supernatant was discarded and some wash steps were performed. While the 
PCR plate was still on the magnetic stand, 200 µl of freshly-prepared 80% absolute 
ethanol (Sigma-Aldrich) was added to each well without disturbing the beads. The 
solutions were left at room temperature for 30 seconds before the supernatant was 
removed. The wash step was repeated once more for a total of two 80% absolute 
ethanol washes. It is important that the PCR plate is completely dry before it is taken 
off the magnetic stand, so it was left to air-dry.  
To resuspend the dried pellets, 52.5 µl of Resuspension buffer was added and the 
solutions were homogenised by pipetting up and down ten times. Following a two-
minute incubation at room temperature, the PCR plate was placed back on the 
magnetic stand until the liquid was clear again. A total of 50 µl of the clear supernatant 
from each well was transferred to a new 96-well 0.3 ml PCR plate. The above 
procedure was repeated once more by using 70 µl of well-dispersed AMPure XP 
Beads and following the same steps. The dried pellets were resuspended by adding 
22.5 µl of Resuspension buffer and finally, a total of 20 µl of the clear supernatant from 
each well was transferred to a new 96-well 0.3 ml PCR plate. The plate could then be 




2.2.6.2.6 Enrichment of DNA fragments 
The last step of the library preparation includes the enrichment via PCR of the DNA 
fragments with adapter molecules on both ends. Fragments with only one or no 
adapters are by-products of inefficiencies during the ligation reaction. This PCR is 
performed with the PCR Primer Cocktail that anneals to the ends of the adapters. To 
retain library representation, the number of PCR cycles was kept to the minimum. For 
this step, reagents from the TruSeq ChIP Sample Prep kit (Illumina) were also used. 
5 µl of thawed PCR Primer Cocktail (Illumina) was added to each well, followed by 
the addition of 25 µl of PCR Master mix (Illumina). Solutions were mixed thoroughly 
by pipetting up and down ten times and the plate was then sealed and placed on a 
thermal cycler. The following program was used: 98 oC for 30 seconds followed by 18 
cycles of 98 oC for 10 seconds, 60 oC for 30 seconds and 72 oC for 30 seconds and a 
final extension step at 72 oC for 5 minutes. Following incubation, 50 µl of well-
dispersed AMPure XP Beads (Beckman Coulter Genomics) was added to each well 
containing 100 µl of End-Repair mix. The solutions were thoroughly mixed by 
pipetting and incubated at room temperature for 5 minutes.  
The PCR plate was then placed on a magnetic stand at room temperature for 15 
minutes until the liquid was clear. Then, the supernatant was discarded and some wash 
steps were performed. While the PCR plate was still on the magnetic stand, 200 µl of 
freshly-prepared 80% absolute ethanol (Sigma-Aldrich) were added to each well 
without disturbing the beads. The solutions were left at room temperature for 30 
seconds before the supernatant was removed. The wash step was repeated once more 
for a total of two 80% absolute ethanol washes. It is important that the PCR plate is 
completely dry before it is taken off the magnetic stand, so it was left to air-dry.  
Solutions were resuspended by adding 32.5 µl of Resuspension buffer were added and 
the solutions were homogenised by pipetting up and down ten times. Following two-
minute incubation at room temperature, the PCR plate was placed back on the 
magnetic stand until the liquid was clear again. A total of 30 µl of the clear supernatant 
from each well was transferred to a new 96-well 0.3 ml PCR plate. The plate could 




2.2.6.2.7 Evaluation of generated libraries 
In order to achieve the highest quality data on the MiSeq® sequencing platform, it is 
essential that the optimal cluster density across all lanes of the flow cell is achieved. 
Therefore, it is a requirement that the DNA library templates are accurately 
quantified. There are two options available, one including a qPCR assay (KAPA 
Biosystems) and the other one using a Bioanalyzer (Agilent Technologies) and the 
High Sensitivity DNA chip. For this study, libraries were evaluated using the KAPA 
Library quantification kit for Illumina sequencing platforms as qPCR specifically 
quantifies only PCR-competent DNA molecules and is highly sensitive allowing for 
accurate quantification of low concentration libraries (KAPABiosystems, 2014). 
Briefly, 1 ml of Illumina Primer premix (10X) was mixed with 5 ml of KAPA SYBR® 
FAST qPCR Master mix to prepare the qPCR/Primer mix. dsDNA libraries were 
diluted 1:2000 in 10 mM Tris-HCl, pH 8.0 + 0.05% Tween 20 (Sigma-Aldrich) (total 
volume of 2,000 µl). For each 10 µl reaction, 6 µl of the qPCR/Primer mix were mixed 
with 4µl of the diluted DNA library or DNA standards (supplied in the kit, 
concentration range 20-0.0002 pM). All reactions were performed in duplicate. The 
qPCR protocol included an initial activation/denaturation step at 95 oC for 5 minutes 
followed by 35 cycles of 95 oC for 30 seconds and 60 oC for 30 seconds. 
The obtained concentrations were adjusted using the average fragment length and the 
following formula: 
Final concentration (pM) = Average concentration (pM) * (452/Average fragment 
length) * 2000 
2.2.6.2.8 Normalisation and cluster generation 
This step describes how DNA templates are prepared for cluster generation. Indexed 
DNA libraries were normalised to 10 nM using Tris-HCl 10 mM, pH 8.5 with 0.1% 
Tween 20. 10 µl of the sample libraries from each well of the PCR plate were pooled 
for a total volume of 240 µl. The entire normalised library was gently mixed by 
pipetting up and down ten times. 
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2.2.6.2.9 Library dilution for sequencing on the MiSeq® 
This step explains how to denature and dilute libraries after sample preparation to 
prepare them for sequencing on the MiSeq® platform including the preparation of the 
PhiX control. The latter is important when analysing low-diversity libraries – libraries 
where a significant number of reads have the same sequence. Using the PhiX control 
prevents potential shifting of the base composition due to the reads being no longer 
random. Firstly, 1 ml of 0.2 N NaOH was freshly prepared before each run by mixing 
800 µl of laboratory-grade water and 200 µl of stock 1.0 N NaOH. A fresh solution is 
required to ensure efficient denaturation of the libraries. Next, libraries were further 
diluted down to 4 nM; by mixing 5 µl of the diluted libraries (4 nM) with 5 µl of 0.2 N 
NaOH. The solution was mixed by vortexing and left at room temperature for at least 
5 minutes to obtain single-stranded DNA. 990 µl of pre-chilled Hybridisation buffer 
(HT1) (Illumina) was then mixed with 10 µl of the denatured DNA, which results in 
20 pM denatured libraries in 1 mM NaOH. However, libraries should be further 
diluted to give 600 µl of the desired input concentration as follows: 
Final Concentration 6 pM 8 pM 10 pM 12 pM 15 pM 20 pM 
20 pM denatured DNA (µl) 180 240 300 360 450 600 
HT1 buffer (µl) 420 360 300 240 150 0 
 
The 10 nM PhiX control library was prepared to 20 pM. Firstly, 2 µl of the provided 
10 nM Phix library were mixed with 3 µl of 10 mM Tris-HCl, pH 8.5 with 0.1% 
Tween 20. Then, 5 µl of the 4 nM PhiX library were added to 5 µl of 0.2 N NaOH 
and incubated for at least 5 minutes at room temperature to ensure complete 
denaturation. Lastly, to obtain a 20 pM PhiX library the above 10 µl denatured library 
was mixed with 990 µl of pre-chilled HT1 Hybridisation buffer. Illumina recommends 
a low-concentration PhiX control spike-in at a minimum 5% for low-diversity 
libraries. Therefore, 60 µl of the denatured and diluted PhiX control was mixed with 
540 µl of the sample library for a final volume of 600 µl. The preparation of the pre-
filled, reagent cartridge and flow cell (Illumina) and the set-up of the instrument were 
followed according to the manufacturer’s instructions (Illumina, 2013b). It should be 
noted that the instrument was set up to run a paired-end read of 150 bp of DNA 
sequence from both ends of the library products. Data was entered in the sample sheet 
to link each sample with the corresponding ligated RNA adapter. Auto analysis was 
set up as a FASTQ-only method. 
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2.3 RNA analysis 
RNA was extracted and analysed for the purpose of mRNA profiling for body 
fluid/tissue identification. 
2.3.1 DNA/RNA co-extraction 
Since DNA is essential for the identification of a body fluid stain’s donor, the method 
to be selected for RNA extraction should allow for simultaneous isolation of both 
nucleic acids. Similarly with the sole DNA extraction, body fluid samples were either 
in a liquid form, deposited on a swab or on a surface (fabric, glass). The whole of these 
swabs or stains was used to co-extract DNA and RNA from cellular material. The 
method used in this study was the AllPrep DNA/RNA mini kit (QIAGEN). 
2.3.1.1 AllPrep DNA/RNA mini (QIAGEN) 
The AllPrep DNA/RNA mini kit allows for simultaneous purification of genomic 
DNA and total RNA from a single cell or tissue sample. The method’s principle is 
based on the fact that lysate is first passed through an AllPrep DNA spin column to 
selectively isolate DNA and then through an RNeasy spin column to selectively bind 
RNA [Figure 2-8]. Depending on the homogenisation conditions, purified DNA 
usually has an average length of 15-30 kb, while the general procedure allows for the 
isolation of RNA molecules longer than 200 nucleotides. This results in an enrichment 
of mRNA, since most <200 bases RNAs (such as rRNAs and tRNAs) are carefully 
removed. The protocol can be adjusted depending on the type of starting material and 
more information can be found in the relevant handbook (Qiagen, 2005). 
In this study an adjusted version of the protocol ‘Simultaneous purification of genomic 
DNA and total RNA from animal cells’ was employed. Before any extraction was 
performed, all bench surfaces, pipettes and consumables were sprayed with 
RNaseZap® RNase decontamination solution (Life Technologies) to prevent possible 
RNA degradation by contaminating, free RNases. Additionally, 10 µl of ß-
mercaptoethanol (ß-ME) (Sigma-Aldrich) was added to 1 ml of buffer RLT Plus 
(QIAGEN) in order to ensure sufficient cell lysis. According to the manufacturer, 
carrier RNA (1 µg/µl) (QIAGEN) was used to enhance DNA binding onto the 
membrane. The carrier RNA working solution was made up as follows; firstly, 2.5 µl 
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of carrier RNA was mixed with 17 µl of buffer RLT Plus and then, the solution was 
further diluted ten times. 
 
Figure 2-8. Overview of the AllPrep DNA/RNA Procedure (Qiagen, 2005) 
Briefly, the stains or swabs were cut using sterile scissors or a scalpel; in case of a 
‘touch’ sample or where the stain was not visible, a swab was moistured with 50 µl of 
RNase-free water and used to swab the ‘suspected’ area. Cotton swabs or stains were 
transferred to a clean 1.5 ml tube and 345 µl of RLT buffer Plus with ß-ME as well as 
5 µl of carrier RNA working solution were added. The samples were mixed by 
vortexing for at least 30 seconds followed by incubation at 56 oC for up to 3 hours. 
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Once incubation was complete, suitable spin baskets (DNA IQ™ spin basket, 
Promega) were applied to dry out any material on the swab/cotton material by 
centrifuging at 13,000 rpm for 5 minutes. Lysates were firstly transferred to the DNA 
spin columns (violet) and centrifuged at 11,000 rpm for 30 seconds. As mentioned in 
Figure 2-8, DNA binds to the membrane of the columns, while RNA passes through 
the flow-through. Regarding RNA isolation, the flow-through samples were mixed 
with 350 µl of freshly-made 70% ethanol and the solutions were mixed by pipetting up 
and down ten times. The solutions were then transferred to the RNA spin columns 
(pink) and centrifuged at 11,000 rpm for 30 seconds. The flow-through was discarded 
since RNA was bound onto the column membrane. 700 µl of RW1 buffer (QIAGEN) 
were added to the columns, which were then centrifuged at 11,000 rpm for 15 
seconds. The spin columns were placed in new collection tubes and 500 µl of RPE 
buffer (QIAGEN) was added followed by centrifugation at 11,000 rpm for 30 seconds. 
This step was repeated once more. Spin columns were centrifuged at maximum speed 
for 1 minute to ensure that membranes had completely dried out. RNA was eluted by 
applying 30 µl of RNase-free water to the centre of the membrane, incubating at room 
temperature for 5 minutes and centrifuging at 11,000 rpm for 1 minute. In suspected 
low-quantity samples, the solution was reloaded back to the column and the elution 
step was repeated to maximise RNA yield. 
Regarding DNA isolation, 500 µl of AW1 wash buffer (QIAGEN) was added to the 
DNA spin columns, which were then centrifuged at 11,000 rpm for 15 seconds. 
Another 500 µl of AW2 wash buffer was added and solutions were centrifuged at 
maximum speed (14,000 rpm) for 2 minutes to completely wash and dry the 
membranes. DNA was eluted by applying 40-80 µl to the centre of the membrane, 
incubating at room temperature for 1 minute and centrifuging at 11,000 rpm for 1 
minute. Both RNA and DNA samples were stored at -20 oC until analysis. 
2.3.2 DNase treatment 
Even though the above protocol promises DNA and RNA separation, extracted RNA 
samples might contain contaminating DNA traces, which are likely to interfere with 
downstream analysis. Therefore, it is essential to remove any DNA present in the 
RNA samples by using DNase. Preferably, this step should follow immediately after 
RNA extraction.  
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2.3.2.1 TURBO™ DNA-free kit (Ambion) 
For this study, the TURBO™ DNA-free kit was used (Ambion, 2012). Briefly, 30 µl of 
RNA solutions were mixed with 3 µl (0.1 of RNA volume) of 10X TURBO™ DNase 
buffer (Ambion) and 1 µl of TURBO™ DNase (Ambion) followed by incubation at 37 
oC for 30 minutes. 3.4 µl (0.1 volume) of DNase Inactivation reagent (Ambion) were 
then added to inactivate the enzyme and solutions were incubated at room 
temperature for 5 minutes while mixed a few times by vortexing. Following 
incubation, RNA solutions were centrifuged at 10,000 rpm for 90 seconds; the 
inactivation reagent forms a visible, white pellet. Approximately 32 µl were then 
transferred to a new 1.5 ml tube. DNA-free RNA solutions were stored at -20 oC until 
needed. 
2.3.3 Synthesis of complementary DNA (cDNA) 
It is important that mRNA is converted to cDNA so that the latter can be analysed by 
means of reverse transcription PCR (RT-PCR). Complementary DNA (cDNA) is the 
DNA synthesised using the mRNA as a template in a reaction catalysed by an enzyme 
known as reverse transcriptase. In general, cDNA can be synthesised using either total 
RNA or poly(A)+-selected RNA primed with oligo(dT), random primers, or a gene-
specific primer. Random hexamers are the most non-specific priming method and are 
usually employed when the mRNA is difficult to copy in its entirety (due to low 
quality/quantity). Therefore, in this study, using random primers, all RNAs in a 
population could be used as templates for cDNA synthesis. Also, it was suggested that 
up to 40% of extracted RNA is used for cDNA synthesis. 
2.3.3.1 SuperScript® III First-Strand Synthesis system (Invitrogen) 
In this project, the SuperScript® III First-Strand Synthesis system for RT-PCR was 
employed according to the manufacturer’s instructions (Invitrogen, 2013). Using this 
protocol, RNA targets from 100 bp to >12 kb can be detected and the amount of 
starting material can vary from 1 pg to 5 µg of total RNA. All reagents mentioned in 
this section were included in the kit. Briefly, 12 µl of DNA-free RNA solutions were 
mixed with 4 µl of RNase-free water, 2 µl of 10mM dNTP mix and 2 µl of random 
primers (2.5 ng/µl) for a total volume of 20 µl. The solutions were incubated at 65 oC 
for 5 minutes and were immediately placed on ice for at least 1 minute. For each 
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reaction, the following reagents were used: 4 µl of 10X RT buffer, 8 µl of 25 mM 
MgCl2, 4 µl of 0.1 M DTT and 2 µl of RNaseOUT™ (40 U/µl). All reagents were 
mixed well by vortexing and added to the 20 µl of RNA/primer mixture for a total 
volume of 38 µl. To create the RT+ and RT- controls, each reaction was divided into 
two tubes (19 µl each) and either 1 µl of SuperScript® III RT (200 U/µl) or 1 µl of 
RNase-free water was added. cDNA synthesis was performed as follows; incubation at 
25 oC for 10 minutes followed by an incubation at 50 oC for 50 minutes. Reactions 
were terminated by heating the samples at 80 oC for 5 minutes. By adding 1 µl of 
RNase H to each tube, any RNA left could be eliminated. cDNA samples were stored 
at -20 oC until further analysis. 
2.3.4 RT-PCR 
Regarding the amplification of complementary DNA, standard PCR parameters can 
be applied as previously mentioned in section 2.2.4. However, it should be noted that 
one of the most important assay design parameters in this type of analysis is the primer 
design, as co-amplification of contaminating genomic DNA should be avoided. 
Therefore, RT-PCR primers were designed to span an exon-to-exon boundary. In this 
study, all used primers together with PCR guidelines were sent by the collaborating 
laboratories. Details on the PCR set up and cycling conditions of each assay tested can 
be found in Chapter 4. 
2.3.5 Post-PCR product purification 
Following amplification, RT-PCR products can be purified to eliminate excess primer 
and dNTPs or any other small molecule present in the solution that could affect 
downstream analysis. Using post-PCR product purification, amplicons can also be 
concentrated by decreasing the elution volume. It should be noted that only fragments 
<40 bp are removed, therefore PCR products should be at least 70 bp long to ensure 
successful recovery. 
2.3.5.1 MinElute PCR purification (QIAGEN) 
In this study, the MinElute PCR purification kit was used according to manufacturer’s 
conditions (Qiagen, 2008). The system is specially designed for fast and easy isolation 
of DNA fragments offering an extremely small elution volume of only 10 µl. The 
method is based on the selective binding properties of a uniquely designed silica 
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membrane that allows the purification of 70 bp – 4 kb long DNA fragments. DNA 
adsorbs to the silica membrane in the presence of high concentrations of salt while 
contaminants pass through the column. Impurities are eventually washed away and the 
pure DNA is eluted with Tris buffer or water (~80% recovery). 
Briefly, 125 µl of Buffer PB (QIAGEN) were added to 25 µl of PCR product and the 
solutions were mixed by pipetting. They were then transferred to the MinElute 
columns and centrifuged at maximum speed (14,000 rpm) for 1 minute. A washing 
step was performed by adding 750 µl of Buffer PE (QIAGEN) and centrifuging at 
maximum speed (14,000 rpm) for 1 minute. Columns were dried out by centrifugation 
for another minute. DNA fragments were eluted by adding 10 µl of buffer EB 
(QIAGEN) to the centre of the membrane, incubating at room temperature for 1 
minute and centrifuging at maximum speed (14,000 rpm) for 1 minute. Purified PCR 
products were stored at -20 oC. 
2.3.6 cDNA fragment analysis 
PCR products were separated and analysed using capillary electrophoresis as 
described in section 2.5.2.2. Similarly with STR amplicons, PCR products were 
fluorescently labelled with various dyes and could be successfully identified by their 
expected fragment length. The adjusted CE parameters are illustrated in Table 2-6. 
Table 2-6. Injection and running conditions for cDNA fragment analysis 
Parameters Value Range 
Oven temperature (oC) 60 18-65 
Polymer filling volume (steps) 6,500 6,500-38,000 
Current stability (uAmps) 5 0-2,000 
Pre-run voltage (kVolts) 15 0-15 
Pre-run time (sec) 180 1-1,000 
Injection voltage (kVolts) 3 1-15 
Injection time (sec) 10 1-600 
Voltage number of steps (nk) 40 1-100 
Voltage step interval (sec) 15 1-60 
Data delay time (sec) 1 1-3,600 
Run voltage (kVolts) 15 0-15 
Run time (sec) 1,800 300-14,000 
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2.4 Data analysis 
This section describes the main methods used in this project regarding data analysis. 
2.4.1 DNA methylation data 
2.4.1.1 Identification of CpG chromosomal locations 
Once specific CpG sites had been selected for analysis, the online Ensembl genome 
browser and in particular the Human (Homo sapiens) Feb 2009 (GRCh37/hg19) 
genome was used to obtain the required genetic information for assay design 
(http://www.ensembl.org/index.html). Their exact chromosomal locations were 
confirmed and the surrounding DNA sequences were identified. Information on the 
genes and their function as well as known SNPs included in the regions of interest was 
also obtained. DNA sequences and locations were also verified using a second online 
browser, the UCSC genome browser (http://genome.ucsc.edu/). An area of around 
500 bp spanning each CpG of interest was used for bisulphite PCR assay design. 
2.4.1.2 Pyrosequencing® data analysis 
This section will describe how methylation data obtained by Pyrosequencing® was 
analysed assuming that pyrograms™ passed the instrument’s quality control. This 
included the detection of desired peaks (no signals in dead injections) as well as 
detected bisulphite conversion rates of >95%. For each CpG site the degree of 
methylation was measured as a frequency of C/T signals in the form of peak heights. 
Pyrosequencing® dispenses both thymine (T) and cytosine (C) for each CpG site; the 
peak height of thymine corresponds to the unmethylated sequence (C), whereas the 
peak height of cytosine corresponds to the methylated sequence (mC). In the initial  
Pyrosequencing® assay development, standard software used for SNP variation 
analysis, PyroMark Q96 MD software was used. For this, methylation levels had to be 
calculated manually by the ratio of mC:C at each CpG site using the following 
formula: 
% Methylation = [(peak height C)/(peak height C + peak height T)] * 100 
There were cases where the peak for the unmethylated cytosines (T signal) of a CpG 
site coincided with the peak of other Ts including converted non-CpG cytosines. In 
these cases, the average peak height was calculated taken into account all peaks 
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included in the pyrogram™ and subtracted from the obtained T signal as many times as 
the number of non-CpG sites included. It was understood that manual calculation 
could result in inaccuracies, thus CpG methylation software, PyroMark CpG SW 1.0 
software (QIAGEN) was then employed. This software has been specifically 
developed for DNA methylation analysis and uses an algorithm for calculating 
methylation levels. One versus multiple peak effect did not impact either the resulting 
peak height calls or the reported methylation values as the software accounts for such 
effects. 
2.4.1.3 MiSeq® data analysis 
This section will describe how methylation data generated by Illumina’s next 
generation sequencing platform was analysed assuming that methylation profiles 
passed the instrument’s quality control. Firstly, auto-analysis by the MiSeq® Reporter 
Software separated the millions of generated sequences into the constituent samples on 
the basis of the ligated adaptor tags that were unique to each sample in the library.  
These collated sequences were packaged in a text-based format (FASTQ files), with 
each sample associated with two of these FASTQ files, one for sequences generated 
during the forward read and one for those produced during the reverse read. FASTQ 
is a modification of a FASTA file to include quality data as well as sequence. 
Sequences within these FASTQ files were aligned to the previously created custom 
genome using a Burrows-Wheeler alignment (BWA) algorithm. This process was 
implemented in the BWA program (Li & Durbin, 2010) using the maximum entropy 
method (MEM) algorithm that matched the sequences generated to the respective 
methylation marker (i.e. a sequence obtained from the PCR product of any specific 
marker would be most similar to the reference sequence for that marker, and hence the 
software would align this sequence with that marker).  In the case of bisulphite 
sequencing, in order to create the custom reference genome (DNA sequences of all 
markers) that the generated sequences would align to, one has to make certain 
assumptions. These inlcude the assumption that all non-CpG cytosines had been 
converted to thymines following bisulphite conversion and PCR, and also that all CpG 
cytosines were methylated, therefore remained cytosines during analysis (Appendix 
IV). It should be noted that no difference in the reported methylation levels was 
observed when assuming all CpG sites in the amplicons were unmethylated. In this 
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way, the millions of sequences contained within the FASTQ file can be associated 
with their respective marker, giving potentially hundreds of thousands of individual 
sequences all aligned in parallel to a specific reference sequence/marker. At the 
conclusion of this alignment process, a sequence alignment/map (SAM) file was 
produced, which was further modified using SAM tools (Li et al., 2009) to convert it 
into a BAM file. 
The Genome Analysis Toolkit (GATK) (McKenna et al., 2010)  was subsequently 
used to interrogate this BAM file by targeting specific positions in these aligned 
sequences (i.e. at each CpG site) and reporting the number of sequences containing a 
C and the number of sequences containing a T at this position.  In this way it was 
possible to assess the methylation state at every studied CpG site.  The unified 
genotyper algorithm was employed within GATK to produce this genotype data for 
each CpG site, and this data was written by the software into a variant call format 
(vcf) file that could subsequently be manipulated in Excel. The command script for 
performing this analysis written by Dr David Ballard at KCL can be found in 
Appendix III. 
2.4.1.4 Calculation of bisulphite conversion rates 
As mentioned earlier when discussing assay design, each assay included at least one 
non-CpG cytosine as a bisulphite conversion control. These cytosines do not belong to 
a CpG site; therefore, they are expected to be converted completely during bisulphite 
treatment. By investigating their methylation, the bisulphite conversion efficiency 
could be assessed; absence of C signals for these locations would indicate 100% 
conversion. Although the Pyrosequencing® software is set up to accept at least 95% 
conversion rates, in some cases (MiSeq® data) these rates were calculated manually to 
assess suspected lower rates. Using the procedure followed when quantifying CpG 
methylation state, the ratio of mC:C was calculated. 
2.4.1.5 Methylation correction by Mathematica 
For all developed CpG assays, DNA standards of known methylation levels (0%-
100%) were used to assess the linearity of methylation quantification obtained using 
either the Pyrosequencing® or MiSeq® instrument. The observed methylation ratio 
was then plotted against the expected and the best-fitted regression line was chosen. 
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As it will be detailed in the Chapters 5, 7 and 8, in many cases the association was not 
linear. It is known from previous studies that PCR amplification of bisulphite-treated 
DNA can often result in a selective enrichment of unmethylated alleles (PCR bias) 
(Moskalev et al., 2011); preferential recovery of methylated forms is also possible, 
although less common. Differences in PCR efficiency are mainly due to differences in 
DNA sequence between the unmethylated and methylated templates following 
bisulphite conversion, which are translated in differences in CG content. Differences 
in hydrogen bonding between A-T and C-G pairs (two and three hydrogen bonds 
respectively) could lead into different separation and amplification rates. For example, 
in case that the methylated allele is preferentially amplified, the resulting graph is 
curved [Figure 2-9d], affecting mainly the low-methylated DNA templates and 
reaching a plateau when highly methylated DNA is present (since the competition 
between unmethylated and methylated templates is in that case lower). The extent of 
such deviations is difficult to predict and can often still remain after extensive PCR 
optimisation.  
Applying the criterion of minimising the sum of squared error, quadratic or cubic 
polynomial regression lines were found to fit best and substantially improve the 
association between the observed and expected methylation ratios. Therefore, the 
obtained equations of these regression lines were used to ‘correct’ the biased detected 
methylation levels in order to increase the accuracy of the proposed methods. To 
achieve this, a computational software program called MATHEMATICA v4.1.2 
(Wolfram Research Europe) was used. Using the appropriate feature, polynomial 
equations were solved to provide the corrected methylation values. If the corrected 
methylation resulted in negative values, methylation was considered as zero. An 
example of this correction for CpG site cg19761273 is illustrated in Figure 2-9. 
2.4.2 Fragment data 
The resulting electropherograms from fragment analysis applications (either STR or 
RNA analysis) were obtained and interpreted using GeneMapper ID v3.2 software 
(Applied Biosystems). The software provides the fragment size of sample peaks by 




(a)  Cubic polynomial equation y= ax3 + bx2 + cx + d  
where y = observed, and x=true methylation value 
Obtained equation for cg19761273:  y = 1.2669x3 - 3.0033x2 + 2.6948x + 0.0255 
(b)  
cg19761273 
DNA methylation levels for each DNA standard 
0 0.05 0.1 0.25 0.5 0.75 1 
Expected 0.0048 0.0493 0.0981 0.2465 0.4930 0.7394 0.9811 
Observed 0.0074 0.1495 0.3297 0.4836 0.7793 0.8952 0.9721 
Parameter d 0.0181 -0.1240 -0.3042 -0.4581 -0.7538 -0.8697 -0.9466 





















Figure 2-9. Correction of methylation values for cg19761273 using MATHEMATICA 
(a) Cubic polynomial equation obtained following analysis of pre-defined DNA methylation standards, 
(b) Observed, expected and corrected methylation values, (c) solutions of cubic polynomial equations 
for each DNA methylation standard, (d) observed vs. expected methylation graphs obtained before 


































For STR applications, the fragment sizes can be converted into alleles (exact number 
of STR repeats) by applying the allelic ladder. An allelic ladder is a collection of all 
possible, common alleles, each of which has a verified repeat number. While being 
separated by the instrument, each known allele will migrate at a particular rate having 
a specific size allowing for comparison with the sizes obtained from the samples. A size 
standard should be added to every injection to correct for any potential fluctuations of 
the instrument’s performance. Sample peaks were assigned a particular allele number 
as long as the corresponding peak in the allelic ladder was not more than ±0.5 bp 
different. 
Lastly, for RNA applications, the fragment sizes of the PCR products were known and 
used to successfully identify each mRNA marker. A peak of >50 rfu height would 
indicate the presence of a particular mRNA. Specifically for the TissueID 20plex, bins 
were set up in the software corresponding to the known size of the fragments, which 
resulted in easier interpretation. The chosen dye label or instrument-to-instrument 
variations could affect the mobility of the fragments; therefore, differences in the 
observed length of up to ±2 bp from the expected were accepted. 
2.4.3 Statistical analysis 
For this section, the IBM SPSS v.22 and STATISTICA v.12 (StatSoft Inc., 2014) 
software were employed. 
2.4.3.1 Data distribution 
For each variable (e.g. age, gender or methylation ratio) the minimum, maximum, 
mean, median and standard deviation (SD) were calculated. If required a histogram 
was produced to see the shape of the distribution. Quartiles of the distribution (1st and 
3rd) were also examined to assess the symmetry.  
2.4.3.2 Hypothesis testing 
In cases where a comparison between variables (e.g. predicted and observed age) or 
groups of subjects was required, an approach known as hypothesis testing was 
employed. Firstly, the statistical null hypothesis was set up which is the negation of the 
research hypothesis that generated the data. Then, the probability that the observed 
data were obtained if the null hypothesis were true was evaluated by calculating the p 
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value; the smaller the p value is the more untenable is the null hypothesis. When p 
values were below the cut-off of 0.05, the result was considered statistically significant 
(and below 0.01 it was considered highly significant), while above 0.05 it was called 
not significant. 
2.4.3.3 Data comparison 
When we had more than one groups of data, it was vital to distinguish the case where 
the data are paired from that where the groups are independent. With paired data the 
average difference between observations and the variability of these differences were 
assessed by paired t test. With independent data, a two sample t test was employed. In 
more complicated analysis, when several groups of data were obtained (e.g. several 
CpG sites to be analysed), an analysis of variance (ANOVA) was employed. 
2.4.3.4 Linear correlation and regression analysis 
The degree of linear association between two variables (e.g. methylation of a CpG site 
and age) was measured by calculating the correlation coefficient (r) which can take 
any value from -1 to +1. The correlation coefficient r measures the degree of ‘straight-
line’ association between the values of the two variables. The linear correlation was 
positive if higher values of one variable were associated with higher values of the other 
and negative if one variable tended to be lower as the other got higher. A correlation 
around zero indicated that there was no linear relation between the values of the two 
variables (uncorrelated). Additionally, assuming that the sample was representative, a 
95% confidence interval for the correlation in the population was obtained. 
To evaluate if the value of one variable could be used to predict the value of the other, 
simple or multiple regression analysis between the outcome (dependent) variable (e.g. 
age) and the predictor(s) (independent) variable(s) (e.g. CpG methylation) was 
performed. Fitting a regression line, the sum squares of the vertical distances of the 
observations from the line is minimised (least squares regression); each distance is the 
difference between the observed value and the value given by the line, known as the 
fitted value or residuals. The fitted regression line explains a proportion of the 
variability in the dependent variable (y) and the residuals indicate the amount of 
unexplained variability. The proportion of the total variation explained by the model 
was also assessed by the goodness-of-fit of the line, which was then achieved by 
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considering the sum of squares explained by the regression as a percentage of the total 
sum of squares (R2 value). In many cases, regression lines were linear but there were 
cases where the relationship between two variables was curved revealing non-linear 
relationships. For example, in methylation quantification by bisulphite PCR the 
polynomial regression was often observed either as quadratic curves (y= ax2 + bx + c) 
or cubic curves (y = ax3 + bx2 + cx + d) as previously discussed. 
2.4.3.5 Multivariate analysis 
Multivariate analysis explores the association between one outcome (dependent) 
variable and one or more predictor (independent) variables. When studying complex 
concepts (for example, ageing), data can be analysed for many continuous and 
categorical variables. In this study, multivariate analysis used to assess if other defined 
factors in the datasets (such as sex) are significantly associated with the studied 
variable, age and create a set of these to be treated as uncorrelated variables as one 
approach to handling multi-collinearity as multiple regression. 
2.4.3.6 Stepwise regression analysis 
Stepwise regression is a semi-automated process of step-by-step iterative construction 
of a regression model by successively adding or removing variables based solely on the 
t-statistics of their estimated coefficients. It can add more power to the model, 
compared to the standard multiple regression option, and is especially useful for sorting 
through large numbers of potential independent variables (e.g. CpG sites) and fine-
tuning a model by adding or removing variables. A forward stepwise regression model 
has been used in this study; variables are added one by one into the model, testing the 
addition of each variable and, adding the variable that best improves the model and 
repeating this process until there is no statistical improvement. 
At each step, the program performs the following calculations: for each variable 
currently in the model, it computes the t-statistic for its estimated coefficient, squares 
it and reports this as its "F-to-remove" statistic, while for each variable not in the 
model, it computes the t-statistic that its coefficient would have if it were the next 
variable added, squares it and reports this as its "F-to-enter" statistic. At the next step, 
the program automatically enters the variable with the highest F-to-enter statistic or 
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removes the variable with the lowest F-to-remove statistic in accordance with certain 
specified control parameters. 
2.4.3.7 Artificial Neural Networks (ANN) analysis 
Artificial neural networks (ANNs) are a family of statistical learning algorithms 
inspired by biological neural networks (mainly the animal central nervous systems) 
and have previously been used to estimate functions that can depend on a large 
number of variables. Due to their adaptive nature, ANNs are generally proposed as 
systems of interconnected ‘neurons’ which can compute values from inputs and are 
capable of pattern recognition. They are characterised by a network topology, a 
connection pattern, neural activation properties and a training strategy to handle data. 
Statistical models are called ‘neural’ if they display the following properties: (a) consist 
of a set of adaptive weights (numerical parameters) tuned by a learning algorithm and 
(b) are capable of approximating non-linear functions of their inputs. 
There are various types of ANNs including multi-layer perceptron (MLP), radial basis 
function network (RBFN), generalised regression neural network (GRNN) and 
probabilistic neural network (PNN). Due to notable capabilities of ANNs such as 
generalisation and non-linear system modelling, they have been extensively studied 
and applied in a range of applications (Amiri et al., 2007). It is believed that ANNs are 
very useful in situations where the functional dependence between the inputs and 
outputs is not very clear. In this study, together with regression analysis, ANNs were 
used for building an age prediction model. It was thought that since ANN analysis 
allows for predicting pattern recognition, it would help in the investigation of a 
complex trait such as age.  
In total, two different functions were applied including the MLP models examined by 
the STATISTICA v.12 software and the GRNN models applied through the Trajan 
v6 software (Trajan Software Ltd., Lincolnshire, UK). In MLPs, a neuron receives its 
input either from other neurons or from external inputs and has one or more hidden 
layers. A weighted sum of these inputs constitutes the argument of a non-linear 
activation function, which results in the neural output. On the other hand, GRNNs are 
made up of four layers of neurons including the input, pattern, summation and output 
layers. The main function of a GRNN is to estimate a linear or non-linear regression 
surface on independent variables (input vectors) given the dependent variables 
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(desired output vectors). Thus the network computes the most probable value of an 
output given only training vectors. An important benefit of GRNNs is its simplicity 
and fast optimisation procedure with a more efficient training process; however, it 
lacks a recurrent structure to filter noise. As a comparison, it has been demonstrated 
that the MLP models as a data modelling tool are more reliable and efficient than 
GRNNs when used for estimation of drug release profiles; nevertheless, when 
optimising drug delivery system formulation, GRNN seemed to surpass (Amiri & 
Derakhshandeh, 2011). The type of ANN to be used depends on the application itself. 
In order to train an ANN model, the most common approach is to divide the dataset 
into two groups, the training and the validation (verification and blind testing) 
datasets. The training group is used to train the model by adjusting the weight matrices 
of the network model, while the validation group is used to make sure that ANN has 
correctly learned the relationship between inputs and outputs. The training and 
validation groups should contain different samples; therefore it is important that the 
data set is large enough; however, it is thought that ANN predicts better when using a 
small dataset. The selection of suitable network architecture is another significant 
feature as it affects the network convergence as well as the accuracy of estimations. 
Generally, the number of hidden neurons depends on factors like the distribution of 
training data and the number of samples. 
It should be noted that ANN analysis was performed by Thomas Miller and Dr Leon 
Barron at KCL. Briefly, optimisation of each ANN type and architecture was 
performed in a number of stages. Firstly, all input variables (selected age-associated 
CpG sites) were included in the design phase followed by a second stage which 
enabled subset selections to assess any improved correlation or performance-limiting 
input variables. In these first two steps, case input variable data were randomised 
across training, verification and blind test experiments. When a suitable architecture 
was identified, a third stage of optimisation involved randomising all but the blind test 
cases to identify the best model. For application, all case datasets were subsequently 
fixed. Networks were set to balance their verification set errors against network 
diversity to cover as many architectures as possible across all model types. For 
multilayer perceptrons (MLPs) in particular, and for each set of design parameters, 
ANN architectures were tested over 30-minute intervals and following this, the best 
50 networks were selected based on correlation and output error. Three- and four-
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layer MLPs were included and within each hidden layer the number of nodes tested 
was ≤14 (software suggested value). For generalised regression neural networks 
(GRNNs), 108 architectures were investigated in each optimisation step. 50 of the best 











































3 Literature review on the identification 













The weight of forensic scientific evidence could be enhanced in court if the cellular 
origin of a body fluid stain was identified. Alongside DNA typing, information 
regarding the cellular origin of a recovered biological stain would be very beneficial 
when reconstructing the events that have taken place at a crime scene. The presence 
of specific body fluids could be linked with particular types of crime; for example the 
presence of semen could indicate sexual assault. However, sometimes it is very 
difficult, if not impossible, to attribute a DNA profile recovered from a stain to a 
specific body fluid type, limiting the evidential significance of a match. Most of the 
current methodologies for body fluid identification use presumptive and sometimes 
destructive biochemical tests to identify specific elements in each fluid. Factors such as 
stain size or substrate material, often affect the way current methods perform limiting 
their capabilities. However, even in cases where a positive presumptive test is 
obtained, no definitive association between DNA profile and body fluid has yet been 
established.  
The ability to accurately detect body fluids in a non-destructive manner is essential in 
order to protect the sample and preserve the DNA evidence. Therefore, new 
technologies are needed to eliminate doubts as to whether the presence of an obtained 
DNA profile is a truly meaningful event in the context of the case, or simply the result 
of innocent contact. For instance, there are a number of case examples where 
confirming the presence of a specific body fluid can be vital. For example, in a case 
where sexual abuse of a young child by a relative is suspected, the DNA profile of a 
person living in the same residence could be proposed to be easily deposited on the 
child’s clothing; therefore, identifying the origin of the cells that the DNA came from 
(e.g. semen), would provide important probative evidence. Moreover, in a case where 
a sexual assault involves vaginal intercourse with a female in menses, if the victim’s 
blood had been transferred to the suspect’s clothing, the ability to identify it as 
menstrual in origin, and not as circulating peripheral blood, would be useful evidence 





3.1 Relevant background 
Body fluid trace evidence found at the crime scene is one of the most significant 
evidence types for forensic scientists as it usually constitutes a valuable source of DNA 
material and can help in identifying or excluding a suspect. Detection of a body fluid 
usually involves a two-step procedure including a presumptive test followed by a 
confirmatory one. Presumptive tests are used to screen areas for suspected biological 
fluids, while confirmatory tests affirm the identity of a stain (Virkler & Lednev, 2009). 
The first step of body fluid identification is crucial as knowing the nature of each fluid 
is very useful per se, but the destructive nature of screening tests must be taken into 
account especially when only a minute amount of material is available. 
3.1.1 Current presumptive testing 
Generally, there are three main methods of detecting biological evidence at the crime 
scene: visual, microscopic, and chemical. Body fluid stains can be either visible to the 
eye or latent and therefore more difficult to detect. This can be due to the limited 
quantity of the sample, the material that the stains are deposited on (for example, dark 
surfaces), or because they may be masked or mixed with another body fluid. 
Nevertheless, some stains like semen have a characteristic colour and texture that can 
be easier to identify. The investigator needs to choose which test to perform first based 
on the physical characteristics of the stain present (Virkler & Lednev, 2009). 
Various conventional immunological, serological or biochemical methods are currently 
used in forensic practice and a systematic biological search of the evidence is 
performed either at the crime scene or at the laboratory. These tests are generally 
quick and easy to perform, although they are generally destructive for the sample. 
They require large amounts of ‘good quality’ material present and can often lead to 
false positive or false negative results (An et al., 2012). Several different body fluids, 
such as blood, semen, saliva, vaginal secretions, menstrual blood, sweat and urine, can 
be recovered from a crime scene, although blood, semen and saliva are the most 
common ones. Each body fluid has a distinctive constitution, and the presence of 
specific components in one fluid in comparison with another is the basis of the 




Blood is the most common body fluid recovered from crime scenes and consists of 
both a liquid component (plasma, 55%) and cellular fraction (erythrocytes, leucocytes 
and thrombocytes, 45%). Most enzymatic and chemical presumptive tests used for 
blood are based on the ability of the haemoglobin present in red blood cells to catalyse 
the oxidation of certain reagents (Matheson & Veall, 2014; Virkler & Lednev, 2009). 
In most cases, the oxidising agent used is a solution of hydrogen peroxide (H2O2). 
Most of these tests such as the Kastle-Mayer (KM) and the Leucomalachite Green 
(LGM) tests make use of reagents that change colour as a result of oxidation (Webb et 
al., 2006). Also, luminol, known to be the most sensitive of the current presumptive 
tests, produces a distinct but temporary glow in a darkened environment when blood 
is present due to a chemiluminescent reaction (Barni et al., 2007). 
3.1.1.2 Semen 
Semen is commonly encountered in cases of rape and sexual assault. It contains both 
seminal fluid and spermatozoa, even though in some cases sperm may be totally absent 
from the seminal fluid, a situation called azoospermia. There are a number of tests that 
can be used for the detection of semen stains (Virkler & Lednev, 2009). A common 
detection method is the observation of the suspected area under ultraviolet light in the 
range 250-365 nm due to the fact that semen usually fluoresces (Kobus et al., 2002). 
However, the most popular and widely accepted presumptive test for semen is the acid 
phosphatase (AP) test based on this enzyme’s ability to catalyse the hydrolysis of 
organic phosphates causing a colour change in the solution (Virkler & Lednev, 2009). 
Some other presumptive tests that may be applied for the detection of semen are based 
on the presence of semen specific proteins and other substances, such as choline 
(Manabe et al., 1991) and seminal polyamine known as spermine (SPM) (Suzuki et al., 
1980). 
Lastly, the most popular and definitive test for the presence of semen is the 
microscopical identification of sperm cells under a high-powered microscope. 
Spermatozoa can be easily identified by their characteristic shape after treatment with 
an appropriate staining reagent such as haematoxylin and eosin (Jones Jr., 2005). 




Saliva is a watery (99%) fluid produced by three main pairs of salivary glands and has 
various functions. Saliva contains mucins, which helps with deglutition and the 
digestive enzyme salivary amylase (also called α amylase), which breaks down starches 
into maltose and dextrins. Cast-off cheek cells and bacteria cells are also present. 
There are only a few well-known and accepted presumptive tests for saliva, but there 
are no definitive tests for this body fluid. The most popular identification method is 
based on the activity of salivary amylase and is known as the starch-iodine test. It is 
based on the fact that starch appears blue when iodine is present and the salivary 
amylase enzyme will break down the starch to produce a colour change (Virkler & 
Lednev, 2009). The Phadebas® amylase test is also commonly employed; the substrate 
used is a water-insoluble cross-linked starch polymer carrying a blue dye, that 
becomes water-soluble (therefore visible) only when it is hydrolysed by α-amylase 
(Martin et al., 2006). 
3.1.1.4 Other body fluids 
Since blood, semen and saliva are the most commonly recovered body fluids, efforts 
on the development of efficient assays have been focused on these; however, 
increasing research is being published on the detection of other body fluids such as 
vaginal fluid, menstrual blood and urine. Vaginal fluid and menstrual blood evidence 
can be very important in particular sexual assault cases. The constituents of these body 
fluids change over a female’s menstrual cycle, making it very hard to develop a body 
fluid-specific test. As recently suggested, one solution to this problem would be to use 
their unique Raman spectroscopic signatures; they seem to be specific and could be 
used for confirmatory identification (Sikirzhytskaya et al., 2012a; Sikirzhytskaya et al., 
2012b). Furthermore, regarding the differentiation of menstrual blood from peripheral 
blood, immunoassays have been proposed using monoclonal antibodies (Baker et al., 
2011; Gray et al., 2012). Lastly, a presumptive test known as para-
dimethylaminocinnamaldehyde (DMAC) has been favoured for the identification of 
urine as it reacts with urea; however it is not entirely specific as it results in false 




To sum up, recovering a biological stain at the crime scene and linking it with a 
suspect through DNA typing is in many cases crucial for the outcome of a trial. 
Locating potential biological material can usually be achieved through visual 
examination; however, as mentioned above, presumptive testing that indicates the 
presence of a specific body fluid can also be employed in situ. Although these tests are 
cheap and easy to perform, it is important to understand that they are not entirely 
specific and require a large amount of biological material.  
In more complex cases, it would be beneficial to be able to identify the cellular origin 
of a stain through a confirmatory test. The development of a genetic body fluid/tissue 
identification system that is compatible with current DNA profiling technologies 
would be very advantageous. Such tests have to be very sensitive, specific and 
maintain the integrity of DNA evidence. A panel of specific identification tests that 
can be performed on a single sample in a multiplex reaction is desirable, especially in 
cases where the sample size is minute. Protein and messenger RNA (mRNA) assays 
have been proven to be valuable since both are expressed in a cell-specific manner. 
Nevertheless, the use of proteomics - the field of multiplex analysis of complex and 
partially degraded protein mixtures present in stains - is relatively new and needs 












3.2 mRNA profiling 
Although the last decade molecular forensic science has been dominated by DNA 
analysis, forensic researchers have also started employing RNA technologies 
worldwide. The first publication dealing with post-mortem RNA analysis was in 1984 
(Oehmichen & Zilles, 1984), while Phang et al were the first to deal with gene 
expression analysis (Phang et al., 1994). Since then, the published work around the use 
of RNA in forensic science has proliferated and the forensic potential of parallel 
analysis is increasingly being investigated and continues to expand (Fleming & 
Harbison, 2010a; Hanson & Ballantyne, 2013b; Juusola & Ballantyne, 2005; 
Lindenbergh et al., 2012). Various mRNA/DNA analysis approaches have been 
published, with most of them applying reverse transcription-PCR (RT-PCR) (Alvarez 
et al., 2004; Bauer & Patzelt, 2003; Parker et al., 2011). A common approach to this 
analysis is summarised in Figure 3-1.  
 
Figure 3-1. mRNA/DNA co-analysis approach 
Common approach used in co-analysis of DNA and RNA in the same workflow. Recovered swabs or 
stains are used for simultaneous DNA/RNA co-extraction. DNA samples are analysed for standard 
DNA profiling, including DNA quantification, PCR and detection of STRs by capillary electrophoresis. 
On the other hand, the mRNA samples go through DNase treatment to eliminate potential DNA 
contaminants and are then used to synthesise the complementary DNA strand (cDNA) through a 
process called reverse transcription. Body-fluid specific mRNA markers are then amplified and detected 
by fragment analysis. 
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3.2.1 mRNA and gene expression 
DNA does not direct protein synthesis itself; RNA acts as a mediator and transfers the 
genetic information from DNA in the nucleus to produce the protein found in the 
cytoplasm. The RNA molecules that are copied from genes during transcription are 
collectively known as messenger RNA (mRNA). It is generally accepted that RNA, 
compared to DNA, is highly unstable and is subject to rapid degradation by 
ubiquitously present ribonucleases which is essential for gene expression control 
(Frazao et al., 2006). The final product of some genes is also RNA and these non-
messenger RNAs are used in regulatory and functional processes. For example, 
ribosomal RNA (rRNA) is found in the centre of ribosomes and transfer RNA (tRNA) 
delivers amino acids during protein synthesis. There is also a class of small RNAs, 
microRNAs (miRNAs), whose regulatory functions in various developmental and 
biological procedures have been identified (Bartel, 2004).  
Terminally-differentiated cells, whether they are lymphocytes (blood), spermatozoa 
(semen) or epithelial cells in the oral cavity (saliva), adopt a unique characteristic 
appearance through a regulated program, in which specific genes are turned on, while 
others are transcriptionally silent (Haas et al., 2013b). Thus, a unique pattern of gene 
expression is created for each cell type, which can be demonstrated through the 
presence and relative abundance of specific mRNAs; a pattern known as 
‘transcriptome’.  
3.2.2 mRNA-based body fluid identification 
For the identification of forensically relevant body fluids, an mRNA-based approach 
would offer a range of advantages including increased sensitivity and the ability to 
simultaneously identify various body fluids in a semi-quantitative manner. However, 
to avoid false positive reactions, the selection of tissue-specific mRNA markers should 
be made with caution and following validation with all possible forensically relevant 
body fluids and tissues. Possible inter- and intra- individual variation of gene 
expression should also be taken into account. Lastly, it is known that single-stranded 





Assessing the quality and quantity of RNA that can be routinely recovered from 
biological stains is essential in order to apply RNA-based analysis in forensic science. 
RNA is considered to be vulnerable to degradation by RNases and researchers initially 
doubted its applicability in forensic casework. However, a number of studies have 
showed that it is possible to detect mRNA in forensically relevant tissues (Juusola & 
Ballantyne, 2003) and very old/degraded stains (Kohlmeier & Schneider, 2012; 
Zubakov et al., 2008). Zubakov et al managed to identify stable mRNA markers for 
blood and saliva identification from stains up to 16 years old. In a more comprehensive 
study, RNA of suitable quality and quantity could be extracted even from stains stored 
at room temperature for up to 547 days (Setzer et al., 2008). Nevertheless, when 
samples were kept outdoors, this time frame was significantly reduced; up to 7 days for 
saliva stains; up to 30 days for blood stains and up to 180 days for vaginal secretion 
stains. External factors such as sunlight, humidity, high temperatures and rain have a 
negative influence in the stability of mRNA, which could differ among different body 
fluids or donors. Also, it cannot be excluded that other features such as gender, age or 
certain medical conditions could have an impact in mRNA patterns. 
3.2.3 Tissue-specific mRNA markers 
A panel of body fluid-specific mRNA markers has been identified over the past few 
years, which enables the identification of various forensically relevant body fluids. 
Although initial research had focused on developing singleplex or multiplex assays for 
each tissue individually, latest advances have allowed for simultaneous identification 
using a single method. 
3.2.3.1 Blood 
The mRNA-based identification of blood has been thoroughly investigated during the 
last decade. Various genes have been proposed to have blood-specific gene expression 
pattern and have been extensively validated by testing other forensically related body 
fluids. Initially, three mRNA candidates were broadly studied including haemoglobin 
beta (HBB), which is the beta-subunit of haemoglobin A (Levings & Bungert, 2002), 
β-spectrin (SPTB) which is an erythrocyte membrane protein (Chu et al., 1994), as 
well as porphobilinogen deaminase (PBGD) which is an enzyme of the haeme 
biosynthetic pathway (Gubin & Miller, 2001). mRNA of these putative blood-specific 
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markers was successfully detected in peripheral blood and to a lesser degree in 
menstrual blood, but was undetectable in saliva, semen or vaginal secretion stains 
(Juusola & Ballantyne, 2005).  
The results of a first collaborative European DNA Profiling group (EDNAP) exercise 
showed that HBB is the most abundantly-detected mRNA, SPTB showed a moderate 
sensitivity, while PBGD was the most difficult marker to detect (Haas et al., 2011a). 
Some of the participating laboratories could not detect either SPTB or PBGD in any 
of the blood dilution series analysed; this could be due to the low level of these two 
mRNA species, compared to that of HBB. These findings agree with those of Patel 
and Peel, who reported inconsistent results for these two markers, possibly due to 
reduced extraction efficiency (Patel & Peel, 2008). Furthermore, researchers have 
tested other potential blood-specific markers such as haemoglobin alpha (HBA), which 
is the alpha-subunit of haemoglobin A (Nussbaumer et al., 2006), erythrocyte 
membrane protein ankyrin (ANK1) (Fang et al., 2006) as well as glycophorin A 
(GlycoA) (Fleming & Harbison, 2010a). Using a different approach, Zubakov and his 
colleagues performed whole-genome gene expression analysis on a series of time-wise 
degraded blood samples and reported the tissue-specific expression patterns of the 
most promising candidate genes by means of quantitative real-time PCR (Zubakov et 
al., 2008). They identified a total of nine stable mRNA markers showing blood-
specific expression signals in aged stains up to 180 days old. However, they reported 
issues with specificity with vaginal secretion due to the complex nature of this body 
fluid. 
Haas et al conducted a comprehensive study analyzing 7 potential blood-specific 
mRNA markers including the above mentioned HBA, HBB, SPTB, PBGD and 
ANK1 in order to identify other mRNA markers (Haas et al., 2011b). The new 
markers included δ-aminolevulinate synthase 2 (ALAS2) which is an erythroid-
specific mitochondrial enzyme catalysing the first step of haeme biosynthesis, the CD3 
gamma molecule (CD3G), a part of the T-cell receptor-CD3 complex, as well as 
aquaporin 9 (AQP9), a water channel protein expressed in peripheral leukocytes. 
While different expression levels were observed, all tested markers demonstrated great 
sensitivity, requiring as little as 1 ng of RNA input; however, there were some 
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problems with specificity (especially regarding AQP9) and tissue/animal cross-
reactivity (Haas et al., 2011b). 
However, the use of singleplex reactions in forensic analysis is ineffective in terms of 
time and cost. Therefore, the above results were further validated by a second 
collaborative EDNAP exercise. Researchers from different laboratories tested the 
ability of two multiplexes to accurately identify blood: a highly-sensitive duplex 
consisting of both heamoglobins (HBA, HBB), as well as a moderately-sensitive 
pentaplex that included ALAS2, CD3G, ANK1, SPTB and PBGD (Haas et al., 
2012). Both multiplexes were successful enabling detection of even minute bloodstains 
as small as 0.01 µl, although some variability among laboratories on specificity and 
sensitivity were reported. Interestingly, low signals of ALAS2 have been detected in 
both semen and vaginal fluid stains (Richard et al., 2012). 
3.2.3.2 Semen 
For the identification of semen, two mRNA candidates that have been widely 
investigated are protamine 1 (PRM1) and protamine 2 (PRM2) (Haas et al., 2009b; 
Juusola & Ballantyne, 2005; Patel & Peel, 2008). During spermatogenesis, protamines, 
which are arginine-rich proteins, replace histones and become the basic nuclear 
proteins of mature spermatozoa (Borghol et al., 2008). Both PRM1 and PRM2 have 
been found to be body fluid-specific, and were detected only in semen stains and 
absent in all other biological fluids tested (Haas et al., 2009b; Juusola & Ballantyne, 
2005). However, these markers were shown to also be present in some of the urine 
samples tested; this could presumably be due to the fact that both fluids use the same 
conduit (Sakurada et al., 2009). The sensitivity of these markers has been tested by 
analysing dilution series, which could be identified from stains as little as 0.1μµl (Haas 
et al., 2009b).  
Nevertheless, semen identification using protamine mRNA can only be useful when 
spermatozoa are present. To address the possibility of azoospermia, researchers also 
focused their efforts to find suitable mRNA markers within the seminal fluid. Fand and 
his colleagues were the first to suggest semenogelin 1 and 2 (SEMG1, SEMG2) and 
transglutaminase 4 (TGM4) as potential markers (Fang et al., 2006). Semenogelin 
proteins are involved in the formation of a gel matrix that coats ejaculated spermatozoa 
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and are usually degraded into smaller fragments by prostate-specific antigen (Zhang et 
al., 2008). Transglutaminases are calcium-dependent enzymes and are synthesised and 
secreted by prostate epithelial cells (Lu & Davies, 1997). Moreover, the mRNA of 
prostate-specific antigen (PSA) (or kallikrein 3, KLK3) has also been proposed as a 
good semen-specific candidate (Nussbaumer et al., 2006). Although these mRNAs 
have been successfully amplified in singleplex assays (Fang et al., 2006; Nussbaumer et 
al., 2006; Richard et al., 2012; Sakurada et al., 2009), having one multiplex that allows 
for the identification of both healthy and azoospermic semen would be advantageous. 
Haas et al developed a 4-plex including PRM1, PRM2, SEMG1 and PSA mRNAs 
that could clearly distinguish azoospermic from normozoospermic men and obtained 
the expected mRNA profiles from up to 20-years-old stains (Haas et al., 2009b). 
3.2.3.3 Saliva 
Mainly two mRNA candidates, statherin (STATH) and histatin 3 (HTN3) have been 
studied for saliva identification (Fleming & Harbison, 2010a; Gomes et al., 2013; 
Juusola & Ballantyne, 2003; Patel & Peel, 2008). STATH is a stable, acidic inhibitor 
of the precipitation of calcium phosphate salts in the oral cavity (Sabatini et al., 1990); 
while HTN3 is a histidine-rich protein involved in the non-immune host defence 
(Sabatini et al., 1993). mRNAs of these saliva-specific markers were exclusively found 
in saliva samples and were undetectable in a variety of other body fluids, like blood 
and semen (Juusola & Ballantyne, 2003; Sakurada et al., 2009). Both STATH and 
HTN3 are sufficiently sensitive and stable, as they were detected in stains as small as 
0.1μµl and were successfully identified in a 6-year-old stain (Sakurada et al., 2009). 
However, some variation in gene expression for both markers has been demonstrated 
and also, when testing nasal secretion and vaginal fluid samples, STATH mRNA was 
occasionally detected, while HTN3 was undetectable (Sakurada et al., 2011). 
Additional potential saliva-specific genes have been suggested, such as the proline-rich 
proteins 1, 2, 3 (PRB1-3) (Juusola & Ballantyne, 2003) and 4 (PRB4) (Fang et al., 
2006). PRB proteins are known to play a role in the defence mechanisms against 
ingested polyhydroxylated phenols like tannins (Carlson, 1993). Additionally, as with 
blood, Zubakov and co-workers identified a set of five saliva-targeted mRNA markers 
using a microarray (Zubakov et al., 2008). These include three members of the family 
of keratins (keratin 4 – KRT4, keratin 6A – KRT6A, keratin 13 – KRT13) known for 
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their role as the major structural proteins of the oral mucosa (Guo et al., 2006), as well 
as two genes that encode for cornified envelope precursor proteins (SPRR1A, 
SPRR3), predominantly expressed in oral and esophageal epithelia (Gibbs et al., 
1993). Although all five markers were predominantly expressed in saliva, keratins 
were also detected to a smaller extent in semen stains (Zubakov et al., 2008). 
3.2.3.4 Vaginal fluid 
Due to its epithelial nature, identifying vaginal fluid-specific mRNA markers is 
considered a difficult task, since other epithelial tissues such as the buccal epithelium 
and skin could have similar gene expression patterns. Nevertheless, two mRNA 
markers have been thoroughly investigated and showed promising results. The first is 
human beta-defensin 1 (HBD1) which is an antimicrobial peptide involved in the host 
defense of urogenital epithelium (Valore et al., 1998). The second mRNA is mucin 4 
(MUC4), a major membrane-spanning mucin of the endocervix that protects against 
pathogens and at the same time controls sperm entry into the uterus (Gipson et al., 
1997). Both mRNA markers are relatively specific; however, HBD1 was not always 
detected in vaginal fluid samples, possibly due to variations during the monthly 
menstrual cycle (Patel & Peel, 2008). Also, although researchers have focused on the 
validation of MUC4 (Juusola & Ballantyne, 2005; Nussbaumer et al., 2006; Richard et 
al., 2012), this mucin has been previously reported to be expressed also in salivary 
glands (Liu et al., 2002). 
In an effort to identify additional potential markers, estrogen receptor 1 (ESR1) was 
suggested for the detection of vaginal secretions as it showed >100-fold higher 
expression in vaginal fluid compared to other tissues (Fang et al., 2006). Also, whole 
transcriptome profiling (RNA-seq) revealed two novel highly specific mRNA markers, 
namely myozenin 1 (MYOZ1) and cytochrome P450, family 2, subfamily B, 
polypeptide 7 pseudogene 1 (CYP2B7P1), both of which demonstrated high 
sensitivity (250 pg - 1 ng) and no cross-reactivity with other tissues (Hanson & 
Ballantyne, 2013a). Although the function of both these gene transcripts is as yet 
unknown, it is thought that MYOZ1 acts as an intracellular binding protein involved 
in linking Z-disk proteins (Takada et al., 2001) and CYP2B7P1 is a non-coding RNA 
(pseudogene) related to the cytochrome P450 gene family involved in the oxidation of 
organic compounds (Laaksonen et al., 1995). 
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Interestingly, latest research published on the identification of vaginal secretions has 
taken account of the body fluid’s microbial signature. Lactobacilli species have been 
reported to be the main vaginal bacteria (Nam et al., 2007) and closely-related species 
can be identified by analysing their 16S-23S rRNA intergenic spacer region (ISR) 
(Song et al., 2000). For example, Lactobacillus crispatus (Lcris) and Lactobacillus 
gasseri (Lgas) have been largely investigated by the forensic community (Fleming & 
Harbison, 2010b; Giampaoli et al., 2012; Song et al., 2013). All tested vaginal swab 
samples showed consistent peaks for these two species; sometimes, the Lactobacillus 
mRNA peaks were higher than the ones obtained for the housekeeping genes 
suggesting a great number of bacteria present (Fleming & Harbison, 2010b). Other 
Lactobacilli species such as Lactobacillus iners (Liners) and Lactobacillus jensenii (Ljen) 
as well as other bacteria like Gardnerella vaginalis (Gvag) and Atopobium vaginae 
(Avag) associated with common bacterial vaginosis have also been reported to be 
vaginal fluid-specific (Akutsu et al., 2012). 
3.2.3.5 Menstrual blood 
Due to its complex nature, menstrual blood is one of the most challenging body fluids. 
Changes throughout the menstrual cycle result in the expression of different gene 
transcripts; therefore, researchers have tried to identify those mRNA markers that are 
constantly detected regardless of the day of the cycle. The family of zinc-dependent 
matrix metalloproteinases (MMP) has been tested since they are specifically expressed 
in the endometrium during menstruation (Goffin et al., 2003). The sensitivity and 
specificity of matrix metalloproteinase 7 (MMP7) has been supported by various 
research groups (Bauer & Patzelt, 2008; Patel & Peel, 2008; Richard et al., 2012); 
MMP7 mRNA was detected in 54/60 menstrual swabs (Bauer & Patzelt, 2008).  
Matrix metalloproteinases 10 and 11 (MMP10, MMP11) were also successfully 
detected in menstrual blood (Fleming & Harbison, 2010a; Hanson & Ballantyne, 
2013b); however, they occasionally gave positive signals in vaginal fluid (Jakubowska 
et al., 2013) or even in semen (Roeder & Haas, 2013). As expected, investigators also 
noticed a fluctuation of marker expression levels between women and during the 
menstrual cycle; MMP11 was mainly detected in the first half of the cycle 
(Jakubowska et al., 2013). Three additional markers have also been investigated, 
namely mshhomeobox 1 (MSX1), secreted frizzled-related protein 4 (SERP4) and 
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left-right determination factor 2 (LEFTY2); however, their specificity when tested in 
other tissues appeared to be questionable (Roeder & Haas, 2013). 
3.2.3.6 Skin 
In specific forensic case scenarios, the identification of skin in touch/contact forensic 
samples is required. Numerous studies have emphasised that due to the minute amount 
of recovered biological material, it is often impossible to determine the tissue source of 
touch DNA evidence (Gilder et al., 2009; Lowe et al., 2002). Nonetheless, five novel 
markers were identified with the ability to detect skin from input RNA as low as 5-25 
pg (Hanson et al., 2011). These mRNAs belong to the late cornified envelope genes 
1C, 1D and 2D (LCE1C, LCE1D, LCE2D), interleukin 1 family member 7 (IL1F7, 
also known as IL37) as well as chemokine ligand 27 (CCL27). The biological function 
of these candidates is consistent with the high specificity in skin; for example, LCE 
proteins are part of the epidermal differentiation complex (Jackson et al., 2005), while 
CCL27 is responsible for recruiting cutaneous lymphocyte-associated antigen (CLA+) 
memory T cells to normal or inflamed skin (Fujimoto et al., 2008). Moreover, IL1F7 
has a significant role in inhibiting inflammatory reactions and is mainly expressed in 
keratinocytes (Nold et al., 2010). LCE1C and CCL27 were the most sensitive markers 
with a limit of detection of 5 pg RNA (Hanson et al., 2011; Hanson et al., 2012).  
Visser and his colleagues further identified three new mRNA transcripts showing a 
strong over-expression in skin, which were able to successfully identify thumbprints 
stored for more than 6 months (Visser et al., 2011). The set of markers included 
corneodesmosin (CDSN), loricrin (LOR) and keratin 9 (KRT9). Both CDSN and 
LOR take part in the assembly of the epidermal cornified cell envelope (Kalinin et al., 
2001), whereas KRT9 is mostly expressed in the suprabasal cells of the epidermis (Chu 
& Weiss, 2002). In their study, KRT9 had the lowest specificity with very low 
expression levels in semen and blood as well as poor sensitivity as it was not detected 
in all the skin samples analysed – more than 70% dropouts in quarter print samples 
(Visser et al., 2011). On the other hand, LOR and CDSN have successfully been 
validated in other studies (Gomes et al., 2013; Lindenbergh et al., 2012). 
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3.2.4 Housekeeping mRNA markers 
The use of housekeeping genes (HKGs) in mRNA profiling could assist in assessing 
the amount of mRNA recovered from a sample and potentially establishing its 
suitability for downstream applications. The importance of co-analysing HKGs to act 
as endogenous positive controls became evident when researchers were still exploring 
the feasibility of mRNA profiling in forensic casework. The mRNAs of ribosomal 
protein S15 or S18 (RPS15/RPS18), beta-actin (ACTB) and glyceraldehyde-3-
phosphatedehydrogenase (GAPDH) have been used together with body fluid-specific 
mRNA markers (Bauer & Patzelt, 2008; Juusola & Ballantyne, 2003; Lindenbergh et 
al., 2012). Furthermore, Fleming and Harbison (2010) suggested another three HKGs 
including encoding translation elongation factor-1a (TEF), glucose-6-phosphate 
dehydrogenase (G6PDH) and ubiquitin-conjugating enzyme E2D 2(UCE); however, 
TEF seemed to have an unexpected pseudogene that could interfere with 
interpretation (Fleming & Harbison, 2010a). 
Even though many body-fluid specific markers have been identified, not enough work 
has been done in identifying and validating constitutively-expressed housekeeping 
genes that could be of forensic value and be used for data normalization. Moreno et al 
tested six HKGs: GAPDH, ACTB together with beta-2 microglobulin (B2M), 
phosphoglycerate kinase 1 (PGK1), cyclophilin A (PPIA) and large/acidic ribosomal 
protein P0 (RPLP0), utilising a two-step real-time PCR assay. B2M appeared to 
provide the strongest overall expression pattern; however, a significant variation in 
expression levels for all markers was observed among different body fluids and 
individuals (Moreno et al., 2012). 
3.2.5 Multi-tissue mRNA based assays 
Clearly an mRNA-based approach for body fluid/tissue identification is very 
promising. mRNA profiling has evolved from singleplex PCRs used to identify body 
fluid-specific mRNAs, to multiplex PCR assays to further validate the identified body 
fluid-specific transcripts. However, the development of a multiplex assay that could 
simultaneously detect several body fluids/tissues would be ideal and a lot of effort is 
currently made towards achieving this goal. The first multiplex mRNA system was 
proposed in 2005 and consisted of two markers per body fluid (e.g. blood, semen, 
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saliva and vaginal secretion) (Juusola & Ballantyne, 2005). Since then and while new 
research continued to reveal potential body fluid-specific mRNAs, two different 
combinations of markers and tissues (including also menstrual blood) were developed 
(Fleming & Harbison, 2010a; Patel & Peel, 2008). 
Lindenbergh et al developed an end-point RT-PCR assay that simultaneously 
amplifies 19 mRNA markers, specific for blood (3), saliva (2), semen (2), menstrual 
secretion (2), vaginal mucosa (2) and skin (2) and allows their differentiation. The 
multiplex also contains three general mucosa markers as well as three housekeeping 
genes. Authors investigated not only the multiplex PCR assay performance and the 
specificity of the selected markers but also their sensitivity. Full RNA profiles were 
obtained with as little as 0.05 µl of starting material whereas full DNA profiles were 
also observed when using at least 0.1 µl. Since skin markers had not been incorporated 
in any multiplex system before, they were analysed in more detail. Interestingly, they 
resulted in successful detection of hand, feet, back and lips samples. The ability of the 
assay to effectively analyse old and degraded specimens up to 28 years old was 
remarkable (Lindenbergh et al., 2012). 
Furthermore, two more multiplex RT-PCR assays using different experimental 
approaches were published. Hanson and Ballantyne (2013) proposed a hexaplex high-
resolution melt (HRM) protocol in order to simplify the mRNA profiling process and 
also reduce the time and cost of the analysis. In their assay, they included one marker 
per body fluid; ALAS2 for blood, HTN3 for saliva, TGM4 for semen, IL19 for 
vaginal secretion, MMP10 for menstrual blood and IL1F7 for skin identification. The 
assay showed high sensitivity (pg of DNA) and no significant cross-reactivity (Hanson 
& Ballantyne, 2013b). Additionally, a multiplex quantitative RT-PCR assay including 
four novel markers – PPBP for blood, FDCSP for saliva, MSMB for semen and 
MSLN for vaginal secretion – was studied (Park et al., 2013). The selected markers 
showed good specificity and sensitivity, though the MSNL was less optimal in 
sensitivity as previously expected. 
Table 3-1 summarises the main body fluid-specific markers reported in literature for 
blood, saliva, semen, vaginal secretion and menstrual blood.  
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Table 3-1. mRNAs found in the literature showing body fluid-specific expression 
Body fluids Body-fluid specific mRNAs 
Blood 
HBA Haemoglobin α MNDA Myeloid nuclear differentiation antigen AQP9 Aquaporin 1 
HBB Haemoglobin ß AMICA1 Adhesion molecule ANK1 Ankyrin 1 
SPTB ß-spectrin CD88 Cluster of differentiation 88 GlycoA Glycophorin A 
PBGD Porphobilinogen deaminase CD93 Cluster of differentiation 93 CD3G CD3 γmolecule 
ALAS2 δ-aminolevulinate synthase 2 PPBP Pro-platelet basic protein CASP1 Caspase 1 
Saliva 
STATH Statherin PRB3 Proline-rich protein 3 KRT13 Keratin 13 
HTN3 Histatin 3 PRB4 Proline-rich protein 4 KRT6A Keratin 6A 
MUC7 Mucin 7 SPRR3 Small proline-rich protein 3 KRT4 Keratin 4 
PRB1 Proline-rich protein 1 SPRR1A Small proline-rich protein 1A   
PRB2 Proline-rich protein 2 FDCSP Follicular dendritic cell secreted protein   
Semen PRM1 Protamine 1 PSA Prostate-specific antigen   
PRM2 Protamine 2 MCSP Mitochondria cysteine-rich protein   
SEMG1 Semenogelin 1 MSMB Beta-microseminoprotein   
SEMG2 Semenogelin 2     
TGM4 Transglutaminase 4     
Vaginal fluid 
HBD1 Human beta-defensin 1 IL19 Interleukin 19 Ljen 16S rRNA 
MUC4 Mucin 4 FUT6 Fucosyltransferase 6 Lcris 16S-23S rRNA 
ESR1 Estrogen receptor 1 SFTA2 Surfactant associated 2 Lgas 16S-23S rRNA 
MYOZ1 Myozenin 1 DKK4 Dickkopf homolog 4 Liners 16S-23S rRNA 
CYP2B7P1 CytP450, fam2, subB, pol7, pseud1 MSLN Mesothelin Avag 16S rRNA 
Menstrual blood 
MMP7 Matrix metalloproteinase 7 SFRP4 Secreted frizzled-related protein 4   
MMP10 Matrix metalloproteinase 10     
MMP11 Matrix metalloproteinase 11     
MSX1 Mshhomeobox 1     
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3.2.6 Interpretation of mRNA profiles 
As shown above, there is substantial evidence to support that mRNA profiling could 
serve as confirmatory testing to identify the cellular tissue of origin. However, 
significant variation in terms of specificity and sensitivity were observed across 
research groups. Also, the majority of published PCR multiplex assays use one or two 
markers for the identification of each body fluid which often leads to false positive 
results. It has been proposed that a minimum of five markers per body fluid should be 
included (Roeder & Haas, 2013).  
Also, given the ‘occasional’ expression of some markers in non-target tissues and the 
observed intra- and inter- individual variation (especially for vaginal fluid and 
menstrual blood markers), it is essential that a scoring system is developed to set the 
standards for the interpretation of mRNA profiles. Recently, the Netherland Forensic 
Institute published their guidelines on how mRNA profiling was implemented in 
forensic casework (Lindenbergh et al., 2013). They developed a stepwise procedure 
that could prevent cognitive (confirmation, expectation or motivational) bias: 
 The researcher who performs the mRNA profiling should remain uninformed 
about the context of the case. 
 mRNA results are generated according to specific guidelines and are presented 
in the form of a table with six different scoring categories. 
 DNA results are generated separately following standard routine analysis. 
 DNA/mRNA profiles are interpreted and a relationship between individuals 
and body fluids detected is established. 
 Results are collated and conclusions are formulated in a final report. 
After analysing specially-designed mock cases, the authors were able to show that 
potential bias was eliminated and that results generated from presumptive testing, 
mRNA profiling and DNA analysis were concordant (Lindenbergh et al., 2013). 
However, one has to be careful when associating cell types and donors as variations in 





As shown above, mRNA profiling using tissue-specific markers can be considered as a 
good confirmatory test as most of the proposed mRNA markers are very sensitive 
giving a positive reaction with as low as 0.05 µl stain (Lindenbergh et al., 2012). 
Selected markers can be multiplexed allowing for simultaneous identification of 
various forensically relevant tissues. However, there are issues regarding tissue-to-
tissue specificity and also when applying these tests in extensively-degraded samples 
where RNA is more difficult to obtain. Such constraints are particularly important 
when re-examining ‘cold cases’, where only DNA has been retained and current 
methods cannot be used. A method that would not consume additional sample during 
nucleic acids co-extraction and at the same time is able to exploit the stability of DNA 
molecule would be preferred.  DNA-based tests could potentially overcome the 
limitations of existing methods and provide a direct link between the recovered DNA 
and its source.  
It is known that DNA methylation is one of the main mechanisms responsible for cell 
differentiation and differential gene expression (Plachot & Lelievre, 2004; Song et al., 
2009). As previously described in section 1.1.2, DNA methylation regulates gene 
expression by mostly silencing (or in some cases activating) gene transcription. 
Therefore, differential DNA methylation patterns could offer a great alternative to 












3.3 Tissue-specific DNA methylation 
Over the last decade, tissue-specific methylation patterns have been investigated either 
by analysing specific gene loci (Illingworth et al., 2008) or entire chromosomes (De 
Bustos et al., 2009). There are numerous studies that have looked at differential 
methylation patterns across various tissues such as between blood and muscle (Liang et 
al., 2008) or between blood and saliva (Thompson et al., 2013). Moreover, researchers 
have investigated how these tissue-specific patterns change over the individual’s 
lifetime (Christensen et al., 2009). Rakyan and co-workers reported a novel resource 
for human genome-wide tissue-specific DNA methylation profiles across 13 normal 
somatic tissues, placenta, sperm and an immortalized cell line (Rakyan et al., 2008). 
Authors used this resource to identify the first comprehensive genome-wide set of 
tissue-specific differentially methylated regions (tDMRs) that could play a role in 
cellular identity as well as the regulation of tissue-specific genome function. DNA 
methylation analysis has already been proposed as a tool for cell typing in cell 
therapeutic approaches. As an example, Baron et al identified panels of cell type-
specific differentially methylated gene regions (CDMs) using a methylation-sensitive 
single-nucleotide primer extension (MS-SNuPE) protocol, which allowed for accurate 
identification and quantification of subpopulations in cell cultures (Baron et al., 2006).  
3.3.1 DNA methylation-based tissue identification 
From a forensic point of view, scientists thought that DNA methylation profiling could 
potentially be very helpful in confirming the presence of a specific tissue. 
Differentiation could be achieved via the identification of suitable DNA methylation 
markers that are differentially methylated amongst forensically relevant tissues. A 
DNA methylation-based approach would potentially overcome limitations of existing 
methods including the additional consumption of evidence or qualitative rather than 
quantitative findings, but also offer further advantages. Such tests are more likely to 
demonstrate great sensitivity and robustness since DNA is very stable. 
Frumkin et al were the first to explore the possibility of DNA methylation-based 
forensic tissue identification (Frumkin et al., 2011). 205 individual CpG islands 
containing a recognition sequence for the methylation-sensitive restriction enzyme 
Hha I were selected for initial screening for differential methylation by comparing 
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signals obtained from pooled DNA samples (10 individuals) for each tissue. As a result, 
a total of 38 genomic loci demonstrated differential amplification patterns, 15 of which 
were used in their tissue identification assay [Table 3-2]. To develop and validate the 
assay, 1 ng of 50 DNA samples including blood, saliva, semen, skin, urine, menstrual 
blood and vaginal secretion were analysed; Figure 3-2 presents an overview of their 
approach. Since highly methylated loci were protected from enzymatic digest and 
amplified with much higher efficiency than loci with lower methylation levels, the 
authors considered only ratios of methylation levels in their analysis. Even though 
variability in methylation ratios due to inter-individual variation or stochastic PCR 
effects were observed, authors suggested that each tissue type had a distinct 
methylation profile. The proposed assay was accompanied by an in-house developed 
algorithm that could correctly report the ‘true’ tissue type for all 50 samples. Further 
analysis also revealed that 100% identification could be achieved by using only seven 
out of the 15 loci. The suggested method could be very promising as a forensic 
application since it utilises the same platform used in standard STR profiling; however, 
incomplete digestion by the methylation-sensitive restriction enzyme could lead to 
erroneous results. Furthermore, methylated loci not amplified because of degradation 
in aged samples could be mistaken to be unmethylated. Interestingly, Gomes et al 
failed to reproduce their results on skin identification since they observed the same 
methylation profile for skin and saliva (Gomes et al., 2011). Consequently, the 
suggested loci require further investigation for possible inter-individual variation. 
Table 3-2. Proposed tissue-specific CpG sites (Frumkin et al., 2011) 
CpG sites Locus Chromosomal location 
1 L91762 12: 73,985,697 
2 L68346 3: 12,175,317 
3 L50468 3: 55,492,965 
4 L14432 22: 29,866,149 
5 L4648 1: 35,815,331 
6 L39664 17: 53,710,330 
7 L30139 17: 36,996,489 
8 L55429 5: 1,548,043 
9 L62086 19: 40,478,538 
10 L76138 19: 3,130,217 
11 L15952 7: 2,741,305 
12 L36599 19: 4,867,642 
13 L26688 17: 77,844,826 
14 L81528 19: 47,395,603 




Figure 3-2. Overview of the tissue identification assay (Frumkin et al., 2011) 
 (a) Description of methodology used, (b) During digestion with methylation-sensitive restriction 
enzyme highly methylated loci remain intact and subsequently are amplified during PCR (locus A), 
whereas low-methylated loci are mostly digested resulting in a weak signal due to inefficient PCR 
amplification (locus B); the methylation ratio (MR) corresponds to the differential methylation level 
between these two loci, (c) Obtained differential methylation ratios in blood, saliva, skin and semen, (d) 
Observed methylation differences between blood and semen samples are greater than differences 
observed due to different PCRs or starting DNA amount. 
Additionally, Lee et al tested previously reported, tissue-specific differentially 
methylated regions (tDMRs) in the literature and proposed a different methodological 
approach that included bisulphite sequencing (Lee et al., 2012a). After testing pooled 
DNA from blood, semen, saliva, menstrual blood and vaginal fluid, the authors 







(DACT1) and ubiquitin carboxyl-terminal hydrolase 49 (USP49) that could potentially 
be applied for semen identification. They also tested another three tDMRs belonging 
to the homeobox protein Hox-A4 (HOXA4), profiling-3 (PFN3) and protein arginine 
N-methyltransferase 2 (PRMT2) genes which had previously displayed varying 
degrees of methylation among blood, brain, muscle and spleen. As the authors 
suggested, the presence of an unmethylated HOXA4 tDMR could possibly be used to 
exclude the presence of blood and the PFN3 tDMR could potentially be used for the 
identification of vaginal secretions. Although the results were promising, sex 
differences and inter-individual variations were once again observed.  
To further validate these tDMRs, the authors employed two more sensitive multiplex 
assay systems using four out of the five proposed markers (DACT1, USP49, PFN3 and 
PRMT2): a methylation-specific restriction enzyme PCR (MSRE-PCR) technique 
and a methylation SNaPshot protocol (An et al., 2013). They investigated age-
associated methylation changes by analysing body fluids from both young and elderly 
men and reported no significant differences. Both systems were able to successfully 
identify semen and differentiate menstrual blood and vaginal fluid from blood and 
saliva samples. However, the discrimination power regarding the non-semen body 
fluids was increased when they integrated selected body fluid-specific microbial DNA 
markers and a previously reported semen-specific marker by Frumkin and co-workers 
(L81528, Table 3-2). As a result, the identification of saliva was achieved by detecting 
saliva-specific bacteria whereas vaginal fluid was differentiated from other body fluids 
via Lactobacillus species (Choi et al., 2013).  
Employing a similar approach, Wasserstrom et al developed a DNA methylation-based 
semen test (Nucleix DSI-Semen kit), which could successfully distinguish between 
semen and non-semen samples and could potentially replace the time-consuming 
microscopic examination of casework samples (Wasserstrom et al., 2013). A panel of 
five genomic loci that were believed to demonstrate substantial DNA methylation 
differences between semen and all other body fluids tested were selected and tested on 
135 DNA samples. The accuracy of the kit was high and the accompanying software 
also developed by the authors made the subsequent data analysis more reliable. LaRue 
et al performed a more comprehensive validation study on the kit’s performance and 
illustrated that the required starting DNA material can be as low as 62 pg (LaRue et 
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al., 2013). Nevertheless, a test that could simultaneously identify all body fluids would 
be preferable. 
Most methods mentioned above use a restriction enzyme-based qualitative approach 
rather than provide accurate quantitative methylation results. Following a similar 
protocol, developed by Paliwal and co-workers which allowed for quantitative 
detection of DNA methylation states in minute amounts of DNA from body fluids 
(Paliwal et al., 2010), Madi et al proposed a sensitive method that could be applied in 
trace levels of forensic samples (Madi et al., 2012). Utilising bisulphite 
Pyrosequencing®, they could accurately evaluate the relative quantity of methylated 
cytosines of various adjacent CpG sites at four different genomic loci. The encoding 
chromosome 20 open reading frame 117 (C20orf117) region was found to be blood-
specific, while zinc finger CCCH-Type Containing 12D (ZC3H12D) and fibroblast 
growth factor 7 (FGF7) showed sperm-specific methylation. Lastly, the region of the 
breast carcinoma amplified sequence 4 (BCAS4) seemed to be saliva-specific although 
it had initially been proposed as a semen-specific marker (Eckhardt et al., 2006). It is, 
however, notable that methylation differences between tissues were not always high 
which could also complicate the analysis of mixed body fluid stains [Figure 3-3]. 
Other forensically relevant body fluid types should also be investigated to establish the 
marker specificity. 
Moreover, Ma et al screened six potentially blood-specific tDMRs using methylation-
sensitive difference analysis and Sequenom Massarray utilising methylation-sensitive 
representational difference analysis (MS-RDA) technology (Ma et al., 2013). The 
authors identified two fragments showing blood-specific hypomethylation and four 
fragments showing blood-specific hypermethylation; however no menstrual blood 





Figure 3-3. Mean methylation values obtained for all analysed genomic loci following 
analysis of four different tissue types (Madi et al., 2012) 













As shown in this review, the identification of forensically relevant body fluids in a 
confirmatory way can be quite challenging. Although efforts towards determining 
tissue-specific mRNA and DNA methylation markers have been made, factors such as 
natural inter-individual variation in gene expression or DNA methylation affect 
marker specificity. As observed in most studies, using either mRNA or epigenetic 
markers the detection of biologically complex body fluids containing more than one 
cell type (e.g. vaginal fluid) has been proved to be particularly difficult. Regarding 
mRNA profiling, multiplex PCR systems that allow for simultaneous identification of 
various tissues has already been developed; however, further validation via developing 
an appropriate analysis strategy and establishing interpretation guidelines is required. 
On the other hand, with the exception of semen, determining highly tissue-specific 
differentially methylated CpG sites for the rest of the analysed tissues still remains a 
challenge. Studies so far show promising results, with several working at picogram 
levels of DNA which is necessary for forensic applications; however, it is important to 
either discover more tissue-specific CpG sites or further validate previously reported 



































As mentioned earlier in section 3.2.3.1, two collaborative exercises on mRNA 
profiling for the identification of blood were organised by the European DNA Profiling 
(EDNAP) group in order to evaluate the robustness and reproducibility of the 
proposed mRNA markers (Haas et al., 2012; Haas et al., 2011a). Various forensic 
genetic laboratories across Europe analysed a set of samples using kits and chemistries 
of their own choice as well as their own instrumentation. Since most of the 
participating laboratories had no experience with RNA prior to the first collaborative 
exercise, the main goal was to implement the method and compare the sensitivities of 
the markers. 
On the same principle, the Institute of Legal Medicine in the University of Zürich, 
Switzerland organised another four collaborative exercises on behalf of the EDNAP 
Group regarding the identification of semen, saliva, vaginal secretion, menstrual blood 
and skin: 
x The third collaborative EDNAP exercise on RNA/DNA co-analysis was related 
to the identification of semen and saliva. It involved testing a saliva triplex 
including HTN3, STATH and MUC7 mRNA markers and a novel semen 
pentaplex allowing for the detection and differentiation of both sperm (PRM1, 
PRM2) and seminal plasma (PSA, SEMG1, TGM4). Therefore, semen stains 
obtained from both healthy and azoospermic men could be identified. In addition 
to the multiplexes, four singleplex PCRs (HTN3, MUC7, PRM2 and SEMG1) 
were analysed permitting a comparison of the results obtained using singleplex and 
multiplex analysis. 
x The fourth EDNAP exercise was related to the identification of menstrual blood. 
It involved testing two menstrual blood multiplexes; the MMP triplex including 
MMP7, MMP10, MMP11 mRNA markers and the MB triplex including the 
markers MSX1, LEFTY2 and SFRP4.  
x The fifth EDNAP exercise was relevant to the identification of vaginal secretion. 
It involved testing two vaginal fluid multiplexes; the human Vag triplex consisted 
of MYOZ1, CYP2B7P1 and MUC4 mRNAs and the bacterial Lacto triplex 
containing the markers Ljen, Lcris and Lgas. Together with the multiplexes, a 
HBD1 singleplex was analysed.  
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x Lastly, the sixth EDNAP exercise was organised to test suitable markers for the 
identification of skin cell deposits and included two multiplexes as well; Skin1 co-
amplifying five mRNA markers (LCE1C, LCE1D, LCE2D, IL1F7 and CCL27) 
and Skin2 amplifying LOR, KRT9 and CDSN mRNA transcripts. Additionally, a 
housekeeping (HKG) triplex was proposed that included the B2M, UBC and 
UCE markers. 
Furthermore, as part of the European Forensic Genetics Network of Excellence 
(EuroForGen), another collaborative mRNA exercise was organised which involved 
testing a ‘corrected’ version of the multi-tissue mRNA system proposed by 
Lindenbergh et al. (2012). This adjusted protocol amplifies 20 mRNA markers in total 
and is able to differentiate between blood, saliva, semen, vaginal secretion, menstrual 
blood and skin. It should be noted that it is the only multiplex mRNA system available 
so far that allows for simultaneous identification of all body fluids and is currently 
being implemented in forensic casework in the Netherlands.  
 
4.1.1 Aim and Objectives 
The aim of this study was to evaluate and assess the performance of several multiplex 
mRNA systems as part of collaborative mRNA profiling projects.  
For each validation exercise, a set of blind samples was analysed. The sensitivity, 
specificity and applicability of each multiplex RT-PCR method were assessed. Lastly, 











Each EDNAP/EuroForGen exercise was accompanied with general remarks and 
recommendations on methods and instrumentation settings. The methodology 
employed in this study regarding DNA/RNA extraction, DNase treatment, cDNA 
synthesis, PCR, PCR product purification and fragment analysis via capillary 
electrophoresis is extensively described in the ‘2.3 RNA analysis’ section of Chapter 2.  
4.2.1 Samples 
All body fluid samples together with the primers were sent on dry ice via post and 
stored at -20 oC prior to analysis. No information regarding the samples was revealed 
until the end of analysis. The whole swab or stain was used for DNA/RNA extraction, 
if not stated otherwise. 
Regarding the EDNAP exercises: 
4.2.1.1 Dilution series 
Dilution series for saliva (10, 5, 1, 0.5, 0.1, 0.05 µl), semen (5, 1, 0.5, 0.1, 0.05, 0.01 
µl), menstrual blood (1/4, 1/8, 1/16, 1/32, 1/64 of a menstrual blood swab), vaginal 
secretion (1/4, 1/8, 1/16, 1/32, 1/64 of a vaginal secretion swab) and skin RNA (200, 
50, 12, 3, 0.8 ng) were analysed with the respective single- or multiplexes in order to 
test the sensitivity of the markers.  Specifically for the housekeeping triplex, three 
dilution series of blood (1, 0.1, 0.01, 0.001 µl), semen (5, 1, 0.2, 0.04 µl) and saliva 
(25, 5, 1, 0.2 µl) were tested. For the dilution series, liquid samples were diluted in 
0.9% NaCl to a final volume of 5 µl per sample and were then deposited on cotton 
swabs. Menstrual blood and vaginal secretion swabs were collected from healthy 
females while commercial skin RNA was acquired (Agilent Technologies). All swabs 
were left to dry at room temperature overnight. 
4.2.1.2 Body fluid stains 
Moreover, each exercise included a blind set of stains consisting of either the tissue of 
interest, non-target tissues, age/degraded stains or non-human samples in order to test 
the specificity of the markers as well as the applicability in forensic casework. The 
analysed stains (34 in total) are presented in Table 4-1. 
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Table 4-1. EDNAP mock casework samples consisted of different body fluids 
Stains Description 
Set 1 
1 5 µl of saliva on paper 
2 3 µl of azoospermic semen on pad 
3 ¼ of a vaginal swab 
4 5 µl of saliva on a glass slide 
5 2 µl of semen on toilet paper 
6 1 µl of semen/5 µl of saliva on a swab 
7 ¼ of a buccal swab (cat) 
8 1 µl of blood/2 µl of saliva on a swab 
9 Plastic spoon 
10 3 µl of semen inside latex glove 
Set 2 
11 Menstrual blood on sanitary towel (fresh) 
12 ¼ of a cotton swab with EDTA-blood (fresh) 
13 ¼ of a menstrual blood swab (fresh) 
14 Menstrual blood on sanitary towel (5 years old) 
15 ¼ of a vaginal swab (fresh) 
16 ¼ of a menstrual blood swab (5 years old, day 1-4) 
17 ¼ of a menstrual blood swab (5 years old, day 1/day 4) 
18 ¼ of a menstrual blood swab (fresh) 
Set 3 
19 ¼ of a vaginal swab (2 years old) 
20 5x5 mm from white worn underpants (fresh) 
21 ½ of a swab with urine (fresh) 
22 ½ of a vaginal swab, pregnant (fresh) 
23 ¼ of a vaginal swab (5 years old) 
24 ½ of a vaginal swab (fresh) 
25 ½ of a buccal swab (fresh) 
26 5x5 mm from sanitary towel (fresh) 
Set 4 
27 Small swab from palm 
28 Hand print on paper, glossy side 
29 Key from computer keyboard 
30 Fingerprint on a glass slide 
31 Small swab with urine 
32 Swab from palm/1 µl of blood 
33 Small swab with saliva 





 For set 1 (semen/saliva identification), freshly collected saliva from ten individuals 
was used to make up the stains by depositing it onto different surfaces like paper 
and glass slides. Licked plastic spoons were also provided. Previously frozen (for up 
to 25 years) semen from nine individuals was used to make up the semen stains onto 
various materials such as pad, toilet paper and latex glove. Also, blood from two 
donors, vaginal swab from a healthy female and buccal swab from a cat were used 
as the non-saliva/semen and non-human samples. All stains were prepared and left 
to dry at room temperature overnight. 
 For set 2 (menstrual blood identification), fresh or stored (for up to 5 years at room 
temperature) menstrual blood from six volunteers was collected on swabs or on 
sanitary towels to make up the different stains. Non-menstrual blood samples were 
collected from three healthy females, while semen from one donor (previously 
frozen for up to 5 years) was used. Stain 12 comprised of half of a swab with 
EDTA-blood, which corresponds to around 10 µl in volume. 
 For set 3 (vaginal secretion identification), fresh or stored (for up to 5 years) vaginal 
secretion was collected from six females either on swabs, sanitary towels or 
underwear. Fresh non-vaginal fluid samples were collected from two volunteers in 
the form of a half of a urine swab (stain 21) and half of a buccal swab (stain 25). 
 For set 4 (skin identification), fresh skin samples from three different individuals 
were used to prepare stains 27, 28, 30, 32 and 34, while stain 29 was a key from a 
used computer keyboard. Non-skin stains (urine, saliva and blood) were provided 
by healthy donors. 
4.2.1.3 In-house samples 
To further validate the proposed RT-PCR assays, each laboratory tested their own 
target/non-target body fluid stains; therefore, additional casework/mock casework 
samples were prepared and tested together with the blind sets. Together with set 2, 
two additional stains were analysed including a menstrual blood swab (day 3) and a 
suspected saliva stain (unknown volume, criminal sample). Together with set 3, four 
additional stains were included in the analysis including a vaginal swab (day 16), half 
of a menstrual blood swab (day 4), a skin swab from palm as well as a 5µl saliva stain. 
Together with set 4, four extra samples were analysed including a skin swab from 
palm, a 5 µl saliva stain, a vaginal swab (day 13) and a hair (including the root). 
[130] 
 
Regarding the EuroForGen exercise: 
4.2.1.4 cDNAs and purified PCR products 
Purified PCR products produced by amplifying six different cell types, namely blood, 
semen, saliva, vaginal fluid, menstrual blood and skin were firstly analysed by all 
laboratories in order to adjust provided bin sets and assess any differences in CE 
sensitivity. Then, triplicates of single-source synthesised cDNA samples derived from 
different RNA inputs were analysed in order to evaluate the overall marker sensitivity. 
These cDNA samples had been prepared by initially extracting 10 µl of blood or 
semen, 20 µl of saliva, a stub of skin or a swab containing menstrual or vaginal 
material. Skin samples were collected using a tape lift stub (1*1 cm), until the stub was 
saturated. The entire stub or swab was processed for extraction; however, the exact 
amount of material on them was not measured by the organising laboratory. All RNA 
extracts were then eluted in 60 µl of RNase-free water and were not quantified. 
Especially for menstrual and vaginal samples, RNA inputs in cDNA synthesis were 
also adjusted to prevent profile overload. 
Together with the above cell type-indicated cDNAs, a set of ten unknown cDNAs 
(including one mixture) were included in the study in order to achieve familiarisation 
with the serial cDNA input approach and assess overall performance of the 20-plex 
(marker drop-in and drop-out). These cDNAs were derived from the following 
samples following RNA elution in 60 µl (the utilised RNA amount into cDNA 
synthesis is indicated in brackets): 
 Stain 1 – a stub of skin (1 µl RNA) 
 Stain 2 – 10 µl of semen (fertile) (0.5 µl RNA) 
 Stain 3 – a menstrual blood swab (1 µl of 1:10 diluted RNA) 
 Stain 4 – 20 µl of saliva (1 µl RNA) 
 Stain 5 – No template/blank 
 Stain 6 – a vaginal swab (1 µl of 1:150 diluted RNA) 
 Stain 7 – 10 µl of semen (sterile) (1 µl RNA) 
 Stain 8 – 10 µl of blood (0.75 µl RNA)/a vaginal swab (1 µl of 1:75 diluted RNA) 
 Stain 9 – 10 µl of blood (1 µl RNA) 




These results were used to determine the optimal cDNA input ranging from 0.5 to 2 
µl. Lastly, to test the usefulness of the scoring system, 4 mixed cDNAs were tested 
[cDNA 1 – blood : saliva (1:1), cDNA 2 – blood : saliva : skin (1:1:1), cDNA 3 – 
vaginal : semen (fertile) (10:1), cDNA 4 – menstrual blood : semen (sterile) : skin 
(10:5:1)]. 
4.2.1.5 Complex mock casework samples 
In order to further test the utility of the proposed system for scoring mRNA profiles 
and its applicability in complex forensic casework, four challenging mock casework 
samples were provided: 
 Stain 1 – swab containing equal amounts of saliva from two donors  
 Stain 2 – piece of fleece containing a menstrual blood/whole blood mixed stain 
 Stain 3 – patch of linen with skin from two donors plus whole blood from one 
 Stain 4 – nail clipping containing skin, vaginal mucosa and azoospermic semen 
To make up these stains, saliva and semen were collected in tubes, whole blood using 
the finger prick method, vaginal fluid on cotton swabs, menstrual secretion on Viba 
brushes (Rovers) and skin by rubbing textiles over the face. 
4.2.2 Multiplex and singleplex RT-PCR assays 
For this study, the amplification set up and conditions were followed as described 
below. Primer sequences and amplicon sizes are presented in Tables 4-2 and 4-3. 
Primers are labelled with commonly used dyes to facilitate correct spectral calibration. 
[132] 
 
Table 4-2. Primer sequences and amplicon sizes of the mRNA markers used for the identification of blood, saliva, semen, vaginal secretion, menstrual blood 
and skin as well as the HKG triplex (EDNAP mRNA profiling exercises) 
Body fluid Gene Accession No. Primer sequence (5’Æ3’) Dye Size (bp) 
Saliva 





















































































































































UBC Ubiquitin C  NM_021009 
F GGGTCGCAGTTCTTGTTTGT 
186 
R TCCAGCAAAGATCAGCCTCT  









Table 4-3. Primer sequences and amplicon sizes of the 20 mRNA markers in TissueID 
system (EuroForGen mRNA profiling exercise) 




































































































12.5 µl of Multiplex PCR Mastermix (2X) (providing a final concentration of 3 mM 
MgCl2) (QIAGEN), 2.5 µl of Q Solution (QIAGEN), 2.5 µl of primer mix (HTN3 - 
0.2 µM, STATH - 0.4 µM, MUC7 - 0.1 µM), 5.5 µl of H2O and 2 µl of cDNA were 
mixed for a total volume of 25 µl. Solutions were denatured at 95 oC for 15 minutes, 
followed by 35 cycles 94 oC for 30 seconds, 57 oC (+0.2 oC per cycle) for 90 seconds, 
72 oC for 60 seconds and a final elongation at 72 oC for 60 minutes.  
Semen 5plex: 
Each 25 µl reaction consisted of 2.5 µl of Buffer II (10X) (Applied Biosystems), 2.5 µl 
of dNTPs (10 mM) (Applied Biosystems), 3.25 µl of MgCl2 (25 mM), 0.3 µl of 
AmpliTaq Gold DNA polymerase (5 U/µl) (Applied Biosystems), 2.5 µl of primer mix 
(PSA - 0.72 µM, PRM2 - 0.048 µM, SEMG1 - 0.2 µM, TGM4 - 0.6 µM, PRM1 - 
0.12 µM), 11.95 µl of H2O and 2 µl of cDNA. Solutions were denatured at 95 oC for 
11 minutes, followed by 35 cycles 94 oC for 20 seconds, 58 oC for 30 seconds, 72 oC 
for 40 seconds and a final extension at 72 oC for 60 minutes.  
Saliva/Semen singleplexes:  
Each 25 µl reaction consisted of 2.5 µl of Buffer I (10X) (Applied Biosystems), 1.25 µl 
of dNTPs (2.5 mM) (Applied Biosystems), 0.25 µl of AmpliTaq Gold DNA 
polymerase (Applied Biosystems), 2 µl of primer mix (0.8 µM each), 17 µl of H2O and 
2 µl of cDNA. Solutions were denatured at 95 oC for 11 minutes, followed by 35 
cycles 94 oC for 20 seconds, 58 oC for 30 seconds, 72 oC for 40 seconds and a final 
extension at 72 oC for 60 minutes.  
MMP/MB/HKG/Vag/Lacto/Skin2 3plexes: 
12.5 µl of Multiplex PCR Mastermix (2X) (QIAGEN), 2.5 µl of Q Solution 
(QIAGEN), 2.5 µl of primer mix (MMP/Vag/Lacto: 2 µM each, MB: MSX1, SFRP4 
- 5 µM, LEFTY2 - 2 µM, HKG: B2M, UBC - 2 µM, UCE - 5 µM, Skin2: 8 µM 
each), 5.5 µl of H2O and 2 µl of cDNA were mixed for a total volume of 25 µl. 
Solutions were denatured at 95 oC for 15 minutes, followed by 35 cycles 94 oC for 30 
seconds, 55 oC (+0.2 oC per cycle) for 90 seconds, 72 oC for 40 seconds and a final 





Each 25 µl reaction consisted of 2.5 µl of Buffer II (10X) (Applied Biosystems), 2.5 µl 
of dNTPs (10 mM) (Applied Biosystems), 3 µl of MgCl2 (25 mM), 0.4 µl of AmpliTaq 
Gold DNA polymerase (5 U/µl) (Applied Biosystems), 2 µl of primer mix (20 µM), 
9.6 µl of H2O and 5 µl of cDNA. Solutions were denatured at 95 oC for 11 minutes, 
followed by 35 cycles 94 oC for 20 seconds, 55 oC for 60 seconds, 72 oC for 45 seconds 
and a final elongation at 72 oC for 30 minutes.  
Skin1 5plex: 
12.5 µl of Multiplex PCR Mastermix (2X) (QIAGEN), 2.5 µl of Q Solution 
(QIAGEN), 2.5 µl of primer mix (LCE1C - 1 µM, LCE1D, LCE2D, IL1F7, CCL27 - 
2 µM), 5.5 µl of H2O and 2 µl of cDNA were mixed for a total volume of 25 µl. 
Solutions were denatured at 95 oC for 15 minutes, followed by 35 cycles 94 oC for 30 
seconds, 58 oC for 90 seconds, 72 oC for 45 seconds and a final extension at 72 oC for 
30 minutes.  
TissueID 20plex: 
12.5 µl of Multiplex PCR Mastermix (2X) (QIAGEN), 5 µl of primer mix, X µl of 
cDNA and (7.5-X) µl of H2O were mixed for a total volume of 25 µl, where X is the 
cDNA input calculated with the serial cDNA input approach. The primer 
concentrations were as follows: HBB - 0.035 µM, CD93 - 0.25 µM, AMICA1 - 0.15 
µM, KRT4, HTN3, GAPDH, ACTB - 0.2 µM, STATH, PRM1 - 0.3 µM, SEMG1, 
HBD1, MUC4, MMP7 - 0.8 µM, MMP11 - 0.4 µM, CYP2B7P1, MMP10 - 1.6 µM, 
LCE1C - 0.02 µM, 18S rRNA - 0.025 µM and CDSN, LOR - 0.6 µM. Solutions 
were denatured at 95 oC for 15 minutes, followed by 33 cycles 94 oC for 20 seconds, 
60oC for 30 seconds, 72 oC for 40 seconds and a final extension at 60oC for 45 
minutes.  
4.2.3 The ‘x=n/2’ scoring system 
As mentioned in section 3.1.3.6, Lindenbergh et al proposed a scoring system that 
could be implemented when interpreting mRNA profiles in casework (Lindenbergh et 
al., 2013). A standard mRNA results table was designed so that the results obtained 
from the mRNA replicates could be presented in categorised evaluations for all cell 
types represented in the 20plex. Five scoring categories were used including the 
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obvious “observed” and “not observed” but also the supplementary ones “observed 
and fits with”, “sporadically observed and fits with” and “sporadically observed, no 
reliable statement possible” (Lindenbergh et al., 2013) [Table 4-4]. Firstly, a set of 
informative mRNA profiles are generated by the serial input approach followed by 
replicate analyses of the most informative input.  The signals of housekeeping genes 
can be very useful as they could determine whether a profile is informative. Even 
though housekeeping genes are expressed across most tissues, their expression levels 
vary resulting in distinct profiling characteristics. Ideally, four mRNA profiles are 
obtained from the same sample. Then, the frequency of a signal (of acceptable peak 
morphology and above detection threshold) (x) relative to the times that a signal could 
have occurred (n) can be determined for each cell type. The ‘n’ changes according to 
how many mRNA replicates and number of cell type-specific markers are available. 
Absence of peaks is translated to the category “not observed”, while observation of at 
least half of potential cell type signals for a particular body fluid or tissue results in the 
term “observed”. An observed cell type is categorised as “observed and fits with” 
when it is expected to be co-expressed with another cell type. For example, detection 
of blood markers in a menstrual blood stain is very common; however, extra caution is 
required so that a ‘true’ presence of blood is not masked. When cell type-specific 
signals are present in less than half of all possible positions, the term “sporadically 
observed” is used. Similarly, the categories “sporadically observed and fit with” and 
“sporadically observed, no reliable statement possible” are employed to assess potential 
co-expression issues or marker drop-in.  




Dilution series and body fluid stains were analysed as proposed resulting in either full 
or partial mRNA profiles. All RT- and PCR negative controls showed no peaks 
confirming that there was no RNA contamination throughout analysis. As a general 
remark, certain amplicons were detected as being 1-2 bp longer than expected; 
although this was suspected to be due to instrumental settings. The results of this study 
will also be discussed in comparison with the ones obtained by other laboratories 
(Haas et al., 2014; Haas et al., 2013a; Haas et al., 2015; van den Berge et al., 2014). 
4.3.1 EDNAP mRNA profiling exercises 
4.3.1.1 Sensitivity of proposed PCR systems 
Semen 5plex and SEMG1/TGM4 singleplexes 
Using the semen 5plex PCR, as little as 0.5 µl of semen stains were successfully 
identified with all five markers being amplified [Figure 4-1a]. However, significant 
variation in expression levels was observed; SEMG1 and TGM4 mRNAs produced 
the highest peaks. Although other laboratories were able to detect PRM1 in even 
smaller stains (down to 0.05 µl), in this study no further peaks for any marker were 
detected when using the pentaplex. These findings are also supported by previously 
published sensitivity studies (Haas et al., 2009b). Nevertheless, when using the 
singleplex reactions, the sensitivity of the mRNA markers increased and stains made of 
only 0.05 µl of semen could be identified using the PRM2 mRNA [Figure 4-1b]. 
Interestingly, a significant difference between the multiplex and singleplex reactions 
was observed, since PRM2 was the least sensitive as part of the 5plex but 
demonstrated the highest sensitivity when amplified alone. A possible explanation 
could be the different PCR conditions as in the singleplex there is no longer 
competition between mRNA molecules regarding the PCR components (e.g. dNTPs). 
Saliva 3plex and HTN3/MUC7 singleplexes 
It should be noted that in all samples a larger amplicon (152 bp) was also detected that 
corresponds to a histatin isoform (HTN1), which has 95% sequence identity to marker 
HTN3 [Figure 4-2a]. This has been previously reported in literature and does not 




















(a) Electropherograms of two semen stains (5 and 0.5 µl semen respectively) analysed with the semen 
pentaplex; all five markers were detected, although some peaks were saturated resulting in split peaks, 
(b) Peak heights obtained by analysing the semen dilution series (5, 1, 0.5, 0.1, 0.05 µl semen) with both 

















(a) Electropherogram of a 5 µl saliva stain analysed with the saliva triplex; as shown, all three markers 
were detected (plus the isoform HTN1, indicated with the arrow), (b) Obtained peak heights of the 
saliva dilution series (10, 5, 1 µl saliva) analysed with the saliva triplex; significant variation (10-fold) in 




Figure 4-1. Sensitivity of the semen mRNA markers 
Figure 4-2. Sensitivity of the saliva mRNA markers 
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Saliva stains were successfully identified down to 1 µl of saliva [Figure 3-3b], whereas 
other laboratories achieved detection down to 0.05 µl of saliva. In contrast with other 
groups, MUC7 demonstrated the least sensitivity since no peaks were detected using 
the singleplex assay. 
Menstrual blood MMP/MB 3plexes 
For the identification of menstrual blood, two 3plexes were tested; however, a 
significant variation in specificity and sensitivity was observed amongst the mRNA 
markers. The metalloproteinase MMP 3plex proved to be the most sensitive, since 
successful identification of menstrual blood was achieved by detecting MMP7 using 
just 1/64 of a stained cotton swab [Figure 4-3b]. Additionally, all three 
metalloproteinases (MMP7, MMP10 and MMP11) were successfully amplified (250 
rfu, 334 rfu and 511 rfu respectively) down to 1/32 of a cotton swab. Comparing the 
results obtained from other laboratories, 14 out of 20 were able to detect MMP10 
when extracting just 1/64 of a menstrual blood swab. On the other hand, the MB 
3plex did not show similar sensitivity since only MSX1 was detected down to 1/16 of 
a stained cotton swab. Remarkably, the marker SFRP4 was not detected in any of the 
dilution series samples indicating its lack of sensitivity for menstrual blood 
identification. Less than 15% of the laboratories identified this marker in their samples. 
It is believed that the markers included in the MB 3plex change their expression 
depending on the day of the menstrual cycle indicating that metalloproteinases might 
be the most suitable markers for the identification of menstrual blood. However, 
possible intra- and inter-individual variation in gene expression was evident and 
should be taken into account since it is known that menstrual blood flow can vary 
significantly (Fraser et al., 1985). Also, since the dilution series were prepared in a 
more ‘qualitative’ way rather than quantitative (portions of swab rather than exact 
volumes), variations in the amount of recovered menstrual blood material cannot be 
excluded either. 
Vaginal Vag/Lacto 3plexes and HBD1 singleplex 
Two 3plexes and one singleplex were tested for vaginal secretion and the results were 
promising. All selected mRNA markers apart from Lgas included in the Lacto 3plex 
demonstrated high sensitivity and were successfully identified in the smallest sample 
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size (1/64 of a vaginal fluid swab) [Figure 4-4b]. Lgas was only sporadically observed 
by other laboratories as well, possibly due to the limited co-presence of different 
Lactobacilli species in the sample used for the dilution series and not as a result of low 
detection sensitivity. As shown in Figure 4-4, Ljen seemed to be the most sensitive 
and abundant mRNA marker since it was constantly detected resulting in very high 
peaks. Lastly, it should be noted that the sample containing 1/32 of a vaginal swab 
resulted in lower peaks for most of the markers compared to the 1/64 sample, either 
due to particular experimental circumstances or potentially because of an ‘uneven’ 




















(a) Electropherogram of a ¼ menstrual blood swab analysed by both menstrual blood triplexes; as 
shown, all three markers were detected for MMP 3plex, and only two (unsuccessful amplification for 
SFRP4) for the MB 3plex (the asterisk (*) indicates a non-specific peak due to dye blob, present in both 
samples and negative control), (b) Obtained peak heights of the menstrual blood dilution series (1/4, 
1/8, 1/16, 1/32, 1/64 of a cotton swab) analysed with both multiplexes; as demonstrated, significant 
variation in sensitivity was observed.  


























Skin Skin1 5plex/Skin2 3plex 
Two different multiplexes – a 5plex and a 3plex – were tested for their ability to 
successfully identify touch samples. It should be noted that the amplification of the 




(a) Electropherogram of a ¼ vaginal fluid swab analysed by both vaginal fluid triplexes plus the HBD1 
singleplex; as shown, all markers were detected apart from the Lgas in Lacto 3plex (the asterisk (*) 
indicates a non-specific peak, more likely resulting from the amplification of an isoform, present in both 
the samples and negative control), (b) Obtained peak heights of the vaginal fluid dilution series (1/4, 
1/8, 1/16, 1/32, 1/64 of a cotton swab) analysed with all assays; as expected, some markers seemed to 
be more abundant and sensitive than others.  




samples are generally considered of low quality and quantity, the post-PCR 
purification step was omitted resulting in a number of non-specific peaks. It is believed 
that these peaks cannot interfere and affect interpretation since they are detected at 
different lengths and are observed in both samples and negative control. As shown in 
Figure 4-5, five out of the total eight mRNA markers were successfully detected even 
at the smallest amount of sample (0.8 ng skin RNA), while CCL27 and CDSN were 
still amplified at 3 ng RNA sample. Interestingly, KRT9 was only detected at 200 ng 
giving a relatively low peak (101 rfu), therefore showing the lowest sensitivity between 
the proposed markers. Undoubtedly, LCE1C and LOR were found to be the most 



















(a) Electropherogram of the sample containing 200 ng of skin RNA analysed by both multiplexes – 
Skin1 pentaplex and Skin2 triplex; as shown, all markers were amplified but there was significant 
variation in peak heights (all non-coloured peaks are non-specific) (b) Obtained peak heights of the skin 
dilution series (200, 50, 12, 3 and 0.8 ng skin RNA) analysed with both assays; most markers (apart 
from KRT9) showed great sensitivity since most of them were successfully detected down to 0.8 ng. 




Housekeeping HKG 3plex 
The definitive identification of the presence of cellular material was successfully 
accomplished with the use of a HKG 3plex. To assess the sensitivity of the assay, 
decreasing amounts of blood, semen, saliva, menstrual blood and skin were tested. As 
expected, peaks for these housekeeping genes were obtained with as low as 0.01 µl of 
blood, 0.2 µl of semen, 1 µl of saliva, 1/64 of a menstrual blood and 0.8 ng of skin 
RNA. B2M seemed to be the most sensitive in most tissues, while UCE was the least 
sensitive. 
4.3.2 Marker specificity and inter-individual variation 
The applicability of each proposed multiplex was investigated by analysing a specific 
blind test of body fluid stains [Table 4-1], which could contain the target tissue, non-
target tissues or non-human cells. Samples also included mixtures, low quality and 
aged body fluid stains. 
Ten body fluid stains (set 1) were analysed using the semen 5plex and saliva 3plex 
PCR systems. In general, no false positives were observed and only one stain resulted 
in no peaks [Table 4-5a]. For stain 1 (5 µl of saliva on paper) none of the saliva 
markers were detected; indeed, only four out of the 19 laboratories managed to predict 
that there was saliva on the paper. This stain appeared to be challenging possibly 
because of the presence of inhibiting substances in the paper. The effect of the paper 
dye in the PCR efficiency should be emphasized, as it has been previously noted to act 
as an inhibitor (data not shown). Stain 2 was semen from an azoospermic male and 
therefore, only the seminal markers (and not PRM1/PRM2) were expected. Also, no 
cross-reactions were detected in the vaginal swab (stain 3), highlighting saliva and 
semen markers’ specificity. Stain 4 (5 µl of saliva on glass slide) was successfully 
identified; however, STATH mRNA was undetectable. Since it had been detected in 
5 µl of saliva when analysing the dilution series, the absence of the STATH peak could 






MMP11 MMP7 MMP10 MSX1 LEFTY2 SFRP4
1 Menstrual blood on sanitary towel (fresh) 2445 390 4244 51 1231  -
2 ¼ cotton swab with EDTA-blood (fresh) 136  -  -  -  -  -
3 ¼ menstrual blood swab (fresh) 9408 9152 9298 7497 8405 8541
4 Menstrual blood on sanitary towel (5 years old) 8174  - 3761 55 1443  -
5 ¼ vaginal swab (fresh)  - 3207  - 101  -  -
6 ¼ menstrual blood swab (5 years old, day 1-4) 132 198 217 50 55  -
7 ¼ menstrual blood swab (5 years old, day 1/day 4) 963 102 1804 116 92 57
8 ¼ menstrual blood swab (fresh) 40  - 234  -  - 59
9 Menstrual blood swab (day 3) 8052 3573 4896 461 103  -
10 Suspected saliva stain (unknown volume)  -  -  -  -  -  -
Stains
MMP 3plex (rfu) MB 3plex (rfu)
Singleplex
MYOZ1 CYP2B7P1 MUC4 Ljen Lcris Lgas HBD1
1 ¼ vaginal swab (2 years old) 979 8333 4567 462 8131  - 8118
2 5x5 mm from white worn underpants (fresh)  - (36) 1390 777 8232 7626  -  -
3 ½ swab with urine (fresh)  -  -  - 8325  - 91  -
4 ½ vaginal swab, pregnant (fresh) 1570 8259 8303 788  - 7929 8014
5 ¼ vaginal swab (5 years old) 364 8076 2767 5792 7765  - 1259
6 ½ vaginal swab (fresh) 971 7820 7577 8010  - 7896 4679
7 ½ buccal swab (fresh)  -  - 154 8702  -  - 443
8 5x5 mm from sanitary towel (fresh)  -  -  - 7735  -  - 497
9 Vaginal swab (day 16) 1063 8311 8282 8055 3865  - 7855
10 ½ menstrual blood (day 4)  - 7808 7818 8011 5533  - 3199
11 Skin swab from palm  -  -  - 2175  -  -  -
12 5µl saliva stain  -  -  - 115  -  -  -
Stains
Vag 3plex (rfu) Lacto 3plex (rfu)
LCE1C IL1F7 LCE1D LCE2D CCL27 LOR KRT9 CDSN
1 Small swab from palm 6160/3780 267 1285 512  - 7866  -  -
2 Hand print on paper, glossy side 1140/259  -  -  -  -  -  -  -
3 Key from computer keyboard  -  -  -  -  -  -  -  -
4 Fingerprint on a glass slide  -  -  -  -  -  -  -  -
5 Small swab with urine  -  -  -  -  -  -  -  -
6 Swab from palm/1 µl of blood 6183/1209 277 537 136  - 7449 311 57
7 Small swab with saliva 185/223  -  -  -  - 136  -  -
8 Scraped skin from the back of the hand 5858/2693 4207 1274 5314 822 7836 155 2178
9 Skin swab from palm (fresh) 7408/2339 467 1859 359  - 8120  - 143
10 5µl saliva stain  -  -  -  -  - 209  -  -
11 Vaginal swab (day 13) 7684/3646 136 1361 825  - 7907  - 1075
12 Hair (including the root) 419/-  -  - (40)  -  -  -  -  -
Stains
Skin1 5plex (rfu) Skin2 3plex (rfu)
HTN3 STATH MUC7 PSA PRM2 SEMG1 TGM4 PRM1
1 5µl saliva on paper  -  -  -  -  -  -  -  - 
2 3µl azoospermic semen on pad  -  -  - 770  - 2429 1650  - 
3 1/4 vaginal swab  -  -  -  -  -  -  -  - 
4 5µl saliva on glass slide 403  - 72  -  -  -  -  - 
5 2µl semen on toilet paper  -  -  - 48 79  -  - 215
6 1µl semen/5µl saliva on swab 7440 695 171 369 122 2358  - 111
7 1/4 buccal swab (cat)  -  -  -  -  -  -  -  - 
8 1µl blood/2µl saliva on swab 238  - 178  -  -  -  -  - 
9 licked plastic spoon 4394  - 155  -  -  -  -  - 
10 3µl semen inside latex glove  -  -  -  - 53 61  - 169





























Four sets of stains were analysed with the corresponding multiplexes and the peak heights (rfu) for each 
marker are presented. Coloured squares (purple, green, red, orange and blue) represent the markers that 
were expected to be detected using each multiplex (Saliva, Semen, MMP/MB, Vag/Lacto/HBD1 and 
Skin1/Skin2), while the ones highlighted in grey were not expected to give any signal. The peak 
heights of non-specific signals are emphasised in red. 
Table 4-5. mRNA profiling of 44 body fluid stains using the proposed EDNAP multiplexes 
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Furthermore, three out of the five semen markers were successfully detected in stain 5 
(2 µl of semen on toilet paper), namely PSA, PRM1 and PRM2; however, the peak 
heights were considered quite low. On the other hand, when using the PRM2 
singleplex a 2,609 rfu peak was obtained. Stain 6 was successfully identified as a 
saliva/semen mixture; interestingly, only half of the laboratories detected TGM4. The 
buccal swab from a cat (stain 7) gave no peaks when tested with both multiplexes, 
indicating that the primers are also human-specific. Similarly to stain 2 results, stain 8 
(blood/saliva mixture) and 9 (used spoon) were correctly identified, however, 
STATH was again not detected. Lastly, stain 10 (3 µl semen inside latex glove) was 
differentiated by detecting three out of five markers and no saliva markers. Similar 
results were noticed in stain 5 in terms of PRM2 singleplex; a 4,771 rfu peak was 
obtained by the singleplex, whereas the semen 5plex gave a very low 53 rfu peak. 
The next set of ten stains (eight EDNAP and two in-house samples) were analysed 
using the menstrual blood MMP and MB PCR systems. In general, no false negatives 
were observed; however, there were cases when menstrual blood markers were 
detected in non-target tissues [Table 4-5b]. More specifically, markers MMP11 and 
MSX1 showed very low peaks in stain 12 (¼ of a cotton swab with fresh EDTA-
blood) and stain 15 (¼ of a fresh vaginal swab) respectively, which is believed to be 
due to natural variation in gene expression amongst individuals. On the other hand, 
MMP7 resulted in a high peak for the vaginal fluid that could be explained by the 
presence of traces of menstrual blood in that particular sample.  
Menstrual blood samples demonstrated a significant variation in peak heights, which 
could be explained by potential inter-individual differences in gene expression or 
changes during the menstrual cycle. In general, the MMP 3plex proved to be more 
robust than the MB 3plex since it resulted in less marker drop-outs and higher peaks. It 
was observed that by day 3 and 4 of menstruation, some these markers (MSX1, 
LEFTU2, SFRP4) became undetectable; these findings were also supported by the 
other laboratories. In more detail, stain 13 (1/4 fresh menstrual blood swab) was the 
only one that showed high signals for both triplexes with an average peak height of 
8,717 rfu and strong amplification of the SFRP4 marker. Stain 11 (fresh menstrual 
blood on sanitary towel), stain 17 (1/4 of 5-years-old menstrual blood swab) and an 
in-house stain (fresh menstrual blood swab – day 3) highly expressed all 
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metalloproteinases, however the expression for the markers included in the MB assay 
had often a 10-fold decrease in peak height. Storage time (up to 5 years) did not seem 
to be an essential factor for the identification since stain 14 (1/4 of 5-years-old 
menstrual blood swab) resulted in the amplification of four out of six markers, while in 
stain 18 (1/4 of fresh menstrual blood swab) only three markers were detected 
(average peak height 111 rfu).  
Similar findings were obtained regarding the identification of vaginal material. Twelve 
stains including eight EDNAP and four in-house samples were analysed [Table 4-5c]. 
Although there were no false negative results, the specificity of certain markers (Ljen, 
MUC4 and HBD1) was questioned due to observed cross-reactivity with other 
tissues. Also, significant variation in gene expression was observed by all laboratories. 
The Vag 3plex demonstrated great robustness; nevertheless, all three markers were not 
detected in stain 26 (5x5 mm from sanitary towel). For the Lacto 3plex, Ljen showed 
the highest peaks but it is considered an unsuitable vaginal marker, as traces of these 
bacteria were also observed in urine, menstrual blood, skin and saliva. Similarly to the 
sensitivity analysis results, Lgas was only found in fresh samples (stains 22 and 24).  
Occurrences of cross-reactivity cannot be disregarded; however, the non-specific 
signal intensities were slightly reduced compared to those in vaginal secretion samples. 
For example, HBD1 had an average peak height of 5,070 rfu in vaginal fluid and gave 
a positive signal for buccal epithelium of 443 rfu. Since saliva and urine contain cells of 
epithelial origin, some cross-reactivity was expected. Also, given that healthy 
menstrual blood usually contains traces of vaginal fluid, the amplification of five out of 
seven vaginal mRNA markers was predictable making the identification of vaginal 
fluid very challenging. 
Lastly, regarding the differentiation of touch evidence, twelve stains (eight EDNAP 
and four in-house samples) were tested using the two proposed skin multiplexes [Table 
4-5d]. For the high input samples such as stain 27 (small swab from palm), stain 32 
(swab from palm/1 µl blood), stain 34 (scraped skin from the back of the hand) and the 
in-house stain (skin swab from palm), most skin markers were detected. However, 
contact traces such as stain 28 (hand print on paper), stain 29 (key from computer 
keyboard) and stain 30 (fingerprint on a glass slide) proved challenging and difficult to 





of biological material for these samples was also confirmed by the HKG 3plex, since 
only one housekeeping marker (B2M) was amplified in stain 28. 
The specificity of the proposed skin-specific markers was tested by analysing urine 
(stain 31), saliva (stain 33 and in-house sample) as well as vaginal fluid (in-house 
sample). Whereas urine gave no peaks, LOR and LCE1C were detected in saliva (140 
and 220 rfu respectively). Also, skin was strongly detected in the vaginal sample, 
possibly due to the way that vaginal swabs were collected. The possible presence of 
skin in saliva or vaginal fluid, or the presence of common cell types in these tissues 
cannot be excluded; that way the observed different levels of gene expression could be 
explained by distinct sets of transcription regulators. Finally, the hair sample gave a 
positive signal for one of the most sensitive skin markers (LCE1C) but this was 
expected since the hair was pulled hence it could contain skin cells from the scalp.  
4.3.3 DNA results 
Although not compulsory, DNA extracts were also analysed to assess that the 
proposed extraction method was efficient not only for differentiating the tissue of 
origin but also for identifying the donor of the stain through standard DNA profiling. 
Following DNA/RNA extraction, DNA extracts of all stains and dilution series were 
eluted in 80 µl of EB buffer and DNA concentrations were quantified using the 
Quantifiler Human DNA quantification kit (Life Technologies). Wherever possible, 
DNA samples were diluted down to 1 ng/µl prior to PCR. STR profiles were then 
obtained using the Powerplex ESI 16 system (Promega). 
4.3.3.1 Dilution series 
Figure 4-6 shows the correlation of starting body fluid volume (µl/part of swab) with 
the total DNA recovery (ng) for semen, saliva, menstrual blood and vaginal fluid 
obtained by the analysed dilution series. As expected, the same volume of semen 
resulted in higher DNA yield compared to saliva (~6-fold increase); for instance, 1 µl 
of saliva yielded 4.1 ng of DNA (0.05 ng/µl), while 1 µl of semen produced a total of 
23.2 ng of DNA (0.29 ng/µl). Similarly, the same part of a menstrual blood swab 
yielded more DNA than the corresponding one stained with vaginal fluid (~6-fold 
increase); for example, 1/8 of menstrual blood swab yielded a total of 2.42 µg of DNA 
(30.27 ng/µl), whereas 1/8 of a vaginal swab resulted in 0.44 µg of DNA (5.45 ng/µl). 
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As illustrated, the relationship between sample volume and DNA yield was linear for 
all body fluids (R2=0.95-0.99) suggesting that the followed DNA/RNA co-extraction 
method performed with the same efficiency regardless of the starting cellular material. 
Full profiles were obtained in the saliva dilution series from 1 µl of starting material and 
in the semen dilution series from as little as 0.5 µl of semen. Also, 1/64 of both a 
menstrual or vaginal swab resulted in a full DNA profile.  
4.3.3.2 Body fluid stains 
As expected, the body fluid stains resulted in a range of DNA concentrations 
depending on the quantity and quality of the starting biological material. For the stain 
set 1 (EDNAP stains 1-10, saliva/semen), most resulted in full STR profiles that 
matched the reference profiles. As expected, stain 7 (cat) and 2 (azoospermic semen) 
gave no profiles. Regarding stain set 2 (EDNAP stains 11-18, menstrual blood), most 
resulted in full STR profiles; interestingly, stain 14 (sanitary towel) and 18 (fresh 
menstrual blood) gave rise to partial profiles. In stain set 3 (EDNAP stains 19-26, 
vaginal fluid), all stains also resulted in full DNA profiles apart from urine (partial 
profile). Lastly, stain set 4 (EDNAP stains 27-34, skin) seemed the most challenging 
one due to the low quantity of touch samples; full profiles were obtained only for stains 
32 (1 µl blood), 33 (swab with saliva) and 34 (scraped skin). All touch samples (stains 
27-30) yielded between 0.06-0.46 ng of DNA in total, which is known to be 
insufficient for successful STR analysis. 
 
Figure 4-6. Total DNA yield versus starting volume for all body fluids tested 
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4.3.4 EuroForGen mRNA profiling exercise 
4.3.4.1 Sensitivity of multi-tissue 20plex 
In order to test the sensitivity of the proposed multi-tissue 20plex, 24 single-source 
cDNA samples derived from three mRNA inputs (plus a RT- control) for each of the 
six cell types (blood, semen, saliva, menstrual blood, vaginal secretion and skin) were 
analysed. Samples were prepared as mentioned in section 4.2.1.4 and only 1 µl of 
cDNA was used for all PCR reactions. This analysis also helped with assessing 
potential differences in marker performance within the 20plex. Results are summarised 
in Table 4-6. Most markers seem to be very sensitive, however a few drop-outs were 
observed. Although findings could be affected by the use of a single donor for each 
tissue type, certain conclusions regarding the assay performance could be made. With 
reference to the housekeeping genes, 18S rRNA appeared to be the most robust and 
GAPDH appeared the least robust marker; findings that are also supported by the 
other laboratories. 
In general, the 20plex performed better than the previously analysed cell type-specific 
multiplexes as detection was achieved down to 0.2 µl of extracted RNA. Nevertheless, 
since RNA solutions were not quantified, conclusions regarding sensitivity should be 
made with caution. The most interesting and challenging body fluid seemed to be the 
vaginal fluid, where only CYP2B7P1 was amplified across all three mRNA inputs, 
while HBD1 and MUC4 were not amplified at all. This could suggest suboptimal 
performance of these two markers in the 20plex, which has previously been discussed 
(Lindenbergh et al., 2012). Additionally, non-specific signals were observed for 
vaginal mucosa: (1) blood (CD93 in particular), which may have been the result of 
traces of menstrual blood (the only amplified blood marker in menstrual blood 
samples) and (2) skin (LOR in particular), which could either question the specificity 






Table 4-6. Sensitivity of the TissueID 20plex 
Detected markers when analysing cDNAs derived from three inputs of single source RNAs. For each 
sample, a profile was obtained by using 1 µl of cDNA input. Green boxes indicate successful detection 
of expected markers, while red indicate non-specific amplification. 
 
4.3.4.2 Impact of cDNA input 
The amount of cDNA template added into the PCR could have an impact on the 
number of markers amplified, hence the number of amplicons detected. To illustrate 
the effect of cDNA input on RNA profiling results, eight single-source cDNA samples 
and a mixture were tested using the TissueID 20plex. Two mRNA profiles per sample 
were generated using a four-fold difference in cDNA input volume (0.5 µl and 2 µl 
respectively). In theory, a total of 32 cell type-specific peaks (without the mucosa and 
housekeeping markers) should have been detected for all nine cDNA specimens with 
each cDNA input. Using 0.5 µl of cDNA, 14 peaks (43.8%) were detected, whereas 
with the higher volume (2 µl), 24 peaks (75%) were observed. Cell type-specific peaks 
RNA input (µl)
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detected using both the 0.5 µl and 2 µl input (15 in total) were on average five times 
higher for the latter, which relatively complies with the four-fold increased cDNA 
input volume. Marker drop-out was predominantly seen for the vaginal secretion 
marker HBD1 as well as the blood marker AMICA1, both of which are among the 
least sensitive markers as shown above. Table 4-7 illustrates the impact of cDNA input 
in the detection of all 20 markers included in the assay; in conclusion, a four-fold 
increase in the cDNA amount resulted in an average increase of 38.7% in the number 
of detected peaks; however, marker drop-in (skin) was observed in the vaginal 
secretion samples when using higher amount of cDNA.  
Furthermore, since some blood, saliva and skin samples used in the previous section 
(Table 4-6) had been prepared under the same experimental conditions but with using 
1 µl of cDNA input, it was thought that the results obtained from 1 and 2 µl of cDNA 
could be further compared. Interestingly, for these three tissues there were no 
significant changes in detected markers between the two cDNA inputs; however 
similar conclusions cannot be made for the rest of the tissues. It is believed that 0.5 µl is 
a small amount that should be used with caution as cDNA input volume since it could 
lead to marker drop-outs due to pipetting errors or insufficient template. 
Table 4-7. Impact of cDNA input in the detection of all expected peaks for each tissue 
Eight single-source samples (two skin samples and an azoospermic semen sample) together with a 
vaginal fluid/blood mixture were analysed using two cDNA inputs (0.5 µl and 2 µl). The expected and 
observed peaks were used to demonstrate the impact of cDNA input in the efficiency of the assay. 
 
Expected Observed Missed Une xpe c te d
0.5 6 3 3 0 50.0%
2 6 5 1 0 83.3%
0.5 6 0 6 0 0.0%
2 6 5 1 0 83.3%
0.5 6 3 3 0 50.0%
2 6 5 1 0 83.3%
0.5 6 1 5 0 16.7%
2 6 4 2 0 66.7%
0.5 7 2 5 0 28.6%
2 7 5 2 2 71.4%
0.5 13 10 3 0 76.9%
2 13 10 3 0 76.9%
0.5 5 3 2 0 60.0%
2 5 5 0 0 100.0%
0.5 4 2 2 0 50.0%
2 4 3 1 0 75.0%
0.5 10 4 6 1 40.0%














4.3.4.3 Applicability in forensic casework 
As previously shown in section 4.3.2, testing single- or double-source body fluid stains 
proved to be somewhat difficult. The low yields of biological material from aged or 
degraded samples, the potential cross-reactivity of certain cell-type specific mRNA 
markers and the significant inter-individual variation in gene expression levels make 
the application of mRNA profiling a challenging task. The need for a robust 
experimental strategy including a suitable scoring system and interpretation guideline 
is clear.  
Usefulness of the ‘x=n/2’ scoring system 
In order to test the utility of the proposed scoring system, four cDNAs coming from 
mixtures of two or three cell types in balanced (1:1) or unbalanced (up to 1:10) ratios 
were analysed. All samples were tested using both 0.5 µl and 2 µl of cDNA input; 
however, the latter was considered as the best option since some marker drop-outs 
were observed when using 0.5 µl. Afterwards, using 2 µl of each cDNA four 
informative mRNA replicates were generated and analysed using the scoring system 
[Table 4-8].  
Briefly, cDNA 1 was correctly identified since both blood and saliva were “observed”; 
however, sporadic peaks for vaginal secretion (3 peaks) and skin (1 peak) were also 
detected. All three components (blood, saliva and skin) were also correctly determined 
in cDNA 2; nevertheless, three peaks for menstrual secretion and vaginal mucosa were 
detected. From these results, it becomes apparent that it is helpful to employ the 
category “sporadically observed” (generally regarded as not observed) as it can 
prevent false positive identification. Detecting six out of the twelve possible skin peaks 
in cDNA 3 (10:1 vaginal fluid:semen) led to a false positive identification of skin; a 
finding confirmed by all participating laboratories. This seems a frequent event, 
possibly a consequence of the unintended responses of LOR (and to a lesser extent 
CDSN) in vaginal secretion. Therefore, it seems beneficial to exclude LOR results 
from interpretation. Lastly, regarding cDNA 4, the lowest component of the mixture 
(skin) was missed as it was only “sporadically observed”. Notably, the assay allowed 




Table 4-8. Interpretation of four mixed mock casework samples using the scoring system 
Colour coding of interpretation cells is: dark green = correct, i.e. not observed when not present or 
observed (& fits) when present; light green = sporadically observed (regarded as not observed) when not 
present; red = incorrect, i.e. observed but not present or not observed when present; light red = 
sporadically observed (regarded as not observed) but present. 
 
Complex mock casework 
To further investigate the applicability of the 20plex and the ‘x=n/2’ counting system, 
four challenging mock casework stains (rather than cDNAs) were also analysed. 
Potential variations between different laboratories could help improve the system for 
future application of mRNA profiling in ‘real’ forensic cases. The methodology used 
was the same as for the previously presented body fluid stains; therefore, results can be 
easily compared. The serial cDNA input approach was followed and an optimal cDNA 
amount was determined prior to generating four replicate mRNA profiles per sample. 
In addition to the differentiation of the tissue of origin, the number and genders of the 
donors were also estimated through DNA profiling of the co-extracted DNA. The 









Blood 8 3*4 x ≥ n/2 Observed
Saliva 7 2*4 x ≥ n/2 Observed
Semen 0 2*4 x = 0 Not observed
Menstrual secretion 0 3*4 x = 0 Not observed
Vaginal mucosa 3 3*4 x ≤ n/2 Sporadically observed, no reliable statement possible
Skin 1 3*4 x ≤ n/2 Sporadically observed, no reliable statement possible
Mucosa 4 1*4 x ≥ n/2 Observed and fits with saliva
Blood 10 3*4 x ≥ n/2 Observed
Saliva 8 2*4 x ≥ n/2 Observed
Semen 0 2*4 x = 0 Not observed
Menstrual secretion 2 3*4 x ≤ n/2 Sporadically observed, no reliable statement possible
Vaginal mucosa 1 3*4 x ≤ n/2 Sporadically observed, no reliable statement possible
Skin 12 3*4 x ≥ n/2 Observed
Mucosa 4 1*4 x ≥ n/2 Observed and fits with saliva
Blood 2 3*4 x ≤ n/2 Sporadically observed, no reliable statement possible
Saliva 0 2*4 x = 0 Not observed
Semen 7 2*4 x ≥ n/2 Observed
Menstrual secretion 3 3*4 x ≤ n/2 Sporadically observed, no reliable statement possible
Vaginal mucosa 8 3*4 x ≥ n/2 Observed
Skin 6 3*4 x ≥ n/2 Observed
Mucosa 4 1*4 x ≥ n/2 Observed and fits with vaginal mucosa
Blood 6 3*4 x ≥ n/2 Observed and fits with menstrual secretion
Saliva 0 2*4 x = 0 Not observed
Semen 4 2*4 x ≥ n/2 Observed
Menstrual secretion 12 3*4 x ≥ n/2 Observed
Vaginal mucosa 8 3*4 x ≥ n/2 Observed and fits with menstrual secretion
Skin 4 3*4 x ≤ n/2 Sporadically observed, no reliable statement possible





































































were thought to be present or absent. Taking into account the results so far using the 
20plex system, the markers LOR and HBD1 were excluded during scoring because of 
either non-specific signals with vaginal fluid (LOR) or insufficient amplification 
(HBD1). 
For stain 1 (mother and daughter contributing saliva), both saliva and menstrual 
secretion were scored as “observed” [Table 4-9]. The false menstrual blood score is 
believed to be related to the analysis of slightly overloaded mRNA profiles (obtained 
optimal cDNA input=4 µl) in which trailing signals are found about ten nucleotides 
before the parent peaks. The trailing signal of saliva marker HTN3 fitted within the 
bin of the MMP7 marker (0.3 nucleotides smaller), however, there were also some 
background signal for MMP10. Housekeeping signals also showed these trailing 
signals. These false positive events can be corrected by re-designing the PCR primers 
and adjusting the PCR product length; however, it is believed that gaining more 
expertise in analysing mRNA profiles would result in successfully recognising these 
events. The peaks for the saliva markers were much higher; therefore, it could be 
concluded that the saliva was the main contributor to the sample. On the other hand, 
no false positive scoring occurred for stain 2 (female menstrual blood/skin and male 
blood). However, due to the co-expression of markers in peripheral and menstrual 
blood, the identification of blood was masked under the “observed and fits” category. 
Even though almost half of the total rfu weight in the obtained DNA profiles 
corresponded to the blood donor, it seemed impossible to assign donors to body fluids 
since menstrual blood gives relatively low DNA signals while blood results in lower 
mRNA signals (Harteveld et al., 2013) [Figure 4-7].  
Furthermore, stain 3 (skin and diluted blood from one female as well as skin from 
another female) contained low amounts of cell material (DNA concentration of 0.16 
ng/µl) and proved to be challenging. Only five out of nine laboratories scored skin as 
“observed” and only one managed to detect blood. It was suggested by the organising 
laboratory that ethanol precipitation of mRNA prior to cDNA synthesis would 
potentially solve the problem of low mRNA signals. Finally, for stain 4 (nail clipping 
from a male, vaginal mucosa of a female, azoospermic semen from another male), the 
seminal fluid was completely undetected since no mRNA peaks were observed. Since 
there were no spermatozoa, no DNA peaks were observed. Since SEMG1 is the only 
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marker that is expected to be amplified, it had to be present in all four replicates to 
reach the ‘x≥n/2’ level. Taking into account the above results, it was concluded that 
the “sporadically observed (& fits)” category was very helpful since it lowered the 
number of false positive results caused by non-specific signals.  













Figure 4-7. DNA and RNA signal comparison in stain 2 consisting of two donors and three 
cell types (♀D1 skin and menstrual blood, ♂D2 blood) 
[157] 
 
Data interpretation exercise 
The overall verbal conclusions given by all laboratories regarding the complex 
casework samples were so variable suggesting that guidelines on reporting final mRNA 
results are also needed. Therefore, the same set of DNA and mRNA profiles (produced 
by the organising laboratory) of the four complex stains was asked to be interpreted by 
all laboratories. The interpretation of DNA results, the conclusions regarding the 
estimated minimum number of contributors as well as the donors’ gender were all 
correct. For the mRNA profiling results, two stains were interpreted correctly while 
the other two led to false conclusions.  
The issues regarding stain 1 (false identification of menstrual blood) was resolved and 
the overall interpretation “The sample is more likely to be a mixture of two females; saliva 
was the only body fluid detected so it belongs to either the major donor only or to both of 
them” was correct. On the other hand, for stain 2, blood was still masked during 
scoring and no statement could be made regarding its presence in the sample. Since 
strong HBB and CD93 peaks were present in all replicates, it should have been 
reported as observed. The statement “The sample is more likely to be a mixture of a 
female contributing menstrual secretion and a male contributing skin” was incorrect and 
misleading as the presence of blood was missed. This wrong classification was also 
shared by other laboratories, highlighting the high possibility of missing blood when 
menstrual blood is present. 
However, for stain 3, blood was reported as “observed” since eleven out of twelve 
blood-specific peaks were present in the mRNA profiles. Even though no statement 
could be made regarding the presence of menstrual blood (three peaks present), the 
final conclusion “The sample is more likely to be a mixture of two female donors 
contributing blood and skin; however, no association can be made between donors and body 
fluids” was correct. Finally, all three contributing tissues were identified in stain 4 and 
the assumption of the presence of azoospermic semen could be made. However, the 
wording in the final statement “The sample is more likely to be a mixture of a female 
contributing vaginal fluid and an azoospermic male as his semen was detected but no DNA 
profile was obtained. Skin cells were also present but no statement can be made regarding its 
donor” was incorrect since there was biological material from two males. 
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4.4 Final remarks 
As discussed above, mRNA profiling could be a very useful tool for the identification 
of forensically relevant body fluids and tissues. A number of multiplex PCR assays 
have been developed such as the tissue-specific EDNAP multiplexes or the revised 
TissueID 20plex (developed by the NFI) that allows for simultaneous identification of 
biological fluids. However, extensive validation was required to assess the overall 
performance of these assays prior to applying such a test in forensic casework. In 
general, all analysed assays were found to be extremely sensitive and able to accurately 
determine the tissue source of a stain from minute amounts of starting material; 
nevertheless, for each body fluid certain mRNA markers were found to be more 
robust. A set of freshly prepared, aged, degraded or mixed body fluid stains together 
with selected complex mock casework were used to further assess the applicability of 
mRNA profiling and to identify any flaws in the overall assay performance. 
False negative results were usually obtained in cases where samples were of very low 
quantity or because of suspected inter-individual variation in gene expression levels. 
On the other hand, false positives were occasionally seen as a result of the low 
expression of cell type-specific mRNAs in non-target tissues. Overall, it was observed 
that the identification of vaginal material was the most challenging task since its gene 
expression pattern often resembled those of saliva and skin, both tissues of epithelial 
origin. In most cases skin mRNA markers were detected in vaginal secretion; however, 
it cannot be excluded that this could also be due to contamination with skin while 
sampling. As a whole, the expression of menstrual blood- and vaginal fluid-specific 
markers can be affected by the menstrual cycle and individual differences in menstrual 
flow but it has not yet been experimentally tested. Furthermore, the use of vaginal-
specific bacterial mRNA markers should be followed with caution since co-expression 
of certain bacteria (such as Ljen) was obtained in other tissues. 
Moreover, technical aspects such as the cDNA input in PCR was found to affect the 
resulting mRNA profiles, since overloaded mRNA profiles contained trailing signals 
that fell within other markers’ bins. These findings strongly support the need for 
adjusting the cDNA amount prior to generating a set of PCR replicates. They also 
suggest the potential advantages of applying a scoring system as well as the set-up of 
specific guidelines in regards to the interpretation of mRNA profiles. The analysis of 
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mixtures revealed that it is possible that some markers are occasionally detected only 
in some of the replicates; therefore, by using a scoring system and including the 
category “sporadically observed (& fits)”, false positives could be avoided. This 
variability of markers presence amongst replicates is significantly enhanced when the 
expression (translated as peak heights) is low and is believed to be due to experimental 
variation (mainly PCR). Additionally, it is essential that not only the presence or 
absence of a peak, but also the strength of each mRNA signal is considered so that 
sporadic detection of markers can be better assessed. Especially in the case of a 
menstrual blood/blood mixture, blood could be easily disguised since the detection of 
blood-specific markers is common in menstrual blood. It can be generally accepted 
that it is almost impossible to compare DNA and mRNA profiles in an attempt to 
correlate donors and tissues, since DNA and RNA peaks do not demonstrate the same 
signal strengths. 
The observed variations in mRNA markers detection can be used to improve the 
existing 20plex assay. Adjusting the primer concentrations could lead to better and 
more even amplification across the markers. For example, the vaginal marker HBD1 
was insufficiently amplified within the multiplex system so either the experimental 
conditions could be adjusted or the marker could be replaced by the highly specific 
marker MYOZ1. Similar suggestions could be made for the blood marker AMICA1 
and the housekeeping marker GAPDH. The skin marker LOR often resulted in false 
positive identification of skin so it should be removed or replaced. Furthermore, the 
mucosa marker KRT4 was not found to be particularly useful since there were always 
other cell-type specific markers amplified when positive KRT4 mRNA signals were 
obtained. In order to avoid false positive identification of menstrual blood in saliva 
stains, the size of the MMP7 fragment should be adjusted to avoid overlap; re-design 
of the primers would be recommended. It was noticed that in cases where azoospermic 
semen was present in the sample, the existence of the seminal fluid-specific SEMG1 
marker was required in all replicates in order to reach the ‘x=n/2’ threshold for 
“observed”. Consequently, the addition of an extra seminal marker would be 
beneficial to prevent false negative results. Finally, alongside mRNA profiling, DNA 
profiling was also carried out. The employed DNA/RNA co-extraction method was 
found to be efficient and independent of the starting biological material. Most body 










5 Identification of body fluid-specific 














As shown in Chapter 3, tissue-specific differentially methylated CpG sites have 
already been investigated for use in forensic tissue identification (Frumkin et al., 2011; 
Madi et al., 2012). Although most of these techniques seem to be quite sensitive and 
therefore, suitable for use in forensic specimens, marker specificity issues have been 
reported. With the exception of semen, the discovery of highly specific methylation 
markers for most analysed tissues including saliva or vaginal fluid has proven a 
challenging task. Consequently, it is important that more potentially tissue-specific 
markers are investigated. 
5.1.1 Approaches for identifying suitable CpG sites 
In general, there are several approaches that can be used in discovering tissue-specific 
differentially methylated CpG sites, each demonstrating their own advantages and 
drawbacks. Firstly, large-scale discovery experiments analysing DNA from various 
tissues of the same or a group of individuals could reveal tissue-specific methylation 
patterns. Genome-wide or chromosome-specific methylation studies have already 
been published in literature such as the study by Rakyan et al (2008) analysing a total 
of 13 different tissues. Therefore, similar genome-wide experiments can be performed 
using forensically relevant tissues. This approach allows for the investigation of 
thousands of CpG sites at once, thus maximising the chance of detecting potential 
methylation differences. Also, CpG sites located in various parts of the genome are 
analysed, therefore this approach does not limit researchers in CpG sites located in 
gene promoter regions only. Nevertheless, such methods are costly and data analysis 
usually requires expertise in bioinformatics. Evaluating existing analysed methylation 
data could potentially overcome some of these challenges; however, it is difficult to 
obtain such data for all forensically relevant tissues (e.g. menstrual blood). 
Furthermore, since DNA methylation is known to regulate various genome functions 
including gene regulation, a second approach includes the investigation of already 
reported genes showing tissue-specific gene expression or DNA methylation patterns. 
As an example, even at the early stages of epigenetic research globin genes were 
reported to be regulated through differential DNA methylation patterns (Bartzeliotou 
& Dimitriadis, 1989; Shen & Maniatis, 1980). Also, as shown in Chapter 4, forensic 
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researchers have identified several mRNA molecules showing tissue-specific gene 
expression. Therefore, the methylation status of the corresponding genes could be 
examined to assess if the reported tissue-specific gene expression is due to differential 
methylation patterns. This approach seems very promising and could lead to the 
identification of highly specific markers. However, since current methodologies such 
as methylation specific PCR or bisulphite Pyrosequencing® permit the analysis of only 
a subset of CpGs, this process could be time-consuming. Also, by employing a 
promoter-focused approach, potential methylation markers outside gene regions would 
be overlooked. 
Lastly, as mentioned earlier in section 3.3, researchers have also identified cell type-
specific differentially methylated markers rather than tissue-specific ones (Baron et al., 
2006). In their study, the authors used CDMs for precise and robust quantification of 
subpopulations in cell cultures, in particular immune cell types in whole blood. 
However, it is believed that CDMs could also be used to differentiate between tissues 
since each tissue contains a different ratio of immune cell types. Although this 
approach offers advantages, proposed methods require large amounts of starting 
material (for example, at least 100 µl of whole blood). As an example, the principle of 
published qPCR assays for immune cell-specific methylation detection is presented in 
Figure 5-1. One should also take into account that any medical condition leading to 
immunological responses such as infectious diseases, allergic responses, autoimmunity 
and cancer could alter the results. 
5.1.2 Selection of the appropriate methodology 
As mentioned in section 1.1.5, depending upon the application and number of CpG 
sites of interest, different methodologies for methylation detection can be applied 
including treatment of DNA with sodium bisulphite, use of methylation-sensitive 
restriction enzymes and use of proteins that interact with methylated cytosines. The 
advantages and drawbacks of each approach were discussed and it was concluded that 
bisulphite treatment was perhaps the most appropriate in the context of forensic 
analysis. This is due to the fact that DNA integrity is maintained during analysis (in 
contrast with the use of restriction enzymes) and the quantity of starting DNA 






Figure 5-1. Immune cell-specific methylation detection via qPCR assays (confidential data 
from Epiontis, 2013) 
(a) Overview of developed methodology to detect Treg-specific methylation. (b) Methylation values 
correspond to number of cells; therefore they are useful for cell counting. 
So far, there have been various reported methods based on bisulphite treatment of 
DNA, which will be presented here. The most common one, methylation-specific 
PCR (MSP), is a standard amplification reaction performed using two different sets of 
primers, which are either specific for methylated or unmethylated DNA respectively 
(Herman et al., 1996).  As a result, the binding site must include the CpG site(s) of 
interest. When analysing multiple CpG sites, validation of each CpG site needs to be 
performed individually. Preferential primer binding may also introduce a degree of 
bias that needs to be taken into consideration.  MSP mainly provides qualitative data 
leading to either a positive or negative result and has given contradictory results in 
some studies (Martin-Subero et al., 2009). This is especially true for samples 
demonstrating an intermediate methylation profile. Likewise, methyLight is a 





are specific for bisulphite converted DNA (Eads et al., 2000). This approach allows for 
the separate analysis of differentially methylated sequences that comprise the binding 
site of the probe used. 
In combined bisulphite restriction analysis (COBRA), bisulphite treated DNA is used 
for amplification by a primer set flanking the recognition site of a restriction 
endonuclease (Xiong & Laird, 1997). An advantage of this method is the use of 
restriction enzymes that are not methylation-specific, however, the analysis is 
restricted to single CpGs. Similarly, methylation-sensitive single nucleotide primer 
extension (MS-SNuPE) is another technique that can be applied (Gonzalgo & Jones, 
2002); the main drawbacks associated with this method include the restriction of the 
primer location as well as the use of radioactive nucleotides posing a health risk. On 
the other hand, high-resolution melting analysis (HRM) enables rapid quantification of 
methylation changes in genomic loci but does not provide information about the exact 
location of the methylated/unmethylated CpG sites (Wong & Dobrovic, 2011). 
Differentially methylated amplicons do not behave in a similar way and could affect 
analysis. Lastly, in bisulphite sequencing (BS), PCR products that have been amplified 
using bisulphite converted DNA are either sequenced directly or first cloned into a 
suitable vector and subsequently transferred into a bacterial genome (Clark et al., 
1994). However, BS is not generally considered suitable for quantitative analysis. 
Most standard methylation techniques give only qualitative or semi-quantitative 
results, which can lead to inaccurate interpretation; however, absolute quantification 
allows for the differentiation of physiologically meaningful methylation changes. It is 
believed that the sensitivity and accuracy of Pyrosequencing® surpass alternative 
methods [Figure 5-2], thereby making its application ideal in forensic science, e.g. 
analysis of autosomal STR markers (Divne et al., 2010), s equencing of mitochondrial 
DNA (Andreasson et al., 2007) and Y-chromosomal STR analysis (Edlund & Allen, 
2009). Pyrosequencing® technology refers to the real-time pyrophosphate detection of 
DNA sequencing.  It is a simple, robust and sensitive technique, which enables 
accurate and quantitative analysis of DNA sequence variation and has demonstrated 
unrivaled performance in determining the methylation status of individual or multiple 
adjacent CpG sites (Dupont et al., 2004). Overall, Pyrosequencing® allows for single 







Pyrosequencing® can reliably determine the nucleotide sequence starting with the first 
base following the primer. Although the read length is limited in comparison to other 
techniques (100-150 bp), the use of a single-stranded binding protein has been 
reported to efficiently allow for longer sequences to be analysed (Ronaghi, 2000). 
Assay design is very versatile as there is no restriction on primer locations; however, 
suitable, non-CpG-containing primers are essential to avoid possible PCR bias. 
Nevertheless, the use of standards with known methylation levels can be used to 
normalise the quantification procedure. Furthermore, extra precautions are also 
needed since non-specific signals are sometimes generated due to the low reaction 
temperature of the sequencing process (28 oC). This problem can be easily overcome 
with the use of quality controls such as dead injections, reference peaks and built-in 
bisulphite conversion controls. 
In a forensic setting, quantitative and reliable estimation of DNA methylation levels 
pose a major challenge; however, recent advances allow for the sensitive detection of 
DNA methylation at multiple CpG sites from less than 1 ng of DNA from trace 
amounts of body fluids (Paliwal et al., 2010; Xu et al., 2012). Paliwal et al proposed a 
method that involves genome-wide amplification of bisulphite-modified DNA 
template and quantitative methylation detection using Pyrosequencing® starting with 
extremely low DNA amounts (100 pg). Genome-wide amplification can overcome the 
limitation of the minute quantities of DNA, however, good quality and quantity of 
starting DNA material remains the most critical determinant of such an experiment. 
Pyrosequencing® 
Methylight 












     Screening/Detection                      CpG analysis                  Specific quantification 
Figure 5-2. Schematic comparison of DNA methylation techniques 
Methylation specific PCR 
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Furthermore, the possibility of any methylated/unmethylated allele bias cannot be 
formally ruled out. In another study, Xu et al recommended a modified, more efficient 
method of bisulphite genomic DNA sequencing from dried blood spot microvolume 
samples. After bisulphite treatment, the methylation status of the differentially 
methylated region (DMR) of the maternally imprinted gene named small nuclear 
ribonucleoprotein polypeptide N (SNRPN) was investigated using methylation-
specific PCR and direct sequencing. 
5.1.3 Aim and Objectives 
The aim of this study was to investigate selected body fluid-specific differentially 
methylated CpG sites and assess the possibility of using a small number of DNA 
methylation markers to accurately differentiate between forensically relevant body 
fluids. 
In order to meet the aim, the following objectives were addressed: 
 A suitable Pyrosequencing®-based method was evaluated using a pre-designed 
HBA1 assay (QIAGEN). Validation of the method was achieved by establishing 
sensitivity, accuracy, reproducibility and linearity of methylation quantification. 
 Potential tissue-specific differentially methylated CpG sites were identified using 
three different approaches: (a) by validating reported body fluid-specific markers 
in the literature, (b) by analysing published methylation data obtained from blood, 
semen and buccal cells, and lastly (c) via validating proposed immune cell-type 
specific markers as part of a collaborative project within the EuroForGen 
consortium. 
 Suitable bisulphite Pyrosequencing® assays were then developed and optimised 
enabling the measurement of the methylation levels of selected CpG sites 
 The specificity of the proposed markers was evaluated by analysing a large set of 
body fluid samples including blood, semen, saliva, menstrual blood, vaginal 
secretion, skin and urine. 
 Promising markers were then further validated by testing their sensitivity and 





5.2.1.1 Fresh body fluid/tissue samples 
All body fluid samples were collected from a total of 168 volunteers of both sexes and 
various ethnic backgrounds with ages ranging from 16 to 70 years old. Individuals had 
the choice to donate one or more body fluids/tissues including whole blood, saliva, 
buccal cells, seminal fluid, vaginal fluid, menstrual secretion, skin, urine and nasal 
fluid. Samples were collected as previously described in section 2.1 and were stored at 
-20 oC until extraction. Additionally, six nasal blood samples were provided by a 
collaborative laboratory as part of the EuroForGen project. As shown in Table 5-1, the 
final dataset comprised of 254 body fluid samples. DNA samples were firstly amplified 
using the PowerPlex® ESI 16 kit (Promega) as described in section 2.2.4.5 to confirm 
that they all were of a single source and no contamination had taken place. 
Table 5-1. Body fluid samples analysed in this study 
 
5.2.1.2 Aged samples 
For validation purposes, a set of aged stains or DNA samples were used which had 
been previously collected for research purposes. The set included: 
 Five blood samples stored for 9-18 years in the dark and at room temperature 
 Four semen samples stored for 16 years at -20 oC 
 Five blood DNA samples stored for 1-9 years at -20 oC 
 
Set Samples ♀/♂ Age range (mean) (years) 
Whole blood 65 28/37 16-70 (38) 
Saliva 46 31/15 19-34 (26) 
Buccal cells 15 12/3 18-50 (32) 
Semen 18 0/18 19-34 (25) 
Vaginal fluid 22 22/0 20-33 (25) 
Menstrual blood 20 20/0 22-33 (26) 
Skin 28 20/5 21-33 (25) 
Urine 20 10/10 21-60 (27) 
Nasal fluid 13 8/5 22-37 (28) 
Nasal blood 6 N/A N/A 
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5.2.1.3 Body fluid stains 
Using freshly collected samples, the following body fluid stains were prepared: 
 Mock casework blood samples including 1 µl on a piece of jeans fabric, 3 µl on shirt 
which was washed afterwards, 3 µl on a towel and 5 µl on tissue paper 
 Mixed stains including 1 µl blood:1 µl semen and 2 µl blood:1 µl saliva on swabs 
 Artificially-degraded blood samples by exposing 1 µl under UV for 0, 10, 30, 60, 
90, 120 and 240 minutes 
 5 µl of blood on fabric stored at various temperatures (-20 oC, 4 oC, 25 oC, 37 oC, 
outdoor) for a week 
All stains were left at room temperature to dry overnight before analysis. 
5.2.2 Selection of suitable tissue-associated CpG sites 
As previously mentioned, there are various ways in identifying potential tissue-specific 
differentially methylated CpG sites; here, three different approaches were followed. 
5.2.2.1 Reported tissue-associated CpG sites in the literature 
Neumann et al analysed the methylation status of the embryonal Fyn-associated 
substrate (EFS) gene in various tissues including blood, buccal cells, sperm, and brain 
and reported tissue-specific methylation patterns (Neumann et al., 2011). In more 
detail, they found that EFS is highly methylated in blood, completely unmethylated in 
sperm and partially methylated in buccal cells. Therefore, it was thought that this 
marker could be a good candidate for blood detection; however, other forensically 
relevant tissues needed to be investigated before any conclusions could be made. 
Authors analysed a total of eleven CpG sites located in the region Chr4: 23,835,859-
23,835,970, which were used for the development of Pyrosequencing® assays. 
5.2.2.2 Tissue-specific CpGs via genome-wide methylation data analysis 
There are various published studies investigating genome-wide methylation patterns 
across various tissues that have either revealed tissue-specific (Rakyan et al., 2008; 
Thompson et al., 2013) or age-associated CpG sites (Rakyan et al., 2010; Zykovich et 
al., 2014). Combining available data from two studies analysed by different large-scale 
methodologies for three forensically relevant tissues (whole blood, buccal cells and 
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sperm), the methylation status of a total of 3,305 CpGs was obtained. Methylation 
data for seven blood and two sperm samples were obtained from the study by Rakyan 
et al (2008), while methylation values for ten buccal swabs were gathered from 
Rakyan et al (2010). 
In order to identify potential CpG sites of interest, the average methylation level of 
each tissue for every CpG site was obtained. Initially, the criterion of choosing suitable 
CpG sites was set as a minimum of 70% methylation difference between the tissue in 
question and the remaining two. For example, a ‘good’ blood specific marker would be 
one that showed to be methylated in blood (>80%) and unmethylated in sperm and 
buccal cells (<10%) or vice versa. As a result, 14 blood-specific, 20 saliva-specific and 
365 semen-specific CpG sites were identified. The number of semen-specific CpG 
sites was relatively high, which could reflect on the different and unique functions of 
sperm DNA. Thus, only for semen the minimum difference of methylation levels was 
increased to 85%, thus, the number of potential CpG sites decreased down to 22. 
Both tissue-specific methylation and non-methylation were observed, although the 
latter was observed comparatively more often. For the purpose of this study, four CpG 
sites demonstrating the highest methylation difference between the selected tissues 
were selected for each body fluid (two tissue-specific unmethylated and two tissue-
specific methylated markers). Therefore, a total of twelve potentially tissue-specific 
CpG sites were chosen for Pyrosequencing® assay design [Table 5-2]. Most of them 
belong to protein-coding genes and are usually located within their 5’ end. 
5.2.2.3 Immune cell-specific CpG sites 
As part of a EuroForGen collaborative project, it was thought that body fluids can be 
successfully differentiated through specific immune cell infiltrates. Initial studies using 
qPCR-based assays revealed a set of potential immune cell-specific methylation 
markers [Figure 5-3]. For this study, six loci specific to the following cell types 
involved in the immune response: T cells, neutrophils, NK cells  and naive CD8+, 




Table 5-2. Identified blood-, semen- and buccal cell-specific methylation markers resulting from analysing genome-wide methylation data (Rakyan et al., 
2008 & Rakyan et al., 2010) 
Essential information regarding chromosomal location of the selected CpG sites, the gene they belong to as well as their exact position within the gene. The mean methylation 
levels obtained by the genome-wide analysis was used to calculate the minimum methylation difference.  
Marker Chromosomal location Gene Position within gene 
Mean DNA methylation levels 
Difference 
Buccal cells Blood Sperm 
cg05761971 2:38,177,677 FAM82A1 5' Upstream sequence 10,8% 87,2% 88,2% 76,4% 
cg16779976 10:98,031,125 BLNK Exon 1 10,5% 85,6% 88,4% 75,1% 
cg15731815 1:6,269,260 RNF207 Intron 5 84,3% 7,9% 7,7% 76,4% 
cg08258650 11:35,441,900 RP4-683L5.1 Intron 1 77,1% 5,5% 5,0% 71,5% 
cg17518965 19:3,178,955 S1PR4 Exon 1 87,7% 2,0% 95,5% 85,7% 
cg26285698 16:29,757,334 C16orf54 5' Upstream  86,1% 8,5% 87,2% 77,6% 
cg13763232 3:14,443,428 SLC6A6 5' Upstream 14,5% 90,3% 6,0% 75,8% 
cg21613754 2:219,133,847 AAMP Intron 2 14,5% 86,1% 12,6% 71,6% 
cg04382920 4:128,651,526 SLC25A31-001 5' Upstream 99,0% 97,0% 2,0% 95,0% 
cg11768416 12:91,348,697 C12orf12 Exon 1 98,1% 95,8% 1,9% 93,9% 
cg01318557 7:73,624,319 LAT2 Exon 1 1,9% 4,3% 95,6% 91,3% 
cg05656364 2:85,804,732 VAMP8 Exon 1 1,5% 5,3% 90,3% 85,0% 
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Figure 5-3. Epigenetic profiles of various immune cell markers in forensically relevant 
body fluids (confidential data from Epiontis 2013) 
A total of six samples from six different tissues were analysed with various qPCR assays. Each column 
corresponds to a different tissue, while each row separated by the horizontal red lines represents an 
assay corresponding to a specific cell type (e.g. AMP1404 measures methylation levels of T cells). The 
horizontal lines within each row correspond to different CpG sites; each assay can measure numerous 
CpG sites at once. Methylation levels are presented using a colour scale (0%-yellow, 100%-blue). Red 
circles indicate potential immune cell-specific differentially methylated CpG sites. 
Table 5-3. Selected loci for analysing immune cell-specific methylation levels 
Loci Immune cell type Chromosomal position Gene 
AMP1404 T cells 11:118,213,614-118,214,043 CD3 
AMP1730 Neutrophils 9:130,911,530-130,911,888 LCN2 
AMP1746 NK cells 11:3,121,298-3,121,543 OSBPL5 
AMP1817 naive CD8+ T cells 11:66,083,367-66,083,805 CD248  
AMP2004 CD8A+ T cells 12:6,899,890-6,900,346 CD4 
AMP2007 CD8B+ T cells 2:87,048,390-87,048,818 CD8b 
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5.2.3 Pre-designed PyroMark CpG assay (HBA1) 
For the purpose of the initial Pyrosequencing® assay development, a PyroMark CpG 
assay capable of analysing four CpG sites belonging to the haemoglobin, alpha 1 
(HBA1) gene was available and chosen for this study. Following the PCR conditions 
mentioned in section 2.2.4.3, the amplicon has a length of 150 bp and the analysed 
sequence is the following: CCCGCGCTGCAGGCGTCG (Chr16: 231,036-
231,054). 
5.2.4 Bisulphite Pyrosequencing® assay design  
Following the guidelines regarding assay design mentioned in sections 2.2.4.1 and 
2.2.6.1.1, bisulphite Pyrosequencing® protocols were designed using the BiSearch 
primer design tool. Each assay includes a 10X PCR primer set (forward and reverse) as 
well as 10X sequencing primer(s). For some assays, two sequencing primers were used 
in order to accommodate all CpG sites of interest. For EFS, ten out of the reported 
eleven CpG sites were investigated due to location and assay design restrictions. 
Furthermore, a total of twelve assays were designed to investigate the CpG sites 
identified via the analysis of genome-wide methylation data. However, assay design 
allowed for the co-analysis of a few adjacent CpG sites per assay resulting in a total of 
48 analysed CpGs. Therefore, to simplify data analysis, these assays were named 
according to the tissue they were specific for (BL- for blood, SE- for semen and BU- 
for buccal cells) and if they were expected to be unmethylated (-U-) or methylated (-
M-) in that specific tissue. As an example, the assay BLM1 (cg13763232) indicated 
that the investigated CpG site is expected to be methylated in blood, while being 
unmethylated in semen and buccal cell samples. Lastly, regarding the immune cell 
markers, only the CpG sites targeted by primer/probes in the previously developed 
Taqman-based assays were investigated (39 CpG sites in total resulting in six 
Pyrosequencing® assays). Information regarding all 19 designed assays measuring the 
methylation status of a total of 97 CpG sites is presented in Tables 5-4 and 5-5. 
5.2.5 Optimised bisulphite PCR conditions 
In initial experiments, the AmpliTaq Gold PCR master mix (QIAGEN), often used in 
forensic DNA profiling as well as the PyroMark PCR (QIAGEN), which is 
specifically designed for Pyrosequencing® analysis were utilised. However, the PCR 
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efficiency was very low and non-specific products or primer-dimers were observed in 
most assays (data not shown). Consequently, it was made clear that a more ‘specific’ 
DNA polymerase was needed to overcome potential difficulties when amplifying 
‘difficult’ and of reduced complexity DNA such as bisulphite-converted DNA 
sequences.  
As mentioned in section 2.2.4.4, ZymoTaq premix (Zymo Research) contains a heat-
activated, “hot start” DNA polymerase, which reduces the occurrence of non-specific 
product or primer-dimer formation when amplifying bisulphite-converted DNA. 
Starting with the standardised PCR conditions previously described in sections 2.2.4.2 
and 2.2.4.4, bisulphite PCR assays were optimised. Briefly, each PCR reaction 
consisted of 12.5 µl of ZymoTaq PreMix, 1 µl of 25 mM MgCl2 for a final 
concentration of 2.75 mM (since the ZymoTaq™ Premix also contains 1.75 mM 
MgCl2), 1µl of each PCR primer (for a final concentration of 0.4 µM), 1 µl of 
bisulphite DNA template and 8.5 µl of nuclease-free water, for a total reaction volume 
of 25 µl. The thermocycling program used was: 95 oC for 10 minutes, followed by 45 
cycles of 94 oC for 30 seconds, Tm for 30 seconds (SEU1 - 48 oC, EFS, BLU1, 
AMP1817 - 50 oC, AMP2007 - 52 oC, AMP1404, AMP1730, AMP1746, AMP2000 
- 54 oC, BLM1, BLU2, SEM1, BUM1, BUM2, BUU1, BUU2 - 55 oC, SEM2 - 57 oC 
and SEU2 - 61 oC), 72 oC for 30 seconds, and a final extension step of 72 oC for 7 
minutes. Specifically for BLU1, BUM1, BUM2, BUU1 and BUU2, the annealing and 
extension step of each cycles were 40 seconds long. Following amplification, the 




Table 5-4. Designed bisulphite PCR assays 
Essential information regarding the designed bisulphite PCR assays are shown, such as the number of analysed CpGs, the score assigned by the primer design software (the lower 
the score the more efficient amplification), the primer sequences and length (F for forward and R for reverse), the % G and C content, the melting temperature (Tm), the number 
of converted cytosines included in the primer sequence (highlighted in red) as well as the length of the final PCR product.  
         Assay CpG sites Score Primer Sequence (5’ Æ 3’) Length (bp) %GC Tm (Co) Converted Cs PCR Product (bp) 
EFS 10 25.4 
F GGTTTTTTTTTTATTAGTTT 20 15.0 55.2 9 
195 
R CTTCATATTATCACTAAAACC 21 28.6 54.5 5 
BLM1 4 11.11 
F TAGTTGATATTGGTTTGGTA 20 30 55.3 5 
159 
R CAAATAACTCAATTTCTCTAC 21 28.6 54.7 3 
BLM2 2 26.27 
F AAGTGTTGGGATTTTAGGAGT 21 38.1 60.1 2 
180 
R CCTCTTAATTTTCTTTTAAAAAC 23 21.7 58.1 1 
BLU1 3 43.64 
F GGTTTATTGTTTTGTATTAT 20 20 53.4 6 
127 
R AAATTCTCCAACACCACC 18 44.4 57.4 2 
BLU2 5 13.17 
F GAGTTATTTTTTTTGGTGTTGGAT 24 29.2 60.7 8 
188 
R ACATCCCCTTAAATTACTTT 20 30 57.2 4 
SEM1 3 20.57 
F ATGATTTAGTGGTTGGTAGGAA 22 36.4 59.6 3 
147 
R AACACCCCTAAAAAAAAC 18 33.3 57.1 7 
SEM2 3 18.77 
F AGTAAGTAGGAAGTGAATTGA 21 33.3 57.1 3 
89 
R ATATCTCAAAACAACCCAAA 20 30 56.6 6 
SEU1 10 41.17 
F TTTTATTAGAAAGTTTAGG 19 21.1 53 7 
280 
R ACAACAATAACTAAAAATAAATAC 24 16.7 56.4 6 
SEU2 5 36.54 
F GGAGGTTGTTTTTTTTTTGGTTT 23 30.4 62.4 6 
134 
R CTACCAACACCTTCCTCC 18 55.6 58.9 1 





BUM1 6 45.49 
F GTAGAGTTTTATTTTTTGTT 20 20 54.4 7 
357 
R CTCCTCCACCATAACCTA 18 50 56.9 3 
BUM2 4 28.1 
F TAGAGATAGATGGGTTTG 19 36.8 54.8 3 
112 
R CTAAATTCCTACAATATTCC 20 30 54.2 4 
BUU1 1 18.15 
F GAAAGGTGAGTTATAGAATAGTT 23 30.4 57.9 3 
198 
R CAAAATAAATCTCTCCCTT 19 31.6 55 2 
BUU2 2 19.99 
F TTGAGATGTTATAAGAGTATTGG 23 30.4 56.8 5 
196 
R ACTACTCCCTAAAAAAAC 18 33.3 55.2 7 
AMP1404 5 14.65 
F ATGGAAAAGGTGGTTTGAATTT 22 31.8 60.4 3 
163 
R TCCTAAAAAAAATCAACCTC 20 30.0 57.0 4 
AMP1730 3 16.97 
F AGAAAGAAATAGTATAAGGAAGG 23 30.4 58.4 3 
182 
R ACCAAAACCAAAAATATAAAACA 23 21.7 59.0 9 
AMP1746 7 16.42 
F TGAGTTTTTTATTTTTGTAGTGG 23 26.1 58.7 7 
137 
R AATCCTACTATCTCTTATCTCTA 23 30.4 56.2 6 
AMP1817 11 36.1 
F GGTAATTTGGTATTTATTT 19 21.1 53.1 6 
188 
R GCTACACTAAAAACTTCC 18 33.3 54.2 5 
AMP2004 5 18.45 
F TTTTGTTTTTGTGGTGGATA 20 30.0 57.4 6 
221 
R ACTCCCACATTAAAAAAAAAAA 22 22.7 59.1 6 
AMP2007 7 22.38 
F GTTAAAGGAGTTGTTAATATTT 22 22.7 56.5 4 
165 
R GCAAAACAAAACCCCATATT 20 30.0 58.0 5 








Table 5-5. Pyrosequencing® DNA methylation assays 
The table includes details of the sequenced chromosomal locations, the sequencing primer sequences as well as the nucleotide dispensation order. The CpG sites in question are 

















BLM1 3: 14,443,420-47 ATATTGGTTTGGTATTTTTTAGAT GCCGGGTGCGTTCCGAGTTCTCTACGCT AGTCGTGATCGTCGAGTCAGTCGT 
BLM2 2: 219,133,845-61 GTTGGGATTTTAGGAGTGAGTTAT CACGCCCGGCCAAAGAT ATCAGTCGATCGATCAGAT 
BLU1 19: 3,178,931-59 GGTTGGAGGATGGCGGTTTGGG GGCCCTGCGGGGGCTGTCGGTGGCCGCCA AGTCGTCGATCGTCGTGTCGTCA 
BLU2 16: 29,757,190-227 AGGTGTAGGTTTGGAGGGTGTAGG 
GCGGTCCGCCTCTCAGACGTAGAGGCCCGGCCT
CGGAT AGTCGATCGTCAGATCGTAGAGTCGATCGAT 
SEM1 7: 73,624,318-35 GATTTAGTGGTTGGTAGGAAGT CCGCCCTGCCCGCCCGCC ATCGTCGATCGATCGATC 
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5.2.6 Sample analysis 
Genomic DNA was extracted using either the QIAamp DNA Investigator kit or the 
BioRobotEZ1® DNA extraction as described in sections 2.2.1.2 and 2.2.1.3. Then, to 
assess the quality and quantity of the resulting solution, DNA samples were quantified 
using the Quantifiler Human DNA investigation kit as described in 2.2.2.1. As 
previously mentioned in section 2.2.3, a total of three different bisulphite conversion 
kits were employed and their efficiency was evaluated through the built-in conversion 
controls. Bisulphite-converted DNA samples were amplified using the optimised PCR 
conditions for each assay together with pre-defined DNA methylation controls (0%-
100%). Afterwards, 10 µl of biotinylated PCR products were sequenced on a 
pyrosequencer as described in section 2.2.6.1 and DNA methylation values were 
obtained via the PyroMark CpG software (QIAGEN). Specific experimental 
































5.3.1 Evaluation of a Pyrosequencing®-based method (HBA1) 
As discussed in the introduction, Pyrosequencing® was thought to overcome existing 
methods’ limitations since it allows for absolute quantification of methylation levels. 
However, it was important to evaluate a Pyrosequencing®-based method using more 
stringent forensically recognised validation criteria. For the purpose of the initial 
Pyrosequencing® protocol evaluation, it was decided that a commercially available 
CpG assay for HBA1 gene would be employed to ensure high PCR efficiency. Since 
HBA1 has been proposed as a blood-specific mRNA marker in the literature (Haas et 
al., 2011b), it was also interesting to investigate the methylation status of this genomic 
locus. The efficiency of bisulphite conversion, the accuracy and linearity of 
methylation quantification as well as the overall sensitivity of the method were 
evaluated. 
5.3.1.1 Bisulphite conversion rates 
Apart from the four CpG sites, the assay also includes a built-in bisulphite conversion 
control [Figure 2-6]. To evaluate the efficiency of bisulphite treatment, 400 ng of six 
blood DNA samples were treated with Epitect® Bisulphite kit as described in section 
2.2.3.1 and analysed using the proposed method. The average obtained peak height 
was 269±178 rfu while the average bisulphite conversion rate was calculated >99% in 
all samples, which was expected since 400 ng of starting DNA material was within the 
kit’s optimal range. Since forensic specimens are likely to be of lower quantity, one of 
the blood samples was chosen to test decreasing amounts of DNA to be treated. 
Therefore, 10, 5, 2 and 1 ng of blood DNA were converted using the same 
experimental conditions, except the maximum DNA input into the PCR was used (7.5 
µl). As a result, the obtained peak heights were significantly lower (average of 55 rfu); 
however, the conversion rate when using only 1 ng was still very high (96.6%). In all 
cases, blood samples showed low methylation levels (<0.08) with an average 
methylation value of 0.033. Since HBA1 is expressed in blood, it was thought that the 





To assess how decreasing starting material affects the methylation quantification, a 
blood sample was treated from 1 ng to 100 pg. As shown in Figure 5-4, the ‘expected’ 
methylation levels (<0.1) were obtained down to the smallest DNA input, although 
average methylation levels slightly increased when decreasing the starting DNA 
material. It is believed that this could be due to the decreasing observed peak heights, 
thereby increasing the background-to-noise ratio.  
 
Figure 5-4. Average detected methylation levels with decreasing starting DNA amount 
using a single blood sample 
Error bars represent standard deviation. 
To further test this, 100 pg of a total of nine blood samples were analysed. As a result, 
the mean peak heights for all dispensations were >60 rfu while the obtained bisulphite 
conversion rates were >96% in all samples. As shown in Table 5-6, CpG sites were 
found to be unmethylated in most samples, but occasionally methylation was slightly 
higher. For example, for blood 8 CpG 4 was found to be completely methylated 
(>0.992). To assess if this was due to stochastic events because of the low template or 
due to natural inter-individual variability, 400 ng of this sample was reanalysed 
resulting in <0.1 methylation. Therefore, it can be concluded that caution is needed 
when analysing less than 1 ng of DNA since methylation levels could be altered due to 
either stochastic events during PCR or incomplete bisulphite conversion for particular 























Amount of treated DNA (ng)
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Table 5-6. Detected methylation levels using 100 pg of blood DNA (n=9) 
 
5.3.1.3 Reproducibility 
To assess the accuracy of methylation quantification, a blood sample was analysed in 
six technical replicates. 100 ng of DNA was treated and 3 µl of converted DNA was 
used as a template in PCR. The obtained results were promising since for each CpG 
site the maximum standard deviation was 0.05. 
5.3.1.4 Linearity 
All blood samples analysed so far showed very low methylation levels; therefore it was 
important to assess how the method performs when analysing samples with partial 
methylation levels. Published research has shown that amplification bias towards 
either the methylated or the unmethylated allele is common in bisulphite PCR 
(Moskalev et al., 2011). Even though extensive optimisation could eliminate possible 
bias, analysing pre-defined DNA methylation controls could be employed to ‘correct’ 
it. Commercially available low- and high- methylated controls were mixed in ratios 
before PCR analysis to create 10%, 20%, 30%, 50%, 70%, and 90% controls. 
Methylation levels on a DNA strand are linked with methylation levels in trans on the 
other strand for a particular CpG site, but also it is believed that methylation levels at a 
CpG site can very likely indicate similar methylation levels at cis-CpGs. Figure 5-5 
shows the generated standard curve showing observed vs. expected methylation ratios. 
Interestingly, a level of at least 80% methylation was detected for all >50% controls 
indicating that the methylated allele of HBA1 gene was undergoing significant 
preferential amplification. The introduced bias could be explained if one of the PCR 
primers contained a CpG site, which somehow favoured primer binding when it is 
methylated. However, this hypothesis could not be confirmed since the employed 
primer sequences were proprietary. The standard curve fitted a cubic polynomial line 
(R2=0.975) that could be used to correct the observed non-linear quantification. 
Blood 1 Blood 2 Blood 3 Blood 4 Blood 5 Blood 6 Blood 7 Blood 8 Blood 9
CpG 1 0.090 0.040 0.091 0.022 0.311 0.019 0.034 0.072 0.022
CpG 2 0.040 0.026 0.061 0.013 0.035 0.013 0.023 0.036 0.020
CpG 3 0.026 0.011 0.085 0.006 0.014 0.012 0.031 0.032 0.017
CpG 4 0.034 0.010 0.067 0.014 0.006 0.000 0.026 0.992 0.005







Figure 5-5. Observed vs. expected mean methylation ratio of pre-defined DNA 
methylation controls for HBA1 assay 
5.3.1.5 HBA1 specificity  
To evaluate the usefulness of the proposed assay in the identification of body fluids, 
initially five samples of each body fluid including blood, semen and saliva were 
analysed. 1 ng of each sample was bisulphite-treated and their methylation levels were 
obtained as before. Interestingly, all body fluid samples analysed showed <0.1 
methylation for all four CpG sites indicating that this marker cannot be used for 
differentiating between the tested body fluids. 
To sum up, taking into account the validation results using the pre-designed HBA1 
assay, bisulphite Pyrosequencing® seems to be very promising for accurate 
methylation quantification of forensic samples. Initial results showed that the proposed 
method demonstrates high conversion rates (>96%), sensitivity (down to 100 pg) and 
accuracy (<0.05 standard deviation); however, caution is needed when minute DNA 
samples are analysed. Also, amplification bias could be common and alter detected 
methylation levels; therefore, analysis of pre-defined methylation controls is required 
to ‘correct’ biased methylation detection. Although pre-designed Pyrosequencing® 
assays could be very useful as extensive optimisation could be avoided, each assay 
analyses only a few CpG sites and identifying potential tissue-specific CpG sites could 
be a time-consuming process. Thus, selecting tissue-specific gene expression is not 
sufficient; it is important that the location of potentially useful CpG sites is identified 
before assay development. 


























5.3.2 Validation of a reported blood-specific marker (EFS) 
5.3.2.1 Embryonal Fyn-associated substrate (EFS) gene 
As mentioned before, Neumann et al (2011) detected differential methylation patterns 
of the EFS gene when analysing various human tissues including the forensically 
relevant tissues blood, sperm and buccal cells. EFS encodes for a protein that plays a 
role coordinating cell adhesion via tyrosine-kinase-based signalling. It has been 
recognised to be a member of the CRISPR-associated (CAS) protein family but little 
is known regarding its function. It contains a Src homology 3 (SH3) domain and has 
already been identified to interact with Src-family kinases in mice (Ishino et al., 1997). 
Research has suggested that it is an adapter protein that is regulated via 
phophorylation but has no enzymatic activity (Tikhmyanova et al., 2010). 
Additionally, its methylation mechanism indicates EFS involvement in the 
differentiation of the hematopoietic cell lineage (T-lymphocyte regulation) but has not 
been linked to cancer yet. However, other members of the CAS family are known 
oncogenes acting as prognostic markers of metastasis (Donlin et al., 2005). 
5.3.2.2 Optimisation of EFS assay 
To avoid mis-priming, primer self-annealing or the generation of non-specific PCR 
products, the EFS assay was optimised using an annealing temperature gradient, 
various concentrations of MgCl2 and primer, as well as different PCR cycling 
conditions. Figure 5-6 shows a critical step of the optimisation process where a set of 
six annealing temperatures (50-65 oC) were tested using a blood sample. 
 
 
Figure 5-6. Final optimisation for EFS assay 
Agarose gel image showing the results of the optimisation step regarding annealing temperature using a 
blood sample (expected PCR product length in brackets); the first column represents the DNA marker 
(M) while the next six columns show the resulted amplification bands for temperatures 50-65 oC. The 
last column represents the PCR negative (no-template) control.  
                Annealing temperature gradient (oC) 




EFS (195 bp) 
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5.3.2.3 Accuracy and linearity of methylation quantification 
As shown when testing the linearity of HBA1 assay, non-linear methylation 
quantification was observed due to potential different amplification efficiencies of the 
unmethylated and methylated allele. To assess the performance of the EFS assay, 100 
ng of each DNA methylation control (0-100%) (EpigenDx) were analysed in 
duplicate. The mean and standard deviation of every control and for each CpG site 
was calculated in order to assess the accuracy of the method. The average standard 
deviation obtained from the duplicate samples was 5%; however the maximum 
reached 18% (75% methylation control, CpG 8). Although the 5% could be 
considered as an acceptable degree of variability, a difference of 26% for the same 
CpG site of the same sample is regarded quite high. It is suspected to be due to events 
during amplification. In general, differences between CpG sites were observed, 
indicating the need to calculate the mean methylation per sample for more accurate 
results. Surprisingly, it was noted that the highly methylated control (100%) resulted 
in an average methylation of 74% (43-92%) [Figure 5-7a]. According to the 
manufacturer, this control demonstrates a genome-wide >85% methylation; however, 
variations in individual CpG sites cannot be excluded. Therefore, to build the standard 
curve of methylation quantification, the expected methylation values were 
‘normalised’ using the values obtained for the non-methylated and methylated controls 
[Figure 5-7b]. 
  
Figure 5-7. Linearity of methylation quantification for EFS assay 
 (a) Box plot showing the minimum, median and maximum methylation levels detected for each 
methylation standard taking into account all ten CpG sites, (b) Standard curve showing the observed 
vs. expected methylation ratio of the average methylation per standard after normalisation. Error bars 





















5.3.2.4 Verification of methylation patterns 
Neumann et al (2011) had found that EFS is highly methylated in blood, completely 
unmethylated in sperm and partially methylated in buccal cells. To verify these 
patterns, 100 ng of one sample for these three tissues was analysed. Figure 5-8 shows 
that the confirmation of the original study’s results was successful; taking into account 
only the first five CpGs the average blood methylation was 0.69, semen was 
completely unmethylated (0.01) while saliva resulted in partial methylation (0.44). 
However, especially for blood, there was a large variation among CpG sites (e.g. CpG 
4 was 1, while CpG 5 was 0.46 methylated); therefore, more samples needed to be 
analysed to both confirm the specificity of EFS assay as well as investigate potential 
inter-individual variation in methylation levels. 
5.3.2.5 EFS specificity 
In order to apply EFS differential methylation patterns for the detection of blood, 
various forensically relevant tissues needed to be investigated; a total of 77 body fluid 
samples (20 blood, 10 semen, 16 saliva, 10 buccal, 10 vaginal fluid and 11 menstrual 
blood samples) were analysed. DNA samples were extracted as described in section 
2.2.1.2 and the quantity of eluates was determined using the Quantifiler Human DNA 
quantification kit (section 2.2.2.1). The average DNA yield per µl of starting material 
was as follows: 17±7 ng for blood, 62±56 ng for semen and 14±31 ng for saliva. As for 
the swabs, a buccal swab yielded an average of 2,802±1,615 ng while a vaginal or 
menstrual secretion swab generated 2,247±1,542 ng and 2,657±2,487 ng of DNA 
respectively.  
For each sample, 100 ng of DNA were bisulphite-treated and amplified using the 
proposed EFS PCR assay. All pyrograms™ passed the quality control of the instrument 
(expected sequence pattern, peak height >70 rfu) and the average bisulphite 
conversion rate of the eight built-in conversion controls was 94±5%. In general, it was 
noticed that the obtained conversion rates decreased slightly as the sequencing 
reaction progressed; possibly due to previously unincorporated cytosines. For each 
body fluid, box-and-whisker plots including data from the first and third quartile as 
well as the median (thin line) and minimum and maximum (error bars) methylation 






Figure 5-8. Verification of reported EFS methylation patterns in blood, sperm and saliva 
As illustrated in Figure 5-9, the average methylation of blood was the highest among 
all body fluids (0.67±0.16), while semen was found completely unmethylated 
(0.06±0.04)  in all samples except for two, where the mean methylation was 0.67 and 
0.54 respectively (shown as outliers in Figure 5-9b]. It is believed that this could be 
due to either natural variability in methylation levels or possible contamination of 
semen with blood. The rest of tested tissues demonstrated partial methylation levels 
(saliva - 0.43±0.12, buccal cells - 0.26±0.1, vaginal fluid - 0.22±0.07 and menstrual 
blood - 0.22±0.05). Overall, there was a mean methylation range of 0.33±0.1 in every 
CpG site when taking into account all samples, with saliva showing the highest mean 
range of 0.5. This range corresponds to the observed inter-individual variability; 
therefore the lower it is the more robust the proposed CpG site is considered. 
Blood – Average methylation 0.69 
Semen – Average methylation 0.01 






Figure 5-9. Box-and-whisker plots showing the detected methylation levels in (a) blood, 
(b) semen, (c) saliva, (d) buccal cells, (e) vaginal fluid, (f) menstrual blood for all ten CpG 
sites included in the EFS assay (total n=77) 
Boxes represent the first and third quartile while the horizontal line represents the median value. Error 
bars correspond to the minimum and maximum detected methylation value. Outliers are shown as red 
‘x’ dots. 
Considering each CpG site separately, it was observed that the first four CpG sites 
(analysed by sequencing primer 1, Table 5-5), and especially CpG 4, seemed to be 
more promising as blood-specific differentially methylated markers. This is due to the 
fact that they show greater methylation difference between blood (~0.8) and the rest 
of the tissues (<0.6). Considering the limitations of existing methods including low 
sensitivity and specificity, a DNA methylation-based approach for the identification of 






method or as a stand-alone assay (especially in cases where only DNA is available). 
However, caution is needed when analysing saliva as there is an overlap of 
methylation; a few saliva samples demonstrated for these four CpGs up to 0.8 
methylation, more likely due to the presence of leucocytes in saliva. 
5.3.2.6 Inter-individual variability of EFS methylation 
To further test potential inter-individual variability of EFS methylation in blood, an 
independent cohort of blood samples was analysed. To account for possible age-, 
ethnicity- and gender-associated effects, this set included a total of 47 blood samples 
from female and male individuals aged 20-70 years from various ethnic backgrounds 
[Figure 5-10]. The exact experimental conditions employed in the specificity 
experiment were used (100 ng DNA) and only the first four CpG sites were analysed. 
The previously obtained levels [Figure 5-9a] were confirmed in this experiment with 
no significant methylation differences and no outliers.  
 
Figure 5-10. Information regarding (a) age and (b) ethnicity of the independent cohort of 
blood samples (n=47) 
As shown in Figure 5-11, CpG 4 was confirmed to be the most useful marker since it 
not only demonstrates the highest level of methylation in blood (>0.8) but also the 
smallest variability. As shown in the graph, the median (horizontal line) is almost 1 
(0.98). On the other hand, CpG 1 demonstrated a great variation amongst blood 
samples (0.2-0.9), which does not allow its use as a blood-specific marker. Lastly, 
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Figure 5-11. Inter-individual variation of methylation levels for the most blood-specific 
CpG sites of the EFS assay 
Boxes represent the first and third quartile while the horizontal line represents the median value. Error 
bars correspond to the minimum and maximum detected methylation value. 
5.3.2.7 Reproducibility of methylation quantification 
To assess the reproducibility of quantification of the proposed Pyrosequencing® assay, 
20 blood samples (10 ng DNA each) were bisulphite-treated and amplified in triplicate 
using the EFS assay. The mean and standard deviation of the observed methylation 
values were calculated for each sample and each CpG site as well. The mean standard 
deviation for CpGs 1, 2 and 3 was 0.08 while an average standard deviation of 0.05 
was obtained for CpG 4 [Figure 5-12]. Although Pyrosequencing® has been proposed 
as a method that allows for accurate results, the increased number of PCR cycles (45) 
as well as the sequencing reaction itself could result in stochastic events. One can 
understand that choosing markers that have at least 40-50% difference between the 
tissue of interest and the other tissues is essential. Analysing in replicates could also 
serve as a solution since in some cases the observed standard deviation was as high as 
26%. 
5.3.2.8 Applicability in forensic casework 
It is essential that the observed methylation status of the EFS gene when analysing 
freshly-collected body fluids is also detected in samples that are of low quality. To 
assess the stability of EFS methylation as well as its applicability as a blood-specific 























Figure 5-12. Standard deviation of methylation quantification of each CpG site as obtained 
when analysing 20 blood samples in triplicate 
Boxes represent the first and third quartile while the horizontal line represents the median value. Error 
bars correspond to the minimum and maximum detected methylation value. 
As mentioned in Chapter 3, one of the most significant advantages of applying DNA 
methylation profiling for the identification of tissues is its potential applicability in cold 
cases. In most of these cases, mRNA profiling cannot be employed either because in 
stored stains mRNA molecules degrade over time or because only DNA samples are 
stored. To assess the stability of EFS methylation, a total of five blood stains stored at 
room temperature protected from light for 9-18 years as well as five blood DNA 
samples stored at -20 oC were analysed. In all cases, the expected methylation ratios 
for the investigated CpG sites were obtained (CpG 1 – 0.72±0.05, CpG 2 – 0.63±0.05, 
CpG 3 – 0.72±0.05 and CpG 4 – 0.94±0.08).  
Furthermore, depending on case circumstances forensic specimens could be mixed or 
degraded due to sun light, temperature and weather conditions. In an attempt to 
recreate ‘forensic-like’ scenarios, various stains were prepared as described in section 
5.2.1.3 and their methylation level regarding the first four EFS CpG sites was 
quantified. The whole swab or stain was used for DNA extraction; then, 10 µl of 
extracted DNA was used for bisulphite treatment and converted DNA was eluted in 
10 µl.  
Briefly, all stains stored at various temperatures for a week yielded the ‘expected’ 
blood methylation pattern indicating that under these conditions the methylation of 
EFS gene is stable. This is very important as crime stains are often exposed to sunlight, 




















groups are stable under these temperatures. On the other hand, regarding the 
artificially UV-degraded samples, the ‘expected’ methylation pattern was observed for 
all bloodstains incubated under UV for up to 90 minutes. The stain that was UV-
degraded for 120 minutes resulted in a completely non-methylated profile. This could 
indicate either that the methylation levels were altered due to the UV light or that a 
non-blood tissue is present. Potential stochastic effects and the effect of drop-in 
contamination cannot also be excluded as it is known to be common in highly 
degraded stains. However, this potential contamination is expected to be very low-
level as following STR profiling the obtained DNA profiles from all time-points were 
found to be single-source. The stain that was incubated for 4 hours under UV light was 
too degraded to produce an amplicon. 
Additionally, bloodstains on the towel and tissue paper gave successful pyrograms™; 
however, the methylation obtained from the washed blood stain was very low (0.08). 
The stained shirt was washed in a public washing machine; therefore potential 
contamination with other body fluids/tissues or the effect of chemical reagents could 
explain this result. These factors should be taken into account when interpreting 
methylation profiles from crime scene stains. Also, a reduced methylation was 
obtained from the stain on jeans (average of 0.33); however in this case it could be 
either due to natural inter-individual methylation variation or due to the effect of dyes 
on the analysis. Lastly, blood, semen and saliva were used to generate two mixed 
stains; the obtained methylation values of both single-source and mixed stains 
regarding CpG 4 are presented in Figure 5-13. Since mixture analysis is considered 
one of the main drawbacks of DNA methylation-based tissue identification, it was 
important to assess how this assay performed when analysing mixed stains. As 
illustrated, using the observed methylation of single-source tissues, the ‘expected’ 
methylation value was calculated. Although in both cases the observed methylation 
ratio was not significantly different from the ‘expected’ value, correction via the 
equation of the linear regression line in the standard curve for CpG 4 [Figure 5-13b] 
improved the accuracy of the results. These results are very encouraging; however, the 







Figure 5-13. Methylation analysis of EFS CpG 4 in mixed stains 
 (a) Observed methylation for all individual and mixed samples. Individual methylation values were 
used to calculate the expected values for the mixed stains. (b) Standard curve for EFS CpG 4 showing 
the observed vs. expected methylation ratios of pre-defined DNA methylation controls. The equation of 









































Samples CpG 4 
Blood Observed 0.97 
Semen Observed 0.00 















5.3.3 Analysis of genome-wide DNA methylation data 
5.3.3.1 Optimisation of Pyrosequencing®-based assays 
As described in section 5.2.2.2, a total of twelve potentially tissue-specific CpG sites 
were identified. All markers belong to a gene and are found either in the 5’-end region 
or within the main body of the gene. A bisulphite Pyrosequencing® assay for each 
CpG was designed using the BiSearch software and following the guidelines 
mentioned in section 2.2.4.1. However, it was necessary to optimise the PCR 
reactions to avoid mis-priming, primer self-annealing or the formation of non-specific 
PCR products. Each assay was optimised using an annealing temperature gradient, 
various concentrations of MgCl2 and primer, as well as different PCR cycling 
conditions. The optimisation of the assay designed for BLM2 marker proved to be 
very challenging as the amplification efficiency was very low in all tested PCR 
conditions; therefore, it was excluded from further analysis. Figure 5-14 shows the 
successful amplification of three samples using the optimised PCR conditions for each 
marker (11 in total). 
 
Figure 5-14. Final optimised PCR amplicons 
Successful amplification of three samples (blood, semen and saliva) using all eleven assays. BLM2 failed 
optimisation so it is not included here. Expected PCR lengths are shown in the boxes, together with the 
expected fragments of the DNA marker on the side of the gel images. As shown, for some markers (e.g. 
BLM1 and BUU2), there was a difference in the bands’ intensity, however it is believed to be due to 
loading errors rather than differences in PCR efficiency among body fluids. M: DNA marker 
[194] 
 
Optimised PCR products were then sequenced and methylation quantification was 
performed. Figure 5-15 illustrates example pyrograms™ obtained from one blood 
sample after analysing for all designed assays. Bisulphite conversion rates were 
calculated using the peak heights of thymine and cytosine of each bisulphite 
conversion control (non-CpG site cytosines) and were in the majority of cases >98%. 
If bisulphite conversion rates were lower than 95%, the treatment with sodium 
bisulphite was repeated. The developed assays demonstrated different PCR 
efficiencies as indicated by the peak heights in Figure 5-13, with SEU1 showing the 
lowest peak heights. Additionally, for certain assays the peaks were too wide 
indicating too much PCR product input or in other cases, the signal decreased towards 
the end of the sequence probably due to incomplete incorporation of nucleotides 
[Figure 5-15g]. Lastly, there were cases where there was a low signal detected for 
internal ‘dead dispensations’ (where no signal is expected); however, it is believed that 
it was due to signal carry-over from previous dispensations rather than another 
fragment being sequenced. 
5.3.3.2 Verification of methylation patterns 
To verify the methylation patterns of the CpG sites reported by Rakyan and co-
workers (2008 & 2010) to be specific for blood, semen and buccal cells [Table 5-2], a 
set of samples were analysed for each assay. It was important to confirm the 
methylation levels of the proposed CpG sites in these three types of tissues first, before 
any analysis is performed using other forensically relevant tissues such as menstrual 
blood or vaginal fluid. However, since the reason for choosing markers that are 
differentially methylated in buccal cells was their potential use in the identification of 
saliva, a set of saliva samples were co-analysed. The aim of this experiment was not 
only to verify the previously reported methylation but also potentially select the best 
CpG sites for further validation. Most assays also investigate adjacent CpG sites and 
their potential in identifying the tissue of origin was tested as well.  
For this analysis, a total of 1 ng of each DNA sample was bisulphite treated using the 
EpiTect bisulphite kit (section 2.2.3.1) and bisulphite converted DNA was eluted in 
20 µl of elution buffer. Then, 1 µl of converted DNA was used in each PCR reaction. 










a - BLM1 
b - BLU1 
c – BLU2 
d – SEM1 
e – SEM2 
f – SEU1 









Figure 5-15. Example pyrograms™ of all designed Pyrosequencing® assays 
Although there are eleven CpGs in question (highlighted in red blocks), in some assays adjacent CpGs 
were also quantified (dark grey boxes). Obtained methylation values are presented on the top, where 
the peak for ‘T’ corresponds to the unmethylated fraction (together with adjacent Ts or non-CpG 
converted Cs) while the peak for ‘C’ to the methylated fraction only. Light grey boxes indicate the 
position of built-in bisulphite conversion controls. 
 
Buccal cell-specific markers 
The markers cg15731815 (BUM1) and cg08258650 (BUM2) have been reported to 
be methylated in buccal cell samples (0.84 and 0.77 respectively) while demonstrating 
low methylation levels in blood and semen (0.05-0.08) [Table 5-2]. Although in the 
current study, their methylation status in blood and semen was confirmed, the 
reported methylation ratio in buccal cells was much lower (average of 0.47 and 0.48 
accordingly) [Figure 5-16b]. Also, even though it was believed that saliva mainly 
consists of buccal cells in the oral fluid, therefore buccal cells and saliva samples would 
h – BUM1 
i – BUM2 
j – BUU1 
k – BUU2 
[197] 
 
share the same methylation profile, this was not observed using the proposed markers. 
Saliva samples resulted in methylation ranging from 0-0.4. Since the mean 
methylation value for saliva samples were 0.17 and 0.12 respectively, these markers 
were excluded from further analysis as the methylation difference with blood and 
semen was too narrow. 
  
Assay CpG site 
Number of samples 
Whole blood Semen Buccal cells Saliva 
BUM1 cg15731815 14 12 8 4 
BUM2 cg08258650 15 11 7 12 
BUU1 cg05761971 14 10 8 15 




Figure 5-16. Methylation levels of the proposed buccal cell-specific markers in blood, 
semen, buccal cells and saliva 
 (a) Number of samples used in the verification experiment, (b) Observed methylation ratio of each of 
the CpG sites of interest included in four assays (BUM1, BUM2, BUU1, BUU2). Data are presented in 
the form of box-and-whisker plots showing the first and third quartiles (boxes), the median (horizontal 
line) and minimum and maximum (error bars) methylation values detected. Outliers (methylation value 







The marker cg05761971 (BUU1) has been previously reported to be unmethylated in 
buccal cells (0.108), while being highly methylated in blood and semen (0.87 and 0.88 
respectively). Similar to the previous two CpG sites, the methylation difference in this 
study was smaller than originally obtained as buccal cells gave an average methylation 
ratio of 0.37. The marker also demonstrated a large inter-individual methylation 
variation in saliva (n=15), hence it was concluded that it is not suitable for saliva 
identification. Finally, although cg16779976 was reported to be methylated in blood 
and semen by the genome-wide analysis, this observation was not confirmed by 
bisulphite Pyrosequencing®. The methylation of buccal cells and saliva was lower than 
the other two body fluids and quite similar but not discriminatory enough to include 
the marker in further analysis. 
In conclusion, although the methylation patterns of three out of four selected CpG 
sites were verified in blood and semen, the methylation difference of these body fluids 
and buccal cells samples was less than previously measured [Table 5-2]. Additionally, 
saliva did not share the same methylation profile with buccal cells but especially for 
cg15731815 (BUM1) and cg08258650 (BUM2), gave similar methylation values with 
blood. It is believed that this could be due to the presence of leucocytes in saliva (e.g. 
gum bleeding). The amount of ‘contaminating’ blood cells or other cell types apart 
from buccal cells in saliva could vary between individuals and this could potentially 
explain the large inter-individual methylation ratio observed in some cases. 
Blood-specific markers 
Although there were a total of four blood-specific CpG sites selected following the 
analysis of genome-wide methylation data, only three of them were tested here since 
one assay (BLM2) failed optimisation. The number of samples analysed per assay 
ranged from 55-66 including 10-20 samples per tissue [Figure 5-17a]. The CpG sites 
cg17518965 (BLU1) and cg26285698 (BLU2) were reported to be non-methylated in 
blood (0.02 and 0.09 respectively) while being highly methylated in semen and buccal 
cells (0.86-0.96). In this study, only blood’s methylation profile was confirmed, 
whereas semen and buccal cells demonstrated large inter-individual variation in 
detected methylation [Figure 5-17b].  
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Interestingly, there were two semen samples that had very low methylation (outliers), 
either because of natural variation in methylation levels and/or possible presence of 
blood in semen. Previous research has reported the presence of white blood cells in 
semen samples of infertile men or men with bacterial infections (Lackner et al., 2006). 
Moreover, these particular two semen samples resulted in a 10-fold decrease in DNA 
yield following DNA isolation using the same starting material as the rest of the semen 
samples, potentially indicating a smaller number of spermatozoa present. Lower sperm 
count is often associated with infertility problems and it has been shown that 
alternations in sperm DNA methylation at particular loci are common with low sperm 
motility and different types of male infertility (El Hajj et al., 2011; Hammoud et al., 
2010; Pacheco et al., 2011). Furthermore, saliva samples once again demonstrated 
very low methylation, even though it was originally thought that they would be 
methylated at these two CpG sites. Even though, it was thought that cg17518965 
could act as a semen-specific marker, it was decided that the similarity of methylation 
profiles between semen and buccal cell samples would not be ideal from a forensic 
perspective. Since buccal cells are of epithelial tissue origin, it came as no surprise 
when vaginal and skin samples resulted in similar methylation values with buccal cells 
when tested with this assay (data not shown).  
Assay 
CpG site 
Number of samples 
Whole blood Semen Buccal cells Saliva 
BLU1 cg17518965 15 12 9 19 
BLU2 cg26285698 15 12 10 20 
 
 
Figure 5-17. Methylation levels of cg17518965 and cg26285698 in blood, semen, buccal 
cells and saliva 
(a) Number of samples used in the verification experiment, (b) Observed methylation ratio of each of 
the CpG sites of interest included in two assays (BLU1, BLU2). Data are presented in the form of box-
and-whisker plots showing the first and third quartiles (boxes), the median (horizontal line) and 
minimum and maximum (error bars) methylation values detected. Outliers (methylation value ≥3*SD) 





On the other hand, findings regarding cg13763232 (BLM1) were more promising. 
Initial results analysing only blood, semen, buccal cells and saliva samples revealed a 
distinct blood methylation profile as all blood samples resulted in >0.85 methylation 
ratio.  Semen and buccal cells verified the expected low methylation since they had an 
average of 0.12 and 0.21 respectively. Also, even though the methylation levels of 
saliva samples ranged between 0.16-0.87 (mean=0.60), it was decided that the analysis 
of other forensically relevant tissues was needed before final conclusions regarding this 
marker’s blood specificity are made. Thus, an additional set of 34 samples (9 vaginal 
fluid, 14 menstrual blood, 5 skin and 6 urine samples) were analysed; detected 
methylation levels are shown in Figure 5-18. 
 
Figure 5-18. Methylation levels of cg13763232 in various body fluids/tissues 
Observed methylation ratio of the CpG sites of interest (BLM1 assay) in various body fluids/tissues. 
Data are presented in the form of box-and-whisker plots showing the first and third quartiles (boxes), 
the median (horizontal line) and minimum and maximum (error bars) methylation values detected. 
As shown in Figure 5-18, cg13763232 was shown to be highly methylated (>0.85) 
only in blood, while the rest of the tested tissues demonstrated various profiles being 
either non- or partially methylated. Similar methylation patterns were also obtained 
for the three adjacent CpG sites, indicating that it is not only cg13763232 that 
demonstrates blood-specific methylation but also the locus itself. 
Furthermore, even though only five skin samples were analysed, a wide range in 
methylation ratio (0.13-0.94) was observed. From a forensic perspective, in cases that 
a stain is to be analysed and DNA methylation profiling is used to confirm positive 
results of presumptive tests, then the fact that some skin samples are highly methylated 
[201] 
 
should not be an issue due to the stain’s colour and characteristics. However, in case of 
an invisible stain or when a DNA sample rather than a stain needs to be tested, 
employing the BLM1 assay would not be able to confirm the presence of blood with 
confidence. On the other hand, differentiation between blood and menstrual blood is 
often required in rape cases where a female in menses is involved. As shown in Figure 
5-18, the methylation ratios obtained from whole blood and menstrual blood samples 
hardly overlap meaning that this marker could be used not only for the identification 
of blood, but also for excluding the presence of menstrual blood if needed. However, 
although there were only two menstrual blood samples (out of 15) that resulted in >0.8 
methylation, analysing more blood and menstrual blood samples would reveal 
potential inter-individual variations. 
Semen-specific markers 
For the identification of semen, a total of four CpG sites were chosen; two 
(cg04382920 and cg11768416) were reported to have no methylation in semen 
(<0.02), while the other two (cg01318557 and cg05656364) were more than 0.9 
methylated in Rakyan and co-workers’ studies (2008 & 2010). The exact opposite 
methylation status was seen in blood and buccal cells [Table 5-2]. These patterns were 
confirmed when initially analysing samples of these three tissues (blood, semen and 
buccal cells) indicating their potential in the identification of semen. However, more 
tissue types needed to be investigated in order to establish their promising specificity. 
As a result up to 110 samples including various tissue types were analysed per assay 
[Figure 5-19a]. 
Regarding cg01318557 (SEM1) and cg05656364 (SEM2), all non-semen tissues 
including whole blood, buccal cells, saliva, vaginal fluid, menstrual blood, skin and 
urine demonstrated very low levels of methylation (mean methylation range of 0.01-
0.06 for cg01318557 and 0-0.06 for cg05656364). In contrast with most of the 
potential blood- and buccal cell-specific CpG sites tested so far, buccal cells and saliva 
samples showed identical methylation ratios. On the other hand, semen samples 
resulted in a mean of 0.40 and 0.59 for cg01318557 and cg05656364 respectively; 
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SEM1 cg01318557 10 12 15 12 10 15 9 7 
SEM2 cg05656364 15 14 15 20 10 15 10 10 
SEU1 cg04382920 9 9 12 11 10 10 2 5 






































(a) Number of samples used in the verification experiment, (b) Observed methylation ratio of each of 
the CpG sites of interest included in four assays (SEM1, SEM2, SEU1, SEU2) in various body 
fluids/tissues. Data are presented in the form of box-and-whisker plots showing the first and third 
quartiles (boxes), the median (horizontal line) and minimum and maximum (error bars) methylation 
values detected. Outliers (methylation value ≥3*SD) are shown separately as red ‘x’ dots. 
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SEM1 cg01318557 10 12 15 12 10 15 9 7 
SEM2 cg05656364 15 14 15 20 10 15 10 10 
SEU1 cg04382920 9 9 12 11 10 10 2 5 





Figure 5-19. Methylation levels of the proposed semen-specific markers in various 
forensically relevant body fluids/tissues 
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Occasionally, there were a few outliers obtained for blood, saliva and urine in 
cg01318557 (SEM1), which is believed to be due to natural methylation variability or 
potential contamination of semen in urine since the particular sample belonged to a 
male volunteer. Although semen clearly demonstrated a different distribution in 
methylation compared to other tissues, it was believed that the observed outliers could 
introduce uncertainties in confirming semen using this CpG site. Similarly, for 
cg05656364 (SEM2) there were two saliva samples resulting in 0.32 and 0.35 
methylation ratio respectively, while there were two semen samples that were found 
completely unmethylated even though this CpG site was proposed to be methylated in 
sperm. Interestingly, these two semen samples were the same with the ones showing an 
‘opposite’ methylation profile in the BLU1 assay and were the ones with low sperm 
count. Since these samples represent 15% of the total analysed semen samples, it was 
thought that this marker will not be included in further analysis in this study.  
On the other hand, as illustrated in Figure 5-19b, both cg04382920 (SEU1) and 
cg11768416 (SEU2) seemed to be highly specific markers for semen. The results of 
the genome-wide methylation analysis were confirmed for both markers, although the 
obtained methylation for cg11768416 in non-semen tissues was slightly lower than 
originally reported (0.75). Even though there were one or two semen samples per 
assay demonstrating higher methylation levels, these were not as high as the ones 
obtained by the non-semen samples. Additionally, there was one saliva sample (out of 
20) that showed low methylation levels, but this is believed to be due to natural 
methylation variability. Thus, using these two CpG sites (cg04382920 and 
cg11768416) no false negative results were obtained and only one out of the total 154 
non-semen samples resulted in a false positive identification of semen, which is 
particularly important in a forensic scenario. Interestingly, most of the co-analysed 
adjacent CpG sites (nine for SEU1 and four for SEU2) also demonstrated the observed 
semen-specific methylation pattern; therefore they can be used together with the two 
proposed CpG site to strengthen the identification of semen. 
5.3.3.3 Validation of SEU1 and SEU2 assays 
Without a doubt, CpGs cg04382920 (SEU1) and cg11768416 (SEU2) demonstrated 
a semen-specific DNA methylation profile; however, in order to implement such 
markers in forensic casework extensive validation of the associated methylation assays 
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is required. Initial validation of these markers included sensitivity and methylation 
quantification linearity analysis as well as testing aged semen samples. 
5.3.3.3.1 Linearity of methylation quantification 
As shown in previous bisulphite PCR assays [Figure 5-5], non-linear methylation 
quantification was observed due to potential different amplification efficiencies of the 
unmethylated and methylated allele. To assess the accuracy of SEU1 and SEU2 
assays, 100 ng of each DNA methylation control (0-100%) (EpigenDx) were analysed 
in duplicate. The mean and standard deviation of each standard was then calculated 
taking into account all CpG sites included in the sequences (ten CpGs in SEU1 and 
five CpGs in SEU2) in order to assess the linearity of quantifying methylation ratios. 
As shown in Figure 5-20, both assays resulted in linear quantification (SEU1 - 
R2=0.97 and SEU2 - R2=0.99) indicating that there was no amplification bias 
observed. The average standard deviation obtained by duplicate analysis was 0.05, 
which relates to previous findings regarding other assays (5% for EFS assay in section 
5.3.2.3). Methylation quantification was less accurate for partially methylated 
standards; however, since both loci are found either methylated or unmethylated in 
the analysed tissues, it was concluded that no methylation correction was needed. 
Obtained differences between observed and expected methylation could be explained 
by ‘expected’ amplification variations and pipetting errors in bisulphite PCR. 
5.3.3.3.2 Sensitivity 
The sensitivity of the proposed semen-specific methylation assays was assessed by 
analysing decreasing amounts of starting DNA material from blood (10 ng, 1 ng, 500 
pg, 100 pg and 50 pg and 10 pg). Since initial development and validation of bisulphite 
Pyrosequencing® revealed the protocol’s potential sensitivity as described in section 
5.3.1.2., amounts down to 10 pg of DNA were bisulphite-treated in duplicate. The 
reason why non-semen DNA (blood) was analysed was to assess if false positive results 
would be obtained due to the low amounts of DNA used. As shown in Figure 5-21a, 
successful amplification and the expected blood methylation pattern for SEU2 was 
obtained down to 50 pg of starting DNA, which further corresponds to less than 10 
cells given that each cell contains around 6 pg of DNA. This is very promising for the 
analysis of low-quantity or degraded samples, indicating the assay’s applicability in 
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forensic casework. Bisulphite conversion did not seem to be affected by the starting 
DNA amount since an average of 91.5% conversion using all three controls included 
in the SEU2 assay was obtained for all amounts [Figure 5-21b]. It should be noted that 
for the first bisulphite control, conversion rates were higher (average of 96.2%) while 
the third control resulted in a mean rate of 85.4%. It is believed that this is due to low 
signal-to-noise ratio (low peak heights) or due to signal carry over from previous 
unincorporated cytosines. Similar results were obtained also for the SEU1 assay (data 
not shown). 
 
Figure 5-20. Linearity of methylation quantification for SEU1 and SEU2 assays 
Standard curves showing the observed vs. expected average methylation ratio of each DNA 
methylation standard for both assays. As shown, for both assays methylation quantification was linear. 
5.3.3.3.3 Aged samples 
To further test the SEU1 and SEU2 assays’ applicability in forensic casework, a set of 
aged and potentially degraded samples were tested. DNA from a set of nine semen 
samples was extracted shortly after collection and following storage at -20 oC for a 
year. Although the obtained DNA amount per extracted µl of semen significantly 
decreased [Figure 5-22], treating 10 ng of DNA the methylation status for all samples 
in both loci was found to be <0.2 methylated. No significant difference was obtained 
between the methylation values of fresh and stored semen samples (p>0.05). Lastly, a 
set of four semen stains on fabric (cotton) stored at -20 oC for 16 years were analysed 
using the proposed assays. Once again, no false negative results were obtained and the 
methylation patterns matched those obtained by freshly collected semen samples 
[Figure 5-19].  
y = 1.0108x + 0.0336
R² = 0.993

































     
Figure 5-19. Sensitivity of SEU2 assay using decreasing amount of starting DNA material 
(a) Obtained pyrograms™  when analysing SEU2 sequence using various starting blood DNA material 
(10 ng, 1 ng, 500 pg, 100 pg and 50 pg and 10 pg); as shown, successful amplification and the expected 
methylation pattern was obtained down to 50 pg, (b) observed bisulphite conversion rates for all three 




Figure 5-21. DNA recovery of the same semen samples shortly after collection and 




























Fresh semen Semen stored for a year 
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SEM1 cg01318557 10 12 15 12 10 15 9 7 
SEM2 cg05656364 15 14 15 20 10 15 10 10 
SEU1 cg04382920 9 9 12 11 10 10 2 5 
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SEM2 cg05656364 15 14 15 20 10 15 10 10 
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5.3.4 Validation of immune cell-specific methylation markers 
5.3.4.1 Optimisation of Pyrosequencing®-based assays 
The third approach involved the investigation of six loci specific to cell types involved 
in the immune response including T cells, neutrophils, NK cells and naive CD8+, 
CD8A+ and CD8B+ T cells, previously reported to be differentially methylated 
among forensically relevant tissues [Figure 5-3]. For each assay, the corresponding 
DNA sequences were obtained from the EuroForGen collaborators highlighting the 
CpG sites included in their qPCR-based assays. Bisulphite Pyrosequencing® assays 
were designed using the BiSearch software and following the guidelines mentioned in 
section 2.2.4.1. However, it was necessary to optimise the PCR reactions to avoid 
mis-priming, primer self-annealing or the formation of non-specific PCR products. 
Each assay was optimised using an annealing temperature gradient, various 
concentrations of MgCl2 and primer, as well as different PCR cycling conditions. 
Figure 5-23 shows a critical step of the optimization process where a set of ten 
annealing temperatures (50-63 oC) were tested using a blood sample. 
5.3.4.2 Verification of methylation patterns 
As illustrated in Figure 5-3, there were three assays showing semen-specific 
methylation (AMP1730, AMP2004 and AMP2007), two assays showing blood 
specific methylation (AMP1404 and AMP2007), while AMP1746 and AMP1817 
demonstrated vaginal-specific methylation and AMP2004 could be used for the 
identification of menstrual blood. Rather than using individual assays per tissue, it was 
proposed that these six assays could be used together for the identification of the 
above-mentioned body fluids; however, it was believed that small methylation 
differences could also be used for the differentiation of saliva and skin (data not 
shown). To verify results obtained by qPCR-based assays (EuroForGen), two samples 
per tissue were analysed for all assays. Urine samples were also included in analysis to 
evaluate if they give false positive results for semen. The obtained results are shown in 
Table 5-7, where methylation ratios are colour-coded to help identifying variations 
among tissues. As illustrated, the results regarding the identification of semen were 
indeed confirmed with semen being completely methylated for AMP1730, 




Figure 5-22. Final optimisation for all six immune cell-specific methylation assays 
Agarose gel images showing the results of the final optimisation step (expected length in brackets) 
regarding annealing temperature (Tm). The first column represents the DNA marker (M) while the next 
ten columns show the resulted amplification bands of a blood sample for temperatures 50-63 oC . The 
last column represents the PCR negative (no-template) control. Red circles indicate the selected 
annealing temperature per assay that was believed to have shown better amplification efficiency. 
Regarding blood, AMP1404 seemed to show blood-specific methylation pattern since 
blood was the only tissue demonstrating partial methylation. However, AMP2007 
failed to give any differential profile for blood. Similarly, AMP1746 and AMP1817 
seemed to be the least useful assays as all tissues exhibited partial or high methylation 
values [Table 5-7]. However, it was thought that CpG 6 in AMP1746 should be 
included in further analysis since both vaginal and menstrual secretion showed ~0.1 
less methylation compared to the other tissues. Also, a skin sample showed lower 
methylation in CpG 4 in AMP1817 assay; therefore, further analysis would reveal if 
this was consistent among other skin samples. 
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Table 5-7. Verification of immune cell-specific methylation patterns by analysing 
two samples per tissue in each bisulphite Pyrosequencing® assay 
Methylation values are colour-coded with blue indicating complete methylation, while yellow 
corresponds to unmethylated CpG sites. BL-blood, SA-saliva, SE-semen, VA-vaginal fluid, ME-
menstrual blood, SK-skin, UR-urine. 
  
1 2 1 2 1 2 1 2 1 2 1 2 1 2
CpG1 0.76 0.65 0.99 1.00 1.00 1.00 1.00 0.98 0.98 0.95 1.00 0.88 1.00 0.86
CpG2 0.69 0.58 0.95 0.92 0.93 0.90 0.89 0.92 0.87 0.90 0.65 0.90 0.93 0.84
CpG3 0.66 0.58 0.99 0.97 0.96 0.96 0.86 0.90 0.87 0.90 0.97 0.96 0.89 0.86
CpG4 0.46 0.44 0.60 0.50 0.57 0.61 0.67 0.59 0.61 0.60 0.67 0.51 0.50 0.58
CpG5 0.58 0.53 0.84 0.78 0.85 0.84 0.86 0.80 0.83 0.83 0.32 0.69 0.75 0.69
CpG1 0.54 0.63 0.07 0.08 1.00 0.95 0.02 0.01 0.06 0.10 0.00 0.00 0.05 0.10
CpG2 0.42 0.49 0.04 0.00 0.91 0.89 0.00 0.03 0.08 0.10 0.00 0.05 0.05 0.06
CpG3 0.55 0.66 0.06 0.07 1.00 0.98 0.04 0.04 0.04 0.13 0.02 0.03 0.08 0.07
CpG1 0.86 0.91 0.99 0.97 0.99 0.97 0.94 0.95 0.89 0.90 0.99 0.95 0.97 0.96
CpG2 0.91 0.92 0.95 1.00 1.00 1.00 0.96 0.96 0.94 0.92 0.89 0.92 0.94 1.00
CpG3 0.88 0.91 0.93 0.94 0.94 0.93 0.94 0.92 0.91 0.92 0.96 0.96 0.89 0.94
CpG4 0.75 0.81 0.77 0.85 0.86 0.79 0.77 0.75 0.70 0.72 0.93 0.82 0.72 0.83
CpG5 0.73 0.77 0.74 0.74 0.76 0.78 0.74 0.71 0.71 0.66 0.80 0.77 0.71 0.76
CpG6 0.83 0.85 0.86 0.86 0.85 0.90 0.80 0.76 0.77 0.74 0.93 0.85 0.81 0.84
CpG7 0.75 0.77 0.82 0.80 0.77 0.80 0.81 0.79 0.80 0.74 0.85 0.75 0.78 0.79
CpG1 0.61 0.53 0.62 0.58 0.63 0.59 0.61 0.61 0.55 0.59 0.56 0.59 0.53 0.54
CpG2 0.58 0.48 0.56 0.50 0.52 0.55 0.55 0.56 0.48 0.50 0.41 0.59 0.50 0.49
CpG3 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00
CpG4 0.88 0.84 0.85 0.90 0.90 0.95 0.89 0.93 0.90 0.87 0.92 0.76 0.92 0.88
CpG5 0.39 0.34 0.47 0.34 0.41 0.41 0.40 0.39 0.34 0.39 0.37 0.45 0.35 0.39
CpG6 0.89 1.00 0.96 0.95 0.94 1.00 1.00 0.97 1.00 0.95 1.00 1.00 1.00 1.00
CpG7 0.94 0.87 0.84 0.83 0.87 0.91 0.85 0.86 0.77 0.83 0.61 0.86 0.87 0.77
CpG8 0.37 0.41 0.41 0.46 0.55 0.42 0.47 0.45 0.34 0.45 0.55 0.58 0.60 0.52
CpG9 0.92 0.85 0.85 0.88 0.76 0.90 0.84 0.86 0.77 0.85 0.77 0.76 0.86 0.78
CpG10 0.54 0.45 0.53 0.53 0.64 0.43 0.56 0.47 0.30 0.46 0.28 0.41 0.96 0.29
CpG11 0.79 0.81 0.75 0.76 0.76 0.82 0.71 0.69 0.60 0.64 0.57 0.77 0.70 0.64
CpG1 0.49 0.39 0.64 0.66 0.83 0.75 0.81 0.77 0.79 0.82 0.33 0.74 0.72 0.64
CpG2 0.84 0.80 0.99 0.99 0.75 0.75 0.98 0.96 1.00 0.97 0.98 1.00 0.98 0.99
CpG3 0.86 0.78 1.00 0.98 0.60 0.58 1.00 1.00 0.96 1.00 1.00 1.00 0.99 0.99
CpG4 0.29 0.27 0.37 0.35 0.18 0.19 0.30 0.31 0.24 0.28 0.46 0.38 0.38 0.35
CpG5 0.76 0.67 0.88 0.85 0.71 0.66 0.88 0.84 0.74 0.87 0.57 0.88 0.84 0.75
CpG1 0.87 0.85 0.89 0.84 0.04 0.16 0.63 0.51 0.66 0.73 0.87 0.95 0.81 0.81
CpG2 0.51 0.28 0.26 0.23 0.01 0.09 0.47 0.16 0.48 0.36 0.64 0.28 0.86 0.33
CpG3 0.37 0.11 0.08 0.11 0.01 0.07 0.38 0.08 0.38 0.16 0.34 0.09 0.69 0.09
CpG4 0.84 0.86 0.93 0.94 0.12 0.15 0.86 0.83 0.86 0.92 0.97 0.92 0.94 0.90
CpG5 0.84 0.83 0.82 0.84 0.12 0.16 0.74 0.71 0.75 0.79 0.77 0.75 0.81 0.79
CpG6 0.83 0.83 0.84 0.88 0.17 0.14 0.77 0.73 0.78 0.85 0.92 0.81 0.88 0.81
CpG7 0.76 0.78 0.61 0.63 0.17 0.13 0.72 0.29 0.70 0.73 0.83 0.46 0.81 0.61












5.3.4.3 Specificity of selected markers 
To further test the specificity of the proposed assays and to reduce the analysis cost 
since in most assays two separate sequencing reactions were required to analyse all 
CpG sites [Table 5-5], the most informative CpG sites per assay that could be 
combined in one sequencing reaction were selected for further testing. These included 
CpGs 1-3 for AMP1404, CpGs 1-2 for AMP1730, CpGs 1-6 for AMP1746, CpGs 1-
5 for AMP1817, CpGs 2-3 for AMP2004 and CpGs 4-6 for AMP2007.  
To validate the specificity of the selected CpG sites and since for some of them the 
methylation differences were quite small (~10%), it was decided that a larger dataset 
should be analysed including around 20 samples per tissue. Also, since one the 
EuroForGen researchers involved in this collaborative project reported the growing 
need to identify nasal blood (mainly in cases of physical assault), six DNA samples 
from nasal blood as well as twelve nasal fluid samples were also co-analysed. Although 
it is appreciated that identifying nasal fluid would be rare in a forensic scenario, it was 
analysed for comparison with the other tissues (nasal blood/epithelial tissues) and 
assess if there are any differences. Therefore, a total of 144-154 tissue samples of both 
females and males of different ages were analysed for each methylation assay. Since 
qPCR assays were based on the co-analysis of all CpG sites included in each assay and 
also since similar methylation levels were obtained among each assay’s CpGs in the 
verification experiment, potential tissue-to-tissue variations were studied utilising the 
average methylation per locus [Figures 5-22 and 5-23]. Methylation differences using 
individual CpG sites were also examined (e.g. CpG 4 in AMP1817) but did not seem 
to be any different from when using the mean (p>0.05). 
Firstly, in the proposed blood-specific AMP1407 locus, whole blood demonstrated 
methylation levels ranged from 0.46-0.90 (mean=0.7), while most of the other tissues 
exhibited higher methylation levels with the exception of skin and urine, where 
significant variation in methylation levels was observed. One can argue that 
differentiating between blood and urine or skin can be supported by visual 
examination of the stain, caution is needed when conclusions regarding the tissue type 





Figure 5-23. Methylation levels of (a) AMP1407, (b) AMP1730 and (c) AMP1746 in 
various forensically relevant body fluids/tissues 
Observed mean methylation ratio in various body fluids/tissues. Data are presented in the form of box-
and-whisker plots showing the first and third quartiles (boxes), the median (horizontal line) and 
minimum and maximum (error bars) methylation values detected. Outliers (methylation value ≥3*SD) 
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SEM1 cg01318557 10 12 15 12 10 15 9 7 
SEM2 cg05656364 15 14 15 20 10 15 10 10 
SEU1 cg04382920 9 9 12 11 10 10 2 5 
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SEM2 cg05656364 15 14 15 20 10 15 10 10 
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SEM1 cg01318557 10 12 15 12 10 15 9 7 
SEM2 cg05656364 15 14 15 20 10 15 10 10 
SEU1 cg04382920 9 9 12 11 10 10 2 5 






Figure 5-24. Methylation levels of (a) AMP1817, (b) AMP2004 and (c) AMP2007 in 
various forensically relevant body fluids/tissues 
Observed mean methylation ratio in various body fluids/tissues. Data are presented in the form of box-
and-whisker plots showing the first and third quartiles (boxes), the median (horizontal line) and 
minimum and maximum (error bars) methylation values detected. Outliers (methylation value ≥3*SD) 
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With regards to AMP1730 and AMP2007 loci, we can conclude that semen-specific 
DNA methylation profiles were obtained in both assays; however, there were two 
semen in particular demonstrating the ‘opposite’ methylation profile (out of 20). These 
two samples are the same ones that have previously been highlighted due to their low 
sperm count indicating potential male infertility issues [Figure 5-17 & 5-19]. Since 
these two samples have consistently given the ‘opposite’ methylation profile, the need 
to include the possibility of disease status while interpreting methylation profiles is 
further highlighted. Interestingly, for both assays the urine samples gave positive 
semen profile; however, it is thought that this could be due to ‘contamination’ of urine 
with semen or epithelial cells (since skin samples resulted in similar profiles with urine). 
Most of these urine samples were obtained from male volunteers (86% for AMP1730 
and 57% for AMP2007), a fact that further supports the above statement. 
Additionally, although AMP2004 seemed to be useful for differentiation of semen and 
blood (partially methylated) from other body fluids (highly methylated) in the 
verification experiment, analysing more samples revealed greater variations in 
methylation levels. It is concluded that this marker cannot be applied in forensic 
casework with confidence, since for example as shown in Figure 5.24b, a sample 
generating methylation of 0.8 could be any of the following: blood, semen, skin, urine 
or nasal fluid. Finally, the assays AMP1746 and AMP1817, although initially reported 
as vaginal-specific markers [Figure 5-3], they failed to reproduce this result in the 











5.4 Final remarks 
In this study, DNA methylation profiling for use in detecting body fluids seemed to be 
very promising. Initial evaluation of a bisulphite Pyrosequencing®-based assay 
(HBA1) revealed that this method can be highly sensitive (successful DNA 
methylation profiles down to 100 pg) and reproducible (average of 5% standard 
deviation). However, it was noticed that PCR amplification bias were present resulting 
in a ‘curved’ linearity graph, supporting the need to ‘correct’ detected methylation 
values. Subsequently, a set of 18 genomic loci were selected using three different 
approaches and tested among forensically relevant body fluids and tissues. In general, 
it was observed that semen and blood demonstrated differential DNA methylation 
patterns and was easy to detect with confidence; however, more complex tissues such 
as saliva, vaginal fluid and menstrual blood were more challenging using the proposed 
markers. Analysing more samples in the future could potentially reveal if observed 
variations in methylation are due to inter-individual changes or other factors. When 
testing mock casework samples, the tissue-specific markers seemed to be applicable 
and DNA methylation profiles seemed to be stable for up to 18 years in blood and 16 










































6 Literature review on estimating the 













The ability to accurately estimate a person’s chronological age would be a great 
advantage in police investigations as it could provide significant investigative leads. In 
a forensic context, predicting age is necessary for both the dead and the living. 
Predicting the age of an unidentified cadaver (age at death) could assist in the personal 
identification process (for example, in mass disasters) by creating a biological profile 
that can potentially be compared to missing persons. For the living, age prediction 
could be used to solve judicial or civil issues concerning age of minors or adults that 
lack valid identification documents or are involved in cases of adoption. Moreover, for 
intelligence purposes, estimating the age of a crime scene stain’s donor could 
potentially narrow down the number of suspects, especially in cases where an eye 
witness is not available. 
There have been various approaches to estimate age at death of human remains or 
chronological age of living individuals that will be described in this chapter; however, 
a common problem is the lack of standardisation of methods and sampling. A 
fundamental assumption of most methods is that the biological age of a person 
corresponds to their chronological age. However, while the chronological age is the 
calendar age which is usually identified in years, the biological age refers to how 
ageing affects the body and how this might be recognised. Naturally, the older the 
person is the larger might be the discrepancy between these two; therefore, age 
estimation is usually less accurate for older individuals. Most of these attempts are 
based on alterations of tissues or organs at the molecular level as a result of the natural 
process of ageing; however, the developed methods are usually relative producing an 
estimate with a large age range.  
Undoubtedly, developing an age prediction model is a major challenge for forensic 
scientists since they would need to be able to apply and validate it using minute or 
degraded samples consisting of a range of tissues and body fluids. This chapter will 
review previously proposed age prediction methods in literature and will discuss their 





6.1 Relevant background 
Ageing is a very complex process influenced by various genetic, lifestyle and 
environmental factors. It causes a variety of modifications and adjustments in tissues 
and organs that accumulate over an individual’s lifetime.  In a medical setting, these 
age-related factors provide useful information for ‘personalised’ medicine as they are 
used as risk factors in the development of many diseases, such as cancer (Teschendorff 
et al., 2010; Tsai & Baylin, 2011). In a forensic scenario, and in cases where a human 
skeleton is recovered, a rough estimation of the age-at-death can often be achieved 
through various morphological age-associated changes in the skeleton or in the 
dentition (Lynnerup et al., 2010). While soft tissue may also be present, forensic 
anthropologists rely on odontological and skeletal maturity to estimate age (Cunha et 
al., 2009). Nevertheless, difficulties arise when skeletons are incomplete and even 
though scientists have focused on studying particular parts of the body (e.g. the 
acetabulum) (Rouge-Maillart et al., 2007), estimation is still not accurate. 
Even though estimating age through skeletal structures is very common, efforts have 
been made to develop a potentially more accurate molecular-based test. Over the 
course of a lifetime, stochastic events lead to gradual changes of biomolecules that can 
be examined and characterised as both the cause and the consequence of our 
‘molecular clock’. There are various age-related mechanisms that have been 
thoroughly studied over the last two decades and could provide promise in their 
application within a forensic scenario. These include various chemical modifications, 
gene expression alterations and variations at the DNA level (Meissner & Ritz-Timme, 
2010; Zapico & Ubelaker, 2013).  
The chemical methods include protein modifications like the aspartic acid 
racemisation (Arany et al., 2004) and formation of advanced glycation end-products 
(Pilin et al., 2007), accumulative exposure to chemicals like lead (Al-Qattan & 
Elfawal, 2010) and also, alterations in cell components like collagen crosslinks 
(Martin-de las Heras et al., 1999). On the other hand, the molecular biology methods 
include gene expression changes (Glass et al., 2013), alterations in the composition of 
metabolomic markers (Menni et al., 2013), accumulation of DNA damage as reflected 
through the amount of deletions seen in mitochondrial DNA (Meissner et al., 1997), 
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shortening of telomeres that occurs along with cell division (Tsuji et al., 2002) and 
lastly, decrease in sjTREC rearrangements (Ou et al., 2011). 
6.1.1 Chemical methods 
6.1.1.1 Lead accumulation 
Lead is one of the most common and important environmental pollutants and its 
concentration in blood can act as an indicator of immediate exposure (Al-Qattan & 
Elfawal, 2010). On the other hand, lead concentration in teeth, particularly in dentine, 
is thought to point out long-term exposure and has been used in the past as a measure 
of lead pollution (Steenhout & Pourtois, 1981). Generally, the correlation between 
lead concentration in teeth and age has not yet been well established. However, Al-
Qattan and Elfawal managed to build an age prediction model using lead accumulation 
in teeth of the Kuwaiti population that could estimate age with a mean error of 1.3±4.8 
years. Authors observed differences in prediction between males and females as males 
demonstrated a higher lead accumulation. Although these results seem promising, 
further research is required to apply similar formulas to other populations. 
6.1.1.2 Collagen crosslinks 
The collagenous matrices of skeletal connective tissues are fixed by covalent crosslinks 
between collagen molecules via intermolecular reactions of aldehyde resides (Eyre, 
1987). There are mainly two crosslink pathways, the lysine aldehyde pathway in skin 
and the hydroxylysine aldehyde pathway in bone and cartilage. These crosslinks have 
been reported to fade as connective tissue matures by converting borohydride-
reducible aldimines to mature non-reducible compounds such as pyridinoline. This 
maturation process is believed to be age-related since a decrease in the reducible 
crosslinks with increasing age has been observed in various tissues (Bailey & 
Shimokomaki, 1971). In a forensic approach, a component of non-reducible crosslinks, 
namely deoxypyridinoline (DPD) was studied in permanent molars from individuals 
aged 15 to 73 years old (Martin-de las Heras et al., 1999). Using an enzyme 
immunoassay method, authors measured the DPD ratio with respect to age and 
obtained an estimated error of ±14.9 years at a 65% confidence level. Interestingly, 
deviations between different age groups were observed. 
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6.1.1.3 Aspartic acid racemisation (AAR) 
In mammals, it is known that only L-amino acids are integrated during protein 
synthesis. However, the chemical stability of some residues, aspartyl and asparaginyl 
residues in particular, has been reported to decrease with age leading to post-
translational non-enzymatic protein modifications (Lowenson & Clarke, 1988). 
Racemisation is a natural process, where active compounds are converted into a 
racemic mixture causing changes in the biological activities or chemical properties of 
proteins. These alterations can be measured as an age-dependent increase of the D-
aspartic acid content in acid hydrolysates of the studied proteins, which is believed to 
be a result of aspartic acid racemisation. Although the mechanisms involved seem to be 
quite complex, the relationship between AAR and age is thought to be very close for 
permanent proteins. The optimal tissue for this type of study is once again the tooth 
dentine; however protocols have also been developed for bone and skin as in theory 
any tissue that contains metabolically-stable proteins can be used for age estimation 
(Ritz-Timme et al., 2003). 
Significant disadvantages of such a method include the need of several teeth of the 
same kind, the fact that racemisation might also occur post-mortem, especially if the 
human remains have been exposed to high temperatures and also the presence of 
bacteria. Despite these drawbacks, several studies have demonstrated the precision of 
the method (mean error of 1.5-4 years) (Dobberstein et al., 2010; Ohtani & 
Yamamoto, 2010); however, one has to have in mind that the reliability of the results 
strongly rely on post-mortem environmental conditions (Dobberstein et al., 2008). 
6.1.1.4 Advanced glycation end-products (AGEs) 
Similarly to racemisation, non-enzymatic reactions between carbohydrates and 
proteins known as Maillard reactions produce a number of age-related protein 
modifications. These reactions are related to browning, fluorescence and cross-linking 
of proteins. Advanced glycation end-products (AGEs) accumulate in long-lived 
proteins like tissue collagens and can promote age-related conditions such as diabetes 
(Thorpe & Baynes, 1996). The accumulation of these non-enzymatic glycation 
products is verified by the colour change of articular cartilage from blue in young age 
to yellow/brown in the elderly. The importance of colour changes was emphasized by 
[221] 
 
investigating age-related colour changes in intervertebral discs excisions, Achilles 
tendons and rib cartilage caused by the formation of AGEs (Pilin et al., 2007). 
Furthermore, using spectroradiometry, Martin-de las Heras et al (2003) analysed 
different colorimetric variables in teeth obtaining an average error of 13.7 years. 
However, this technique is not suitable for specimens after extended post-mortem 
intervals since differences in dental colour were observed. 
In conclusion, the proposed chemical methods mentioned in this section demonstrate 
either low age prediction accuracy or can be mainly applied in connective tissues and 
skeletal or dental remains. Therefore, these methods are primarily for use in cases 
where age prediction is required in post-mortem specimen and should be applied with 
caution. 
6.1.2 Molecular biology methods 
6.1.2.1 Metabolomic markers 
Metabolomics is a novel technology which aims to profile all low-molecular-weight 
metabolites present in a biological sample that could be correlated with various 
physiological and pathophysiological processes (Psychogios et al., 2011). It is therefore 
a useful platform for investigating in a single approach all possible ways that 
metabolism is affected by a certain variable such as age. Changes in protein, energy 
and lipid metabolism have been observed with increasing age while these metabolites 
are also statistically linked with sex and race (Lawton et al., 2008). In a much wider 
approach, a study using 2,162 healthy individuals (32-81 years old) investigated a 
large set of metabolites via Flow Injection Analysis/Mass Spectrometry (FIA-
MS/MS) and showed that metabolic profiles are strongly correlated with age (Yu et 
al., 2012).  
A total of 71 metabolite concentrations in women and 34 metabolites in men were 
significantly associated with age; five of them were common in both genders. All 
reported metabolites are involved in major biological functions such as altered cellular 
membrane composition, mitochondrial metabolism and oxidative stress. However, 
sexual dimorphisms were extensively observed and authors suggested that 
metabolomic variations should be analysed separately for women and men. Also, no 
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conclusions could be made whether these changes were a result of ageing, other 
physiological aspects or as part of responses to damaging agents (Yu et al., 2012). 
Similarly, 280 different metabolites were investigated in a data set of 6,055 individuals 
(17-85 years old) and a panel of 22 age-associated metabolites was identified (Menni et 
al., 2013). These metabolites included nine lipids, seven amino acids, two 
intermediates in the energy pathway, two xenobiotics, one carbohydrate and one 
nucleotide. One metabolite in particular, namely C-glycosyl tryptophan (C-glyTrp) 
correlated strongly not only with age, but also with lung function, bone mineral 
density and weight at birth. Using a Cox regression model, researchers also performed 
a test for association with mortality as a function of the linear combination of all 22 
metabolites [Figure 6-1]. The derived variable was used as the independent variable, 
while potential death was the outcome variable (mean follow-up time 7.33±4.46 
years). 
 
Figure 6-1. Metabolic profile measures and age (Menni et al., 2013) 
Using the coefficients from the stepwise regression on age of the 22 metabolites, a metabolic profile 
measure was obtained for each individual taking part in the study. The mean and standard error of this 
variable was computed for intervals of five years of age. 
6.1.2.2 Gene expression patterns 
Several gene expression studies of ageing and ageing-associated disorders have 
revealed that there are various genes that are turned on or off in an age-dependent 
manner. For example, a study in post-mortem human brain from 30 individuals aged 
26-106 years old revealed that almost 4% of the 11,000 analysed genes demonstrated 
age-related expression patterns in individuals aged above 40 years (Lu et al., 2004). 
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Likewise in kidney, 985 age-associated genes were identified after analysing 74 
individuals aged 27-92 years old (Rodwell et al., 2004). In an attempt to determine 
genes and pathways involved in age in multiple tissues, the gene expression of skin, 
adipose tissue and various lymphoblastoid cell lines (LCLs) from 856 female twins 
aged from 39-85 years old was investigated by Glass and his colleagues (2013). Most 
age-associated genes were linked to fatty acid metabolism, mitochondrial activity, 
cancer and splicing; however, significant tissue-specific differences were evident 
(Glass et al., 2013). Interestingly, LCLs lacked age-related genes suggesting that the 
transformation to an immortalised cell masks (or even removes) any age-related gene 
expression signatures. 
Moreover, from a forensic point of view the analysis of tissue cytochrome c oxidase 
(CCO) activity as well as the quantification of its protein content and mRNA 
expression was proposed (Ishikawa et al., 2011). As expected, CCO activity was found 
to gradually decrease with age in the human heart tissue (r=0.83). Nevertheless, one 
has to take into account that the measurement of CCO activity is only useful in cases 
where samples can be collected shortly after death. 
6.1.2.3 Mitochondrial DNA (mtDNA) deletions 
It is known that mitochondria are semi-autonomous organelles having their own 
protein synthesis and DNA replication machineries. Mitochondrial processes mainly 
involve five enzyme complex mechanisms essential for respiration and oxidative 
phosphorylation, where lipids and glucose are oxidised to produce ATP. During this 
procedure 0.2% of the utilised oxygen is released as free radicals like hydrogen 
peroxide or superoxide, which are highly reactive oxygen species causing damage to 
proteins, lipids and especially mitochondrial DNA (Mandavilli et al., 2002). 
Mitochondrial mutagenesis is mostly found in the form of stochastic deletions of 
mtDNA that show a tissue-specific accumulation pattern and usually increase with 
advancing age (Meissner et al., 2006).  
The 4,977 bp deletion, also known as the common deletion, has been analysed for 
forensic applications in various tissues using PCR-based assays. A study on skeletal 
muscle revealed a correlation (r=0.83) between the frequency of the 4,977 bp deletion 
and the age at death (Meissner et al., 1999). However, scientists were unable to 
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reproduce the same results in whole blood (Mohamed et al., 2004). Some of the main 
challenges of applying such method for age estimation include the exponential nature 
of PCR that could lead to differences within the same sample, the significant 
differences that have been observed among tissues as well as possible mosaicism even 
between neighbouring cells (Storm et al., 2002). Further research is required to assess 
if the 4,977 bp could serve as an alternative for age estimation since external factors 
such as pathologic conditions (hypoxia, ischemia and sudden cardiac death) have been 
reported to affect the rate of deletion generation, more likely due to increased 
production of free radicals (Polisecki et al., 2004). 
6.1.2.4 Telomeres 
Telomeres have been recognised for their role in cell survival and replicative capability 
of dividing somatic cells; without telomeres cells would not be able to differentiate 
between DNA breaks within the genome and the chromosome ends (Jiang et al., 
2007). Telomeres are found at the end of linear chromosomes consisting of thousands 
of tandem repeat units and are stabilised by telomere-binding proteins. This telomere 
capping is responsible for maintaining chromosomal stability and preventing cell cycle 
arrest (de Lange, 2004). However, due to the end-replication problem of DNA 
polymerase, or processing of telomeres during the cell cycle, telomere shortening is 
common after each cell division and can only be fixed by inducing the expression of 
telomerase (von Figura et al., 2009). 
The use of telomere length for biological age prediction has been explored in blood, 
where it has been observed that the mean terminal restriction fragment length 
decreases 20-60 bp every year during a human life (von Zglinicki & Martin-Ruiz, 
2005). In another study, using Southern blot analysis the correlation between telomere 
length and age was significant (r=0.83); however, there were cases where young and 
old individuals shared the same length (Tsuji et al., 2002). Therefore, telomere length 
could more likely be used to assign an age interval rather than a specific age 
demonstrating limited accuracy. These variations are suspected to be a result of 
genetic and environmental factors such as oxidative stress (von Figura et al., 2009; Von 
Zglinicki, 2000). Differences in telomere attrition rate between different chromosomes 
are also evident (Britt-Compton et al., 2006). 
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6.1.2.5 sjTREC rearrangements 
Another mechanism that has been proposed to reliably estimate biological age is the 
use of T-cell DNA rearrangements (Ou et al., 2011; Zubakov et al., 2010). T 
lymphocytes possess specific receptors encoded by the T-cell receptors (TCRs) genes 
to recognise unknown antigens. To create a wide range of TCR molecules, each T cell 
experiences distinctive somatic rearrangements at these particular loci, where 
intervening DNA sequences are deleted forming episomal DNA molecules called 
signal joint TCR excision circles (sjTRECs) (Breit et al., 1997). It is believed that the 
number of sjTRECs declines as age increases. 
Zubakov et al (2010) developed a robust and sensitive (down to 5 ng of starting DNA 
material) real-time quantitative PCR protocol using 195 whole blood samples derived 
from healthy Dutch individuals ranging in age from a few weeks to 80 years. However, 
the standard error of the estimate remained high at ±8.9 years [Figure 6-2]. Storage 
time of blood samples did not seem to affect age prediction, however statistically 
significant gender differences on sjTREC quantification were observed. Applying a 
similar approach, another study was carried out in 248 Chinese Han individuals aged 
between 0 (new-borns, cord blood) to 78 years old (Ou et al., 2011). The authors were 
able to obtain a correlation coefficient of r=-0.82 by regression analysis between 
sjTREC levels and age with 65.3% of age estimates lying within 10 years of the actual 
age of the subjects. It is very likely that conditions affecting the immune system’s 
health status such as HIV/AIDS or leukaemia could further affect the proposed age 
estimation. It should also be noted that such a test is restricted to blood and it would 
not be possible to apply this method in other tissues such as semen or saliva since they 




Figure 6-2. Age prediction in blood using sjTREC abundance (Zubakov et al., 2010) 
Linear regression model of the relationship between chronological age and normalised sjTREC numbers 
in whole blood. Dotted lines correspond to 95% prediction interval. 
All methods mentioned above show limitations. Tests based either on chemical or 
molecular biology protocols so far are more likely to suggest an age group (generation) 
rather than accurately predict age. Some of these tests could result in the destruction 
of the original sample, limiting downstream analysis and therefore their applicability in 
crime scene samples. While some of these tests, especially methods based on chemical 
modifications, can be applied in predicting age using human remains, in this study 









6.2 Age-associated DNA methylation 
Epigenetic analysis could serve as an alternative or supplementary method for age 
prediction since particularly DNA methylation is well-known to be one of the 
mechanisms responsible for cell differentiation and the cellular response to ageing (Bell 
et al., 2012; Day et al., 2013). It is generally suggested that there is an increase in 
global epigenetic drift with age (Teschendorff et al., 2013) and various genome-wide 
methylation analyses have revealed a substantial decrease in global DNA methylation 
levels with advancing age (Gentilini et al., 2013). Comparing new-born and 
centenarian genomes it could be seen that the centenarian DNA had a lower DNA 
methylation content with a reduced correlation in the methylation status of 
neighbouring CpG sites across the genome in comparison with the more 
homogenously methylated new-born DNA (Heyn et al., 2012). These CpGs covered 
all genomic compartments including promoters, exonic, intronic and intergenic 
regions.  
Changes in DNA methylation patterns due to ageing are quickly observed during the 
first months of an individual’s life and throughout childhood (Alisch et al., 2012; 
Martino et al., 2013). Cumulative evidence points towards the distinct contributions of 
genetic (Bell et al., 2011), environmental (Gronniger et al., 2010; Lee & Pausova, 
2013) and stochastic factors to DNA methylation levels at single genomic areas. 
However, as shown in previous chapters, epigenetic changes can also be tissue-specific 
(Thompson et al., 2013). Genome-wide methylation changes have been investigated in 
various forensically relevant tissues including blood (Johansson et al., 2013), skin 
(Koch et al., 2011; Raddatz et al., 2013), brain (Horvath et al., 2012) and skeletal 
muscle (Zykovich et al., 2014). 
6.2.1 Age-associated CpG sites in blood 
In order to identify specific age-associated differentially methylated CpG sites for a 
particular body fluid, Horvath et al (2012) have chosen to perform genome-wide 
studies that enable analysis of thousands of CpGs at the same time. It is believed that 
monozygotic twins serve as an ideal model to study these dynamic epigenetic marks as 
they share the same DNA sequence and start life with almost identical methylation 
patterns (Fraga et al., 2005; Li et al., 2013). In a recent study, the heritability and 
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relationship with age and gender of selected DNA methylation profiles was 
investigated using genomic DNA derived from whole blood of various twin pairs 
(Boks et al., 2009). Genes that contained age-associated CpG sites were identified 
including activin A receptor type I (ACVR1), interleukin 6 (IL6), caspase recruitment 
domain-containing protein 15 (CARD15), platelet-derived growth factor receptor 
alpha (PDGFRA), nuclear factor kappa-B subunit 1 (NFKB1) and the ETS-domain 
protein (ELK) gene. Most of these genes were also included in the list of the top 100 
age-associated CpG sites identified by Christensen and his team, where they also 
showed that these alterations are dependent upon genes’ CpG island context 
(Christensen et al., 2009).  
Utilising Illumina’s 27K array which allows determination of bisulphite conversion-
based, single-CpG resolution, DNA methylation levels at 27,578 different CpG sites 
within more than 14,000 promoters in the human genome, Rakyan et al (2010) 
observed a total of 213 CpG sites that become more methylated with age and another 
147 CpGs that lose methylation over time in blood.  Interestingly, >95% of these sites 
were located within 500 bp of the transcriptional start site of the associated gene, 
implying a connection with regulation of gene expression. In an attempt to correlate 
blood age-associated DNA methylation changes with other tissues, Horvath and his 
colleagues analysed 2,442 Illumina DNA methylation arrays from brain and blood 
tissues. Consensus module analysis revealed common and robust co-methylation 
relationships suggesting that age effects on DNA methylation levels are well-preserved 
between these two tissues (Horvath et al., 2012).  
Additionally, another three promising epigenetic markers of age were identified by 
analysing 494 whole blood samples from individuals aged 9-99 years old using 
Illumina’s 450K array (Garagnani et al., 2012). These included the ELOVL fatty acid 
elongase 2 (ELOVL2), four and a half LIM domains 2 (FHL2) and perproenkephalin 
(PENK) genes. For all three sites, methylation levels increased with age with ELOVL2 













Circles represent methylation values in mothers while triangles the ones in offspring. 
6.2.2 Effect of various environmental factors 
It is known that similar to other physiological biochemical modifications DNA 
methylation is a reversible biological signal (Ramchandani et al., 1999) that responds 
to various internal and external stimuli. Most of the observed age-associated DNA 
methylation profiles above are a result of various environmental factors including 
susceptibility to diseases and lifestyle. This phenomenon can be observed in 
monozygotic twins since older twin pairs demonstrate greater DNA methylation 
differences than younger ones (Fraga et al., 2005) [Figure 1-3]. While environment 
during early embryogenesis may cause extensive, soma-wide DNA methylation 
modifications that can lead to fatal programing of adult disorders, environment later 
during life is more likely to induce less extensive, tissue-specific changes bringing 
about tissue-specific carcinogenesis (Lee & Pausova, 2013).  
As an example, in a locus-by-locus analysis of exposure-related methylation, 
researchers identified 24 asbestos-related, 30 drinking-related and 138 smoking-
related differentially methylated CpG sites in pleural tissues, blood and lung tissues 
respectively (Christensen et al., 2009). Furthermore, chronic sun exposure has been 
reported to alter the methylation status of various keratin genes in human skin 
(Gronniger et al., 2010). Additionally, following acute or chronic high dose (5 Gy) 
exposure of ionising radiation, researchers studied DNA methylation in liver, spleen 
and lung tissues of mice and found sex-, tissue- and dose-dependent radiation-induced 
DNA methylation changes (Pogribny et al., 2004). 
(a) (b) (c) 
Figure 6-3. DNA methylation of selected CpG sites in (a) ELOVL2, (b) FHL2 and (c) 
PENK genes with respect to age (Garagnani et al., 2012) 
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6.3 Age prediction models 
From a forensic perspective, it would be very advantageous to be able to translate 
observed age-associated DNA methylation differences in a way that the chronological 
age of an individual is revealed. Even though building age prediction models using 
DNA methylation profiles is a relatively new field, there are a few studies that have 
focused on forensically relevant tissues, such as blood, saliva, and brain. 
6.3.1 Blood 
Hannum and his team performed one of the largest and highest-resolution genome-
wide methylation studies to date using the whole blood of 656 individuals aged 19-101 
years old (Hannum et al., 2013).  They obtained methylome-wide profiles by 
measuring the methylation status of more than 450,000 CpG sites with the Illumina 
Infinium Human Methylation 450K BeadChip assay. Remarkably, it was revealed that 
~15% of the tested CpGs showed significant associations between their methylation 
levels and age. Applying a penalised multivariate regression method, the authors built a 
quantitative model using 71 highly age-predictive markers with a correlation between 
true and predicted age of 0.96 and an average error of 3.9 years [Figure 6-4a]. Nearly 
all of the markers applied in the model lay within or near genes with a known link to 
age-related conditions including DNA damage, cancer and Alzheimer’s disease. As an 
example, there are two CpG sites that are located within the somatostatin gene (SST), 
which is known to play a key role in the regulation of the endocrine and nervous 
systems (Yacubova & Komuro, 2002). Given that the associations between ageing and 
prolonged life with metabolic activity are well established (Jumpertz et al., 2011), it 
was expected that most of the methylation markers are connected with metabolism.  
Interestingly they noticed that the methylome of men appeared to age approximately 
4% faster than that of women [Figure 6-4b] and there were always a few individuals 
that appeared to be ageing faster or slower than what the model would predict. The 
model was also validated using an independent cohort of 174 samples and the same 
methodology; predictions were still highly accurate, with an error of 4.9 years 
(correlation of 91%) (Hannum et al., 2013). Furthermore, the model was able to 
distinguish between very young and old individuals even when samples were 





Predicted vs. chronological age for all individuals based on the ageing model. The red arrow indicates 
an individual that the predicted age was much higher than the actual age (fast ageing individual); 
similarly, the blue arrow shows an individual whom the model predicts as much younger (slow ageing 
individual). 
From a forensic perspective, to analyse samples with this methodology would require 
large amounts of DNA which are usually not available. In an attempt to narrow down 
the number of age-associated markers needed for accurate prediction, Weidner et al 
performed a comprehensive analysis of methylation profiles and found that the 
methylation levels of only three CpGs – located in the integrin, alpha 2b (ITGA2B), 
aspartoacylase (ASPA) and phosphodiesterase 4C, cAMP specific (PDE4C) genes – 
were enough to create an epigenetic-ageing-signature (Weidner et al., 2014). They 
developed a bisulphite Pyrosequencing® protocol after testing 82 whole blood samples 
that allowed age prediction with a mean absolute deviation (MAD) from chronological 
age of 5.4 years (RMSE=7.2 years) [Figure 6-5a]. The model was further validated 
using 69 blood samples and the observed predictions correlated with age even better 
(MAD=4.5 years, RMSE=5.6 years) [Figure 6-5b]. 
6.3.2 Saliva 
Apart from blood, buccal epithelium has also been used for age-associated methylation 
analysis.  Bocklandt et al performed a genome-wide methylation analysis using saliva 
samples of 34 pairs of male identical twins (21-55 years old) using Illumina’s Human 
Methylation 27K microarray (Bocklandt et al., 2011).  The authors identified a total of 
88 novel loci that were significantly correlated with age (absolute correlation values 
greater than 0.57) and were located near genes involved in cardiovascular, 
neurological or genetic diseases. Using only three CpG sites – located in the Edar 
Figure 6-4. Age model predictions using 71 CpG sites in blood (Hannum et al., 2013) 
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associated death domain (EDARADD), target of myb1 (chicken)-like 1 (TOM1L1), 
and neuronal pentraxin II (NPTX2) genes – they built a regression model that was 
linear with age over a range of five decades and explained 73% of the variance 
(MAD=5.2 years) [Figure 6-6]. 
 
Figure 6-5. Age prediction model using three CpG sites in blood (Weidner et al., 2014) 
(a) Multivariate ageing model based on three CpG sites belonging to the genes ITGA2B, ASPA and 
PDE4C that allowed for accurate age prediction (MAD=5.4 years), (b) Slightly higher precision was 
obtained during validation with an independent set of 69 blood samples (MAD=4.5 years). 
 
Figure 6-6. Predicted vs. observed age using a leave-one-out model in saliva (Bocklandt et 
al., 2011) 
Age prediction model by multivariate regression analysis showing high correlation between predicted 




As previously mentioned, each tissue or body fluid shows a different age-associated 
DNA methylation pattern.  It would be very useful to develop an age prediction test 
that could be applied in all human tissues and Kock and Wagner have gone some way 
towards this.  They analysed several publicly available DNA methylation datasets that 
examined more than 27,000 CpG sites in 13 different cell types (Koch & Wagner, 
2011). Initially they identified 431 age-associated hypermethylated, and 25 age-
associated hypomethylated CpG sites.  Next, they chose a subset of five markers – 
located in the tripartite motif containing 58 (TRIM58), potassium voltage-gated 
channel, KQT-like subfamily, member 1 downstream neighbour (non-protein coding) 
(KCNQ1DN), NPTX2, BIRC4-binding Protein (BIRC4BP) and glutamate receptor, 
ionotropic, AMPA 2 (GRIA2) genes – to be integrated into their epigenetic-ageing-
signature test. Interestingly, one of these CpG sites (NPTX2) is also included in the 
previous study by Bocklandt and his colleagues. Based on these five CpG sites, their 
predictions had an average precision of ±9.3 years.  
Predicting age across a broad spectrum of human tissues and cell types appears to be a 
very challenging task; using a much larger dataset could, however, potentially 
overcome the difficulties and provide a more accurate age prediction.  Horvath 
developed a multi-tissue predictor of age by employing ~8,000 samples from publicly 
available Illumina DNA methylation array datasets (both 27K and 450K) comprised of 
51 healthy tissues and cell types (Horvath, 2013).  The author used a regression 
analysis that avoids over-fitting of the model (penalised regression with elastic net 
analysis) and selected 353 CpGs, named as the ‘epigenetic clock’.  Across all test data, 
the age correlation was 0.96 with an error of 3.6 years, which appears very promising.  
Individual models according to tissue type were also built to improve accuracy 
(Horvath, 2013).  The age predictor worked well even in heterogeneous tissues such 
as whole blood, buccal epithelium, uterine cervix and saliva, but in sperm the 






As shown in this chapter, accurate molecular age estimation from different types of 
biological material is not a simple task as ageing is biologically complex. However, 
age-associated DNA methylation profiling is very promising and future research has 
the potential to influence our understanding of ageing and allow for more accurate 
predictions. Either considering healthy or diseased samples, the employed 
methodologies that analyse thousands of CpG sites at once usually require large 
amounts of intact DNA, which is often not available in forensic samples. Therefore, it 
is important to further investigate previously reported age-associated CpG sites in an 























7 Chronological age prediction in blood 












As shown in Chapter 6, there have been various chemical- or biological-based 
methods that have been proposed in the literature; all of which suffer from limitations. 
In forensic science, accurate biological age estimation is not an easy task since 
specimens could be of different types of biological material and are often minute or 
degraded. Recent research shows that age-associated DNA methylation profiling 
could be a good alternative to current methods but further research is needed to allow 
for more accurate predictions. As described in section 6.3, proposed age prediction 
models are based on a large set of CpG sites analysed with genome-wide methylation 
analysis protocols meaning that large amounts of intact DNA are required. Therefore, 
it is important to assess the significance of each of the reported CpG sites and select the 
‘best’ for further validation. Consequently, the purpose of this chapter was to further 
investigate previously reported age-associated CpG sites in an attempt to develop 
assays that could be applicable in a forensic setting where samples are often degraded. 
An ideal forensic age prediction method should require minimal starting DNA material 
and analyse as few markers as possible without at the same time sacrificing prediction 
accuracy and reproducibility.  
So far, research has focused on predicting biological age in various tissues since the 
‘calculated’ degree of ageing could act as a predictor in several age-related diseases. 
On the other hand, from an investigative perspective where information such as 
disease state or environmental exposure is rarely available, it is important that the CpG 
sites selected for further analysis are chosen only from control DNA samples. Also, 
since the focus of this project is the age prediction of living individuals and blood is the 
most common body fluid found at crime scenes, it was decided that efforts would be 
initially focused on creating an age prediction model that could be applied in 
bloodstains. 
Again since forensic samples are very often of low quantity and quality, applying 
genome-wide DNA methylation analysis techniques would not be appropriate. Thus, 
it is important to develop suitable and sensitive assays that can accurately quantify the 
methylation levels of specific CpG sites. Since bisulphite Pyrosequencing® was 
successfully applied in identifying the tissue source of a sample as shown in Chapter 5, 
it was believed that it could serve as a potential method for the application of age 
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estimation as well. As demonstrated in various ageing studies, bisulphite 
Pyrosequencing® has been effectively applied as a confirmation method to validate 
age-associated CpG sites reported in array-based results (Alisch et al., 2012; Bocklandt 
et al., 2011; Christensen et al., 2009; Weidner et al., 2014). 
 
7.1.1 Aim and Objectives 
The aim of this study was to investigate selected age-associated CpG sites and assess 
the possibility of using a small number of DNA methylation markers to accurately 
predict chronological age. 
 
In order to meet the aim, two different approaches were followed: 
 Firstly, a set of reported age-associated CpG sites in blood was selected and 
bisulphite Pyrosequencing® assays were designed to further validate their 
methylation levels. Once these assays were developed and optimised, whole blood 
samples of known age were analysed. Age predictions were then performed and 
the accuracy of the designed model was assessed.  
 Secondly, a set of reported age-associated CpG sites in various tissues was 
selected and publicly available genome-wide DNA methylation data in blood 
were collected regarding these markers. The resulting dataset was analysed by 
various analysis methods in order to create an accurate age prediction model. The 














7.2.1 Approach 1 
7.2.1.1 Blood samples 
Whole peripheral blood was collected from 90 healthy volunteers (53 males and 37 
females from various ethnic backgrounds) aged 1 week to 85 years old (mean age 
35.1±17.4 years) as described in section 2.1 [Figure 7-1]. Blood samples were stored at 
2-8 oC either as a liquid (200-1,000 µl) or spotted onto a Whatman classic card.  
 
Figure 7-1. Age distribution within the blood sample database (n=90) 
The histogram illustrates the age distribution of all individuals participated in the study, which 
resembles the normal (or Guassian) distribution. 
7.2.1.2 Selection of age-associated CpG sites in blood 
As previously mentioned, all age prediction models found in the literature show good 
prediction accuracy, however, not without limitations. For this part of the project, the 
study by Hannum et al. (2013) was selected as the most appropriate to investigate 
further for a number of reasons including the number of samples and sites used. 
Considering that this study was the first to investigate more than 450,000 CpG sites 
(high resolution), analyse more than 650 samples (large dataset) and build an age 
prediction model with less than 4 years of error (high accuracy), it was concluded that 
it was the most appropriate dataset to validate methylation markers from. 
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The authors categorised the group of 71 markers included in the model using an age 
coefficient, ranging from -22.7 to 28. This coefficient represents the link between the 
particular methylation marker and ageing and can be either positive or negative. A 
positive coefficient indicates that methylation increases with age, while a negative 
coefficient is a sign of a decrease in methylation with time. As expected, the more 
positive or negative the coefficient is, the higher the importance of the CpG site is in 
the age model. When selecting the set of CpG sites for further investigation, the age 
coefficient was the only parameter available regarding the relationship of the markers 
with ageing so it was the sole basis for marker selection. Ten of these CpG sites that 
showed the ‘strongest’ positive or negative correlation with age were chosen for the 
development of Pyrosequencing® assays [Table 7-1]. All selected sites are located near 
human genes across six chromosomes and half of them belong to a ‘CpG island’ too 
(300-3000 bp long, >55% GC content). Also, most of them (7/10) are positively 
associated with age (positive age coefficient). 
7.2.1.3 Bisulphite Pyrosequencing® assay design 
Following the guidelines regarding assay design mentioned in sections 2.2.4.1 and 
2.2.6.1.1, bisulphite Pyrosequencing® protocols were designed using the BiSearch 
primer design tool. Two of the selected CpG sites were in close proximity 
(cg11067179 and cg22213242) so a common assay was designed resulting in nine 
assays in total (AGE1-9) [Tables 7-2 & 7-3]. Each assay includes a 10X PCR primer 
set (forward and reverse) as well as a 10X sequencing primer for use in the 
Pyrosequencing® reaction (all reverse primers are 5’ biotin-labelled). Sequencing 
primers were designed to bind in a location close to the CpG site in question avoiding 
(where possible) the presence of another CpG site. Finally, all primers were designed 
to include converted cytosines in their sequence so they only bind to bisulphite-
converted DNA. 
7.2.1.4 Sample analysis 
Genomic DNA from 4 µl or a 1.2 mm dried spot of each blood sample was extracted 
using the manually performed Chelex method as described in section 2.2.1.1. A total 
of 10 µl of extracted DNA (~10 ng) or 100 ng of each DNA methylation standard 
were then treated with sodium bisulphite using the MethylEdge™ Bisulphite 
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Conversion System (Promega) as described in section 2.2.3.3; bisulphite-converted 
DNA was eluted in 15 µl of elution buffer and stored at 2-8 oC for up to one week. All 
samples were amplified in duplicate using the ZymoTaq™ premix (Zymo Research) 
and following the optimised conditions of each PCR assay. Briefly, each PCR reaction 
consisted of 12.5 µl of ZymoTaq PreMix, 1 µl of 25 mM MgCl2 for a final 
concentration of 2.75 mM (since the ZymoTaq™ Premix also contains 1.75 mM 
MgCl2), 1 µl of each PCR primer (for a final concentration of 0.4 µM), 1 µl of 
bisulphite DNA template and 8.5 µl of nuclease-free water, for a total reaction volume 
of 25 µl. The thermocycling program used was: 95 oC for 10 minutes, followed by 45 
cycles of 94 oC for 30 seconds, Tm (AGE1/3 - 50 oC, AGE6 - 51 oC, AGE2/5 - 53 oC, 
AGE4/7/8/9 - 55 oC) for 30 seconds, 72 oC for 30 seconds, and a final extension step 
of 72 oC for 7 minutes. Following amplification, the quality of PCR products was 
assessed on a 2% agarose gel as described in section 2.2.5.1. Lastly, using 10 µl of 
biotinylated PCR products Pyrosequencing® was performed as described in section 
2.2.6.1 and DNA methylation values were obtained via the PyroMark CpG software 
(QIAGEN). 
Table 7-1. Selected age-associated CpG sites for validation via bisulphite Pyrosequencing® 
Genomic information of each marker including chromosomal position, associated gene(s) and CpG 




Genes CpG island Coefficient 
cg05442902 22:21,369,010 
LZTR1, MIR649, P2RX6, 
SLC7A4, THAP7 
No -22.7 
cg09651136 15:72,525,012 PARP6, PKM2 No -15.8 
cg20822990 1:17,338,766 ATP13A2, SDHB No -15.7 
cg11067179 11:66,083,541 CD248, RIN1, TMEM151A No 14.7 
cg21139312 17:55,663,225 MSI2 No 17.1 





cg22213242 11:66,083,573 CD248, RIN1, TMEM151A Yes 23.7 
cg08097417 7:130,419,133 KLF14 Yes 27.3 




Table 7-2. Designed bisulphite PCR assays 
Essential information regarding the designed bisulphite PCR assays is shown, such as the score assigned by the primer design software (the lower the score the more efficient 
amplification), the primer sequences and length (F for forward and R for reverse), the % G and C content, the melting temperature (Tm), the number of converted cytosines 
included in the primer sequence (highlighted in red) as well as the length of the final PCR product.  
       CpG site Assay Score Primer Sequence (5’ Æ 3’) Length (bp) %GC Tm (Co) Converted Cs PCR Product (bp) 
cg03399905 AGE1 39.54 
F TATAGATATTGGTAATAATG 20 20.0 49.8 5 
170 
R TAACTACCCTAAACTAAA 18 27.8 53.4 5 
cg08097417 AGE2 28.35 
F GGTTAAGTTATGTTTAATAGT 21 23.8 55.0 3 
198 




F GTTATTAGTTTTTAGTTTATG 21 19.0 53.4 9 
171 
R AACTACAACTACCACTAT 18 33.3 52.8 4 
 
cg05442902 AGE4 25.20 
F TTTTGTGTTTTTTAGTTATTTTG 23 17.4 57.4 6 
120 
R AACTAACCCTTACAAATTTC 20 30.0 56.9 4 
cg20426994 AGE5 21.05 
F AATAGGTTTTGGTGTAGTT 19 31.6 56.0 4 
138 
R CAACCTCTAATAAATTCTCT 20 30.0 54.6 6 
cg14692377 AGE6 37.93 
F GATTTATTTGTTAGGTTG 18 27.8 51.8 8 
148 
R ATCAAACCATATAAAAAC 18 22.2 51.1 6 
cg21139312 AGE7 13.98 
F AGAAAGTTTTGAGTTGAGAA 20 30.0 56.5 3 
194 
R CCAACAAAAAATACCAAAAC 20 30.0 57.3 7 
cg09651136 AGE8 13.05 
F AAATTAAGAATAGTGGTGGAT 21 28.6 56.5 3 
95 
R CTACACCCAAACAATTTAAAACT 23 30.4 60.1 3 
cg20822990 AGE9 19.99 
F GTTTGTTTTATAGAGAATTGTTG 23 26.1 57.1 7 
183 
R CTCTTTTTACCCATACTAAAAT 22 27.3 57.4 5 
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Table 7-3. Pyrosequencing® DNA methylation assays 
The table includes details of the sequenced chromosomal locations, the sequencing primer sequences as well as the nucleotide dispensation order. The ten CpG sites in question 




Sequencing primer (5’ Æ 3’) Sequence to be analysed (5’ Æ 3’) Dispensation order 
AGE1 15:79,576,059-068 TAGATATTGGTAATAATGG ACGCTGGCAC GATCGTCAGTCATC 
AGE2 7:130,419,112-135 TAATAGTTTTAGAAATTATTTTG TCTCCGCGTTCTTTCTTCTGCCGG ATCGTCGTCAGTCG 





AGE4 22: 21,369,009-021 TTGTATGTTTTGGTTTTTGTAT ACGCTGCTCCCTG GATCGTCGATCG 
AGE5 7:130,418,302-328 TTTGGTAGTAGGTGTGATAG ACCTCCTCCGGGGCGCCTGATCCGCGG TATCGTCGTCGAGTCGTCG 
AGE6 17: 28,562,680-695 GGTTGGGTAGGCGGGTTGG CCTCGCGCCCTCGAGG ATCGTCGATCGAG 
AGE7 17:55,663,213-239 TTTTGTGGTTTTTAGAGTAGAT GCGGAGGCGGCACGTCCTCGTGCCCTT AGTCGAGTCGTCATCGATCGTGTC 
AGE8 15:72,525,009-018 ATATTGGGATGGTAAGGATTT GGCCGATGCT AGTCGATAGTC 
AGE9 1:17,338,763-777 TATATAAGAAAATGTTTGTTAATT GGGCGTGGTGGCGCA AGTCGTGATGTCGTCA 
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7.2.2 Approach 2 
7.2.2.1 Publicly available DNA methylation data 
Genome-wide profiling has led to more comprehensive understanding of gene 
regulation epigenetic mechanisms. Illumina’s Human Methylation BeadChip  
technology is one of the most commonly used genome-wide methylation platforms 
that allows for simultaneous measurement of the methylation status of over 27,000 
(27K chip) or 450,000 (450K chip) CpG sites in the genome at single nucleotide 
resolution (Bibikova et al., 2011). Thousands of samples have been assayed using this 
platform in the literature and researchers have made some of these genome-wide 
methylation data available in online databases. For the purpose of this study, due to 
restrictions in time and resources it was decided that online datasets would be selected 
that could offer a large pool of samples for age prediction. 
Prior to collection of the DNA methylation data for the selected age-associated CpG 
sites, these genome-wide DNA methylation datasets underwent a quality control 
analysis. Experimental biases on these genome-wide platforms are common and efforts 
should be made to eliminate these prior to data analysis. In this study, these analyses 
took into account, where available, the chip used, the order of each sample on the chip 
and the dataset (factor variables). Ideally, the reported bisulphite conversion rates 
should have been used too, however these data were not available for any dataset 
included in this study. Using a linear regression model, the normalised methylation 
beta values on these factor variables (resulting residuals) were created and used for age 
prediction analysis. 
Whole blood 
In his study, Horvath (2013) used available methylation data gathered from whole 
blood, cord blood or individual blood cell types such as peripheral blood mononuclear 
cells (PBMCs) or CD4+ cells. Furthermore, it was assumed that certain disease 
statuses such as schizophrenia had negligible effect on age relationships; therefore, 
diseased samples were also included in the model. For the purpose of this project, 
which was predicting age from blood stains, it was decided that only data obtained 
from whole peripheral blood of volunteers used as controls was suitable.  
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Datasets included in Horvath’s study together with recently published data that 
included age as one of their parameters comprised the final sample database of this 
study as shown in Table 7-4. The database included a total of 1,156 whole blood 
samples collected from individuals aged between 2-90 years old (mean age=44)  and 
from various ethnic backgrounds as part of seven genome-wide DNA methylation 
studies. Samples were carefully collected so that there was an equal representation of 
samples for all age groups aiming for ~100-150 samples per decade, which was quite 
challenging [Figure 7-2]. Since the gathered samples were either healthy control 
samples in studies investigating DNA methylation changes of various diseases (usually 
above 40 years old) or were part of studies investigating epigenetic effects of ageing 
(usually either very young or very old), collecting sufficient samples of ‘middle’ age 
(especially 30-40 years old) was quite difficult. Also, even though the database 
included both genders in equal amounts (597 females and 559 males), there was an 
uneven gender distribution within the age groups due to the selected studies’ design 
[Figure 7-2]. However, it was concluded that this should not affect age prediction 
since none of the sex-specific differentially methylated CpG sites reported in the 
literature following analysis with the Illumina’s 27K platform were included in the 
group of the selected 45 markers (Chen et al., 2011). 
 
 
























Table 7-4. DNA methylation datasets from various healthy tissues 
The table provides an overview of the selected DNA methylation data. Information regarding the 
sample size, gender (F/M), age range, mean age and applied Illumina platform are included in the table. 
All data are publicly available and can be assessed using the Accession No in the Gene Expression 
Omnibus (GEO) database. 
 
In more detail, set 1 includes methylation profiles of 235 healthy boys aged 4-18 years 
as part of a study into paediatric age-associated DNA methylation (Alisch et al., 2012), 
while set 2 consists of 12 female and 12 male samples in an attempt to investigate 
autosomal sex difference in the DNA methylome (Chen et al., 2011). Set 3 includes 
170 methylation profiles of individuals across a large age range as part of a study into 
human ageing rates (Hannum et al., 2013), whereas set 4 and 5 are comprised of 385 
and 33 healthy control Dutch subjects of a study investigating DNA methylation 
changes in schizophrenia patients using Illumina’s 27K and 450K arrays respectively 
Tissue Set Samples ♀/♂ Age range 
(mean) (years) 
Platform Accession No 
Whole 
blood 
1 235 0/235 4-18 (10) 27K GSE27097 
2 24 12/12 2-35 (14) 27K GSE23638 
3 170 77/93 32-90 (65) 450K GSE40279 
4 385 187/198 16-88 (40) 27K GSE41037 
5 33 12/21 18-65 (29) 450K GSE41169 
6 91 91/0 49-74 (63) 27K GSE20236 
7 218 218/0 52-78 (65) 27K GSE19711 
8 40 40/0 47-77 (62) 450K GSE53128 
9 66 66/0 33-68 (56) 27K GSE58045 
Saliva 
10 69 0/69 21-55 (35) 27K GSE28746 
11 196 54/142 21-55 (32) 27K GSE34035 
Buccal 
cells 
12 5 3/2 15 27K GSE25892 
13 4 2/2 4-5 450K GSE42409 
14 10 5/5 28-47 (35) 450K GSE50586 
Skin 
15 15 15/0 6-73 (34) 27K GSE22595 
16 30 30/0 18-59 (39) 27K E-MTAB-625 
17 8 8/0 43-62 (49) 27K GSE29661 
Cervix 18 167 167/0 19-69 (29) 27K GSE30758 
Muscle 
19 11 6/5 53-78 (68) 27K GSE38291 
20 51 0/51 21/77 (50) 27K GSE49908 
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(Horvath et al., 2012). Lastly, set 6 includes 91 methylation profiles of females aged 
49-74 years as part of a study investigating age-associated hypermethylation (Rakyan 
et al., 2010) and set 7 is comprised of 218 methylation profiles of healthy females aged 
52-78 years participating in an ovarian cancer population study (Teschendorff et al., 
2010). 
In order to investigate environmental influences on age prediction, the developed 
model was further validated using an independent cohort of healthy blood samples 
comprising of 53 female monozygotic twin pairs collected from two genome-wide 
studies [Table 7-4]. Set 8 includes 40 methylation profiles of females aged 47-77 years 
that were used to investigate differential methylation patterns involved in pain 
sensitivity (Bell et al., 2014), while set 9 is comprised of 66 female individuals aged 33-
68 years participating in an age-associated methylation study (Bell et al., 2012). 
Other tissues 
Since the set of 353 age-associated CpG sites included in the ‘epigenetic clock’ was 
suggested to be robust across various tissues, it was believed that the results of the 
developed model based on blood could potentially be also applicable in other tissues. 
Tissues including saliva, skin, cervix and muscle were chosen since they could be of 
forensic value. Sperm was not included in this study since there was no significant 
correlation between the predicted and the chronological age of the donors (Horvath, 
2013). The main challenge was that compared to blood there were not as many studies 
available that had used one of the Illumina platforms and had information regarding 
the volunteers’ age at the same time. This was considered as one of the key limitations 
when aiming to build a model in tissues other than blood. However, a final set of 566 
samples for the five selected tissues was assembled using methylation data from eight 
different genome-wide methylation studies [Table 7-4].  
In more depth, a total of 265 saliva samples from individuals aged 21 to 55 years were 
collected from two different studies. Set 10 includes 69 samples as part of an age-
associated genome-wide epigenetic analysis (Bocklandt et al., 2011), while set 11 is 
comprised of 196 individuals aged 21 to 55 years that volunteered in a study on the 
influence of sex on genome-wide methylation (Liu et al., 2010). As for buccal cells, 
three studies were chosen including five adolescents (15 years old) recruited in a study 
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of early developmental adversity (set 12) (Essex et al., 2013), four children aged 4-5 
years old (set 13) (Price et al., 2013) and also, ten individuals participated in a study 
investigating DNA methylation patterns in Down syndrome (set 14) (Jones et al., 
2013). Moreover, 53 skin samples from females aged 6 to 73 years were collected from 
three studies including a study investigating age-associated DNA methylation changes 
in dermal fibroblasts (set 15) (Koch et al., 2011), an epigenetic analysis of ethnic 
variations (set 16) (Winnefeld et al., 2012) as well as a study tracking cellular ageing 
(set 17) (Koch et al., 2012). Also, cervix samples were collected from 167 females (19-
69 years old) from a study investigating the association between epigenetic variability 
and risk of future morphological transformation (set 18) (Zhuang et al., 2012). Lastly, 
62 skeletal muscle samples from individuals aged 21-78 years were collected from two 
different studies, both invesigating methylation differences between muscle and other 
tissues (set 19 and 20) (Day et al., 2013; Ribel-Madsen et al., 2012). 
Diseased samples 
According to Horvath (2013), the correlation between the observed and expected age 
in cancer/affected tissues was generally weak as there was evidence of significant age 
acceleration in most patients included in his study (n=5,826). However, since there is 
usually no information regarding possible disease status in a forensic blood stain of 
unknown origin, it is important that the proposed age prediction model can be 
universally applied. To assess potential variability in age prediction, a data set 
including blood samples from a total of 1,011 (577 females and 434 males) individuals 
aged 17 to 91 years suffering from various diseases and cancers analysed on Illumina’s 
27K or 450K platforms was analysed [Table 7-5]. 
7.2.2.2 Selection of multi-tissue age-associated CpG sites 
The ability to accurately predict age regardless of the tissue would be very 
advantageous in forensic science where the identification of the tissue source of a 
sample is often challenging. Even if the purpose of this project was to identify age-
associated CpG sites in blood, the ability to apply a potential model in other tissues 
would save both time and resources. In an attempt to select more robust age-associated 
differentially methylated markers, the study by Horvath (2013) was chosen for a 
number of reasons. 
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Type 1 diabetes 194 (98/96) 24-74 (Bell et al., 2010) GSE20067 
Anaemia 28 (24/4) 23-85 (Day et al., 2013) GSE49904 





77 (31/46) 28-90 (Perez et al., 2013) GSE42042 
Ovarian cancer 262 (262/0) 49-91 (Teschendorff et al., 2010) GSE19711 
Breast cancer 
30 (30/0) 50-70 (Zhuang et al., 2012) GSE32396 
35 (35/0) 24-70 (Anjum et al., 2014) GSE57285 
Mainly, the proposed multi-tissue model based on 353 CpG sites was built using the 
largest dataset published so far containing more than 8,000 samples gathered from 
dozens of genome-wide studies. The selected publicly available data were obtained 
from various laboratories worldwide employing either Illumina’s 27K or 450K 
platform. Since the author decided to analyse only the common CpG sites between 
these platforms (21,369 in total), a larger dataset could be created. It was believed that 
this approach accounted for potential lab-to-lab variations or potential artefacts 
resulting in more dominant outcomes. Also, the ability of the test to predict age in 
whole blood with such high accuracy (mean absolute error=3.7 years, age 
correlation=0.95, test data) was a great advantage. The author categorised the group of 
353 markers using a coefficient value (ranging from -1.719 to 3.067) that relates the 
CpG sites to a transformed version of age as well as a marginal (positive or negative) 
age relationship. In order to cover all potential correlation with age and maximise the 
change of selecting ‘strong’ markers, it was decided that a total of 45 CpG sites would 
be investigated. These include three sets, the first one containing the top 15 CpG sites 
displaying negative coefficients (-0.578 to -1.719), the second one containing the top 
15 CpGs with positive coefficients (0.745 to 3.067) as well as a set with 15 CpG sites 
having coefficient values around zero (-0.002 to 0.006) [Table 7-6]. However, it 
should be noted that a future approach could include all 353 CpG sites. Their location 
was confirmed using the Ensembl genome browser; most of them are located across 
the genome within or near a gene. Interestingly, there is one common marker 
(cg05442902) with the previously selected set of CpG sites (Hannum et al, 2013). 
[249] 
 
Table 7-6. Selected 45 age-associated CpG sites from Horvath 2013 
 
CpG sites Coefficient Value Age Relationship Gene
cg16408394 -1.719 negative RXRA
cg25683012 -1.392 positive BAZ2A
cg19761273 -0.887 negative CSNK1D
cg27544190 -0.869 negative C21orf63
cg03588357 -0.859 positive GPR68
cg03286783 -0.855 negative CASC4
cg19273182 -0.755 positive PAPOLG
cg15703512 -0.731 negative MGC50721
cg01511567 -0.686 negative SSRP1
cg09441152 -0.683 negative PQLC1
cg02047577 -0.658 negative UCKL1
cg17338403 -0.645 negative SLCO3A1 
cg07158339 -0.626 negative FXN
cg01873645 -0.604 positive C9orf85
cg05442902 -0.578 negative P2RXL1
CpG sites Coefficient Value Age Relationship Gene
cg04999691 -0.002 negative C7orf29
cg24450312 -0.002 positive RASSF5
cg04452713 -0.001 negative DST
cg22613010 -0.001 negative CLCN2
cg09646392 0.000 negative TNFSF13B
cg17274064 0.000 negative ERG
cg16984944 0.000 negative TBC1D23
cg00436603 0.000 negative CYP2E1
cg24126851 0.001 positive DCHS1
cg14723032 0.001 positive PITPNM3
cg06926735 0.001 negative UBE2V1
cg14308452 0.003 positive MGC24975
cg00374717 0.005 positive ARSG
cg07455279 0.006 positive NDUFA3
cg02085507 0.006 positive TRIP10
CpG sites Coefficient Value Age Relationship Gene
cg20692569 0.745 positive FZD9
cg04528819 0.772 positive KLF14
cg08370996 0.813 positive NR2F2
cg26297688 0.960 positive C12orf23
cg23092072 1.000 negative AFF1
cg04084157 1.034 positive VGF
cg01968178 1.169 positive REEP1
cg25505610 1.502 positive hfl-B5
cg06993413 1.503 positive DPP8
cg00864867 1.600 positive PAWR
cg22736354 1.719 positive NHLRC1
cg06493994 1.858 positive SCGN
cg02479575 1.875 positive C19orf30
cg16241714 2.552 positive CEBPD







7.3.1 Investigation of 10 age-associated CpG sites via Pyrosequencing® 
7.3.1.1 Optimisation of Pyrosequencing®-based assays 
As already mentioned in Chapter 5, bisulphite-treated DNA is considered as one of 
the most challenging templates to amplify. Therefore it was necessary to optimise the 
PCR reactions for each marker to avoid mis-priming, primer self-annealing or non-
specific PCR products. Each assay was optimised using an annealing temperature 
gradient, various concentrations of MgCl2 and primer as well as different PCR cycling 
conditions. Figure 7-3 shows the successful amplification of the designed PCR 
products on a 2% agarose gel using a commercially available DNA methylation 
standard. As shown, even though PCR efficiency was higher for some assays, non-
specific products were absent. 
 
Figure 7-3. Final optimised PCR amplicons for assays AGE1-9 
Successful amplification of a methylation DNA standard using all nine assays. Expected PCR lengths 
are shown on the top of the picture, together with the expected fragments of the DNA marker on the 
left. It is important to note that no non-specific amplification is present in any of the assays; however 
assays AGE1 and AGE4 seem to result in a weaker signal. 
 
Optimised PCR products were then sequenced and methylation quantification was 
performed. Figure 7-4 provides example pyrograms™ obtained for one blood sample 
following analysis with all designed assays (AGE1-9). Bisulphite conversion rates were 
in most cases >98%; if bisulphite conversion rates were lower than 95%, the treatment 
with sodium bisulphite was repeated. Also, there was no chemiluminescence observed 
in the control injections suggesting that it was only the PCR product being sequenced. 
However, for certain assays the peaks were wider than expected indicating too much 
DNA input due to high PCR efficiency [Figure 7-4b]. Also, it was noted that 
occasionally the signal was decreased towards the end of the sequence probably due to 



























a – AGE1 
b – AGE2 
c – AGE3 
d – AGE4 

























f – AGE6 
g – AGE7 
h – AGE8 
i – AGE9 
Figure 7-4. Example pyrograms™ of all designed pyrosequencing® assays AGE1-9 
Although there are ten CpGs in question (highlighted in red blocks), in some assays adjacent CpGs 
were also quantified. Obtained methylation values are presented on the top, where the peak for ‘T’ 
corresponds to the unmethylated fraction (together with adjacent Ts or non-CpG converted Cs) while 




7.3.1.2 Epigenetic drift in blood 
Bisulphite-treated DNA samples obtained for 90 individuals (age range 1 week to 85 
years old) were tested for all ten CpG sites following the experimental procedure 
explained in section 8.2.1.4. Only samples that passed the pyrosequencer’s inbuilt 
quality controls in each assay were included in the analysis. The obtained individual 
methylation values were used to calculate the mean, standard deviation and 
methylation range for each assay [Table 7-7]. Some CpG sites showed higher 
variation than others. The range of methylation varied between 0.12 (cg03399905) 
and 0.99 (cg09651136), although for the latter marker the range would decrease to 
0.59 if one single sample (0.01, 39 years old) was excluded.  
Methylation fractions (zero to one) were then plotted against the actual age of each 
individual in order to investigate potential correlation between methylation levels and 
age. In general, no significant linear correlation (p>0.05) was observed for any of the 
ten CpG sites tested. As depicted in Figure 7-5, methylation levels for four markers 
cg03399905, cg05442902, cg21139312 and cg09651136 decrease with age; this is in 
accordance with the previously published negative age coefficient values for three of 
them (cg05442902, cg21139312 and cg09651136). Interestingly, during the marker 
selection process cg03399905 was chosen because it had the highest positive 
coefficient value at 28, yet methylation levels are shown to decrease with age from the 
data presented here. Also, there were three markers comprising cg08097417 and the 
two markers included in the AGE3 assay showing an increase in methylation with age. 
The rest did not seem to exhibit any significant distribution.  





Minimum Maximum Range Mean ± StDev 
cg03399905 58 0 0.39 0.39 0.117 ± 0.125 
cg08097417 72 0 0.12 0.12 0.031 ± 0.021 
cg11067179 76 0.02 0.92 0.9 0.541 ± 0.201 
cg22213242 74 0.26 0.71 0.45 0.552 ± 0.109 
cg05442902 79 0.06 0.39 0.33 0.136 ± 0.060 
cg20426994 84 0 0.34 0.34 0.031 ± 0.052 
cg14692377 77 0.06 0.35 0.29 0.121 ± 0.051 
cg21139312 68 0 1 1 0.738 ± 0.244 
cg09651136 89 0.01 1 0.99 0.749 ± 0.159 















































Figure 7-5. Correlation between obtained methylation levels and 
chronological age for all ten CpG sites 
As shown in the graphs, no significant linear correlation between methylation and 
age (p>0.05) was observed; however, for some of them such as cg05442902 and 
cg20822990 methylation tends to decrease with age. 
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7.3.1.3 Age prediction 
Although the obtained methylation values showed no significant linear correlation 
with age when taken individually, multiple regression analysis was explored as it could 
assess all markers’ methylation changes together. Occasionally, there were one or two 
missing methylation values per sample so for this type of analysis a final set of 65 
samples with complete data for all markers was used. As shown in Figure 7-6, simple 
multiple regression involving only a limited number of variables has shown a 
significant association with chronological age (r=0.54, p=0.025); however, the resulted 
prediction showed significant error. Two variables, namely cg05442902 and 
cg20426994, were the most important in predicting age (p=0.002 and p=0.025 
respectively). 
 
Figure 7-6. Age prediction using multiple regression analysis (n=65, 10 CpGs) 
Blue dots symbolise individual age predictions, while the red line represents the regression line with 
95% age prediction range (dashed red line). The black dashed line illustrates the ‘ideal’ prediction. As 
shown, the resulted regression mostly overestimates young individuals, while underestimates older 
individuals. 
Since some variables were shown to be more important in predicting age than others, 
it was concluded that the use of neural network analysis could take advantage of the 
variability in all of these imprecise associations and apply differential weights. Models 
could be built from a selection of data (training set), which are then verified 
(verification set) and tested (blind test) from other subsets of available data. 
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The ageing model, performed by Thomas Miller and presented in Figure 7-7, was 
trained using the methylation results of a total of 54 blood samples applying artificial 
neural networks (ANN). The accuracy of the model was high, with a correlation 
between observed and predicted age of 95% and an average error of 4.27 years. In 
order to verify the model, the methylation data of six random samples were employed, 
where the obtained error was 6.09 years. Moreover, when the last three samples were 
used as a blind test, the error was significantly higher (10.36 years). 
 
Figure 7-7. Age prediction model created by applying ANN (n=65, 10 CpGs) 
Methylation data of 65 whole blood samples of individuals aged 1 week to 85 years were employed to 
create an age prediction model using ANN (mean absolute error=4.27 years in the training set). 
Different-coloured dots correspond to the training (blue), verification (green) and blind test (red) data. 
The red dashed lines indicate the 95% prediction interval. 
Although the obtained results were promising indicating the potential usefulness of the 
proposed age-associated DNA methylation markers, the limitations of the method 
including the small data set could not be overlooked. Furthermore, since issues with 
amplification bias during bisulphite PCR have been previously observed and the 
observed methylation variation was in some cases very small, it was decided that a 
linearity analysis for the proposed Pyrosequencing® assays should be performed before 
any conclusions on the age prediction model can be made. 
y=1.0043x – 0.0238 
R2=0.9502 
ANN development and analysis by T. Miller 
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7.3.1.4 Linearity of methylation quantification by Pyrosequencing® 
As shown in Chapter 5, non-linear methylation quantification is common in bisulphite 
PCR-based protocols; since there are two different DNA templates available 
(methylated/unmethylated), PCR efficiencies could differ resulting in amplification 
bias. To assess the performance of the designed assays regarding methylation 
quantification, DNA methylation controls (0-100%) (EpigenDx) were used. 100 ng of 
each standard were bisulphite-treated in duplicate and amplified using all assays 
(AGE1-9); the average methylation per standard was then calculated [Table 7-8]. 
Table 7-8. Mean observed methylation values of the tested DNA controls. 
The grey box represents missing data.  
 
While the unmethylated DNA (<0.05) was correctly sequenced in all assays (mean 
detected methylation=0.02), issues regarding the methylated standard (>0.85) were 
observed for certain CpGs. For example, for cg05442902 and cg14692377, the 
average methylation values were 0.58 and 0.46 respectively. Interestingly, the 
maximum obtained methylation values for these particular CpGs when analysing the 
blood samples were also 0.39 and 0.35 [Table 7-7]. Furthermore, as a general 
statement, it was noted that there was bias towards the methylated allele in low 
methylated standards (5-25%), while the opposite bias towards the unmethylated 
allele was observed in highly methylated standards (75-100%). This phenomenon 
resulted in methylation over-estimation and underestimation respectively. Taking into 
account the above, a graph of observed vs. ‘normalised’ expected methylation for each 
marker was drawn and the best-fitted trendline (quadratic or cubic polynomial) was 
chosen as previously discussed in section 2.4.1.5 [Figure 7-8].  
0 0.05 0.1 0.25 0.5 0.75 1
cg03399905 0.01 0.03 0.09 0.19 0.39 0.61 0.96
cg08097417 0.01 0.02 0.10 0.34 0.45 0.65 0.80
cg11067179 0.00 0.13 0.26 0.45 0.59 0.72 0.81
cg22213242 0.00 0.10 0.32 0.48 0.49 0.68
cg05442902 0.06 0.12 0.20 0.28 0.46 0.57 0.58
cg20426994 0.01 0.15 0.12 0.32 0.49 0.62 0.90
cg14692377 0.01 0.04 0.10 0.18 0.32 0.28 0.46
cg21139312 0.06 0.20 0.18 0.25 0.46 0.60 0.95
cg09651136 0.04 0.08 0.13 0.37 0.72 0.80 0.99
cg20822990 0.02 0.12 0.33 0.53 0.73 0.81 0.86






Figure 7-8. Observed vs. expected methylation of known DNA methylation standards for 
all ten CpG sites 
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7.3.1.5 Verification of the developed model 
In an attempt to verify these results, the same blood samples were reanalysed using the 
same experimental conditions in order to fill any ‘gaps’ in the previous methylation 
dataset; the final dataset consisted of 86 blood samples with methylation data for all 
ten CpG sites in question. Using the equations derived from the linearity analysis, the 
methylation values of these blood samples were also ‘corrected’ as described in section 
2.4.1.3. Both the original and corrected methylation datasets were employed and 
reanalysed to assess if there was an improvement in age prediction. 
Again, simple multiple regression analysis did not result in a significant correlation 
with age (r=0.44, p=0.08 using the original and r=0.39, p=0.19 using the corrected 
methylation values); however, using analysis of variance (ANOVA) the importance of 
each marker could be considered individually. Using a stepwise model it was 
confirmed that cg20822990 was highly associated with age in both datasets (p=0.002 
for the original and p=0.023 for corrected data) followed by cg05442902 (p=0.039 for 
the original and 0.048 for the corrected data); the other age variables did not seem to 
improve the model. These two markers alone could explain 15% of variation in age in 
this sample set. Interestingly, cg05442902 seemed to demonstrate the highest 
correlation with age also in the previous multiple regression model [Figure 7-6]. These 
results were also verified by univariate analysis where age prediction using all ten CpG 
sites was not drastically better than when using only the cg05442902 and cg20822990 
for the uncorrected data [Figure 7-9]. However, the age prediction resulted in a high 
standard error of estimate of 16-17 years in all models tested. Surprisingly, similar 
results were also obtained using neural networks where creating an accurate prediction 
model was rather challenging. 
In general it was observed that the correction of the methylation quantification using 
the equations obtained by analysing known DNA methylation standards did not 
improve age prediction; the correlation was actually better using the original 
methylation values obtained by the pyrosequencer. It is believed that this is due to the 
low range in methylation levels observed for certain markers; therefore, correction did 
not actually change the obtained values. Also, the resolution of the method itself 
should be taken into account since there was an average difference of detected 




Figure 7-9. Age prediction by univariate analysis in the original methylation data (n=86) 
(a) Age prediction using all ten predictors, (b) Age prediction using only cg05442902 and cg20822990. 
Red lines indicate linear regression while the dashed black lines show the expected age prediction. 
Failing to reproduce the age prediction results using a slightly larger dataset could not 
only be due to experimental parameters and the method’s accuracy, but could also 
indicate that applying only the ten selected age-associated CpG sites is not enough to 
predict age. It is known that ANN models predict better using fewer cases, hence the 
promising age prediction after the first attempt [Figure 7-7]. It is believed that a larger 
set of CpG sites gathered by a larger genome-wide methylation analysis containing 
thousands of samples could potentially overcome existing challenges and reveal more 














7.3.2 Age prediction model through artificial neural networks (ANN) 
7.3.2.1 Age-associated DNA methylation changes in blood 
In an attempt to test more robust CpG sites, a set of 45 CpG sites were selected from 
the study by Horvath (2013) according to the criteria already mentioned in section 
7.2.2.2 [Table 7-6]. Methylation data regarding these CpG sites were collected from a 
total of 1,156 whole blood samples from individuals 2-90 years old included in seven, 
publicly available methylation databases. Box and whisker plots were obtained for 
each essay that indicate the median, quartiles (1st and 3rd) as well as methylation range 
for each assay [Figure 7-10]. As expected, some CpG sites showed higher variation 
than others; cg07455279 demonstrated the highest methylation range (0.815) while 
cg05442902 usually showed low methylation levels (0.118 to 0.387). Since the latter 
is the only common marker with the previous approach, it is worth noting that the 
methylation pattern matches with that previously reported via Pyrosequencing® 
(0.06-0.39) [Table 7-9]. 
Methylation fractions (zero to one) were then plotted against the actual age of each 
individual in order to investigate potential correlation between the methylation levels 
and age. In general, the methylation of certain CpG sites such as cg19761273, 
cg01511567, cg07158339 and cg05442902 was clearly decreasing with advancing 
age, while some others, cg20692569, cg04528819, cg04084157 and cg22736354 to 
name but a few were increasingly methylated over time. These observations align with 
the age relationship that Horvath reported in his study. Interestingly, at least 16 CpG 
sites (e.g. cg02047577 and cg01873645) were found constantly unmethylated (<0.2), 
while three CpG sites – cg24126851, cg14308452 and cg00374717 – demonstrated 
high methylation levels for all ages.  
7.3.2.2 Identification of the epigenetic ageing signature 
The observed age-associated methylation changes were assessed for their statistical 
significance for all markers in an attempt to identify the ones that could form the 
proposed epigenetic-ageing-signature. Firstly, using multivariate analysis and testing 
the effect of gender or ethnicity on age-associated methylation, no significant 





























































































































































































































































Using linear regression analysis, a significant correlation between methylation levels 
and age (p<0.05) was confirmed for 25 out of the 45 CpG sites (shaded in green on 
Table 7-9). As expected, most of these markers are the ones that were identified earlier 
for having a decreasing or increasing trend in their methylation status with advancing 
age; however, using multiple regression analysis, it was observed that not all markers 
significantly improved age prediction. Applying stepwise regression for variable 
selection, the results regarding the importance of the markers was similar, although the 
order of the markers was slightly different [Table 7-10]. In order to perform this type 
of analysis, the markers were added one by one into the age prediction model until 
there was no statistical improvement. As shown in Table 7-10, the addition of 23 CpG 
sites resulted in a value of R2=0.923, which was not further improved with the addition 
of more markers. All 23 age-associated CpG sites that were revealed following 
stepwise regression are also included in the set of markers identified after multiple 
regression analysis. Interestingly, in both analyses the marker cg22736354 was found 















Table 7-9. Correlation of selected CpG sites with age as assessed by their p-values 

















































Table 7-10. Summary of stepwise regression for the first 28 CpG sites used in the model 
The markers contributing to the model are highlighted in green, while the ones in red are those that do 
not significantly change age prediction. 
CpG sites Step +in/-out Multiple R Multiple R2 R2 change p value 
cg22736354 1 0.835200 0.697559 0.697559 0.0000001 
cg19761273 2 0.910351 0.828740 0.131181 0.0000001 
cg20692569 3 0.920375 0.847090 0.018350 0.0000001 
cg06493994 4 0.928244 0.861636 0.014547 0.0000001 
cg27544190 5 0.939846 0.883311 0.021674 0.0000001 
cg17274064 6 0.943643 0.890461 0.007151 0.0000001 
cg04084157 7 0.946874 0.896571 0.006110 0.0000001 
cg04528819 8 0.949625 0.901787 0.005216 0.0000001 
cg01511567 9 0.951676 0.905687 0.003900 0.0000001 
cg02085507 10 0.953522 0.909204 0.003517 0.0000001 
cg07158339 11 0.954730 0.911510 0.002306 0.000001 
cg05442902 12 0.956017 0.913968 0.002458 0.0000001 
cg02479575 13 0.956845 0.915552 0.001583 0.000030 
cg08370996 14 0.957458 0.946727 0.001175 0.000290 
cg24450312 15 0.957983 0.917732 0.001005 0.000744 
cg03286783 16 0.958845 0.919383 0.001652 0.000013 
cg23092072 17 0.959382 0.920414 0.001030 0.000526 
cg14308452 18 0.959720 0.921063 0.000650 0.005678 
cg16408394 19 0.959903 0.921414 0.000350 0.041706 
cg24126851 20 0.960074 0.921742 0.000329 0.048114 
cg04452713 21 0.960309 0.922194 0.000452 0.020294 
cg22613010 22 0.960498 0.922556 0.000362 0.037302 
cg17338403 23 0.960724 0.922990 0.000434 0.022426 
cg19273182 24 0.960791 0.923119 0.000129 0.212676 
cg04999691 25 0.960858 0.923247 0.000129 0.213073 
cg06993413 26 0.960937 0.923400 0.000153 0.170420 
cg06926735 27 0.961028 0.923575 0.000174 0.146738 
cg14723032 28 0.961108 0.923728 0.000154 0.172929 
 
The methylation change over time regarding the first 16 CpG sites proposed by the 
stepwise regression analysis is also illustrated in Figure 7-11. Information regarding the 
genes that the CpG sites lay near or within was acquired to identify their function and 
potential involvement in ageing. The exact chromosomal locations of the CpG sites 
comprising the epigenetic ageing signature as well as the involved genes are also shown 



















Figure 7-11. Change of methylation levels over advancing age for the 16 most important 
age-associated CpGs (n=1,156) 
Each dot represents the observed methylation of an individual for the CpG site in question. It should be 
noted that in these graphs age is shown as age-in-months. Black lines correspond to linear regression.  
 
7.3.2.3 Age prediction in blood  
Applying multiple regression analysis on the methylation values of all 1,156 individuals 
for the selected 16 best CpG sites using the STATISTICA software, the correlation 
between predicted and true age was significantly strong (linear correlation, 
R2=0.9258), while the mean absolute error using all data was 4.89 years (standard 
deviation = 4.36 years) [Figure 7-12]. As shown in the graph, 60.5% (700/1,156) of 
individuals were predicted within a ±5 year error range, while 89% (1,029/1,156) 
samples were predicted within a ±10 year error range.  As indicated in Figure 7-12, 
there were individuals that seemed to age fast (red circles) while there were others that 
were predicted as much younger (green circles). Notably, as shown in Figure 7-12b, 
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the prediction error in older individuals (>60 years old) was higher compared to 
younger ones. This is believed to be expected as older individuals have been exposed 
to more environmental stress throughout their lifetime that could have potentially 
caused changes in DNA methylation patterns (epigenetic drift). 
Table 7-11. Epigenetic ageing signature consisting of 16 CpG sites 
 
 
Figure 7-12. Age prediction using multiple regression analysis (16 CpG sites) 
(a) Predicted vs. Chronological age (years) for all 1,156 individuals used in this study (linear correlation 
R2=0.92, mean absolute error=4.89 years, standard deviation=4.36 years), (b) Predicted error (years) 
over advancing age. As shown most individuals were predicted within a ±5 year error range (0.61), 
while 1,029 out of 1,156 samples were predicted within a ±10 year error range (0.89). Red circles 
indicate individuals that were anticipated to age fast, while green circles indicate individuals that were 





cg19761273 17: 80,232,096 CSNK1D - casein kinase 1; delta isoform 1 
cg27544190 21: 33,785,434 C21orf63 - chromosome 21 open reading frame 63 
cg03286783 15: 44,580,973 CASC4 - cancer susceptibility candidate 4 isoform a 
cg01511567 11: 57,103,631 SSRP1 - structure specific recognition protein 1 
cg07158339 9: 71,650,237 FXN –frataxin, mitochondrial isoform 1 preproprotein 
cg05442902 22: 21,369,010 P2RXL1 - purinergic receptor P2X-like 1; orphan receptor 
cg24450312 1: 206,681,158 RASSF5 - Ras association domain family 5 isoform B 
cg17274064 21: 40,033,892 ERG - v-etserythroblastosis virus E26 oncogene like isoform 2 
cg02085507 19: 6,739,192 TRIP10 - thyroid hormone receptor interactor 10 
cg20692569 7: 72,848,481 FZD9 - frizzled 9 
cg04528819 7: 130,418,315 KLF14 - Kruppel-like factor 14 
cg08370996 15: 96,874,031 NR2F2 - nuclear receptor subfamily 2; group F; member 2 
cg04084157 7: 100,809,049 VGF - nerve growth factor inducible precursor 
cg22736354 6: 18,122,719 NHLRC1 – malin 
cg06493994 6: 25,652,602 SCGN - secretagogin precursor 
cg02479575 19: 4,769,653 C19orf30 - hypothetical protein LOC284424 
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The potential of applying artificial neural networks was once again explored since it is 
believed that it could result in a better prediction, especially for complex variables like 
age. For the purpose of this study, two different ANN models were investigated 
including a multilayer perceptron (MLP) and a generalised regression neural network 
(GRNN). Applying the first approach using the standard settings specified within the 
STATISTICA software, the age prediction was slightly better (mean absolute 
error=3.54 years, standard deviation=2.9 years, training) than the one obtained by 
regression analysis (mean absolute error=4.9 years, standard deviation=4.4 years).  
On the other hand, neural network models developed by Dr Leon Barron using Trajan 
6.0 software showed that the age prediction accuracy could be significantly improved 
using these data. This prediction was also shown to be repeatable and is presented as 
an average of the predicted values acquired from n=10 replicate networks from the 
optimised GRNN architecture. The results were promising as they resulted in a 
correlation between predicted and true age of 96% and a mean absolute error of 3.3 
years (standard deviation=3.7 years) [Figure 7-13a]. In more detail, a total of 694 
samples were used to train the model, while 231 samples were used for each of the 
verification and blind tests (for a total of 1,156 samples). Predictions were still highly 
accurate for the both test sets (error of 4.6 and 4.4 years correspondingly). As shown 
in Figure 7-13b, 95.6% of the samples was predicted within 10 years, while 82.8% 
were predicted within 5 years. Interestingly, the graph showing the age residual error 
obtained by ANN (Figure 7-13b) has a noticeably different pattern than the one 
obtained by multiple regression analysis (Figure 7-12b). While the latter resulted in a 
more randomly distributed error pattern around the mean, errors obtained by ANN 
revealed at least two (or potentially three) different patterns within the graph. Looking 
at the graph (Figure 7-13b], one can notice that there are parts within the graph 
showing that predicted errors decrease with age (even demonstrating a linear trend). 
These findings could indicate a potential ANN bias in age prediction within specific 
age groups that could perhaps be corrected. Furthermore, Figure 7-13c shows a 
sensitivity analysis on the contribution of each marker to the age prediction produced 
by the GRNN models, where the network error ratio upon systematically removing 
one CpG at the time was assessed. Interestingly, the order that ANN categorised the 
CpG sites resembled the one obtained by multiple regression and stepwise analysis 




Figure 7-13. Age prediction using artificial neural networks (16 CpG sites) 
 (a) Predicted vs. Chronological age for all 1,156 individuals included in the study as calculated by 
averaging the prediction values of 10 replicate networks (linear correlation R2=0.96, mean error (test) 
=4.4 years), (b) Predicted error (years) over advancing age; as shown most individuals were predicted 
within a ±5 year error range (0.83), while 95.6% of the samples were predicted within a ±10 year error 
range, (c) This graph represents the network error ratio upon systematic removal of each CpG site from 
10 replicate networks. Boxes include data from the 25th-75th percentile as well as the median (thin line) 
and mean (thick line); error bars include the 5th and 95th percentile. As shown the most useful age-
associated CpG site was found to be cg22736354, while the least useful was cg03286783, (d) The graph 
represents the absolute error in years for the blind test only. 
7.3.2.4 Validation through an independent cohort of monozygotic twins 
The obtained model was validated using a secondary independent cohort, consisting of 
an additional 106 blood samples of 53 monozygotic twin pairs aged 33-77 years. 
Monozygotic twins were chosen since they begin life with nearly identical genetic and 
epigenetic profiles and it is the effect of various environmental factors that alters their 
genome-wide DNA methylation profile later in life. Therefore, it would be possible to 
ANN development and analysis by L. Barron 
[270] 
 
assess these types of variations and conclude if age acceleration is highly heritable. The 
methylation values of each sample for all 16 CpG sites were imported into the model as 
a blind test (the identity of the twin pairs was not indicated) and the obtained overall 
prediction errors are shown in Table 7-12. 
In general, the obtained age prediction accuracy was lower than the one obtained from 
the blind test with an average mean absolute error of 7.07 years (standard 
deviation=5.78 years). More specifically, regarding the 20 twin pairs analysed on the 
Illumina 450K platform the mean error was 9.86±7.16 years, while for the 23 twin 
pairs analysed on the Illumina 27K platform the mean error was 5.38±3.97 years. 
Interestingly, there were twin pairs that were predicted to be either much older or 
much younger than their actual age, but the differences within the twin pairs were not 
statistically significant as obtained by paired t-test analysis (p=0.99). The mean 
difference of age prediction between twins was 2.65±2.37 years. These results are very 
interesting since they indicate a possible ‘inherited’ function of ageing and could 
confirm the belief of ‘good genes’. The DNA damage theory of aging proposes that 
aging is a consequence of the accumulation of naturally occurring DNA damages, 
shown as DNA alterations, which also include the mechanism of DNA methylation. 
Since it is accepted that DNA methylation patterns adjust according to environmental 
exposure, this could potentially indicate that the response mechanisms involved have a 
genetic basis. For example, the DNA repair processes are regulated by DNA repair 
enzymes that can potentially have different efficiencies depending on the isoform and 
the inherited DNA sequence in question. Furthermore, one can assume that twins 
within the same pair are more likely to be exposed to similar environmental conditions 
than twins from different pairs, therefore the differences in DNA methylation (as 
translated in age prediction) within the same pair is expected to be smaller than the 
differences amongst different twin pairs. 
Also, considering that the twins (apart from one pair) were all >45 years old, the effect 
of environmental conditions and lifestyle should also be considered. According to 
Horvath, while the heritability of age acceleration was found to be 100% in new-
borns, it was only 39% in older subjects suggesting that non-genetic factors become 
more relevant later in life (Horvath, 2013). Also, although all twins were volunteered 
as healthy controls, it would be very beneficial if information regarding disease 
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susceptibility was available. It is believed that together with differences in lifestyle, it 
could possibly explain the observed large differences in age prediction between twins 
in four pairs highlighted in black in Table 7-12. 
Table 7-12. Age prediction in an independent cohort of monozygotic twin pairs 
Twin pairs (1-53) are presented below in age order (33-77 years old). ‘X’ represents the age prediction 
error of each twin, which can be classified in five categories (0-2.5, 2.5-5, 5.-7.5, 7.5-10 and>10 years). 
Results in orange correspond to 20 pairs (Illumina 450K platform, mean error of 9.86±7.16 years), while 
results in blue correspond to 23 pairs (Illumina 27K platform, mean error of 5.38±3.97 years). 
 




4 47.28 X X
5 48.3 X X
6 49.08 X X
7 49.14 XX
8 49.2 X X
9 49.6 X X
10 50.11 X X
11 50.82 X X
12 50.98 X X
13 51.55 X X
14 51.58 XX
15 52.96 X X
16 54.2 X X
17 54.31 X X
18 54.55 X X
19 54.71 X X





25 56.77 X X
26 57.33 XX
27 58.31 XX
28 58.49 X X
29 58.59 XX




34 60.06 X X
35 61.91 X X
36 62.75 XX
37 63.61 X X
38 63.84 X X
39 63.9 XX
40 64.35 X X




45 65.55 X X
46 66.79 XX
47 67.08 X X
48 67.7 X X
49 68.13 X X
50 68.26 XX
51 69.3 X X
52 75.1 XX
53 76.5 X X
29 18 18 13 28Number of predictions
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7.3.2.5 Applying the age prediction model in diseased tissues 
Although Horvath reported that the predicted age from cancer tissues correlated 
poorly with patient age in his study, six datasets including diseased samples were 
analysed in an attempt to further validate the proposed age prediction model [Table 7-
5]. As previously mentioned, one has to bear in mind that in contrast with a medical 
setting, information regarding possible disease status is usually not available when 
trying to predict chronological age from an unknown blood stain during a criminal 
investigation. Consequently, it is important to build a robust age prediction model 
containing DNA methylation markers that would not show differential methylation 
patterns due to diseases. Figure 7-14 shows the predicted vs. chronological age for all 
1,011 samples included in this analysis; combining all diseases together, a correlation 
of 73.5% and a mean absolute error of 7.18 years was obtained. However, when 
analysing separately samples suffering from blood and non-blood diseases it becomes 
evident that the error is higher for blood diseases (error=12.74 years). This is expected 
since the methylation data were gathered by analysing whole blood samples. Also, it 
was noted that as expected (due to the higher environmental stress), the prediction 
error for older individuals (>60 years old) was higher compared to the younger ones. 
In more detail, the obtained mean absolute errors for each disease were as follows: 
 Type 1 diabetes – error=8.63±6.38 years 
 Anaemia – error=14.38±5.29 years 
 Bone marrow disorders (including leukaemia) – error=11.09±8.39 years 
 Ovarian cancer – error=7.45±5.79 years 
 Breast cancer – error=6.77±4.94 years 
 Schizophrenia – error=5.03±4.90 years 
Schizophrenia showed the lowest age prediction error, while anaemia demonstrated 
the lowest correlation with age. While changes in expression of one of the markers 
included in the model - the VGF neuropeptide linked with cg04084157 - have been 
detected in the cerebrospinal fluid of patients with different neurological and 
psychiatric conditions such as schizophrenia (Huang et al., 2006), it did not seem to 
affect prediction in blood. It should also be noted that schizophrenia patients consisted 
the largest dataset test; therefore a better prediction error could also be due to the 
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greater number of samples. On the other hand, the results regarding anaemia (n=28) 
come as no surprise since anaemia is one of the most common blood disorders which 
could add extra ‘stress’ on the body and especially in blood. Interestingly, cg07158339 
is located near the frataxin gene (FXN) which has been associated with selectively and 
non-covalently interacting with ferric ion Fe (III) to assemble the iron-sulfur cluster 
(Gentry et al., 2013). Consequently, differential methylation patterns due to the 
disease status in blood cannot be excluded. Another example includes the ERG 
oncogene associated with cg17274064, which is an erythroblast transformation-
specific transcription regulator typically mutated in myeloid leukaemia (Yi et al., 
1997). As shown, the dataset comprised by various bone marrow disorders including 
leukaemia demonstrated the second largest mean error (11.09 years). 
 
Figure 7-14. Age prediction in diseased samples (n=1,011) 
7.3.2.6 Applying the age prediction model in other tissues 
As mentioned in the Experimental section, a final set of 566 samples for five selected 
tissues including saliva, buccal cells, skin, cervix and muscle was assembled using 
methylation data from eight different genome-wide methylation studies [Table 7-4]. 
Initially, a subset of this dataset was used to import the methylation values into the 
ANN development and analysis by L. Barron 
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already developed prediction model in blood to assess if accurate prediction was 
possible. This subset consisted of 102 samples - 19 buccal cells, 20 saliva, 15 skin, 20 
cervix and 28 muscle samples. In general, prediction was very poor; as an overall 
remark it can be noted that there was an over prediction in young ages as well as an 
underestimation of age in older individuals [Figure 7-15]. These results indicate the 
need to build age prediction models in each forensically relevant tissue separately; 
however the main challenge is still to obtain a large methylation dataset for analysis. 
 
Figure 7-15. Age prediction in other tissues using the developed blood prediction model 
 
7.3.2.7 Age prediction in saliva and cervix 
Saliva and cervix were the only tissues where sufficient genome-wide methylation 
data was available for robust analysis. Issues on building ANN models using less than 
100 samples had been previously observed; therefore it was concluded that 19 buccal 
cells, 53 skin samples and 62 muscle tissues were not enough to build new prediction 
models. Saliva is one of the most common types of biological evidence found at crime 
scenes in the form of used glasses, cigarette butts or stamps, whereas vaginal cells are 
commonly recovered in sexual crime. The purpose of this study was mainly to assess 
tissue-specific variations in age prediction; therefore, it was decided to focus on these 
two tissues. For saliva, methylation values regarding the selected 16 CpG sites were 
collected from a total of 265 samples aged 21-55 years. Similarly, 167 cervix samples 
from individuals aged 19-69 years were used to build the age prediction for this tissue. 
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For saliva, 159 samples were used to train a GRNN model, while 53 samples were 
used for the verification and another 53 for the test set. As shown in Figure 7-16a, a 
correlation between predicted and true age of 73% was observed while the mean error 
was 3.18 years (training), 6.26 years (verification) and 4 years (test). The prediction 
accuracy was great considering the size of the dataset; however, the small age range 
(21-55 years) cannot be ignored. Also, as shown in the graphs representing the age 
residuals, age prediction seemed to be more accurate in younger individuals where 
underestimation of age was not very common, while there was a larger variation in 
prediction errors for older individuals. On the other hand, the age prediction success  
in cervix was surprisingly high with a linear correlation of R2=0.86, while the mean 
error was 1.01 years (training), 4.44 years (verification) and 5.03 years (test). This 
should be explained by the fact that, compared to blood or saliva, cervix is a more 
homogenous tissue made up by distinct cell types. Nevertheless, one should also take 
into account that the resolution and variation in age was not great for this dataset, 




Figure 7-16. Age prediction models in saliva (n=265) and cervix (n=167) 
Predicted vs. Chronological age (years) for (a) 265 saliva samples (linear correlation R2=0.73, mean 
absolute error=4 years (test), standard deviation=3.4 years), (b) 167 cervix samples (linear correlation 
R2=0.86, mean absolute error=5.03 years (test), standard deviation=2.97 years) 
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7.4 Final remarks  
Since there have been a few studies that successfully created models using either 
dozens (Hannum et al., 2013) or hundreds of CpG sites (Horvath, 2013), it was 
believed that biological age can be predicted using age-associated DNA methylation. 
From a forensic perspective, the main challenge to be faced is the low quality and 
quantity of forensic specimens, making it impossible to implement such models in 
forensic casework in their current form. The purpose of this study was to investigate 
age-associated CpG sites reported in the literature and assess the possibility of using a 
small number of markers to accurately predict biological age in blood. To meet the 
aim, two different approaches were followed.  
The first one included the validation of a set of ten CpG sites via bisulphite 
Pyrosequencing® using 90 blood samples in an attempt to create an age prediction 
model. Initially, using the methylation data of 65 samples multiple regression analysis 
revealed that two markers, namely cg05442902 and cg20426994, were the most 
important in predicting age, however the proposed model lacked accuracy. On the 
other hand, ANN analysis resulted in an age prediction model with a correlation 
between observed and predicted age of 95% and an average error of 4.27 years. 
However, both multiple regression and ANN analysis failed to reproduce the obtained 
results using a larger dataset. The failure in verifying the genome-wide data could be 
due to the methodology used. Bisulphite Pyrosequencing® has been effectively applied 
as a confirmation method in the literature and is considered capable of accurately 
quantifying DNA methylation levels. However, the resolution of quantification is 
perhaps not sufficient enough for the purpose of age prediction, where differences in 
methylation levels are for certain markers very low. Prior to analysis, bisulphite-
converted DNA is amplified using 45 PCR cycles which could introduce amplification 
bias and alter the detected methylation. Using fewer cycles could be a solution; 
however, this could mean sacrificing the method’s sensitivity.  
To overcome these challenges, a second approach was designed and a new set of 45 
age-associated CpG sites was selected using a recently published age prediction model 
based on more than 8,000 samples (Horvath, 2013). While the study proposed a total 
of 353 age-associated CpG sites, only 45 of them were used in this approach. 
However, in future work all 353 markers could be included, rather than only a subset, 
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that could potentially reveal more ‘strong’, suitable markers that could be incorporated 
into the age prediction model. Since genome-wide methylation data are available via 
online databases, it was decided that there was no need to re-analyse blood samples 
using Illumina’s platforms in an effort to minimise both cost and time. As a whole, 
methylation data for these markers from a total of 1,156 blood samples from healthy 
individuals aged 2-90 years was collected from seven different studies. On a future 
approach, these variations could be assessed in more detail by investigating available 
variables such as ethnicity or lifestyle, so that studies can be excluded if they are 
considered not suitable. Additionally, the way that methylation levels change with 
advancing age was observed to be quite different for each marker. As Horvath 
reported, DNA methylation levels only change very gradually with age and the age 
effects on individual CpGs can be substantially variable.  
Simple multiple regression analysis revealed that the methylation levels of 25 out of the 
45 markers tested were significantly associated with age (p<0.05) and the 16 ‘best’ 
were used to build a model for age prediction. As expected, all 16 methylation markers 
are located near or within genes involved in age-related conditions and processes such 
as DNA repair, cancer and Alzheimer’s disease. As shown in Figure 7-12, the 
correlation between predicted and true age was significantly strong (linear correlation, 
R2=0.9258), while the mean absolute error using all data was 4.89 years (standard 
deviation = 4.36 years). As expected, it was observed that subjects age at a different 
rate with some ageing faster or slower than average, while as expected the higher 
prediction errors were found in the older age groups (>60 years old).   
Age prediction was considerably improved by using artificial neural networks [Figure 
7-13]. The results were very promising as they revealed a correlation between age and 
predicted age of 96% and a mean absolute error of 3.3 years (standard deviation=3.7 
years). Predictions were still highly accurate for both the verification and blind test 
(error of 4.6 and 4.4 years respectively). Overall, 95.6% of the samples were predicted 
within 10 years, while 82.8% were predicted within 5 years. Considering that similar 
prediction accuracy was observed when using 353 CpG sites in Horvath’s study (age 
correlation of 0.96 with an median absolute error of 3.6 years), it can be concluded 
that predicting age using a small number of CpG sites could be possible; however 










8 Development of a next generation 
















The ability to access the epigenetic status of a set of genes or the entire genome deeply 
facilitates researchers’ insight into the nature of gene regulation and various epigenetic 
mechanisms involved in the interaction between cells and environment. Overall, 
current methodologies can be divided into genome-wide or gene-specific depending 
on the number of CpG sites being analysed. As previously mentioned in Chapter 1, 
they can also be further categorised based on how the methylation status is examined; 
a) methods that discriminate the bisulphite-stimulated ‘cytosine to thymine’ transition, 
b) methods based on DNA cleavage by methylation-sensitive restriction enzymes and 
lastly, c) methods that employ methyl-binding proteins or antibodies to 
immunoprecipitate against methylated cytosines (Ammerpohl et al., 2009). Each 
approach has its own advantages and limitations resulting in either qualitative or 
quantitative assessment of methylation patterns. Bisulphite-based methods are usually 
sensitive but have to encounter the reduced genome complexity following DNA 
conversion that results into technical issues regarding target-specific probe design. On 
the other hand, methylation-sensitive restriction enzymes cannot often probe every 
CpG site, whereas immunoprecipitation techniques lack the single-base resolution of a 
targeted sequence. 
Taking into account the sensitivity and accuracy of the available approaches, it was 
decided that bisulphite-based methods could prove the best choice since they are 
compatible with technology already available in forensic laboratories. However, most 
of these methods can be labour-intensive, result in qualitative results and can be 
limited to the measurement of the methylation status of only one or very few CpG 
sites. On the other hand Pyrosequencing® technology has proven to overcome some of 
these limitations requiring only a few nanograms of starting DNA material to obtain 
high reproducible results (Dejeux et al., 2009). Therefore, since Pyrosequencing® has 
successfully been used in previous age prediction studies (Weidner et al., 2014) it was 





However, while Pyrosequencing® is useful, it is limited in its quantitative accuracy, 
read length and sample throughput; the analog nature of its sequence output (light 
signal) limits its quantitative power. In this study issues regarding reproducibility and 
precision were observed [Figure 5-7]. In cases where differentiation was based on a 
DNA methylation marker being in an unmethylated (<0.05) state in one sample while 
in a highly methylated (>0.85) state in another, one could confidently discriminate 
them using methylation patterns. Difficulties were raised when the observed 
methylation differences were much smaller as shown in some of the proposed tissue-
specific methylation markers and for most of the age-associated CpG sites [Figure 7-
11]. Considering that the obtained bisulphite conversion rates usually varied between 
90-100% and that amplification bias in bisulphite PCRs was quite common, it is 
believed that errors in methylation quantification could be easily introduced. 
Therefore, even though analysing replicates could serve as a solution, accurate and 
high-resolution methylation quantification that will allow for discriminating 
methylation differences of less than 0.05 remains a challenging task.  
8.1.1 Next generation sequencing in epigenetics 
Searching for a more accurate and higher-resolution sequencing method, next 
generation sequencing (NGS) technology was considered to be superior. It is generally 
believed that NGS technology has transformed the way scientists extract genetic 
information from biological material by introducing sequencing in a massively parallel 
fashion. NGS allows for rapid sequencing of not only large DNA fragments but even 
entire genomes in a matter of hours or days. Therefore, technical issues of conventional 
sequencing such as Sanger sequencing or Pyrosequencing® concerning throughput, 
scalability, speed, and resolution can be overcome. Also, even though the latest high-
throughput sequencing instruments are capable of massive data output, its technology 
offers high flexibility and scalability but still using the same underlying chemistry. This 
scalability allows for simultaneous sequencing of hundreds of targeted regions for a 
large number of samples by applying individual ‘barcode’ sequences to differentiate 




Figure 8-1. Conceptual overview of sample multiplexing (Illumina, 2013a) 
(A) Two representative DNA fragments from two different samples, each attached to a specific barcode 
sequence used to identify the sample from which it originated, (B) Libraries for each sample are pooled 
together and sequenced in parallel; each new read contains both the fragment sequence and its sample-
identifying barcode, (C) Barcode sequences are used to de-multiplex, or differentiate reads from each 
sample, (D) Each set of reads is aligned to the reference sequence. 
Next generation sequencing technology was quickly adopted by the epigenetics 
community. So far, epigenetic approaches based on various NGS platforms include 
whole-genome bisulphite sequencing, methylation beadchips, reduced representation 
bisulphite sequencing and methylated DNA immunoprecipitation sequencing. NGS-
based methods could overcome common technical problems of commonly-used 
microarray analysis (Hurd & Nelson, 2009). For example, since bisulphite-treated 
DNA is directly sequenced and not interrogated by hybridisation to specific 
sequences, any experimental bias and cross-hybridisation issues from analysis can be 
eventually eliminated. Also, NGS offers single-nucleotide resolution; therefore 
researchers can monitor expression from gene alleles that differ in as little as one 
nucleotide. Most importantly, the quantification of signal from sequence-based 
approaches is based on measuring sequence tags rather than relative measure between 
samples resulting in unlimited, fully quantitative dynamic range of signal. Lastly, only 
a few nanograms of material are sufficient for NGS, reducing the reliance on 
amplification of material.  
The advantages of having single-base resolution have been illustrated in many studies, 
where genome-wide DNA methylome analysis via the combination of bisulphite DNA 
with NGS platforms revealed not only tissue-specific but also age-associated 
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differentially methylated CpG sites (Almen et al., 2014; Thompson et al., 2013). 
However, genome-wide sequencing methods do require large amounts of DNA by 
forensic standards; their capability to use trace DNA samples will therefore be crucial 
to the application of such methods in forensic epigenetic analysis. While whole 
bisulfitome amplification meaning genome-wide amplification of bisulphite-modified 
DNA template has been proposed to overcome this problem (Paliwal et al., 2010), it is 
believed that it could introduce further bias in the methylation quantification. As 
shown in previous chapters, these studies can be successfully employed to select 
suitable markers for validation using other instrumentation but it would not be suitable 
to analyse thousands of CpG sites when only a few need to be investigated.  
8.1.2 Next generation sequencing in forensic genetics 
Forensic DNA samples are usually of limited quality/quantity often failing to meet the 
requirements of simultaneously examining multiple genomic loci. This leads to 
difficulties in providing sufficient information, therefore limiting their use as legal 
evidence (Yang et al., 2014). Nowadays, the forensic community worldwide is 
investigating the value and potential of NGS in improving not only DNA testing but 
also current workflows. Even though there are plenty of different applications for 
which NGS can be employed (Illumina, 2013a), targeted sequencing is believed to be 
more relevant for forensic applications. Using this approach, only a subset of genes or 
defined regions spanning hundreds of base pairs in the genome are sequenced, which 
could potentially allow forensic scientists to detect significant genetic variations. So 
far, scientists have applied the sequencing by synthesis (SBS) technology to sequence 
large number of PCR amplicons allowing for successful analysis of even the smallest, 
most compromised and highly-mixed biological evidence samples [Figure 8-2].   
Potential forensic genomic applications that NGS can be successfully applied include 
STR typing (Warshauer et al., 2013), mitochondrial genome sequencing (Parson et al., 
2013), Y-chromosome analysis (Xue et al., 2009), differentiation of twins (Weber-
Lehmann et al., 2014), microbial forensics (Brenig et al., 2010), species identification 
(Hajibabaei et al., 2011), ancestry studies and phenotypic inferences (Yang et al., 
2014). Even though the implementation of such a technology would still need to go 




Figure 8-2. Sequencing by Synthesis (SBS) technology workflow (Illumina, 2013b) 
 
8.1.3 Highly multiplexed PCR amplicon sequencing on Illumina MiSeq® 
During the last few years, new sequencing platforms have been released such as the 
Ion Torrent Personal Genome Machine (PGM), the Pacific Biosciences RS (PacBio) 
and the HiSeq® or MiSeq® system (Illumina), all capable of generating operational 
sequences (Quail et al., 2012). With respect to Illumina platforms, while the HiSeq 
2000 has set the standard for high throughput massively parallel sequencing, Illumina’s 
smallest NGS sequencer, MiSeq® is a lower throughput fast-turnaround instrument 
aimed for smaller laboratories and the diagnostic market. Therefore, it was considered 
that the MiSeq® system could be more suitable for the development of forensic-type 
tests. In particular, while MiSeq® supports various applications, combining Illumina’s 
accurate SBS chemistry with an effective workflow allowing for long 150 bp paired-
end reads would be ideal for highly multiplexed PCR amplicon sequencing and the 
analysis of particular genetic variations.  
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Illumina has recently focused on potential forensic applications and the development of 
suitable protocols (Illumina, 2013b). For instance, the Illumina Nextera® XT DNA kit 
allows for the amplification of forensic loci from 1 ng of starting DNA. Beginning with 
amplified DNA, the protocol employs a single enzymatic ‘tagmentation’ reaction to 
fragment and tag amplicons with sequencing adaptors, making the library compatible 
with the MiSeq® flow cell. However, PCR amplicons should be larger than 300 bp to 
ensure even coverage across the length of the DNA fragment as a sequencing coverage 
about 50 bp from each distal end of a fragment might drop off. To accommodate 
analysis of more challenging, degraded samples, additional library preparation methods 
are under development, such as the TruSeq Forensic Amplicon protocol (Illumina). 
8.1.4 Illumina MiSeq® for accurate methylation quantification 
In this study the ability of NGS based on the MiSeq® system to accurately quantify 
methylation levels of specific CpG sites will be assessed. Illumina suggests two forms of 
bisulphite sequencing-based applications that can be employed on a MiSeq® system 
including whole-genome bisulphite sequencing (WGBS) and reduced representation 
bisulphite sequencing (RRBS). However, there has been one research group so far that 
has tested the abilities of MiSeq® in targeted methylation analysis of specific genomic 
regions (Masser et al., 2013). The authors developed a new approach, termed 
Bisulphite Amplicon Sequencing (BSAS), for hypothesis-driven and focused, absolute 
DNA methylation analysis. This method was suggested to be applicable not only to 
targeted DNA methylation studies but also to confirmation of genome-wide studies, 
overcoming technical issues faced in predominant approaches like Pyrosequencing®. 
Briefly, the BSAS method involves bisulphite conversion of genomic DNA followed 
by PCR amplification of the regions of interest using target- and converted DNA-
specific primers. Libraries are prepared using the transposome mediated (Nextera XT) 
NGS library preparation technology and the amplified regions are sequenced using the 
benchtop MiSeq® sequencer. By analysing both rat and mouse DNA methylation 
standards in replicates, the authors reported a greater precision of methylation 
quantitation and a 16-fold increase in accuracy compared to Sanger/epigenetic 
sequencing methylation analysis (ESME) data (Masser et al., 2013) [Figure 8-3]. Also, 
the variation in methylation quantification was much smaller in BSAS, where there 






Figure 8-3. BSAS and Sanger/ESME methylation quantification of (I) mouse and (II) rat 
whole-genome methylation standards (Masser et al., 2013) 
(A, B) Observed vs. expected methylation (%) as generated from BSAS and Sanger/ESME methods 
(C, D) Average observed methylation for each standard across the CpG sites within analysed amplicon  
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Based on confidence interval analysis, methylation quantification was not significantly 
improved at sequencing read depths greater than 1000; therefore, it could be 
concluded that 1000 reads are sufficient for accurate quantification. While MiSeq® 
has previously been proposed for high-output CpG validation or evaluation of 
traditional NGS library construction methods, the authors proposed MiSeq® as a tool 
for precise orthogonal absolute 5-mC quantitation and validation in this study (Masser 
et al., 2013). It was also suggested that the MiSeq® system’s sensitive optics and more 
precise base calling permit the sequencing of low-diversity samples. Nevertheless, one 
has to have in mind potential PCR bias in the original bisulphite PCR as well as bias 
introduced during library preparation and adapter ligation. 
To conclude, next generation sequencing technology has been reported to overcome 
technical issues of traditional sequencing with regards to throughput, scalability, speed, 
and resolution. Various epigenetic approaches have been proposed, mostly analysing 
genome-wide methylation patterns; however, targeted sequencing that would allow 
for accurately detecting C/T ratios could be achieved. Masser et al (2013) reported a 
bisulphite amplicon sequencing method based on the Illumina’s MiSeq® system that 
enables accurate, high-resolution methylation quantification. Furthermore, since the 
forensic community already appreciated the advantages of a NGS approach by 
applying it in various forensic applications such as single nucleotide polymorphisms 
(SNP) analysis, it was believed that NGS could serve as a better option for validating 









8.1.5 Aim and Objectives 
The purpose of this chapter was to develop an NGS protocol based on the Illumina 
MiSeq® platform that would potentially allow for age prediction in a forensic scenario 
through accurate quantification of the methylation levels of the previously proposed 
age-associated CpG sites.   
In order to achieve the aim, the following objectives were met: 
 Suitable bisulphite PCR assays for all 16 CpG sites included in the age prediction 
model were designed and optimised. 
 An NGS protocol specifically designed for forensic amplicon analysis was 
obtained and adjusted for this study. 
 The protocol was validated by pre- and post-PCR linearity analysis using DNA 
standards of known methylation levels. 
 The age prediction accuracy was assessed by analysing a total of 34 whole blood 
samples. 
 The reproducibility of the overall method was assessed by studying multiple 













8.2.1 Blood samples 
Whole peripheral blood was collected from 34 healthy volunteers (21 males and 13 
females from various ethnic backgrounds) aged 2 to 76 years old (mean age 38.4±21.2 
years) [Figure 8-4]. Most blood samples were collected as liquid (200-1,000 µl) and 
only for the three youngest participants (2-4 years old) a small amount of blood was 
deposited on a cotton swab. Liquid blood samples were stored at 2-8 oC, while swabs 
were stored at -20 oC (to minimise DNA degradation) for up to 2 months. 
 
Figure 8-4. Age distribution within blood samples (n=34) 
Age distribution of all individuals participated in the study (a) individually and (b) in age groups (years) 
8.2.2 Bisulphite PCR assay design 
Following the guidelines regarding primer design mentioned in section 2.2.4.1, 
bisulphite PCRs were designed using the BiSearch primer design tool in order to 
amplify the genomic regions surrounding the 16 proposed age-associated CpG sites 
[Table 7-11]. Each assay includes a 10X PCR primer set (forward and reverse) 
specifically designed to amplify only bisulphite-converted DNA sequences by 
including converted cytosines in their sequence; however, none of them contains CpG 
sites to avoid potential bias [Tables 8-1 & 8-2]. Moreover, information on the 
obtained amplicons including their chromosomal location and number of included 
bisulphite-conversion controls and CpG sites are presented in Table 8-3, while the 





Table 8-1. Designed bisulphite PCR assays (1-8) 
Essential information regarding the designed bisulphite PCR assays are shown, such as the strand that the CpG is located (F for forward and R for reverse), the score assigned by 
the primer design software (the lower the score the more efficient amplification), the primer sequences and length (forward/reverse), the % G and C content, the melting 
temperature (Tm), the number of converted cytosines included in the primer sequence (highlighted in red) as well as the length of the final PCR product. 
CpG site DNA strand Score Primer Sequence (5'-3') Length (bp) % GC Tm (Co) Converted Cs PCR Length (bp) 
cg19761273 F 16.71 
F TGTTTAGTTTGAAGATTGAG 20 30 54.8 4 
150 
R CCTTATTTCCTTTACAAAAA 20 25 56.2 4 
cg27544190 F 20.77 
F GGGTAGGATTAAAGTTGA 18 38.9 55.4 0 
106 
R CTTAAAAATAACAATCCCC 19 31.6 55.6 7 
cg03286783 R 41.17 
F GTTTTAGTTAGTGGGTG 17 41.2 54 5 
181 
R CCCCTCCTCAAATCAAA 17 47.1 56.5 2 
 
cg01511567 F 18.58 
F TATTAGATTTAGTATAGGGG 20 30 54 3 
132 
R CCCACAACTATTCAAATA 18 33.3 53.1 1 
cg07158339 R 20.95 
F GGAATATGTTTTGTTTAAAA 20 20 54.4 6 
122 
R TAATTAACCTCTCTATACCT 20 30 54.6 2 
cg05442902 R 13.61 
F GTATGTTTTGGTTTTTGT 18 27.8 53.9 5 
109 
R AATAACCTCTAAACTAACC 19 31.6 55 4 
cg24450312 F 24.42 
F GTTATTTATAGAGTTTGAG 19 26.3 51.2 5 
201 
R TCTACTACAAACCAAA 16 31.2 50.2 5 
cg17274064 R 20.72 
F AGGGAATAAGTATTTTTT 18 22.2 53.2 4 
139 
R CTCACAATCAAACTTCTATATAC 23 30.4 56 4 
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Table 8-2. Designed bisulphite PCR assays (9-16) 
Essential information regarding the designed bisulphite PCR assays are shown, such as the strand that the CpG is located (F for forward and R for reverse), the score assigned by 
the primer design software, the primer sequences and length (forward/reverse), the % G and C content, the melting temperature (Tm), the number of converted cytosines 
included in the primer sequence (highlighted in red) as well as the length of the final PCR product. 
CpG site DNA strand Score Primer Sequence (5'-3') Length (bp) % GC Tm (Co) Converted Cs PCR Length (bp) 
cg02085507 R 15.01 
F GTTAATGGATTTGGTTTTG 19 31.6 55.3 4 
186 
R AACTCAAAAAATCCTTCCT 19 31.6 56.8 2 
cg20692569 F 31.34 
F TTGTTGTTGTGGTAGT 16 37.5 51.8 5 
160 
R AACCCAACAAATTAAA 16 25 51.8 8 
cg04528819 R 13.14 
F AATAGGTTTTGGTGTAGTT 19 31.6 56 4 
138 
R CAACCTCTAATAAATTCTCT 20 30 54.6 6 
 
cg08370996 R 29.24 
F GTGTTAAAGTTTATTATATAGA 22 18.2 53.3 3 
187 
R AAAAAAAAAAACACACAC 18 22.2 54.1 3 
cg04084157 F 20.49 
F GAGGGTGTTTGTTTTTTT 18 33.3 56.6 7 
111 
R AACATTTCATTCATTCATTC 20 25 53.1 1 
cg22736354 F 16.33 
F GTTGAGTTTAGGAGTTTTAT 20 30 55.8 6 
201 
R CTTTAAAAAATTTAACCACC 20 25 56.4 5 
cg06493994 R 20.26 
F GGAGAGTAAGTTAAGAAATA 20 30 54.7 2 
150 
R AACCTACCAAAAACCAAC 18 38.9 57.5 5 
cg02479575 F 16.08 
F GGAGGAGAATGTTATTTATT 20 30 55.1 1 
143 
R CTATCCAAAATTCTAAAAAC 20 25 54.4 7 





Table 8-3. MiSeq® DNA methylation assays (16) 
Assay Conversion 
controls 
CpG sites Chromosomal location 
to be sequenced 
1 cg19761273 42 2 17: 80,232,017-80,232,166 
2 cg27544190 18 4 21: 33,785,414-33.785.519 
3 cg03286783 40 10 15: 44,580,864-44,581,044 
4 cg01511567 12 3 11: 57,103,582-57,103,713 
5 cg07158339 23 1 9: 71,650,150-71,650,271 
6 cg05442902 32 2 22: 21,368,989-21,369,097 
7 cg24450312 66 27 1: 206,681,003-206,681,203 
8 cg17274064 23 2 21: 40,033,806-40,033,944 
9 cg02085507 38 12 19: 6,739,164-6,739,349 
10 cg20692569 37 20 7: 72,848,365-72,848,524 
11 cg04528819 35 8 7: 130,418,073-130,418,210 
12 cg08370996 41 13 15: 96,873,886-96,874,072 
13 cg04084157 19 8 7: 100,808,988-100,809,098 
14 cg22736354 47 18 6: 18,122,551-18,122,751 
15 cg06493994 33 11 6: 25,652,542-25,652,691 
16 cg02479575 31 10 19: 4,769,688-4,769,830 
 
8.2.3 Sample analysis 
Genomic DNA from 200 µl of each blood sample or the whole swab was extracted 
using the EZ1 Blood DNA kit as described in section 2.2.1.3 and eluted in either 200 
µl (liquid) or 50 µl (swabs) of elution buffer. DNA samples were then quantified in 
duplicate using the Quantifiler Human DNA Quantification kit as described in section 
2.2.2.1. Afterwards, 100 ng of extracted DNA or each of the DNA methylation 
standard was treated with sodium bisulphite using the MethylEdge™ Bisulphite 
Conversion System (Promega) as described in section 2.2.3.3; bisulphite-converted 
DNA was eluted in 40 µl of elution buffer and stored at 2-8 oC for up to one week.  
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All samples were amplified using the ZymoTaq™ premix (Zymo Research) and 
following the optimised conditions of each PCR assay. In order to reduce cost, half-
volume PCR reactions were used throughout analysis. Briefly, each PCR reaction 
consisted of 6.25 µl of ZymoTaqPreMix, 0.75 µl of 25 mM MgCl2 for a final 
concentration of 3.2 mM (since the ZymoTaq™ Premix also contains 1.75 mM 
MgCl2), 0.5 µl of each PCR primer (for a final concentration of 0.4 µM), 1 µl of 
bisulphite DNA template and 4 µl of nuclease-free water, for a total reaction volume of 
13 µl. The thermocycling program used was: 95 oC for 10 minutes, followed by 30 or 
45 cycles of 94 oC for 30 seconds, Tm for 30 seconds, 72 oC for 30 seconds, and a final 
extension step of 72 oC for 7 minutes. The optimised Tm was as follows: 48 oC for 
cg07158339, cg17274064, cg02085507, cg20692569 and cg02479575, 50 oC for 
cg19761273, cg27544190, cg01511567, cg24450312 and cg04528819 and 52 oC for 
cg03286783, cg05442902, cg08370996, cg04084157, cg22736354, cg06493994.  
Finally, for each sample 2 µl of each PCR product were pooled for a total volume of 32 
µl. In particular, to ensure that sufficient amounts were present for downstream 
analysis, 10 µl of each PCR product for the 0% and 100% methylation DNA controls 
were pooled instead (total volume=160 µl). Post-PCR methylation controls were made 
up by mixing appropriate amounts of the unmethylated (0%) and methylated (100%) 
pooled PCR products as shown in Table 8-4. Subsequently, final pooled PCR 
products were sequenced using the TruSeq Forensic Amplicon protocol (Illumina). 
Information regarding all different methodological steps included in this approach as 
well as comprehensive experimental conditions are extensively described in section 
2.2.6.2; any changes will be stated otherwise. 
Table 8-4. Composition of post-PCR linearity DNA methylation controls 
Post-PCR linearity controls 
Pooled PCR product (µl) 
0% control 100% control 
0% 31 0 
10% 27.9 3.1 
20% 24.8 6.2 
30% 21.7 9.3 
50% 15.5 15.5 
70% 9.3 21.7 
80% 6.2 24.8 
90% 3.1 27.9 




8.3.1 Optimisation of bisulphite PCR assays 
As mentioned in Chapters 5 and 7, bisulphite-treated DNA is considered as one of the 
most challenging templates to amplify due to its less complex nature (T-rich). 
Therefore it was necessary that PCR reactions for each marker were well optimised 
before downstream analysis. Each assay was optimised using an annealing temperature 
gradient, various concentrations of MgCl2 and primer as well as different PCR cycling 
conditions. Figure 8-5 shows the final step of the optimisation process where a set of 
three annealing temperatures (48 oC, 50 oC and 52 oC) were tested for each assay. As 
shown, there was a variation in PCR efficiency, with cg17274064 and cg20692569 
being the weakest markers. Since cg20692569 has one of the ‘worst’ scores given by 
the primer design software, it is believed the low PCR yield could be due to its 
‘difficult’, CpG-rich sequence. 
 
Figure 8-5. Final optimisation for all 16 designed bisulphite PCR assays (45 PCR cycles) 
Agarose gel images show the results of the final optimisation step for all PCR amplicons (expected 
length in brackets) regarding annealing temperature. For each assay, the first column represents the 
DNA marker (M), the next three columns show the resulting amplification bands for temperatures 48 
oC, 50 oC and 52 oC respectively, while the last column represent the PCR negative (no-template) 
control which was amplified at 50 oC. Red stars indicate the final selected temperature for each assay. 
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For most assays no non-specific amplicons were present; however the optimisation of 
cg27544190, cg03286783 and cg05442902 was challenging due to unwanted products 
resulting from primer interactions. Nevertheless, the signal of the desired amplicons 
was much stronger than the non-specific one, so the proposed PCR conditions were 
accepted; the MiSeq® will only use the reads from the expected DNA sequence for 
analysis. Also, although primers had already been designed for cg05442902 as part of 
the bisulphite Pyrosequencing® analysis in Chapter 7, primers were redesigned in an 
attempt to increase its low PCR efficiency [Figure 7-3]. For certain assays such as 
cg07158339 all temperatures seemed to work well, therefore one temperature was 
chosen arbitrarily; red stars in Figure 8-5 indicate the selected annealing temperature 
for each assay. Since all assays share similar PCR conditions, it might be feasible to 
amplify them in a multiplex reaction. For this project, singleplex PCRs were used in 
order to avoid potential marker-to-marker PCR amplicon imbalance, but developing a 
multiplex PCR reaction could be assessed in the future. 
8.3.2 Validation of methylation quantification 
To test the performance of the method as well as assess the accuracy of quantitative 
methylation analysis, seven enzymatically-generated whole-genome human 
methylation controls at mixed ratios (0%, 5%, 10%, 25%, 50% and 100%) were 
analysed in duplicate for CpG methylation levels using the proposed protocol.  
8.3.2.1 Assessment of pooled PCR amplicons 
A total of 100 ng of each control were bisulphite-treated and eluted in 40 µl of elution 
buffer. Since Promega suggests that there is likely a ~20% loss of DNA during 
treatment, the final bisulphite-converted DNA solutions were expected to have a 
concentration of ~2 ng/µl; therefore, a total of ~2 ng of DNA template was added in 
each PCR reaction. Furthermore, to assess amplification bias in designed bisulphite 
PCRs, methylation controls were amplified for 30 and 45 cycles to assess the effect of 
PCR cycles upon linearity of methylation quantification. Using the PCR optimisation 
results as a guide for individual PCR efficiency [Figure 8-5], 1 to 5 µl of each 
individual PCR product (16 in total) were pooled for a final volume of 30 µl. Pooled 
PCR products were assessed using the Qubit dsDNA HS assay as described in section 




Qubit reading (ng/ml) 
30 cycles 45 cycles 
1 2 Average 1 2 Average 
0 6.01 5.8 5.905 55.3 51.7 53.5 
0.05 6.01 5.9 5.955 58.8 58 58.4 
0.1 5.71 5.76 5.735 58.2 57.4 57.8 
0.25 6.32 6.24 6.28 72.7 72.3 72.5 
0.5 6.1 6.01 6.055 63.8 63.1 63.45 
0.75 6.25 6.15 6.2 70.9 69.8 70.35 
1 6.05 5.91 5.98 68.6 68.1 68.35 
Mean   6.02   63.48 
Standard deviation   0.18   7.19 
 
 
Figure 8-6. Concentration readings of pooled PCR products after 30 and 45 PCR cycles 
Pooled PCR products for all seven methylation controls produced by either 30 or 45 PCR cycles were 
quantified using the Qubit dsDNA HS assay (Life Technologies). All samples were analysed in 
duplicate. 
As shown in Figure 8-6, all controls gave similar readings to one another when using 
30 or 45 PCR cycles. However, the extra 15 cycles resulted in a 10-fold increase in 
concentration as expected (30 cycles –1,203 ng/ml, 45 cycles – 12,696 ng/ml). Since 
Illumina suggests a 20-2000 pg/µl DNA input, for the first set of controls (30 cycles) 
all 30 µl was used for library preparation (average=722 pg/µl), while for the second set 
(45 cycles) only 4 µl of pooled PCR products were used (856-1160 pg/µl). 
8.3.2.2 Evaluation of generated libraries 
Once the library preparation was complete, libraries were evaluated using a qPCR 
library quantification kit (KAPA). The average obtained concentration was 397±239 
nM. There was significant variation in the final yield of libraries, which is suspected to 
be due to the extensive tube manipulation during preparation. The numerous washes 
using the magnetic beads could also introduce variation; however these quantities 
were sufficient since final library requirements were only 6-20 pM. Only two controls, 
namely the 25% and 50% methylation standards amplified using 45 cycles yielded 

























PCR product concentrations were high, this could be due to experimental error. 
Excluding these samples, comparing the 30- and 45-PCR cycle libraries there was no 
statistically significant difference between them (p=0.98). 
8.3.2.3 Quality control of MiSeq® run 
In this first attempt, the MiSeq® run was set up to perform 110 cycles for each 
sequencing direction, which indicates how many nucleotides are added in total from 
each direction of sequencing. Since all PCR amplicons are between 106-201 bp long, 
110 cycles were considered sufficient; however as a result a decrease of read numbers 
at the ends of each sequence was observed. As shown in Figure 8-7a, 91.5% of total 
reads passed the MiSeq® quality control (Q>30); 96.1% in the first read and 87.4% in 
the second one. Also, the flow cell demonstrated a cluster density of 985 K/mm2that 
closely matches the desired 1000 K/mm2 recommended by Illumina [Figure 8-7b]. 
There were a total of 19 million reads, 89.86% of which were successfully identified. 
The contribution of each sample to the total identified reads was an average of 3.2% 
(standard deviation=0.96%). From this pool, almost all (98.9%) had less than three 
errors (number of usable cycles); therefore the total error rate was as low as 0.26%. 
Furthermore, in all cases bisulphite conversion rates were confirmed to be >98% by 
analyzing the cytosine to thymine ratio for non-CpG cytosine positions.  
    
Figure 8-7. MiSeq® run quality control parameters 
(a) Distribution of Q score among samples, with 91.5% passing the instrument’s quality control (Q30) 
(b) Average cluster density (K/mm2) of the flow cell. Blue bars indicate the ‘ideal’ 1000 K/mm2, while 





8.3.2.4 Distribution among samples and amplicons 
As illustrated in Table 8-3, each sequenced DNA fragment contained between 1 to 27 
CpG sites; however for this analysis only data from the CpG sites in question (16 in 
total) were used. The total reads of each sample were calculated by adding each 
marker’s individual read number (16 CpGs) while the average reads for each CpG site 
was also obtained using data for all methylation controls. Read numbers ranged 
between 492,201 to 1,159,547 and there was a good distribution between them 
[Figure 8-8]; however the 25% and 50% methylation standards for the 45 cycles set 
failed to produce sufficient reads. Since these two samples had resulted in very low-
quality libraries before, it is assumed that the failure was not due to sequencing issues.  
On the other hand, the distribution of individual assays was not as even as desired 
[Figure 8-9]. While some markers resulted in large numbers of reads (e.g. cg05442902 
constantly gave >100,000 reads), there were some that had relatively few reads (e.g. 
average of 2,303 reads for cg17274064). This could be due to PCR efficiency issues; 
for example, cg17274064 and cg20692569 had demonstrated weaker bands in Figure 
8-5. Also, errors during pooling the individual PCR amplicons could have been 
introduced since 1 to 5 µl of each PCR product were pooled; however, this deviation 
could potentially be avoided if the individual PCR amplicons are quantified before 
pooling. Lastly, variations caused during library preparation could also be the reason of 
this deviation, since the generated libraries had been normalized, yet diluted hundreds 
of times. 
 
Figure 8-8. Total reads for each methylation standard as obtained for all 16 CpG sites 
Methylation controls had been amplified either using 30 (purple) or 45 (green) cycles. Red arrows 
























Figure 8-9. Average read number per assay (16) 
The average reads used in this graph were calculated by using all methylation standards except the two 
samples that resulted in very low reads. As shown, there was a large difference among the different 
DNA fragments which could be due to differences in PCR efficiency or variations during pooling and 
library preparation. Error bars correspond to standard deviation values. 
8.3.2.5 Pre-PCR linearity of methylation quantification 
To assess how linear the methylation quantification was, standard curves were 
generated from each set of methylation controls (amplified by 30 and 45 PCR cycles) 
either by taking the mean methylation level across all measured CpG sites (151 CpGs 
in total) [Figure 8-10a, b] or by averaging the obtained methylation levels of only the 
16 CpG sites of interest [Figure 8-10c, d]. It should be noted that the 25% and 50% 
controls for the 45-cycle set were not included as they generated very low reads. For 
the first set of standards (30 cycles), both standard curves were able to fit linear lines 
(R2=0.992), while for the second set (45 cycles) the observed linear correlation was 
slightly weaker (R2=0.973 and R2=0.982 respectively). Generally, for all sets of 
controls the methylation quantification was accurate as evidenced from the high 
correlation coefficients (r=0.99 in all four graphs); however the precision was greater 
for the standards amplified only using 30 cycles, more likely due to the weaker effect 
of amplification bias during PCR. The latter is more evident when looking at each 
CpG site individually (data not shown). It is believed that the extra 15 PCR cycles 
introduce further amplification bias especially in the low methylated samples. It was 


















Moreover, it was noted that using only the methylation data from the 16 CpG sites did 
not significantly change the quantification accuracy compared to when using all 151 
CpGs [Figure 8-10a, c]. In fact, for the second set of controls (45 cycles), the linear 
correlation between observed and detected methylation was slightly improved. On the 
other hand, as indicated by the error bars (standard deviation) the variation in 
detected methylation was still considerably high and did not match the reported 
maximum 5% error in the study by Masser et al. (2013). Nevertheless, the small 
overestimation of methylation observed in the 5%-25% standards had also been 
detected in the Masser study. 
 
 
Figure 8-10. Standard curves generated by 30- (a, c) and 45-cycle (b, d) PCR amplicons 
The observed quantified methylation was plotted against the expected methylation fraction for all 
standards. Points represent the mean of either 151 (a,b) or 16 (c,d) CpG sites analysed for each 
methylation standard. Error bars correspond to standard deviation. 










































































































30 cycles                                        45 cycles 
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By using genome-wide methylation standards to generate methylation fraction 
standard curves, it was demonstrated that the proposed method was capable of 
accurately quantify CpG methylation but significant variation was observed among 
individual markers. The graphs above were made under the assumption that the 
standards used had the ‘correct’ methylation levels. According to the manufacturer 
(EpigenDx), the low methylated standard (0%) is actually less than 5%, while the 
highly methylated one is definitely above 85%. Considering that these two standards 
were used to prepare the remaining standards (5%, 10%, 25%, 50% and 75%), it was 
thought that the methylation values could be slightly different from the expected. In an 
attempt to eliminate errors, it was decided that the expected values should be 
‘normalised’. Using the average methylation detection for the low and highly 
methylated controls obtained by both sets of controls, the expected methylation values 
were calculated for the rest of the controls. The individual ‘normalised’ observed vs. 
expected methylation graphs of each CpG site (30 cycles) are shown in Appendix V. 
Most standard curves fit linear lines; however quadratic or cubic polynomial curves 
provided better fits for some markers resulting in improved correlation. In most cases, 
it seemed that the unmethylated or methylated allele was favored during amplification 
therefore resulting in underestimation or overestimation of methylation respectively. 
Figure 8-11 shows four different examples; (a) marker cg19761273 showed 
preferential quantification of the methylated allele, (b) in marker cg06493994 the 
unmethylated allele was preferred, (c) marker cg04084157 resulted in linear 
quantification and (d) marker cg20692569 showed a more complicated pattern.  
Similar results regarding non-linear amplification of bisulphite-treated DNA have 
previously been reported in the literature (Fernandez-Jimenez et al., 2012; Moskalev et 
al., 2011). To date, no common experimental approach has been suggested to 
overcome this problem; therefore scientists have applied effective methods of 
‘correcting’ these types of bias instead. Once methylation standards are analysed and 
the observed deviation from the expected methylation values is plotted, then the 
equation of the best-fitting regression curve can be used for correction. This process 
could be applied to any CpG site of interest without the need for time-consuming 
PCR optimization. The equations used to correct the observed biased methylation 





Figure 8-11. Different patterns of methylation quantification observed in four CpG sites 
(a) cg19761273 showing preferential quantification of the methylated allele, (b) cg06493994 showing 
preferential quantification of the unmethylated allele, (c) cg04084157 demonstrating linear 
quantification and (d) cg20692569 showing a more complicated pattern where low methylated samples 
are overestimated while highly methylated samples are underestimated. 
Table 8-5. Equations obtained from the best-fitting regression line for all 16 CpG sites 
16 CpG sites R2 value Equation (y=observed, x=expected) 
cg19761273 0.9913 y = 1.2669x3 - 3.0033x2 + 2.6948x + 0.0255 
cg27544190 0.9968 y = -0.3803x2 + 1.3179x + 0.0215 
cg03286783 0.9934 y = 0.5103x2 + 0.4824x + 0.006 
cg01511567 0.9983 y = -0.5805x2 + 1.5621x - 0.0014 
cg07158339 0.9939 y = 1.1725x3 - 2.605x2 + 2.4224x - 0.0215 
cg05442902 0.9906 y = 1.5036x3 - 3.2402x2 + 2.7272x + 0.0022 
cg24450312 0.9758 y = 1.2559x3 - 1.9871x2 + 1.7805x - 0.051 
cg17274064 0.9912 y = 0.6402x3 - 1.4133x2 + 1.7862x - 0.0209 
cg02085507 0.9905 y = 0.6715x3 - 1.2861x2 + 1.6257x + 0.007 
cg20692569 0.9836 y = 2.1951x3 - 4.0068x2 + 2.8105x - 0.0085 
cg04528819 0.9903 y = 0.8618x3 - 0.9387x2 + 1.0871x + 0.0317 
cg08370996 0.9673 y = 1.1402x3 - 2.5073x2 + 2.3218x + 0.0038 
cg04084157 0.9940 y = 0.9907x + 0.0322 
cg22736354 0.9855 y = 0.1132x2 + 0.7958x - 0.0086 
cg06493994 0.9943 y = 0.8393x2 + 0.1352x + 0.0225 
cg02479575 0.9979 y = 0.8236x2 + 0.1745x + 0.0138 












































































































8.3.2.6 Post-PCR linearity of methylation quantification 
To further validate the method and potentially identify the source of bias, nine 
methylation controls at mixed ratios (~10% intervals) were prepared post-PCR and 
analysed in a second run.  The 0% and 100% methylated controls were amplified with 
all assays using the same experimental conditions as before and the concentration of 
each individual assay was measured. Only small differences amongst the two PCR 
products for each assay were observed so 2 µl of each were pooled into the final pooled 
amplicons. It was calculated that the unmethylated control contained a total of 256 ng 
in 10 µl, while 10 µl of the methylated control were comprised of 331 ng. Since all 
experimental conditions were the same, it can be assumed the methylated allele was 
amplified with higher efficiency. Considering this difference, the rest of the controls 
were generated as described in section 8.3.2; their exact methylation levels were also 
calculated and normalised (0.6%, 11.8%, 22.9%, 33.5%, 52.9%, 70.5%, 78.7%, 
86.5% and 93.9%).  
The standard curve of the average observed vs. expected methylation fitted a linear 
line (R2=0.991) and did not change significantly compared to the pre-PCR linearity 
(data not shown). However, when looking at CpG sites individually, it was observed 
that for some of them the quantification turned to linear (cg27544190, cg03286783, 
cg04528819) whereas for some others the bias was not eliminated (cg19761273, 
cg08370996, cg22736354). These results could further support that the 0% and 100% 
methylated controls are amplified with different rates, bias that could not abolished 
through the proposed normalization. Yet, they could also indicate that potential bias 
occur post-PCR during the sequencing process. 
8.3.2.7 Cross-evaluation of cg05442902 between sequencing platforms 
As previously mentioned, in the final set of age-associated CpG sites selected for 
validation via next generation sequencing, there was one marker (cg05442902) that 
had previously been validated using Pyrosequencing® (section 7.3.1.4). Therefore, it 
was interesting to compare the accuracy of methylation quantification using the same 
set of standards with pre-defined methylation status. The primer sets used were not the 
same; however conclusions concerning both instruments’ capability to accurately 
measure methylation levels could be assessed. As shown in Figure 8-12, although both 
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techniques generated a high correlation coefficient (r=0.96), Pyrosequencing® failed to 
detect higher than 60% methylation indicating that possible amplification bias could 
have a greater effect in this method. One should note that a standard bisulphite 
Pyrosequencing® protocol includes a total of 45 PCR cycles.  
cg05442902 
Methylation fraction 
0.01 0.05 0.10 0.25 0.49 0.74 0.97 
MiSeq® 0.02 0.10 0.31 0.46 0.75 0.85 0.97 
Pyro® 0.05 0.13 0.21 0.28 0.46 0.56 0.59 
 
Figure 8-12. Comparison of quantification accuracy between sequencing platforms 
The same set of methylation standards were analysed by both Pyrosequencing® and MiSeq® and their 
observed methylation values were plotted against the expected ‘normalised’ ones. As shown, MiSeq® 
demonstrates higher accuracy. The best-fitted regression line for both methylation data point sets was a 
cubic polynomial curve. 
This first validation showed that the proposed method based on MiSeq® was capable 
of generating high quality libraries and accurately quantifying methylation levels. 
However, it was believed that the accuracy could be further improved based on key 
findings. To obtain accurate methylation values, using 30 PCR cycles was preferable; 
not only did it result in sufficient amounts of amplicons that could be used directly for 
library preparation, but also resulted in smaller variation and greater accuracy 
compared to 45 PCR cycles. However, a correction of detected amplification bias is 
required and should be performed for each marker individually. Also, the strategy 
when pooling the various PCR products could be adjusted so that better distribution 
among markers is achieved. Although the markers showing low PCR efficiency during 
PCR optimisation resulted in fewer reads, there was a significant variation of marker 





























8.3.3 Implementation in blood for age prediction 
To test the method’s ability to predict age, a set of 34 blood samples were tested. 
Analysing six replicates of one blood sample also assessed the reproducibility of 
methylation quantification.  
8.3.3.1 Blood DNA yield 
As mentioned in the experimental section, for this study a total of 34 blood samples 
from individuals aged 2-76 years old were collected. The samples were either stored in 
liquid form or spotted onto cotton swabs for up to 2 months before analysis. Following 
isolation of DNA using 200 µl or the whole swab of blood, samples were quantified in 
duplicate using Quantifiler (Life Technologies). Regarding the liquid blood samples, 
the average measured concentration was 40.71±12.66 ng/µl which corresponds to a 
total DNA yield ranging between 3.31-12.6 µg (average=7.53 µg). In some cases, the 
extraction method proved to be even more efficient than the manufacturer suggested 
(4-8 µg). Since only 100 ng of DNA was needed for bisulphite conversion and further 
analysis, we could assume that 2-5 µl of blood would be sufficient as starting material. 
However, no sensitivity analysis was performed in this study but could be assessed in 
the future. Additionally, as shown in Figure 8-13 it seemed that storage time (6-70 
days) at 4 oC did not have any effect on total DNA yield. 
 
Figure 8-13. Effect of storage time in total DNA yield 
The total DNA yield for each blood sample plotted against the number of days that was stored at 4 oC. 
The blue bar represented the expected DNA yield suggested by the manufacturer when using 200 µl of 























Days stored in the fridge
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8.3.3.2 PCR product pooling strategy 
In the previous section when analysing DNA standards with pre-defined methylation 
levels, PCR optimisation results were used as a guide before pooling individual PCR 
products [Figure 8-5]; therefore 1 to 5 µl of each PCR product were pooled depending 
on PCR efficiency. However, even though the concentration among pooled amplicons 
was quite similar [Figure 8-6], there was a significant variation in read numbers among 
markers [Figure 8-9]. Consequently, it was believed that these differences could be 
avoided by adjusting the pooling strategy via quantifying the singleplex PCR reactions 
prior to pooling. The latter was not feasible to be done for all samples since there were 
more than 700 reactions in total. Nevertheless, even though the employed method 
(Qubit dsDNA HS assay) also quantifies primer-dimers and secondary structures of 
unused bisulphite DNA strands, therefore it does not provide very accurate results, 
individual PCR products were quantified for one blood sample in duplicate. 
As illustrated in Figure 8-14 (green column), all individual PCR assays seemed to have 
resulted in successful amplification with concentrations ranging from 1.3 to 2.6 ng/µl. 
If 2 µl of each marker were pooled together for this sample, the total amount of PCR 
amplicons would be 56.31 ng resulting in a final concentration of 1.77 ng/µl. Since the 
reported variation of different concentrations was not high, it was concluded that this 
would be a good pooling strategy. Therefore, for all samples, 2 µl of each individual 
PCR product were pooled to form the final amplicon pool, which was then quantified 
using Qubit [Figure 8-14, grey column]. The mean concentration measured for the 
pooled PCR products was 2.16 ng/µl with a standard deviation of 0.2 ng/µl. The 
whole volume of these solutions (31 µl) was then used for library preparation. 
8.3.3.3 Evaluation of generated libraries 
Libraries were prepared following the same experimental steps as when analysing the 
methylation controls using KAPA’s library quantification kit. The average 
concentration (diluted 1:2000) was 178±30.8 nM, which is slightly lower than the one 
obtained in the first run (397±239 nM) but showing much less variation. There was 
only one library (blood sample 23) that resulted in a 3-fold decreased concentration 




Figure 8-14. PCR product concentration (ng/ml) as measured by Qubit for both individual 
and pooled amplicons 
The green column corresponds to the average concentration as measured in all individual PCR products 
for one blood sample (16). The grey column corresponds to the average concentration as measured in 
the pooled PCR products (2 µl of each individual product) of all blood samples (48). Errors bars 
represent standard deviation. 
8.3.3.4 Distribution among samples and amplicons 
As demonstrated in section 7.4.2.4, there was a large variation in read depths not only 
between samples but also among individual amplicons. It was believed that this could 
be due to differential PCR efficiency or variation during PCR product pooling and 
library preparation. In an attempt to minimise these differences, individual PCR 
products were quantified before pooling. However, it is generally accepted that Qubit 
does not only quantify PCR amplicons but also unused primers or bisulphite DNA 
strands. Taking into account all 34 samples, the average total reads per sample was 
1,108,814±406,596 reads. This indicates a great coverage across all 16 markers; 
however, once again the distribution among them was uneven. Table 8-6 shows the 
minimum, maximum, average and range of reads for each CpG site. It was observed 
that the five markers showing the smallest average read number including cg17274064 
(1,914), cg24450312 (2,055) and cg08370996 (3,730) correlated with previously 
obtained results [Figure 8-9]. Although these numbers might be considered small 
compared to other markers (e.g. cg04084157 – 154,988), based on confidence interval 
analysis Masser et al suggested that methylation quantification is not massively 
improved at sequencing read depths greater than 1,000 reads (Masser et al., 2013). 
However, to increase the representation of these markers, their PCR assays could 
either be further optimised in the future or more PCR products could be added in the 
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Table 8-6. Read numbers per individual CpG site (16) 
CpG site Read number 
Minimum Maximum Average St. Deviation 
cg19761273 3,980 41,770 15,938 8,956 
cg27544190 10,306 291,415 103,305 58,350 
cg03286783 40,906 219,615 112,227 47,113 
cg01511567 75,747 292,657 167,919 58,944 
cg07158339 4,022 20,864 10,250 4,660 
cg05442902 15,579 299,169 135,538 62,418 
cg24450312 873 5,010 2,055 1,056 
cg17274064 414 3,601 1,914 893 
cg02085507 3,694 53,987 30,672 14,538 
cg20692569 4,381 42,706 17,138 8,715 
cg04528819 51,489 301,616 127,746 50,494 
cg08370996 1,023 8,957 3,730 1,782 
cg04084157 769 414,868 154,988 77,520 
cg22736354 17,026 88,772 43,753 21,157 
cg06493994 56,751 359,595 148,357 70,654 
cg02479575 7,535 81,549 33,283 15,758 
 
8.3.3.5 Reproducibility/Precision 
In order to assess how precise methylation quantification is based on the proposed 
MiSeq® method, six technical replicates of the same blood sample were analysed. 200 
µl of blood from a male aged 55 years were used to isolate genomic DNA, 100 ng of 
which were treated with sodium bisulphite in six replicates. The samples were then 
analysed as described in section 8.2.3 along with the rest of the blood samples. The 
obtained methylation data for all replicates are shown in Figure 8-15a. As illustrated 
from the generated graph, the variation in methylation quantification ranged from 0 to 
over 0.2 with an average of 0.061 [Figure 8-15b]. It should be noted that the standard 
deviation (SD) was generally low in most cases (<0.05) but three markers 
(cg07158339, cg05442902 and cg20692569) resulted in SD~0.1 while cg02085507 
demonstrated the highest variation (0.22). Interestingly, cg02085507 showed one of 
the least accurate quantifications when the known methylation controls were analysed 
[Figure 8-11d]. In most cases, these observations correlate with the ones obtained by 
Masser et al (2013), where authors reported a maximum of 0.05 standard deviation 





CpG sites Detected DNA methylation ratio for each replicate 
Mean St Dev 
1 2 3 4 5 6 
cg19761273 0.134 0.177 0.235 0176 0.195 0.166 0.181 0.033 
cg27544190 0.087 0.044 0.041 0.085 0.061 0.036 0.059 0.023 
cg03286783 0.002 0.002 0.002 0.002 0.002 0.002 0.002 0 
cg01511567 0.102 0.116 0.058 0.070 0.128 0.087 0.093 0.027 
cg07158339 0.334 0.569 0.458 0.338 0.305 0.353 0.393 0.101 
cg05442902 0.365 0.138 0.229 0.292 0.179 0.094 0.216 0.100 
cg24450312 0 0.001 0.001 0.001 0.001 0 0.001 0 
cg17274064 0.121 0.049 0.167 0.134 0.139 0.066 0.113 0.046 
cg02085507 0.303 0.532 0.410 0.772 0.887 0.572 0.579 0.219 
cg20692569 0.145 0.349 0.368 0.255 0.077 0.169 0.227 0.117 
cg04528819 0.120 0.060 0.085 0.132 0.075 0.078 0.092 0.028 
cg08370996 0.129 0.093 0.006 0.010 0.205 0.007 0.075 0.082 
cg04084157 0.013 0.156 0.002 0.006 0.055 0.003 0.039 0.061 
cg22736354 0.055 0.142 0.056 0.037 0.052 0.113 0.076 0.041 
cg06493994 0.095 0.219 0.056 0.092 0.144 0.092 0.116 0.058 
cg02479575 0.039 0.002 0.001 0.051 0.092 0.093 0.046 0.041 
 
 
Figure 8-15. Observed methylation levels among six technical replicates of a blood sample 
 (a) Reported methylation ratio of all replicates together with calculated mean and standard deviation 
for each of the 16 CpG sites. As shown, most CpGs had <0.05 standard deviation; however there were 
seven markers (highlighted in red) that demonstrated a higher variation. (b) Box-and-whisker plots for 
























8.3.3.6 Age prediction accuracy 
To assess the capability of the proposed method to predict age, blood samples’ 
methylation values for all 16 age-associated CpG sites were inserted into the 
previously described age prediction ANN model [Figure 7-13]. One sample (no. 23) 
resulted in reads <1,000 for most markers so it was excluded from analysis; therefore, a 
total of 33 blood samples were applied. Taking into account the outcomes of the 
linearity graphs and employing the individual equations described in Table 8-5, 
methylation values were corrected as described in section 2.4.1.5. Lastly, for 
predictions both original and ‘corrected’ methylation values were used. Figure 8-16 
presents the predicted vs. true age graph as well as the observed predicted error for all 
individuals using both original (purple) and corrected data (green). As a whole, the age 
correlation using the original data was 0.67 with a mean absolute error of 13.32 years 
while the age correlation using the corrected data was 0.66 with a mean absolute error 












Figure 8-16. Age predictions using the developed NGS method (n=33) 
 (a) Predicted vs. true age for both sets of methylation data (original and corrected); the coloured lines 
correspond to linear correlation (R2=0.67 and R2=0.66 respectively) while the black dotted line 
represents the ‘ideal’ age correlation, (b) predicted error in years for both sets of methylation data 

















































8.4 Final Remarks 
As shown in Figure 7-11, the observed age-associated DNA methylation changes of 
the selected 16 CpG sites were quite small, especially for certain markers. It was also 
shown that there were issues with the precision and accuracy of bisulphite 
Pyrosequencing® when trying to predict age; therefore, it was decided that the 
potential of next generation sequencing is explored since it was previously reported to 
be able to accurately measure methylation levels (Masser et al., 2013). In this study, an 
NGS protocol based on MiSeq® specifically developed by Illumina for forensic 
applications was developed and validated through linearity analysis and the use of pre-
defined DNA methylation standards. Issues regarding sample representation and 
marker distribution were observed, but it is believed that further optimisation will 
potentially reduce these problems. The proposed method showed that is capable of 
accurately quantifying methylation levels; however by testing two sets of standards 
amplified by either 30 or 45 cycles revealed that PCR amplification biases occurred. 
Therefore, methylation correction was performed to assess if accuracy is improved 
when using the obtained methylation values for age prediction. The method’s 
capability on predicting age was tested in a total of 33 samples, where the mean 
absolute error was 13.32 years (original data) and 10.65 years (corrected data). 
Prediction differences within age groups were observed, with prediction of older 
people being significantly improved when correct values were used. In conclusion, 
although the proposed method resulted in poorer predictions comparing to the 
developed ANN model (Chapter 7), it seems to be very promising for age prediction; 































9.1 Tissue-specific mRNA profiling 
For the purpose of identifying the tissue source of a recovered body fluid stain, forensic 
researchers have focused on identifying suitable mRNA molecules showing tissue-
specific expression (Fleming & Harbison, 2010a; Haas et al., 2009a). In this study, a 
number of multiplex PCR systems developed by other research groups were assessed 
as part of ongoing European collaborative projects to assess inter-laboratory variation 
in the performance of the developed methods, prior to applying the proposed markers 
in forensic casework. Overall, both tissue-specific (EDNAP) and multi-tissue 
(EuroForGen) mRNA-based methods were found to be very sensitive and able to 
accurately differentiate between forensically relevant body fluids and tissues from 
minute amounts of starting material. However, differences in marker specificity were 
observed when testing various mock casework samples. Although false negative results 
were regularly obtained in very low quantity samples, false positive results as a result of 
a low expression of tissue-specific mRNAs in non-target tissues were also seen. It is 
believed that the use of endogenous controls (housekeeping genes) should not only be 
used for the confirmation of the presence of cellular material (as in TissueID 20plex) 
but also in a more quantitative way to potentially correct for these ‘stochastic’ 
variations, more likely caused by the large and varying amount of cells analysed 
(sample overload). It was observed however, that by using replicates of the same 
sample and introducing a category of ‘sporadically observed’ in the interpretation 
guidelines, false positives could be eliminated. 
Although for body fluids like semen and blood these problems rarely occured, the 
identification of vaginal secretion using mRNA profiling proved to be more 
challenging due to the occasional detection of menstrual blood-, saliva- or skin-specific 
markers [Table 4-5 & 4-6]. It is understood that menstrual blood- and vaginal fluid-
specific mRNAs can be affected by the menstrual cycle as well as by individual 
differences in menstrual flow; however, to the best of my knowledge this has not yet 
experimentally been tested. In the future, gathering information regarding the day of 
menstrual cycle, possible use of contraceptives or other similar information when 
collecting vaginal fluid and menstrual blood samples could help with identifying the 
source of these variations. In addition, it is believed that due to the epithelial tissue of 
origin, vaginal secretion, saliva and skin might display similar gene expression patterns. 
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This was highlighted by the detection of putative vaginal fluid-specific markers in 
buccal and saliva stains as well as the detection of skin markers in both saliva and 
vaginal fluid using the tissue-specific EDNAP multiplexes [Table 4-5]. Nevertheless, 
the use of bacterial-specific markers showed themselves to be very promising for 
vaginal fluid detection since it is known that the presence and concentration of 
particular Lactobacillus species are specific within this body fluid. However, research is 
still needed to select the best bacterial species since, for example, one marker (Ljen) 
was found to be co-expressed in urine, buccal, skin, saliva and menstrual blood 
samples [Table 4-5]. 
Although it is generally accepted that mRNA profiling could serve as a suitable 
confirmatory test for differentiation among tissues, future optimisation of existing 
multiplex mRNA-based methods would allow for a more accurate identification. It is 
believed that a test that would simultaneously analyse markers for various tissues in a 
single reaction would surpass methods that are tissue-specific (determining only one 
tissue at a time). Optimising the proposed 20plex system (EuroForGen) could result in 
a better performance in casework. Adjustments could include the addition of more 
specific markers gathered by the analysis of tissue-specific assays (EDNAP) and the 
removal of mRNAs that seem to give non-specific signals (such as the skin marker 
LOR). Also, further method optimisation will ensure equal amplification efficiencies 
across mRNA molecules since in this study a large variation in detected peak heights 
(rfu) was observed. Lastly, from the analysis of complex mock casework containing up 
to three different tissues in a single stain, as well as from the data interpretation 
exercise, it was recognised that guidelines on interpreting RNA profiles were needed 
and forensic scientists would require special training in interpretation. 
Careful interpretation is especially necessary when menstrual blood markers are 
interpreted. When analysing a menstrual blood/whole blood mixed sample (section 
4.3.4.3), although the identification of menstrual markers was successful, the detection 
of blood was masked under the ‘observed and fits’ category due to the co-expression of 
markers in peripheral and menstrual blood. It was suggested that in these cases the 
peak height of blood peaks as well as the obtained DNA profiles could be used to 
assess if these are due to the ‘true’ presence of non-menstrual blood or due to co-
expression in menstrual blood. However, Harteveld et al have shown that not only 
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RNA peaks cannot be associated to DNA peaks but also RNA peak heights can vary 
between replicates of the same sample (also observed in this study) (Harteveld et al., 
2013).  
Except for further optimisation of the TissueID 20plex assay for tissue identification, 
future work could include the analysis of a larger set of mock casework samples, where 
lessons can be learned regarding the best experimental and interpretation strategy. 
Furthermore, following the example of other countries such as the Netherlands and 
New Zealand, the application of mRNA profiling for tissue identification should be 
routinely used, therefore efforts towards setting up validation and interpretation 
criteria is vital. 
9.2 Tissue-specific DNA methylation profiling 
Although forensic researchers have investigated in depth the potential of applying 
mRNA profiling in tissue identification (Gomes et al., 2013; Lindenbergh et al., 2013) 
and research on developing robust assays is still ongoing (Xu et al., 2014), it is thought 
that in certain forensic scenarios its application would not be feasible. For example, 
RNA is not yet routinely analysed in forensic laboratories, and also, for cold cases it is 
usually only the original stains or extracted DNA samples that have been stored (and 
are often several years old). Considering the instability of RNA molecules (even if 
studies have shown successful detection of mRNA profiles in aged stains (Kohlmeier & 
Schneider, 2012)), a method based on DNA would be preferable. 
For this purpose, DNA methylation patterns among tissues were evaluated for their 
potential in differentiating tissues. When the present study was initiated, no research 
had been published assessing the application of epigenetic markers in forensic tissue 
identification, but the potential as well as challenges of such approach were soon 
apparent (Frumkin et al., 2011; Lee et al., 2012a). As an example, even though 
Frumkin et al proposed the use of seven loci for the simultaneous identification of 
blood, semen, saliva, skin, urine, menstrual blood and vaginal secretion, Gomes et al 
failed to reproduce their results on skin identification (Gomes et al., 2011).  
It is known that DNA methylation regulates gene expression and controls cellular 
differentiation during development (Shen et al., 2007; Song et al., 2009); however, in 
the medical field differential epigenetic patterns among tissues are mainly assessed in 
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order to evaluate if observed differential patterns in diseased tissues are meaningful 
events or part of natural tissue-to-tissue variation. The main challenge faced in this 
study regarding the identification of suitable CpG sites was the lack of methylation 
data in forensically relevant body fluids such as vaginal fluid and menstrual blood. 
Therefore, an extensive validation of the selected markers as well as the identification 
of novel ones was needed to assess their specificity. 
Firstly, it was thought that since DNA methylation is involved in gene silencing 
(Newell-Price et al., 2000), it would be interesting to investigate the methylation status 
of genes included in the proposed mRNA-based systems. For example, it has been 
previously reported that the blood-specific haemoglobin genes are regulated by DNA 
methylation (Bartzeliotou & Dimitriadis, 1989), while evidence is also available 
regarding the DNA methylation of semen-specific protamine genes and its 
involvement in determining their expression during spermatogenesis in mouse (Trasler 
et al., 1990). Furthermore, it has been shown that for MUC4, previously suggested as a 
vaginal marker (Juusola & Ballantyne, 2005), DNA methylation in its 5’-flanking 
region plays an important role for its gene expression in carcinomas (Yamada et al., 
2009). However, the exact chromosomal location of potentially useful CpG sites was 
not always known, and therefore a promoter screening approach was decided to be 
more suitable. For this purpose, the promoter regions of selected genes such as HBB 
and MUC4 were used for the design of Sanger sequencing assays since this method 
allows for the sequencing of up to 500-600 bp in a single reaction. However, it was 
soon evident that amplifying long fragments of bisulphite-treated DNA is very 
challenging due to its low complexity; and primer re-design or extensive optimisation 
did not necessarily eliminate non-specific products present that interfered with 
methylation detection (data not shown). 
Therefore, the selection of previously reported differentially methylated CpG sites as 
well as the development of a method that would allow for the amplification and 
sequencing of shorter fragments were needed. The capabilities of bisulphite 
Pyrosequencing® on quantifying methylation levels have been previously assessed 
(Dejeux et al., 2009) and its advantages over other methods have also been established 
(Reed et al., 2010). Therefore, using a commercially available CpG assay for HBA1, a 
Pyrosequencing® method was validated for its sensitivity, bisulphite conversion 
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efficiency as well as reproducibility. Even though the results were very promising, the 
four CpG sites quantified in this assay failed to demonstrate differential methylation 
patterns among blood, semen and saliva, results that further support the need for either 
identifying existing tissue-specific CpG sites or discovering novel ones through a 
genome-wide analysis. 
In a first approach, a reported blood-specific region of the EFS gene consisting of ten 
CpG sites was investigated using various forensically relevant tissues and, as shown in 
Figure 5-9, its potential for blood detection was confirmed. However, saliva 
demonstrated a wide range of average methylation levels among individuals even 
though buccal samples showed a lower one. It is believed that this could be due to the 
presence of leukocytes in saliva, due to either immunological conditions or simply due 
to gum bleeding. Nevertheless, one of the analysed CpG sites (CpG 4) was found to be 
the most useful marker since it was only highly methylated (>0.8) in blood, allowing 
not only for the discrimination between blood and saliva but also between blood and 
menstrual blood. Additionally, the assay successfully passed the validation phase 
showing that methylation levels among a total of 65 blood samples were consistent and 
reproducible [Figure 5-11 & 5-12]; this was also demonstrated in aged and degraded 
samples (e.g. the expected methylation profiles were successfully obtained from stains 
deposited 18 years prior to analysis). 
In a second approach, analysis of genome-wide methylation data gathered from blood, 
semen and buccal cell samples identified a set of eleven body fluid-specific CpG sites. 
In this case, following analysis with bisulphite Pyrosequencing® only the selected 
semen markers were confirmed as suitable. This was once again due to similar 
methylation profiles among blood and saliva samples, which further supports the 
previous theory on the presence of naturally occuring white blood cells in saliva 
(Calonius, 1958), further supported by the difference in methylation between buccal 
cells and saliva as shown in Figure 5-16b and 5-17b. Nevertheless, one CpG site 
(cg13763232, BLM1) demonstrated a similar pattern with EFS, showing high 
methylation levels only in whole blood (>0.85). Interestingly, this CpG site belongs to 
the promoter region of the solute-carrier family 6, member 6 (SLC6A6) gene that 
encodes for a sodium- and chloride-dependent transporter of the neurotransmitters 
taurine and beta-alanine (Han & Chesney, 2003). Taurine plays an important role in 
[319] 
 
many biological activities including osmoregulation, membrane stabilisation and anti-
oxidation (Han et al., 2006). It has been reported that this gene is regulated by 
controlling transcription factor binding sites in its promoter; therefore, the involvement 
of DNA methylation in this control cannot be excluded. Lastly, a very recent study 
implicated its role in colorectal cancer via inactivation of cell apoptosis (Yasunaga & 
Matsumura, 2014). 
As shown in similar studies (An et al., 2013; Lee et al., 2012a; Madi et al., 2012), 
identifying semen-specific methylation patterns has shown to be rather simple. This 
comes as no surprise since sperm cells have a unique composition in terms of histones 
and proteins. This was highlighted further for DNA methylation, since initial selection 
of highly differentially methylated sites between semen and blood/buccal cells using 
the genome-wide methylation data obtained by Rakyan et al (2008 & 2010) resulted 
in hundreds of potential markers. As shown in Figure 5-17, all four tested CpG sites 
demonstrated semen-specific differential methylation; however, two of them 
(cg01318557 and cg05656364) did not seem to be sufficiently robust.  
Looking at the biological functions of the involved genes for the best two semen-
specific CpG sites to potentially understand and justify the observed differential 
methylation in semen, some very interesting observations were made. The sequence 
analysed by the SEU1 assay belongs to a gene encoding for the solute carrier family 25 
(mitochondrial carrier; adenine nucleotide translocator), member 31 protein 
(SLC25A31) which catalyses the exchange of cytoplasmic ADP with mitochondrial 
ATP across the mitochondrial inner membrane. It is believed that it mediates energy 
generating and energy consuming processes in the distal flagellum, possibly as a 
nucleotide shuttle between flagellar glycolysis, protein phosphorylation and 
mechanisms of motility (Dolce et al., 2005). It has previously been reported that its 
SLC25A31 mRNA transcripts are exclusively present in liver, testis and brain (Dolce 
et al., 2005); therefore, differential DNA methylation in its promoter (where 
cg04382920 is found) could regulate its expression. A recent study supports this 
assumption, as SLC25A31 was found to be one of the few differentially methylated 
genes in semen following a genome-wide analysis of 38 semen samples (Schutte et al., 
2013). It was reported to be involved in spermatogenesis and associated with 
inflammation and autoimmune processes interfering with fertility.  
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Moreover, cg11768416 (SEU2) belongs to the gene encoding for the coiled coil 
glutamate rich protein 1 (Ccer1 or C12orf12). Remarkably, this gene has been 
previously reported to have dense promoter CpG island methylation and gene 
silencing in normal tissues except testis and sperm (Shen et al., 2007); a finding that 
was confirmed in this study. Authors tested various healthy and diseased tissues and 
found that hypomethylation of this gene in non-semen tissues is associated with gene 
activation in cancer.  
Furthermore, using the proposed markers, successful detection in aged stains of up to 
16 years old as well as high sensitivity (using as little as 50 pg of starting DNA 
material) was obtained making their application in forensic casework possible. The 
sensitivity of DNA methylation assays for tissue identification have also been 
demonstrated in the study by Larue et al (2013), where positive results for semen were 
obtained down to 31 pg using the proposed DSI-Semen™ kit developed by 
Wasserstrom and co-workers (2013). 
Lastly, a set of six immune-cell specific methylation markers was tested using all types 
of forensically relevant tissues mentioned so far, together with nasal fluid and nasal 
blood. Although semen-specific DNA methylation profiles of two loci (AMP1730 and 
AMP2007) were confirmed and one potential blood-specific marker was identified, 
the rest of the assays failed to demonstrate differential methylation levels for the other 
body fluids as originally suggested by our European collaborator (personal 
communication) [Figure 5-3].  
Interestingly, methylation results obtained by the analysis of nasal blood showed that 
the differentiation between different ‘types’ of blood - whole, menstrual and nasal - is 
particularly challenging. However, it is noteworthy to mention that as expected, nasal 
blood demonstrated a ‘mixed’ profile between nasal fluid and blood, which could 
potentially be used for their differentiation if samples of the individual in question are 
available. It should also be noticed that a few urine samples gave positive reactions 
when testing the semen-specific markers. However, 74% of these urine samples belong 
to male volunteers and these false-positive results could be explained since both male 
urinary and reproductive systems share the same tract.  
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As a comment, it should be noted that caution is needed when applying DNA 
methylation markers for tissue identification since changes in DNA methylation 
patterns have been reported in various diseases (Teschendorff et al., 2012; Tsai & 
Baylin, 2011). With regards to semen detection it has been shown that alternations in 
sperm DNA methylation patterns in particular loci are seen with low sperm motility 
and different types of male infertility (El Hajj et al., 2011; Hammoud et al., 2010; 
Pacheco et al., 2011). In fact, in this study there were two semen samples in particular 
that showed an ‘unexpected’ methylation ratio for most semen-specific assays tested as 
shown in Figure 5-17b for SEM2, SEU1 and SEU2, in Figure 5-22 for AMP1730 and 
in Figure 5-23 for AMP2007. Interestingly, these two samples resulted in a 10-fold 
decrease in DNA yield following DNA isolation using the same starting material as the 
rest of the semen samples, potentially indicating a smaller number of spermatozoa 
present. 
The observations above, including the implication of some of these markers in cancer 
via an ‘abnormal’ methylation profile as well as the possible ‘connection’ between low 
sperm counts and altered methylation levels, highlights the need for validation of the 
proposed markers prior to implementation by analysing diseased samples. Ideally, 
together with samples from ‘healthy’ volunteers, samples from patients suffering from 
various diseases should be co-analysed so that a better representation of the general 
population is achieved. Due to the ethic restrictions, gathering personal data regarding 
disease status from crime scene stains is not permitted; therefore, all possible reasons 
that could lead to altered methylation profiles should be taken into account. 
As a general comment and following this study, it can be concluded that an important 
drawback of applying DNA methylation profiling into forensic casework is the analysis 
of mixed stains. Since DNA methylation results are presented in a more quantitative 
manner compared to the mRNA profiling (percentages rather than the 
presence/absence of peaks), a result regarding one tissue-specific marker would be 
insufficient to report the tissue source. Therefore, a serial analysis including at least 
two or three CpG sites per tissue (similar to the proposed mRNA strategy) would be 
necessary in order to include or exclude the presence of a body fluid. Afterwards, the 
obtained ratios for each marker could be used to figure out which tissues are involved 
in the case of mixed stains. 
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Future work regarding the tissue-specific DNA methylation profiling could include 
not only an extensive validation of the blood- and semen-specific markers found in this 
study, but also the investigation of more genomic loci showing potential tissue-specific 
DNA methylation patterns. Using the same approaches but further developed (for 
example, collecting genome-wide methylation data for all forensically relevant tissues) 
could reveal more markers of interest that could be selected during the discovery phase 
for assay development. Also, to account for potential, common inter-individual 
differences in DNA methylation and consequently, gene expression, a larger dataset of 
body fluids and tissues should be collected. 
9.3 Implementation of tissue identification to live casework 
As gathered from both the literature and this study, DNA methylation markers can be 
a useful additional method for use in forensic casework. As demonstrated during the 
validation phase of the proposed tissue-specific CpG sites, these seemed to be stable 
not only over time but also under harsh conditions (high temperatures, outdoors, UV-
degraded), highlighting their potential for application in forensic-type samples. Any 
newly proposed tissue-specific marker need to undergo an externsive validation phase, 
which following this study can be further extended. To our knowledge, mRNA and 
DNA methylation profiling have not yet been implemented in forensic casework in the 
UK and following this study, we were able for the first time to apply the best tissue-
specific markers for confirmatory tissue identification in two cold cases (data not 
shown).  
The applicability of the two semen markers identified through genome-wide 
methylation data analysis (SEU1 and SEU2) was tested in a sexual assault cold case 
where differentiation of semen vs vaginal fluid was required. The advantages of DNA 
methylation profiling in comparison to mRNA-based approach were obvious since 
there was only a DNA sample available. As a result, we were able to conclude that it 
was very unlikely that semen was present in the analysed DNA sample since the 
observed methylation levels at both loci were 0.85 and 0.88 (semen exhibits low levels 
of methylation for both markers). A level of uncertainty due to potential natural inter-
individual variations could be eliminated in the future by analysing more semen 
samples as part of the assessment of markers’ specificity as well as by introducing 
guidelines on interpreting DNA methylation profiles for forensic casework. Finally, 
[323] 
 
having more information regarding the sperm count could be useful, however this is 
often not possible when only the DNA sample rather than a semen stain is retained. 
Additionally, the usefulness of combining mRNA and DNA methylation profiling was 
assessed in a case involving a reported sexual assault of a female in menses. In this case 
there was only a stained duvet cover available. The stains on this item had returned 
positive for blood using presumptive testing; however, scientists were unable to say if 
the stains were of peripheral or menstrual origin. Using the TissueID mRNA 20plex, 
validated in Chapter 4, together with the blood markers proposed in Chapter 5 (EFS 
and AMP1404), we were able to conclude that the stain of interest was most likely 
menstrual blood. Firstly, this was achieved by the detection of peaks for menstrual 
secretion (MMP10), blood (HBB) and housekeeping genes (ACTB and 18S rRNA) 
using the TissueID 20plex. The presence of the blood peak would be expected in a 
menstrual blood stain, since it is known that co-expression of blood and vaginal fluid 
markers is common in menstrual blood (Lindenbergh et al., 2012). Secondly, detected 
EFS methylation was very low (<0.2) for all CpG sites, a profile that contradicts the 
one of whole blood, which is highly methylated [Figure 5-9]. Similarly, the AMP1404 
locus was found to be completely methylated (>0.95), whereas in this study, whole 
blood samples resulted in partial methylation (average of 0.7) [Figure 5-22a].  
This case particularly demonstrates the advantages of using a combined genetic and 
epigenetic approach, since the presence of menstrual blood was confirmed by means of 
menstrual blood-specific mRNA profiling and the presence of whole blood was 
excluded by using blood-specific CpG sites (since menstrual blood-specific CpG sites 
are not available at the moment). Together with the results obtained from presumptive 
testing, conclusions drawn from mRNA- and DNA methylation-based tests could be 
further strengthened.  
9.4 Age-associated DNA methylation profiling 
The ability to accurately estimate a person’s chronological age would be a great 
advantage in police investigations as it could provide significant investigative leads. 
Although there have been various approaches to estimate age in human remains and 
living individuals, current methods suffer from low accuracy of age prediction, usually 
producing an estimate with a large age range. Since DNA methylation is known to act 
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as an interphace between the genome and environment, age-associated DNA 
methylation patterns have been observed (Gentilini et al., 2013; Heyn et al., 2012). 
Also, using genome-wide methylation analysis, researchers have been able to predict 
chronological age in a variety of tissues (Horvath, 2013); however, they all suffer from 
low sensitivity and use hundreds of loci which make them not applicable in forensic 
casework in their current form. In this study, a total of 55 potentially age-associated 
CpG sites were investigated. These CpG sites have been reported in two of the largest 
and highest-resolution genome-wide methylation studies in ageing (Hannum et al., 
2013; Horvath, 2013).  
Regarding the first approach, a set of ten CpG sites was selected for further 
investigation. Most of the genes associated with the proposed markers were found to 
be linked with age-related conditions, such as cancer, arthritis and Parkinson disease. 
In particular, two of the selected markers belong to the transcription factor KLF14 
(Krüppel-like factor 14), which is known as the ‘master regulator’ of obesity and other 
metabolic traits (Small et al., 2011). Furthermore, thanatos-associated protein 7 
(THAP7, ‘thanatos’ meaning death in greek) is also another protein involved in 
transcriptional regulation (Macfarlan et al., 2006). Also, two markers included in the 
initial set that are in close proximity, lie within the gene CD248, which encodes for a 
transmembrane glycoprotein found on the surface of activated perivascular and 
fibroblast-like cells and has a known function in inflammatory arthritis (Maia et al., 
2010). Lastly, mutations in a transmembrane lysosomal P5-type ATPase gene 
(ATP13A2) have been reported to unravel an essential role in lysosomal function and 
cell viability and suggested as a therapeutic target against Parkinson’s disease (Dehay 
et al., 2012). 
Subsequently, their epigenetic drift in blood of individuals belonging to different age 
groups was assessed and, as shown in Figure 7-5, it was changing slightly over time but 
regression analysis revealed no statistically significant correlation (p>0.05). Since these 
markers have been previously reported to be age-associated in the literature (Hannum 
et al., 2013), it is believed that this could be due to various reasons. It could be due to 
the small sample set or it could be due to failure of bisulphite Pyrosequencing® to 
accurately detect such small methylation differences (<0.1). An average of 5% 
standard deviation has been obtained in other bisulphite Pyrosequencing® assays 
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(section 5.3.1.3 and Figure 5-12) but there were cases where higher deviation was also 
observed. Moreover, in this method, a total of 45 PCR cycles was used which could 
introduce amplification bias and alter ‘true’ methylation levels. These results were 
confirmed by multiple regression analysis which revealed that only two markers from 
this set (cg05442902 and cg20426994) were important for age prediction using this 
particular dataset. 
To assess potential non-linear correlation of these markers with age, artificial neural 
networks (ANN) were applied. ANN models have been successfully applied in 
medical research and seemed to be able to detect complex relationships in various 
biological functions (Patel & Goyal, 2007). Initially, using a methylation dataset of 65 
samples, ANN analysis resulted in an age prediction model with a correlation between 
observed and predicted age of 95% and an average error of 4.27 years. However, the 
sample set used was considered relatively small (six samples in the verification set and 
only three in the blind test) so analysing more samples was required before drawing 
any conclusion. Surprisingly, the analysis of a larger dataset failed to reproduce the 
above age prediction accuracy, indicating that a different approach should be followed 
to both overcome the method’s low accuracy and reproducibility but also to take 
advantage of reported age-related markers with stronger association with age. 
Thus, a set of 45 CpG sites was selected from a genome wide methylation study that 
used not only blood samples but also other tissues, potentially resulting in more robust 
results. Although in this study, only 45 CpG sites were selected from the Horvath 
study (2013) which included a total of 353 age-associated markers, a future approach 
could include all these markers together with newly published potential markers. 
Thus, a much larger pool of age-associated CpG sites (up to thousands) could be 
created and used for age prediction analysis. 
Once again, all these 45 sites belong to genes involved in age-related conditions. For 
example, cg19761273 is associated with casein kinase 1 (CSNK1D), which is a serine-
threonine protein kinase involved in essential cell pathways including circadian 
rhythms and DNA repair. It is believed that CSNK1D has a role in arranging the 
microtubule network during mitosis to prevent DNA damage (Behrend et al., 2000). 
On the same theme, the structure specific recognition protein 1 (SSRP1) linked with 
cg01511567 seems to be crucial to anticancer mechanisms since it forms a chromatin-
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specific transcriptional elongation factor (FACT) that interacts specifically with 
histones and prevents DNA damage (Yarnell et al., 2001). Additionally, cg03286783 
belongs to the cancer susceptibility candidate 4 gene (CASC4), which appears to 
produce a single-pass membrane protein related to Golgi membrane protein 1 
(GOLM1); increased expression levels of CASC4 have been associated with proto-
oncogene overexpression in 30% of breast and 20% of ovarian cancers (Oh et al., 
1999).  
Moreover, cg05442902 is not only associated with THAP7 as shown earlier, but also 
with the purinergic receptor P2X-like 1 (P2RXL1) known for its involvement in a 
broad range of physiological processes via extracellular adenine nucleotides. These 
include inflammatory and immune responses and neurotransmitter release that could 
be affected by ageing (Kendall Harden et al., 1995). A recent study has also linked the 
thyroid hormone receptor interactor 10 (TRIP10) (cg02085507) with the regulation 
of cancer cell growth and death in a cancer type-specific manner; in fact differential 
DNA methylation of its gene has been suggested to promote cell survival or death 
(Hsu et al., 2011). Once again, one of the markers belongs to the transcription factor 
KLF14 (cg04528819) which, as mentioned earlier, is known as the ‘master regulator’ 
of obesity and other metabolic traits (Small et al., 2011). Lastly, the nerve growth 
factor VGF associated with cg04084157 has been linked with the age-associated 
Alzheimer’s disease, where its expression levels were found to be altered (Carrette et 
al., 2003).  
Analysis of 1,156 blood samples gathered from a total of 7 genome-wide methylation 
studies using both multiple and stepwise regression as well as ANN analysis revealed 
that an accurate prediction could be obtained by using 16 out of the 45 CpG sites. 
Multivariate regression revealed that none of the available factor variables (gender, 
ethnicity) influenced age-associated DNA methylation patterns in a statistically 
significant way. Although multiple linear regression analysis resulted in an accurate age 
prediction model (mean average error of 4.89 years), it was shown that once again the 
application of ANN analysis resulted in a more accurate model. In particular, the 
ANN age prediction model seemed very promising as it resulted in a correlation 
between predicted and true age of 96% and a mean absolute error of 3.3 years 
(standard deviation=3.7 years) [Figure 7-13]. It is believed that ANN models have the 
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ability to recognise complex patterns, which are often observed in complex traits like 
chronological age. 
Furthermore, analysis of 1,011 diseased blood samples (of various pathological 
conditions) resulted in a less accurate prediction, which was expected. Even though 
the prediction for individuals suffering from conditions like schizophrenia (error=5.03 
years) did not seem to greatly change, the samples from blood disorders resulted in a 
poor age prediction (error=12.74 years). Even though it is believed that the small size 
of the sample dataset could have an influence in these observations (n=105), it is 
suggested that CpG sites involved in blood diseases such as anaemia and bone marrow 
disorders should be excluded in future work so that these variations are avoided. One 
has to bear in mind that DNA methylation-based age prediction models actually 
predicts the biological age of tissues, rather than chronological age; therefore, ‘stressed’ 
cells could show an accelerated aging effect. In fact, as shown in Figure 7-14, the age 
prediction in diseased samples was getting worse in older individuals (>60 years old). 
Also, the influence of environment could be demonstrated by analysing 53 pairs of 
monozygotic twins. In general, the obtained age prediction resulted in an average 
mean absolute error of 7.07 years; however, it was noted that the model gave either 
very accurate or very inaccurate predictions. The age prediction differences within the 
twin pairs were 2.65 years on average and were not statistically significant as obtained 
by paired t-test analysis (p=0.99), suggesting that age acceleration could be inherited. 
These findings further support the hypothesis that environmental influences including 
lifestyle, smoking, diet or disease susceptibility could influence DNA methylation 
patterns; and as long as this information is not available, age prediction might still 
remain poor. 
Lastly, the possibility of applying the proposed model built on blood methylation 
profiles on other healthy tissues was assessed by analysing four different tissues 
including saliva, cervix, skin and muscle. Initially, by testing 15-28 samples per tissue, 
the ANN model failed to produce an accurate prediction. It was concluded that this 
could be not only due to the different biological nature of these tissues but also because 
of the small size of sample set used. It was therefore decided to focus only on saliva and 
cervix as there were few methylation datasets available for the other two tissues. The 
ANN was retrained using a total of 265 saliva and 167 cervix samples and as shown in 
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Figure 6-22 the potential of applying the selected blood CpG sites in other tissues 
seemed promising. However, it is believed that age prediction would be improved if 
more samples are gathered. Also, it is recommended that the potential of other CpG 
sites from the pool of 353 CpG sites suggested by Horvath is explored so that possible 
tissue-specific age-associated CpG sites can be investigated. 
Considering that a similar prediction accuracy was observed when using 353 CpG 
sites in Horvath’s study (age correlation of 0.96 with a median absolute error of 3.6 
years), predicting age using a smaller number of CpG sites could be possible. This is 
also supported by a study where researchers obtained a mean absolute deviation 
(MAD) from chronological age of 5.4 years using only three CpGs in blood (Weidner 
et al., 2014). Furthermore, in the forensic field, two very recent studies were published 
further supporting the possibility of predicting age using only a small set of DNA 
methylation markers. Firstly, applying a very different methodological approach 
(methylation-sensitive representational difference analysis, MS-RDA), Yi et al 
identified eight age-associated gene fragments.  Using 65 samples they built a 
regression model by using two CpG sites from each fragment (16 in total) that 
explained 95% of the variance in age (Yi et al., 2014). Also, even though the 
correlation with age was good (r=0.91), the small number of samples (n=65) as well as 
the large amount of DNA used (3 µg) makes its forensic application still questionable. 
Secondly, a recent study examined the methylation status of seven CpG sites located 
in the promoter region of the previously reported age marker ELOVL2 by means of 
bisulphite Pyrosequencing® (Zbieć-Piekarska et al., 2015). A total of 303 blood 
samples from individuals aged 2-75 years old were tested and multivariate regression 
analysis allowed for the selection of the best two CpG sites (namely, CpG 5 and CpG 
7). Notably, CpG 7 alone explained 83% of variation in age. The developed model 
(R2=0.859) explained 86% of variation in age and gave an average error of 6.85 years 
(MAD=5.03 years). Following validation with an additional set of 124 samples, 68.5% 
were predicted with an error of ±7 years; interestingly individuals above 60 years old 
resulted in poorer predictions (Zbieć-Piekarska et al., 2015). Moreover, sensitivity 
analysis revealed that the same prediction rates were obtained with as little as 2.5 ng of 
starting DNA material while the storage of bloodstains at room temperature (up to 15 
years) did not seem to correlate with prediction success rate either. This study seems 
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to be very promising for forensic age prediction which could potentially be improved if 
other age-associated markers apart from ELOVL2 are incorporated into the model. 
As shown in the present study and considering the weak age effects on individual 
CpGs, the contribution of each marker was found to be different with cg22736354, 
cg19761273 and cg02479575 showing the strongest input while cg03286783 
demonstrated the weakest influence in the model mirroring the methylation graphs on 
Figure 7-11. For a future approach it is recommended that the selection of age-
associated CpG sites is not only based on age coefficient values but also on their 
methylation change with age. Potentially, the age correlation of all 353 CpG sites 
proposed in Horvath’s study could be assessed via plotting their methylation levels 
against the subjects’ age and the CpGs showing a more noticeable variation could be 
chosen. Consequently, CpG sites with low contribution in the proposed model could 
be replaced by others with greater potential in age prediction as reported in the studies 
above (Yi et al., 2014; Zbieć-Piekarska et al., 2015).  
Since this is the first study where artificial neural networks are implemented in age 
prediction using DNA methylation markers, it can be concluded that ANN could offer 
a useful alternative to the regression models reported in the literature as it significantly 
improved the prediction accuracy resulting in lower prediction errors. The model 
seemed very promising for use in criminal investigation since it is based only on 16 loci 
(as a comparison most current DNA profiling methods are based on 15-16 STR loci as 
well); however, the proposed genome-wide techniques needed to obtain the 
methylation values require too much DNA for forensic use. Therefore, there was a 
strong need to develop methylation assays for the analysis of the selected 16 CpG sites 
that are both accurate and sensitive.  
9.5 Next generation sequencing for age prediction 
Next-generation sequencing technology has been adopted by the epigenetics 
community and its advantages compared to existing technologies have already been 
identified (Hurd & Nelson, 2009). Recently, a study tested the abilities of a bench-top 
sequencer (MiSeq®) in targeted methylation analysis of specific genomic regions 
(Masser et al., 2013). Authors suggested that their proposed method was not only 
applicable to targeted DNA methylation studies but it could also be used to confirm 
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genome-wide studies, potentially overcoming technical issues faced in predominant 
approaches like Pyrosequencing®. 
Adjusting a protocol that has specifically been developed for forensic SNP analysis, 
the methylation status of the proposed age-associated 16 CpG sites was successfully 
quantified. After validating the method in terms of linearity and reproducibility of 
methylation quantification and improving the methods based on experimental design, 
data from a total of 33 samples were used to test the age prediction accuracy using the 
ANN model [Figure 7-13]. Results were very encouraging in terms of sensitivity and 
accuracy of methylation quantification; however, age prediction accuracy was not as 
great (average absolute error of 13.32 years) as obtained when testing the ANN model 
using genome-wide methylation data. It is believed that there are mainly two possible 
explanations for this observation. Firstly, it should be noted that the data used to train 
the ANN model were obtained using a different methodology (Illumina’s 27K and 
450K Human methylation BeadChip technology (Bibikova et al., 2011)). From this 
study, comparing the methylation detection between Pyrosequencing® and NGS, it is 
obvious that different methods could measure methylation in a different way; it may 
be consistent within the method but could vary between methods, since different types 
of ‘bias’ towards the detection of either the methylated or the unmethylated allele 
could be introduced. Therefore, it is believed that if the ANN model was trained on 
data obtained using the proposed next generation sequencing method, then the age 
prediction could potentially be better. 
On the other hand, by testing two sets of DNA methylation standards amplified either 
using 30 or 45 PCR cycles, it was evident that amplification bias in bisulphite PCR 
could add variance [Figure 8-10]. This comes as no surprise as this type of bias had 
also been previously reported when testing tissue-specific differentially methylated 
CpG sites (Figure 5-5). ‘Correcting’ the obtained methylation levels was attempted by 
employing the equations of the observed vs. expected methylation levels of predefined 
DNA methylation controls. As a result, prediction accuracy was improved (average 
absolute error of 10.65 years), especially for older individuals. However, certainly for 
most markers, the PCR cycles could be further reduced since the resulting amplicon 
concentrations were much higher than the DNA amount needed for library 
preparation (only 1 µl out of 13 µl were used for each marker). Lastly, apart from bias 
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during the amplification of bisulphite-converted DNA, bias can be introduced post-
PCR during the sequencing process as discussed in section 8.3.2.6. Adjusting the 
protocol to include fewer tube manipulations could possible reduce these bias. 
Moreover, further optimisation of the protocol in terms of library input, library 
amplification and quantification could further improve the accuracy of methylation 
quantification and the distribution between markers and samples. Similar to the 
genome-wide DNA methylation data, MiSeq data can also undergo different 
normalisation strategies prior to analysis. Not only the ‘linearity’ graphs can be used 
for data correction for improved age prediction as shown in the present study, but also 
the data can be further corrected by using the average bisulfite conversion rates per 
amplicon for each sample. It is also believed that running samples in replicates (e.g. 
triplicates) would further reduce the prediction error by accounting for run-to-run 
variations in methylation detection, similar to the batch effects shown in the genome-
wide platforms. In the future, running a larger number of samples would be vital before 
making any conclusions regarding the age prediction accuracy of the overall method. 
Nevertheless, the results of this study are very encouraging as predicting age from an 
unknown sample looks possible (at least at the generation level at the moment). 
Although other forensic research groups have tried to predict age using other methods 
such as Pyrosequencing® (Zbieć-Piekarska et al., 2015), it is believed that the MiSeq® 
will surpass the proposed current methods. As discussed in section 8.1.2, next 
generation sequencing (NGS) using MiSeq® is a very promising option for future 
forensics, since it can potentially incorporate STR typing (Warshauer et al., 2013), 
mitochondrial genome sequencing (Parson et al., 2013), Y-chromosome analysis (Xue 
et al., 2009), differentiation of twins (Weber-Lehmann et al., 2014), microbial 
forensics (Brenig et al., 2010), species identification (Hajibabaei et al., 2011), ancestry 
studies and phenotypic inferences (Yang et al., 2014). Furthermore, the potential of 
NGS for tissue source identification was also proposed by a recent study (Bartling et 






9.6 Final remarks 
As shown in this study, tissue- and age-specific DNA methylation profiling, together 
with tissue-specific mRNA profiling could be very useful in answer forensic questions, 
such as ‘which body fluid/tissue is this crime scene stain/sample consists of?’ or ‘how 
old is the suspect?’. Although the results from the experiments included in this thesis 
are very promising and encouraging regarding these applications, it is believed that 
future experiments will further improve and strengthen the discussed conclusions. All 
the proposed tissue- and age-specific markers together with ones discovered in the 
future could be combined in multiplex PCR reactions (for example, a TissueID CpG 
multiplex and a MethAge multiplex) and be analysed in a simultaneous manner 
together with STR and SNP markers in an NGS platform. That way, information 
regarding the identity, ethnicity, age and physical characteristics of an individual 
together with the tissue source of the stain can be identified at the same time in a single 
experimental workflow. The forensic community is currently working through such a 


































ABI (2014). Quantifiler Human and Y Human Male DNA Quantification kits - User 
Guide. 
Akutsu, T., Motani, H., Watanabe, K., Iwase, H., Sakurada, K. (2012). Detection of 
bacterial 16S ribosomal RNA genes for forensic identification of vaginal fluid. Legal 
Medicine (Tokyo) 14(3), 160-162. 
Al-Qattan, S.I., Elfawal, M.A. (2010). Significance of teeth lead accumulation in age 
estimation. Journal of Forensic and Legal Medicine 17(6), 325-358. 
Alisch, R.S., Barwick, B.G., Chopra, P., Myrick, L.K., Satten, G.A., Conneely, K.N., 
Warren, S.T. (2012). Age-associated DNA methylation in pediatric populations. 
Genome Research 22(4), 623-632. 
Almen, M.S., Nilsson, E.K., Jacobsson, J.A., Kalnina, I., Klovins, J., Fredriksson, R., 
Schiöth, H.B. (2014). Genome-wide analysis reveals DNA methylation markers that 
vary with both age and obesity. Gene 548(1), 61-67. 
Alvarez, M., Juusola, J., Ballantyne, J. (2004). An mRNA and DNA co-isolation 
method for forensic casework samples. Analytical Biochemistry 335(2), 289-298. 
Ambion (2012). TURBO DNA-free kit. 
Amiri, M., Derakhshandeh, K. (2011). Applied artificial neural networks: from 
associative memories to biomedical applications. InTech. 
Amiri, M., Menhaj, M.B., Fallah, A. (2007). Stability analysis of self-feedback neural 
network structures. Amirkabir Journal of Science and Technology 14, 103-109. 
Ammerpohl, O., Martin-Subero, J.I., Richter, J., Vater, I., Siebert, R. (2009). Hunting 
for the 5th base: Techniques for analyzing DNA methylation. Biochimica et Biophysica 
Acta 1790(9), 847-862. 
An, J.H., Shin, K.J., Yang, W.I., Lee, H.Y. (2012). Body fluid identification in 
forensics. BMB reports 45(10), 545-553. 
An, J.H., Choi, A., Shin, K.J., Yang, W.I., Lee, H.Y. (2013). DNA methylation-
specific multiplex assays for body fluid identification. International Journal of Legal 
Medicine 127(1), 35-43. 
Andréasson, H., Nilsson, M., Styrman, H., Pettersson, U., Allen, M. (2007). Forensic 
mitochondrial coding region analysis for increased discrimination using 
pyrosequencing technology. Forensic Science International: Genetics 1(1), 35-43. 
Anjum, S., Fourkala, E.O., Zikan, M., Wong, A., Gentry-Maharaj, A., Jones, A., 
Hardy, R., Cibula, D., Kuh, D., Jacobs, I.J., Teschendorff, A.E., Menon, U., 
Widschwendter, M. (2014). A BRCA1-mutation associated DNA methylation 
signature in blood cells predicts sporadic breast cancer incidence and survival. Genome 
Medicine 6(6), 47. 
[335] 
 
Arany, S., Ohtani, S., Yoshioka, N., Gonmori, K. (2004). Age estimation from 
aspartic acid racemization of root dentin by internal standard method. Forensic Science 
International  141(2-3), 127-130. 
Bailey, A.J., Shimokomaki, M.S. (1971). Age-related changes in the reducible 
crosslinks of collagen. FEBS Letters 16(2), 86-88. 
Baker, D.J., Grimes, E.A., Hopwood, A.J. (2011). D-dimer assays for the 
identification of menstrual blood. Forensic Science International 212(1-3), 210-214. 
Baran, Y., Subramaniam, M., Biton, A., Tukiainen, T., Tsang, E.K., Rivas, M.A.,  
Pirinen, M., Gutierrez-Arcelus, M., Smith, K.S., Kukurba, K.R., Zhang, R., Eng, C., 
Torgerson, D.G., Urbanek, C., GTEx Consortium, Li, J.B., Rodriguez-Santana, J.R., 
Burchard, E.G., Seibold, M.A., MacArthur, D.G., Montgomery, S.B., Zaitlen, N.A., 
Lappalainen, T. (2015). The landscape of genomic imprinting across diverse adult 
human tissues. Genome Research 25(7), 927-936. 
Barni, F., Lewis, S.W., Berti, A., Miskelly, G.M., Lago, G. (2007). Forensic 
application of the luminol reaction as a presumptive test for latent blood detection. 
Talanta 72(3), 896-913. 
Baron, U., Turbachova, I., Hellwag, A., Eckhardt, F., Berlin, K., Hoffmuller, U., 
Gardina, P., Olek, S. (2006). DNA methylation analysis as a tool for cell typing. 
Epigenetics 1(1), 55-60. 
Bartel, D.P. (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell   
116(2), 281-297. 
Bartling, C.M., Hester, M.E., Bartz, J., Heizer, E.Jr., Faith, S.A. (2014). Next-
generation sequencing approach to epigenetic-based tissue source attribution. 
Electrophoresis 35(21-22), 3096-3101. 
Bartzeliotou, A.J., Dimitriadis, G.J. (1989). The state of DNA methylation of human 
e-globin gene in erythroid and non-erythroid cells. Cell Differentiation and 
Development 26(2), 97-106. 
Bauer, M., Patzelt, D. (2003). A method for simultaneous RNA and DNA isolation 
from dried blood and semen stains. Forensic Science International 136(1-3), 76-78. 
Bauer, M., Patzelt, D. (2008). Identification of menstrual blood by real time RT-PCR: 
technical improvements and the practical value of negative test results. Forensic Science 
International 174(1), 55-59. 
Behrend, L., Stöter, M., Kurth, M., Rutter, G., Heukeshoven, J., Deppert, W., 
Knippschild, U. (2000). Interaction of casein kinase 1 delta (CK1delta) with post-
Golgi structures, microtubules and the spindle apparatus. European Journal of Cell 
Biology 79(4), 240-251. 
Bell, C.G., Teschendorff, A.E., Rakyan, V.K., Maxwell, A.P., Beck, S., Savage, D.A. 
(2010). Genome-wide DNA methylation analysis for diabetic nephropathy in type 1 
diabetes mellitus. BMC Medical Genomics 3, 33. 
[336] 
 
Bell, J.T., Loomis, A.K., Butcher, L.M., Gao, F., Zhang, B., Hyde, C.L., Sun, J., Wu, 
H., Ward, K., Harris, J., Scollen, S., Davies, M.N., Schalkwyk, L.C., Mill, J., 
MuTHER Consortium, Williams, F.M., Li, N., Deloukas, P., Beck, S., McMahon, 
S.B., Wang, J., John, S.L., Spector, T.D. (2014). Differential methylation of the 
TRPA1 promoter in pain sensitivity. Nature Communications 5, 2978. 
Bell, J.T., Pai, A.A., Pickrell, J.K., Gaffney, D.J., Pique-Regi, R., Degner, J.F., Gilad, 
Y. Pritchard, J.K. (2011). DNA methylation patterns associate with genetic and gene 
expression variation in HapMap cell lines. Genome Biology 12(1), R10. 
Bell, J.T., Tsai, P.C., Yang, T.P., Pidsley, R., Nisbet, J., Glass, D., Mangino, M., Zhai, 
G., Zhang, F., Valdes, A., Shin, S.Y., Dempster, E.L., Murray, R.M., Grundberg, E., 
Hedman, A.K., Nica, A., Small, K.S., MuTHER Consortium, Dermitzakis, E.T., 
McCarthy, M.I., Mill, J, Spector, T.D., Deloukas, P. (2012). Epigenome-wide scans 
identify differentially methylated regions for age and age-related phenotypes in a 
healthy ageing population. PLoS Genetics 8(4), e1002629. 
Bibikova, M., Barnes, B., Tsan, C., Ho, V., Klotzle, B., Le, J.M., Delano, D., Zhang, 
L., Schroth, G.P., Gunderson, K.L., Fan, J.B., Shen, R. (2011). High density DNA 
methylation array with single CpG site resolution. Genomics 98(4), 288-295. 
Bird, A. (2002). DNA methylation patterns and epigenetic memory. Genes & 
Development 16(1), 6-21. 
Bird, A. (2007). Perceptions of epigenetics. Nature 447, 396-398. 
Bock, C. (2009). Epigenetic biomarker development. Epigenomics 1(1), 99-110. 
Bocklandt, S., Lin, W., Sehl, M.E., Sanchez, F.J., Sinsheimer, J.S., Horvath, S., 
Vilain, E. (2011). Epigenetic predictor of age. PLoS One 6(6), e14821.  
Boks, M.P., Derks, E.M., Weisenberger, D.J., Strengman, E., Janson, E., Sommer, I. 
E., Kahn, R.S., Ophoff, R.A. (2009). The relationship of DNA methylation with age, 
gender, genotype in twins and healthy controls. PLoS One 4(8), e6767. 
Borghol, N., Blachére, T., Lefèvre, A. (2008). Transcriptional and epigenetic status of 
protamine 1 and 2 genes following round spermatids injection into mouse oocytes. 
Genomics 91(5), 415-422. 
Bouakaze, C., Keyser, C., Crubezy, E., Montagnon, D., Ludes, B. (2009). Pigment 
phenotype and biogeographical ancestry from ancient skeletal remains: inferences from 
multiplexed autosomal SNP analysis. International Journal of Legal Medicine 123(4), 
315-325. 
Breit, T.M., Verschuren, M.C., Wolvers-Tettero, I.L., Van Gastel-Mol, E.J., Halhen, 
K., van Dongen, J.J. (1997). Human T cell leukemias with continuous V(D)J 




Brenig, B., Beck, J., Schütz, E. (2010). Shotgun metagenomics of biological stains 
using ultra-deep DNA sequencing. Forensic Science International: Genetics 4(4), 228-
231. 
Britt-Compton, B., Rowson, J., Locke, M., Mackenzie, I., Kipling, D., Baird, D.M. 
(2006). Structural stability and chromosome-specific telomere length is governed by 
cis-acting determinants in humans. Human Molecular Genetics 15(5), 725-733. 
Bruder, C.E., Piotrowski, A., Gijsbers, A.A., Andersson, R., Erickson, S., Diaz de 
Ståhl, T., Menzel, U., Sandgren, J., von Tell, D., Poplawski, A., Crowley, M., Crasto, 
C., Partridge, E.C., Tiwari, H., Allison, D.B., Komorowski, J., van Ommen, G.J., 
Boomsma, D.I., Pedersen, N.L., den Dunnen, J.T., Wirdefeldt, K., Dumanski, J.P. 
(2008). Phenotypically concordant and discordant monozygotic twins display 
different DNA copy-number-variation profiles. American Journal of Human Genetics 
82(3), 763-771. 
Butler, J.M. (2012). Advanced Topics in Forensic DNA Typing - Methodology. 
Elsevier. 
Calonius, P.E. (1958). The leukocyte count in saliva. Oral surgery, oral medicine, and 
oral pathology 11(1), 43-46. 
Carlson, D.M. (1993). Salivary proline-rich proteins: biochemistry, molecular biology, 
and regulation of expression. Critical reviews in oral biology and medicine 4(3-4), 495-
502. 
Carrette, O., Demalte, I., Scherl, A., Yalkinoglu, O., Corthals, G., Burkhard, P., 
Hochstrasser, D.F., Sanchez, J.C. (2003). A panel of cerebrospinal fluid potential 
biomarkers for the diagnosis of Alzheimer's disease. Proteomics 3(8), 1486-1494. 
Chaikind, B., Kilambi, K.P., Gray, J.J., Ostermeier, M. (2012). Targeted DNA 
methylation using an artificially bisected M.HhaI fused to zinc fingers. PLoS One 7(9), 
e44852. 
Chen, Y.A., Choufani, S., Ferreira, J.C., Grafodatskaya, D., Butcher, D.T., 
Weksberg, R. (2011). Sequence overlap between autosomal and sex-linked probes on 
the Illumina HumanMethylation27 microarray. Genomics 97(4), 214-222. 
Choi, A., Shin, K.J., Yang, W.I., Lee, H.Y. (2014). Body fluid identification by 
integrated analysis of DNA methylation and body fluid-specific microbial DNA. 
International Journal of Legal Medicine 128(1), 33-41. 
Christensen, B.C., Houseman, E.A., Marsit, C.J., Zheng, S., Wrensch, M.R., 
Wiemels, J.L., Nelson, H.H., Karagas, M.R., Padbury, J.F., Bueno, R., Sugarbaker, 
D.J., Yeh, R.F., Wiencke, J.K., Kelsey, K.T. (2009). Aging and environmental 
exposures alter tissue-specific DNA methylation dependent upon CpG island context. 
PLoS Genetics 5(8), e1000602. 
Chu, P.G., Weiss, L.M. (2002). Keratin expression in human tissues and neoplasms. 
Histopathology 40(5), 403-439. 
[338] 
 
Chu, Z.L., Wickrema, A., Krantz, J.C., Winkelmann, J.C. (1994). Erythroid-specific 
processing of human β spectrin I pre-mRNA. Blood 84(6), 1992-1999. 
Clark, S.J., Harrison, J., Paul, C.L., Frommer, M. (1994). High sensitivity mapping of 
methylated cytosines. Nucleic Acids Research 22(15), 2990-2997. 
Cosma, M.P., Tanaka, T., Nasmyth, K. (1999). Ordered recruitment of transcription 
and chromatin remodeling factors to a cell cycle- and developmentally regulated 
promoter. Cell  97(3), 299-311. 
Cunha, E., Baccino, E., Martrille, L., Ramsthaler, F., Prieto, J., Schuliar, Y., 
Lynnerup, N., Cattaneo, C. (2009). The problem of aging human remains and living 
individuals: a review. Forensic Science International 193(1-3), 1-13. 
Danielson, P.B. (2011). Isolation of highly specific protein markers for the 
identification of biological stains - Adapting comparative proteomics to forensics. U.S. 
Department of Justice, pp. 1-37. 
Das, P.M., Singal, R. (2004). DNA methylation and cancer. Journal of Clinical 
Oncology 22(22), 4632-4642. 
Day, K., Waite, L.L., Thalacker-Mercer, A., West, A., Bamman, M.M., Brooks, J.D., 
Myers, R.M., Absher, D. (2013). Differential DNA methylation with age displays 
both common and dynamic features across human tissues that are influenced by CpG 
landscape. Genome Biology 14(9), R102. 
De Bustos, C., Ramos, E., Young, J.M., Tran, R.K., Menzel, U., Langford, C.F., 
Eichler, E.E., Hsu, L., Henikoff, S., Dumanski, J.P., Trask, B.J. (2009). Tissue-
specific variation in DNA methylation levels along human chromosome 1. Epigenetics 
& chromatin 2(1), 7. 
de Lange, T. (2004). T-loops and the origin of telomeres. Nature Reviews Molecular 
Cell Biology 5(4), 323-329. 
Dehay, B., Martinez-Vicente, M., Ramirez, A., Perier, C., Klein, C., Vila, M., Bezard, 
E. (2012). Lysosomal dysfunction in Parkinson disease: ATP13A2 gets into the 
groove. Autophagy 8(9), 1389-1391. 
Dejeux, E., El abdalaoui, H., Gut, I.G., Tost, J. (2009). Identification and 
quantification of differentially methylated loci by the pyrosequencing technology. 
Second ed, pp. 189-205. Humana Press. 
Divne, A.M., Edlund, H., Allen, M. (2010). Forensic analysis of autosomal STR 
markers using Pyrosequencing. Forensic Science International: Genetics 4(2), 122-129. 
Dobberstein, R.C., Huppertz, J., von Wurmb-Schwark, N., Ritz-Timme, S. (2008). 
Degradation of biomolecules in artificially and naturally aged teeth: Implications for 
age estimation on aspartic acid racemization and DNA analysis. Forensic Science 
International  179(2-3), 181-191. 
[339] 
 
Dobberstein, R.C., Tung, S.M., Ritz-Timme, S. (2010). Aspartic acid racemisation in 
purified elastin from arteries as bases for age estimation. International Journal of Legal 
Medicine 124(4), 269-275. 
Dogde, J.E., Ramsahoye, B.H., Wo, Z.G., Okano, M., Li, E. (2002). De novo 
methylation of MMLV provirus in embryonic stem cells: CpG versus non-CpG 
methylation. Gene 289(1-2), 41-48. 
Dolce, V., Scarcia, P., Iacopetta, D., Palmieri, F. (2005). A fourth ADP/ATP carrier 
isoform in man: identification, bacterial expression, functional characterization and 
tissue distribution. FEBS Letters 579(3), 633-637. 
Donlin, L.T., Danzl, N.M., Wanjalla, C., Alexandropoulos, K. (2005). Deficiency in 
expression of the signaling protein Sin/Efs Leads to T lymphocyte activation and 
mucosal inflammation. Molecular and Cellular Biology 25(24), 11035-11046. 
Dupont, J.M., Tost, J., Jammes, H., Gut, I.G. (2004). De novo quantitative bisulfite 
sequencing using the pyrosequencing technology. Analytical Biochemistry 333(1), 
119-127. 
Eads, C.A., Danenberg, K.D., Kawakami, K., Saltz, L.B., Blake, C., Shibata, D., 
Danenberg, P.V., Laird, P.W. (2000). MethyLight: a high-throughput assay to 
measure DNA methylation. Nucleic Acids Research 28(8), E32. 
Eckhardt, F., Lewin, J., Cortese, R., Rakyan, V.K., Attwood, J., Burger, M., Burton, 
J., Cox, T.V., Davies, R., Down, T.A., Haefliger, C., Horton, R., Howe, K., Jackson, 
D.K., Kunde, J., Koenig, C., Liddle, J., Niblett, D., Otto, T., Pettett, R., Seemann, S., 
Thompson, C., West, T., Rogers, J., Olek, A., Berlin, K., Beck, S. (2006). DNA 
methylation profiling of human chromosomes 6, 20 and 22. Nature Genetics 38(12), 
1378-1385. 
Edlund, H., Allen, M. (2009). Y chromosomal STR analysis using Pyrosequencing 
technology. Forensic Science International: Genetics 3(2), 119-124. 
El Hajj, N., Zechner, U., Schneider, E., Tresch, A., Gromoll, J., Hahn, T., Schorsch, 
M., Haaf, T. (2011). Methylation status of imprinted genes and repetitive elements in 
sperm DNA from infertile males. Sexual Development 5(2), 60-69. 
Espada, J., Esteller, M. (2010). DNA methylation and the functional organization of 
the nuclear compartment. Seminars in Cell & Developmental Biology 21(2), 238-246. 
Essex, M.J., Boyce, W.T., Hertzman, C., Lam, L.L., Armstrong, J.M., Neumann, 
S.M., Kobor, M.S. (2013). Epigenetic vestiges of early developmental adversity: 
childhood stress exposure and DNA methylation in adolescence. Child Development 
84(1), 58-75. 




Fang, R., Manohar, C.F., Shulse, C., Brevnov, M., Wong, A., Petrauskene, O.V., 
Brzoska, P., Furtado, M.R. (2006). Real-time PCR assays for the detection of tissue 
and body fluid specific mRNAs. International Congress Series 1288, 685-687. 
Fernandez-Jimenez, N., Plaza-Izurieta, L., Lopez-Euba, T., Jauregi-Miguel, A., 
Ramon Bilbao, J. (2012). Cubic regression-based degree of correction predicts the 
performance of whole bisulfitome amplified DNA methylation analysis. Epigenetics 
7(12), 1349-1354. 
Fernandez, A.F., Huidobro, C., Fraga, M.F. (2012). De novo DNA 
methyltransferases: oncogenes, tumor suppressors, or both? Trends in genetics 28(10), 
474-479. 
Fleming, R.I., Harbison, S. (2010a). The development of a mRNA multiplex RT-
PCR assay for the definitive identification of body fluids. Forensic Science 
International: Genetics 4(4), 244-256. 
Fleming, R.I., Harbison, S. (2010b). The use of bacteria for the identification of 
vaginal secretions. Forensic Science International: Genetics 4(5), 311-315. 
Fraga, M.F., Ballestar, E., Paz, M.F., Ropero, S., Setien, F., Ballestar, M.L., Heine-
Suñer, D., Cigudosa, J.C., Urioste, M., Benitez, J., Boix-Chornet, M., Sanchez-
Aguilera, A., Ling, C., Carlsson, E., Poulsen, P., Vaag, A., Stephan, Z., Spector, T.D., 
Wu, Y.Z., Plass, C., Esteller, M. (2005). Epigenetic differences arise during the 
lifetime of monozygotic twins. Proceedings of the National Academy of Sciences of the 
U.S.A. 102(30), 10604-10609. 
Fraga, M.F., Esteller, M. (2002). DNA methylation: A profile of methods and 
applications. BioTechniques 33, 632-649. 
Fragou, D., Fragou, A., Kouidou, S., Njau, S., Kovatsi, L. (2011). Epigenetic 
mechanisms in metal toxicity. Toxicology Mechanisms and Methods 21(4), 343-352. 
Fraser, I.S., McCarron, G., Markham, R., Resta, T. (1985). Blood and total fluid 
content of menstrual discharge. Obstetrics and gynecology 65(2), 194-198. 
Frazão, C., McVey, C.E., Amblar, M., Barbas, A., Vonrhein, C., Arraiano, C.M., 
Carrondo, M.A. (2006). Unravelling the dynamics of RNA degradation by 
ribonuclease II and its RNA-bound complex. Nature  443(7107), 110-114. 
Frumkin, D., Wasserstrom, A., Budowle, B., Davidson, A. (2011). DNA methylation-
based forensic tissue identification. Forensic Science International: Genetics 5(5), 517-
524. 
Frumkin, D., Wasserstrom, A., Davidson, A., Grafit, A. (2010). Authentication of 
forensic DNA samples. Forensic Science International: Genetics 4(2), 95-103. 
Fujimoto, S., Uratsuji, H., Saeki, H., Kagami, S., Tsunemi, Y., Komine, M., Tamaki, 
K. (2008). CCR4 and CCR10 are expressed on epidermal keratinocytes and are 
involved in cutaneous immune reaction. Cytokine 44(1), 172-178. 
[341] 
 
Garagnani, P., Bacalini, M.G., Pirazzini, C., Gori, D., Giuliani, C., Mari, D., Di 
Blasio, A.M., Gentilini, D., Vitale, G., Collino, S., Rezzi, S., Castellani, G., Capri, M., 
Salvioli, S., Franceschi, C. (2012). Methylation of ELOVL2 gene as a new epigenetic 
marker of age. Aging Cell 11(6), 1132-1134. 
Gentilini, D., Mari, D., Castaldi, D., Remondini, D., Ogliari, G., Ostan, R., Bucci, L., 
Sirchia, S.M., Tabano, S., Cavagnini, F., Monti, D., Franceschi, C., Di Blasio, A.M., 
Vitale, G. (2013). Role of epigenetics in human aging and longevity: genome-wide 
DNA methylation profile in centenarians and centenarians' offspring. Age (Dordrecht, 
Netherlands) 35(5), 1961-1973. 
Gentry, L.E., Thacker, M.A., Doughty, R., Timkovich, R., Busenlehner, L.S. (2013). 
His86 from the N-terminus of frataxin coordinates iron and is required for Fe-S cluster 
synthesis. Biochemistry 52(35), 6085-6096. 
Giampaoli, S., Berti, A., Valeriani, F., Gianfranceschi, G., Piccolella, A., Buggiotti, L., 
Rapone, C., Valentini, A., Ripani, L., Romano Spica, V. (2012). Molecular 
identification of vaginal fluid by microbial signature. Forensic Science International: 
Genetics 6(5), 559-564. 
Gibbs, S., Fijneman, R., Wiegant, J., van Kessel, A.G., van De Putte, P., Backendorf, 
C. (1993). Molecular characterisation and evolution of the SPRR family of 
keratinocyte differentiation markers encoding small proline-rich proteins. Genomics 
16(3), 630-637. 
Gilder, J., Koppl, R., Kornfield, I., Krane, D., Mueller, L., Thompson, W. (2009). 
Comments on the review of low copy number testing. International Journal of Legal 
Medicine 123, 535-536. 
Gipson, I.K., Ho, S.B., Spurr-Michaud, S.J., Tisdale, A.S., Zhan, Q., Torlakovic, E., 
Pudney, J., Anderson, D.J., Toribara, N.W., Hill, J.A. 3rd. (1997). Mucin genes 
expressed by human female reproductive tract epithelia. Biology of reproduction 56(4), 
999-1011. 
Glass, D., Vinuela, A., Davies, M.N., Ramasamy, A., Parts, L., Knowles, D., Brown, 
A.A., Hedman, A.K., Small, K.S., Buil, A., Grundberg, E., Nica, A.C., Di Meglio, P., 
Nestle, F.O., Ryten, M., UK Brain Expression consortium, MuTHER consortium, 
Durbin, R., McCarthy, M.I., Deloukas, P., Dermitzakis, E.T., Weale, M.E., Bataille, 
V., Spector, T.D. (2013). Gene expression changes with age in skin, adipose tissue, 
blood and brain. Genome Biology 14(7), R75. 
Goffin, F., Munaut, C., Frankenne, F., Perrier D'Hauterive, S., Beliard, A., Fridman, 
V., Nervo, P., Colige, A., Foidart, J.M. (2003). Expression pattern of 
metalloproteinases and tissue inhibitors of matrix-metalloproteinases in cycling human 
endometrium. Biology of reproduction 69(3), 976-984. 
Gomes, I., Kohlmeier, F., Schneider, P.M. (2011). Genetic markers for body fluid and 
tissue identification in forensics. Forensic Science International: Genetics Supplement 
Series 3(1), e469-e470. 
[342] 
 
Gomes, I., Strohbücker, B., Rothschild, M.A., Schneider, P.M. (2013). Evaluation of 
mRNA specific markers using a pentaplex system for the identification of skin and 
saliva from contact trace evidence. Forensic Science International: Genetics Supplement 
Series 4(1), e180-e181. 
Gonzalgo, M.L., Jones, P.A. (2002). Quantitative methylation analysis using 
methylation-sensitive single-nucleotide primer extension (Ms-SNuPE). Methods  
27(2), 128-133. 
Gray, D., Frascione, N., Daniel, B. (2012). Development of an immunoassay for the 
differentiation of menstrual blood from peripheral blood. Forensic Science International 
220(1-3), 12-18. 
Grönniger, E., Weber, B., Heil, O., Peters, N., Stäb, F., Wenck, H., Korn, B., 
Winnefeld, M., Lyko, F. (2010). Aging and chronic sun exposure cause distinct 
epigenetic changes in human skin. PLoS Genetics 6(5), e1000971. 
Gubin, A.N., Miller, J.L. (2001). Human erythroid porphobilinogen deaminase exists 
in 2 splice variants. Blood 97(3), 815-817. 
Guo, J.H., Maltha, J.C., He, S.G., Krapels, I.P., Spauwen, P.H., Steegers-Theunissen, 
R.P., Von den Hoff, J.W. (2006). Cytokeratin expression in palatal and marginal 
mucosa of cleft palate patients. Archives of oral biology 51(7), 573-580. 
Haas, C., Hanson, E., Anjos, M.J., Ballantyne, K.N., Banemann, R., Bhoelai, B., 
Borges, E., Carvalho, M., Courts, C., De Cock, G., Drobnic, K., Dötsch, M., Fleming, 
R., Franchi, C., Gomes, I., Hadzic, G., Harbison, S.A., Harteveld, J., Hjort, B., 
Hollard, C., Hoff-Olsen, P., Hüls, C., Keyser, C., Maroñas, O., McCallum, N., 
Moore, D., Morling, N., Niederstätter, H., Noël, F., Parson, W., Phillips, C., 
Popielarz, C., Roeder, A.D., Salvaderi, L., Sauer, E., Schneider, P.M., Shanthan, G., 
Syndercombe Court, D., Turanská, M., van Oorschot, R.A., Vennemann, M., Vidaki, 
A., Zatkalíková, L., Ballantyne, J. (2014). RNA/DNA co-analysis from human 
menstrual blood and vaginal secretion stains: Results of a fourth and fifth collaborative 
EDNAP exercise. Forensic Science International: Genetics 8(1), 203-212. 
Haas, C., Hanson, E., Anjos, M.J., Banemann, R., Berti, A., Borges, E., Carracedo, A., 
Carvalho, M., Courts, C., De Cock, G., Dötsch, M., Flynn, S., Gomes, I., Hollard, C., 
Hjort, B., Hoff-Olsen, P., Hríbiková, K., Lindenbergh, A., Ludes, B., Maroñas, O., 
McCallum, N., Moore, D., Morling, N., Niederstätter, H., Noel, F., Parson, W., 
Popielarz, C., Rapone, C., Roeder, A.D., Ruiz, Y., Sauer, E., Schneider, P.M., Sijen, 
T., Syndercombe Court, D., Sviežená, B., Turanská, M., Vidaki, A., Zatkalíková, L., 
Ballantyne, J. (2013a). RNA/DNA co-analysis from human saliva and semen stains--
results of a third collaborative EDNAP exercise. Forensic Science International: 






Haas, C., Hanson, E., Anjos, M.J., Bar, W., Banemann, R., Berti, A., Borges, E., 
Bouakaze, C., Carracedo, A., Carvalho, M., Castella, V., Choma, A., De Cock, G., 
Dötsch, M., Hoff-Olsen, P., Johansen, P., Kohlmeier, F., Lindenbergh, P.A., Ludes, 
B., Maroñas, O., Moore, D., Morerod, M.L., Morling, N., Niederstätter, H., Noel, F., 
Parson, W., Patel, G., Popielarz, C., Salata, E., Schneider, P.M., Sijen, T., Sviežena, 
B., Turanská, M., Zatkalíková, L., Ballantyne, J. (2012). RNA/DNA co-analysis from 
blood stains: results of a second collaborative EDNAP exercise. Forensic Science 
International: Genetics 6(1), 70-80. 
Haas, C., Hanson, E., Ballantyne, J. (2013b). mRNA and MicroRNA for Body Fluid 
Identification, Encyclopedia of Forensic Sciences, 2nd edition, pp. 402-408. 
Haas, C., Hanson, E., Banemann, R., Bento, A.M., Berti, A., Carracedo, A., Courts, 
C., De Cock, G., Drobnic, K., Fleming, R., Franchi, C., Gomes, I., Hadzic, G., 
Harbison, S.A., Hjort, B., Hollard, C., Hoff-Olsen, P., Keyser, C., Kondili, A., 
Maroñas, O., McCallum, N., Miniati, P., Morling, N., Niederstätter, H., Noël, F., 
Parson, W., Porto, M.J., Roeder, A.D., Sauer, E., Schneider, P.M., Shanthan, G., 
Sijen, T., Syndercombe Court, D., Turanská, M., van den Berge, M., Vennemann, 
M., Vidaki, A., Zatkalíková, L., Ballantyne, J. (2015). RNA/DNA co-analysis from 
human skin and contact traces - results of a sixth collaborative EDNAP exercise. 
Forensic Science International: Genetics 16, 139-147. 
Haas, C., Hanson, E., Bär, W., Banemann, R., Bento, A. M., Berti, A., Borges, E., 
Bouakaze, C., Carracedo, A., Carvalho, M., Choma, A., Dötsch, M., Durianciková, 
M., Hoff-Olsen, P., Hohoff, C., Johansen, P., Lindenbergh, P.A., Loddenkötter, B., 
Ludes, B., Maroñas, O., Morling, N., Niederstätter, H., Parson, W., Patel, G., 
Popielarz, C., Salata, E., Schneider, P.M., Sijen, T., Sviezená, B., Zatkalíková, L., 
Ballantyne, J. (2011a). mRNA profiling for the identification of blood--results of a 
collaborative EDNAP exercise. Forensic Science International: Genetics 5(1), 21-26. 
Haas, C., Hanson, E., Kratzer, A., Bär, W., Ballantyne, J. (2011b). Selection of highly 
specific and sensitive mRNA biomarkers for the identification of blood. Forensic 
Science International: Genetics 5(5), 449-458. 
Haas, C., Klesser, B., Maake, C., Bär, W., Kratzer, A. (2009a). mRNA profiling for 
body fluid identification by reverse transcription endpoint PCR and realtime PCR. 
Forensic Science International: Genetics 3(2), 80-88. 
Haas, C., Muheim, C., Kratzer, A., Bär, W., Maake, C. (2009b). mRNA profiling for 
the identification of sperm and seminal plasma. Forensic Science International: Genetics 
Supplement Series 2(1), 534-535. 
Hajibabaei, M., Shokralla, S., Zhou, X., Singer, G.A., Baird, D.J. (2011). 
Environmental barcoding: a next-generation sequencing approach for biomonitoring 
applications using river benthos. PLoS One 6(4), e17497. 
Hammoud, S.S., Purwar, J., Pflueger, C., Cairns, B.R., Carrell, D.T. (2010). 
Alterations in sperm DNA methylation patterns at imprinted loci in two classes of 
infertility. Fertility and sterility 94(5), 1728-1733. 
[344] 
 
Han, X., Chesney, R.W. (2003). Regulation of taurine transporter gene (TauT) by 
WT1. FEBS Letters 540(1-3), 71-76. 
Han, X., Patters, A.B., Jones, D.P., Zelikovic, I., Chesney, R.W. (2006). The taurine 
transporter: mechanisms of regulation. Acta physiologica (Oxford, England) 187(1-2), 
61-73. 
Hannum, G., Guinney, J., Zhao, L., Zhang, L., Hughes, G., Sadda, S., Klotzle, B., 
Bibikova, M., Fan, J.B., Gao, Y., Deconde, R., Chen, M., Rajapakse, I., Friend, S., 
Ideker, T., Zhang, K. (2013). Genome-wide methylation profiles reveal quantitative 
views of human aging rates. Molecular Cell 49(2), 359-367. 
Hanson, E., Haas, C., Jucker, R., Ballantyne, J. (2011). Identification of skin in 
touch/contact forensic samples by messenger RNA profiling. Forensic Science 
International: Genetics Supplement Series 3(1), e305-e306. 
Hanson, E., Haas, C., Jucker, R., Ballantyne, J. (2012). Specific and sensitive mRNA 
biomarkers for the identification of skin in 'touch DNA' evidence. Forensic Science 
International: Genetics 6(5), 548-558. 
Hanson, E.K., Ballantyne, J. (2013a). Highly specific mRNA biomarkers for the 
identification of vaginal secretions in sexual assault investigations. Science & Justice 
53(1), 14-22. 
Hanson, E.K., Ballantyne, J. (2013b). Multiplex high resolution melt (HRM) 
messenger RNA profiling assays for body fluid identification. Forensic Science 
International: Genetics Supplement Series 4(1), e125-e126. 
Harteveld, J., Lindenbergh, A., Sijen, T. (2013). RNA cell typing and DNA profiling 
of mixed samples: can cell types and donors be associated? Science & Justice 53(3), 
261-269. 
Herman, J.G., Graff, J.R., Myohanen, S., Nelkin, B.D., Baylin, S.B. (1996). 
Methylation-specific PCR: A novel PCR assay for methylation status of CpG islands. 
Proceedings of the National Academy of Sciences of the U.S.A. 93(18), 9821-9826. 
Heyn, H., Li, N., Ferreira, H.J., Moran, S., Pisano, D.G., Gomez, A., Diez, J., 
Sanchez-Mut, J.V., Setien, F., Carmona, F.J., Puca, A.A., Sayols, S., Pujana, M.A., 
Serra-Musach, J., Iglesias-Platas, I., Formiga, F., Fernandez, A.F., Fraga, M.F., 
Heath, S.C., Valencia, A., Gut, I.G., Wang, J., Esteller, M. (2012). Distinct DNA 
methylomes of newborns and centenarians. Proceedings of the National Academy of 
Sciences of the U.S.A. 109(26), 10522-10527. 
Horvath, S. (2013). DNA methylation age of human tissues and cell types. Genome 
Biology 14(10), R115. 
Horvath, S., Zhang, Y., Langfelder, P., Kahn, R. S., Boks, M. P., van Eijk, K., van 
den Berg, L.H., Ophoff, R.A. (2012). Aging effects on DNA methylation modules in 
human brain and blood tissue. Genome Biology 13(10), R97. 
[345] 
 
Hsu, C.C., Leu, Y.W., Tseng, M.J., Lee, K.D., Kuo, T.Y., Yen, J.Y., Lai, Y.L., Hung, 
Y.C., Sun, W.S., Chen, C.M., Chu, P.Y., Yeh, K.T., Yan, P.S., Chang, Y.S., Huang, 
T.H., Hsiao, S.H. (2011). Functional characterization of Trip10 in cancer cell growth 
and survival. Journal of Biomedical Science 18, 12. 
Human Tissue Act (HTA) (2014). Code of practice 1 - Consent (H. T. Authority, 
Ed.). 
Hua, D., Hu, Y., Wu, Y.Y., Cheng, Z.H., Yu, J., Du, X., Huang, Z.H. (2011). 
Quantitative methylation analysis of multiple genes using methylation-sensitive 
restriction enzyme-based quantitative PCR for the detection of hepatocellular 
carcinoma. Experimental and molecular pathology 91(1), 455-460. 
Huang, D., Lin, X., Chen, H., Yang, Q., Jie, Y., Zhai, X., Yin, H. (2008). Parentally 
imprinted allele (PIA) typing in the differentially methylated region upstream of the 
human H19 gene. Forensic Science International: Genetics 2(4), 286-291. 
Huang, J.T., Leweke, F.M., Oxley, D., Wang, L., Harris, N., Koethe, D., Gerth, 
C.W., Nolden, B.M., Gross, S., Schreiber, D., Reed, B., Bahn, S. (2006). Disease 
biomarkers in cerebrospinal fluid of patients with first-onset psychosis. PLoS Medicine 
3(11), e428. 
Hurd, P.J., Nelson, C.J. (2009). Advantages of next-generation sequencing versus the 
microarray in epigenetic research. Briefings in Functional Genomics & Proteomics 8(3), 
174-183. 
Illingworth, R., Kerr, A., DeSousa, D., Jorgensen, H., Ellis, P., Stalker, J., Jackson, D., 
Clee, C., Plumb, R., Rogers, J., Humphray, S., Cox, T., Langford, C., Bird, A. (2008). 
A novel CpG island set identifies tissue-specific methylation at developmental gene 
loci. PloS Biology 6(1), e22. 
Illumina (2013a). An Introduction to Next-Generation Sequencing Technology. 
Illumina (2013b). MiSeq System User Guide. 
Invitrogen (2010). Qubit dsDNA HS Assay kits. 
Invitrogen (2013). Superscript III FirstStrand Synthesis system for RT-PCR. 
Ishikawa, N., Hara, J., Takasaka, T., Kobayashi, M., Yoshimoto, K., Ikegaya, H. 
(2011). Age estimation using cytochrome c oxidase activity analysis. Forensic Science 
International 209(1-3), 48-52. 
Ishino, M., Ohba, T., Inazawa, J., Sasaki, H., Ariyama, Y., Sasaki, T. (1997). 
Identification of an Efs isoform that lacks the SH3 domain and chromosomal mapping 
of human Efs. Oncogene 15(14), 1741-1745. 
Jacinto, F.V., Ballestar, E., Esteller, M. (2008). Methyl-DNA immunoprecipitation 




Jackson, B., Tilli, C.M., Hardman, M.J., Avillion, A.A., MacLeod, M.C., Ashcroft, 
G.S., Byrne, C. (2005). Late cornified envelope family in differentiating epithelia-
response to calcium and untraviolet irradiation. The Journal of Investigative 
Dermatology 124(5), 1062-1070. 
Jakubowska, J., Maciejewska, A., Pawlowski, R., Bielawski, K.P. (2013). mRNA 
profiling for vaginal fluid and menstrual blood identification. Forensic Science 
International: Genetics 7(2), 272-278. 
Jiang, H., Ju, Z., Rudoplh, K.L. (2007). Telomere shortening and ageing. Journal of 
Gerontology and Geriatry 40(5), 314-324. 
Johansson, A., Enroth, S., Gyllensten, U. (2013). Continuous Aging of the Human 
DNA Methylome Throughout the Human Lifespan. PLoS One 8(6), e67378. 
Jones Jr., E.L. (2005). The identification of semen and other body fluids. Forensic 
Science Handbook, pp. 329-382. Prentice Hall, Upper Saddle River, NJ. 
Jones, M.J., Farre, P., McEwen, L.M., Maclsaac, J.L., Watt, K., Neumann, S.M., 
Emberly, E., Cynader, M.S., Virji-Babul, N., Kobor, M.S. (2013). Distinct DNA 
methylation patterns of cognitive impairment and trisomy 21 in down syndrome. BMC 
Medical Genomics 6, 58. 
Jumpertz, R., Hanson, R.L., Sievers, M.L., Bennett, P.H., Nelson, R.G., Krakoff, J. 
(2011). Higher energy expenditure in humans predicts natural mortality. The Journal 
of Clinical Endocrinology and Metabolism 96(6), E972-E976. 
Juusola, J., Ballantyne, J. (2003). Messenger RNA profiling: a prototype method to 
supplant conventional methods for body fluid identification. Forensic Science 
International 135(2), 85-96. 
Juusola, J., Ballantyne, J. (2005). Multiplex mRNA profiling for the identification of 
body fluids. Forensic Science International 152(1), 1-12. 
Kalinin, A., Marekov, L.N., Steinert, P.M. (2001). Assembly of the epidermal 
cornified cell envelope. Journal of Cell Science 114(17), 3069-3070. 
KAPA Biosystems (2014). KAPA Library Quantification Kits for Illumina sequencing 
platforms. 
Kendall Harden, T., Boyer, J.L., Nicholas, R.A. (1995). P2-Purinergic receptors: 
subtype-associated signaling responses and structure Annual Review of Pharmacoloogy 
and Toxicology 35, 541-579. 
Kobus, H.J., Silenieks, E., Scharnberg, J. (2002). Improving the effectiveness of 
fluorescence for the detection of semen stains on fabrics. Journal of Forensic Sciences 
47(4), 819-823. 
Koch, C.M., Joussen, S., Schellenberg, A., Lin, Q., Zenke, M., Wagner, W. (2012). 
Monitoring of cellular senescence by DNA-methylation at specific CpG sites. Aging 
Cell 11(2), 366-369. 
[347] 
 
Koch, C.M., Suschek, C.V., Lin, Q., Bork, S., Goergens, M., Joussen, S., Pallua, N., 
Ho, A.D., Zenke, M., Wagner, W. (2011). Specific age-associated DNA methylation 
changes in human dermal fibroblasts. PLoS One 6(2), e16679. 
Koch, C.M., Wagner, W. (2011). Epigenetic-aging-signature to determine age in 
different tissues. Aging (Albany NY) 3(10), 1018-1027. 
Kohlmeier, F., Schneider, P.M. (2012). Successful mRNA profiling of 23 years old 
blood stains. Forensic Science International: Genetics 6(2), 274-276. 
Kovatsi, L., Georgiou, E., Ioannou, A., Haitoglou, C., Tzimagiorgis, G., Tsoukali, H., 
Kouidou, S. (2010). p16 promoter methylation in Pb2+ -exposed individuals. Clinical 
Toxicology (Philadelphia) 48(2), 124-128. 
Laaksonen, M., Kaliste-Korhonen, E., Karenlampi, S., Hanninen, O. (1995). P450 
enzyme CYP2B catalyses the detoxification of diisopropyl fluorophosphate. Chemico-
Biological Interactions 94(3), 197-213. 
Lackner, J.E., Herwig, R., Schmidbauer, J., Schatzl, G., Kratzik, C., Marberger, M. 
(2006). Correlation of leukocytospermia with clinical infection and the positive effect 
of antiinflammatory treatment on semen quality. Fertility and Sterility 86(3), 601-605. 
LaRue, B.L., King, J.L., Budowle, B. (2013). A validation study of the Nucleix DSI-
Semen kit--a methylation-based assay for semen identification. International Journal 
of Legal Medicine 127(2), 299-308. 
Lasken, R.S., Egholm, M. (2003). Whole genome amplification: abundant supplies of 
DNA from precious samples or clinical specimens. Trends in Biotechnology 21(12), 
531-535. 
Lawton, K.A., Berger, A., Mitchell, M., Milgram, K.E., Evans, A.M., Guo, L., 
Hanson, R.W., Kalhan, S.C., Ryals, J.A., Milburn, M.V. (2008). Analysis of the adult 
human plasma metabolome. Pharmacogenomics 9(4), 383-397. 
Lee, H.Y., Park, M.J., Choi, A., An, J.H., Yang, W.I., Shin, K.J. (2012a). Potential 
forensic application of DNA methylation profiling to body fluid identification. 
International Journal of Legal Medicine 126(1), 55-62. 
Lee, K.W., Pausova, Z. (2013). Cigarette smoking and DNA methylation. Frontiers in 
Genetics 4, 132. 
Lee, P.Y., Costumbrado, J., Hsu, C.Y., Kim, Y.H. (2012b). Agarose gel 
electrophoresis for the separation of DNA fragments. Journal of Visualised Experiments 
Apr 20, 62. 
Levings, P.P., Bungert, J. (2002). The human β-globin locus control region. European 
Journal of Biochemistry 269(6), 1589-1599. 
Li, C., Zhang, S., Que, T., Li, L., Zhao, S. (2011). Identical but not the same: The 
value of DNA methylation profiling in forensic discrimination within monozygotic 
twins. Forensic Science International: Genetics Supplement Series 3(1), e337-e338. 
[348] 
 
Li, C., Zhao, S., Zhang, N., Zhang, S., Hou, Y. (2013). Differences of DNA 
methylation profiles between monozygotic twins' blood samples. Molecular Biology 
Reports 40(9), 5275-5280. 
Li, E., Beard, C., Jaenisch, R. (1993). Role of DNA methylation in genomic 
imprinting. Nature 366(6453), 362-365. 
Li, H., Durbin, R. (2010). Fast and accurate long-read alignment with Burrows-
Wheeler Transform. Bioinformatics 26(5), 589-595. 
Li, H., Handsaker, B., Wysoker, A., Fennel, T., Ruan, J., Homer, N., Marth, G., 
Abecasis, G., Durbin, R., 1000 Genome Project Data Processing Subgroup. (2009). 
The Sequence Alignment/Map format and SAMtools. Bioinformatics 25(16), 2078-
2079. 
Li, S.X., Liu, L.J., Jiang, W.G., Sun, L.L., Zhou, S.J., Le Foll, B., Zhang, X.Y., 
Kosten, T.R., Lu, L. (2010). Circadian alteration in neurobiology during protracted 
opiate withdrawal in rats. Journal of Neurochemistry 115(2), 353-362. 
Liang, Q., Liu, L., Peng, J., Sun, Z., Jiang, S. (2008). Determination and Difference 
Analysis of DNA Methylation Content Both in Blood and Muscle Tissue of Pigs. 
Agricultural Sciences in China 7(8), 1010-1015. 
Life Technologies (2014). DNA Fragment Analysis by Capillary Electrophoresis. 
Lindenbergh, A., de Pagter, M., Ramdayal, G., Visser, M., Zubakov, D., Kayser, M., 
Sijen, T. (2012). A multiplex (m)RNA-profiling system for the forensic identification 
of body fluids and contact traces. Forensic Science International: Genetics 6(5), 565-
577. 
Lindenbergh, A., Maaskant, P., Sijen, T. (2013). Implementation of RNA profiling in 
forensic casework. Forensic Science International: Genetics 7(1), 159-166. 
Liu, B., Lague, J.R., Nunes, D.P., Toseli, P., Oppenheim, F.G., Soares, R.V., Troxler, 
R.F., Offner, G.D. (2002). Expression of membrane-associated mucins MUC1 and 
MUC4 in major human salivary glands. The Journal of Histochemistry and 
Cytochemistry 50(6), 811-820. 
Liu, J., Morgan, M., Hutchison, K., Calhoun, V.D. (2010). A study of the influence of 
sex on genome wide methylation. PLoS One 5(4), e10028. 
Lowe, A., Murray, C., Whitaker, J., Tully, G., Gill, P. (2002). The propensity of 
individuals to deposit DNA and secondary transfer of low level DNA from individuals 
to inert surfaces. Forensic Science International  129(1), 25-34. 
Lowenson, J., Clarke, S. (1988). Does the chemical instability of aspartyl and 
asparaginyl residues in proteins contribute to erythrocyte aging? The role of protein 
carboxyl methylation reactions. Blood Cells 14(1), 103-118. 
Lu, S., Davies, P.J. (1997). Regulation of the expression of the tissue transglutaminase 




Lu, T., Pan, Y., Kao, S.Y., Li, C., Kohane, I., Chan, J., Yankner, B.A. (2004). Gene 
regulation and DNA damage in the ageing human brain. Nature  429, 883-891. 
Lynnerup, N., Kjeldsen, H., Zweihoff, R., Heegaard, S., Jacobsen, C., Heinemeier, J. 
(2010). Ascertaining year of birth/age at death in forensic cases: A review of 
conventional methods and methods allowing for absolute chronology. Forensic Science 
International 201(1-3), 74-78. 
Ma, L.L., Yi, S.H., Huang, D.X., Mei, K., Yang, R.Z. (2013). Screening and 
identification of tissue-specific methylation for body fluid identification. Forensic 
Science International: Genetics Supplement Series 4(1), e37-e38. 
Macfarlan, T., Parker, J.B., Nagata, K., Chakravarti, D. (2006). Thanatos-associated 
protein 7 associates with template activating factor-Ibeta and inhibits histone 
acetylation to repress transcription. Molecular Endocrinology 20(2), 335-347. 
Madi, T., Balamurugan, K., Bombardi, R., Duncan, G., McCord, B. (2012). The 
determination of tissue-specific DNA methylation patterns in forensic biofluids using 
bisulfite modification and pyrosequencing. Electrophoresis 33(12), 1736-1745. 
Maeda, H., Ishikawa, T., Michiue, T. (2011). Forensic biochemistry for functional 
investigation of death: concept and practical application. Legal Medicine (Tokyo) 13(2), 
55-67. 
Maeda, H., Zhu, B.L., Ishikawa, T., Michiue, T. (2010). Forensic molecular 
pathology of violent deaths. Forensic Science International 203(1-3), 83-92. 
Maia, M., de Vriese, A., Janssens, T., Moons, M., van Landuyt, K., Tavernier, J., 
Lories, R.J., Conway, E.M. (2010). CD248 and its cytoplasmic domain: a therapeutic 
target for arthritis. Arthritis and Rheumatism 62(12), 3595-3606. 
Manabe, F., Tsutsumi, A., Yamamoto, Y., Hashimoto, Y., Ishizu, H. (1991). 
Identification of human semen by a chemiluminescent assay of choline. Japanese 
Journal of Legal Medicine 45(3), 205-215. 
Mandavilli, B.S., Santos, J.H., van Houten, B. (2002). Mitochondrial DNA repair and 
aging. Mutation Research 509(1-2), 127-151. 
Martin-de las Heras, S., Valenzuela, A., Villanueva, E. (1999). Deoxypyridinoline 
crosslinks in human dentin and estimation of age. International Journal of Legal 








Martin-Subero, J.I., Kreuz, M., Bibikova, M., Bentink, S., Ammerpohl, O., 
Wickham-Garcia, E., Rosolowski, M., Richter, J., Lopez-Serra, L., Ballestar, E., 
Berger, H., Agirre, X., Bernd, H.W., Calvanese, V., Cogliatti, S.B., Drexler, H.G., 
Fan, J.B., Fraga, M.F., Hansmann, M.L., Hummel, M., Klapper, W., Korn, B., 
Küppers, R., Macleod, R.A., Möller, P., Ott, G., Pott, C., Prosper, F., Rosenwald, A., 
Schwaenen, C., Schübeler, D., Seifert, M., Stürzenhofecker, B., Weber, M., 
Wessendorf, S., Loeffler, M., Trümper, L., Stein, H., Spang, R., Esteller, M., Barker, 
D., Hasenclever, D., Siebert, R., Molecular Mechanisms in Malignant Lymphomas 
Network Project of the Deutsche Krebshilfe. (2009). New insights into the biology 
and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, 
and transcriptional profiling. Blood 113(11), 2488-2497. 
Martin, N.C., Clayson, N.J., Scrimger, D.G. (2006). The sensitivity and specificity of 
red-starch paper for the detection of saliva. Science & Justice 46(2), 97-105. 
Martino, D., Loke, Y.J., Gordon, L., Ollikainen, M., Cruickshank, M.N., Saffery, R., 
Craig, J.M. (2013). Longitudinal, genome-scale analysis of DNA methylation in twins 
from birth to 18 months of age reveals rapid epigenetic change in early life and pair-
specific effects of discordance. Genome Biology 14(5), R42. 
Masser, D.R., Berg, A.S., Freeman, W.M. (2013). Focused, high accuracy 5-
methylcytosine quantitation with base resolution by benchtop next-generation 
sequencing. Epigenetics & Chromatin 6(1), 33. 
Matheson, C.D., Veall, M.A. (2014). Presumptive blood test using Hemastix® with 
EDTA in archaeology. Journal of Archaeological Science 41, 230-241. 
McKenna, A., Hanna, M., Banks, E., Sivanchenko, A., Cibulskis, K., Kernytsky, A., 
Garimella, K., Altschuler, D., Gabriel, S., Daly, M., DePristo, M.A. (2010). The 
Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation 
DNA sequencing data. Genome Research 20(9), 1297-1303. 
Meissner, C., Bruse, P., Oehmichen, M. (2006). Tissue-specific deletion patterns of 
the mitochondrial genome with advancing age. Experimental Gerontology 41(5), 518-
524. 
Meissner, C., Ritz-Timme, S. (2010). Molecular pathology and age estimation. 
Forensic Science International 203(1-3), 34-43. 
Meissner, C., von Wurmb, N., Oehmichen, M. (1997). Detection of the age-
dependent 4977 bp deletion of mitochondrial DNA. A pilot study. International 
Journal of Legal Medicine 110(5), 288-291. 
Meissner, C., von Wurmb, N., Schimansky, B., Oehmichen, M. (1999). Estimation of 
age at death based on quantitation of the 4977-bp deletion of human mitochondrial 





Menni, C., Kastenmuller, G., Petersen, A.K., Bell, J.T., Psatha, M., Tsai, P.C., 
Gieger, C., Schulz, H., Erte, I., John, S., Brosnan, M.J., Wilson, S.G., Tsaprouni, L., 
Lim, E.M., Stuckey, B., Deloukas, P., Mohney, R., Suhre, K., Spector, T.D., Valdes, 
A.M. (2013). Metabolomic markers reveal novel pathways of ageing and early 
development in human populations. International Journal of Epidemiology 42(4), 1111-
1119. 
Mohamed, S.A., Wesch, D., Blumenthal, A., Bruse, P., Windler, K., Ernst, M., 
Kabelitz, D., Oehmichen, M., Meissner, C. (2004). Detection of the 4977 bp deletion 
of mitochondrial DNA in different human blood cells. Experimental Gerontology 39(2), 
181-188. 
Moreno, L.I., Tate, C.M., Knott, E.L., McDaniel, J.E., Rogers, S.S., Koons, B.W., 
Kavlick, M.F., Craig, R.L., Robertson, J.M. (2012). Determination of an effective 
housekeeping gene for the quantification of mRNA for forensic applications. Journal of 
Forensic Sciences 57(4), 1051-1058. 
Moskalev, E.A., Zavgorodnij, M.G., Majorova, S.P., Vorobjev, I.A., Jandaghi, P., 
Bure, I.V., Hoheisel, J.D. (2011). Correction of PCR-bias in quantitative DNA 
methylation studies by means of cubic polynomial regression. Nucleic Acids Research 
39(11), e77. 
Naito, E., Dewa, K., Fukuda, M., Sumi, H., Wakabayashi, Y., Umetsu, K., Yuasa, I., 
Yamanouchi, H. (2003). Novel paternity testing by distinguishing parental alleles at a 
VNTR locus in the differentially methylated region upstream of the human H19 gene. 
Journal of Forensic Sciences 48(6), 1275-1279. 
Naito, E., Dewa, K., Yamanouchi, H., Takagi, S., Kominami, R. (1993). Sex 
determination using the hypomethylation of a human macro-satellite DXZ4 in female 
cells. Nucleic Acids Research 21(10), 2533-2534. 
Nakatome, M., Orii, M., Hamajima, M., Hirata, Y., Uemura, M., Hirayama, S., Isobe, 
I. (2011). Methylation analysis of circadian clock gene promoters in forensic autopsy 
specimens. Legal Medicine (Tokyo) 13(4), 205-209. 
Nakayashiki, N., Takamiya, M., Shimamoto, K., Aoki, Y. (2009a). Analysis of the 
methylation profiles in imprinted genes applicable to parental allele discrimination. 
Legal Medicine (Tokyo) 11 Suppl 1, S471-S472. 
Nakayashiki, N., Takamiya, M., Shimamoto, K., Aoki, Y., Hashiyada, M. (2008). 
Studies on differentially methylated parental allele in imprinted genes. Forensic Science 
International: Genetics Supplement Series 1(1), 572-573. 
Nakayashiki, N., Takamiya, M., Shimamoto, K., Aoki, Y., Hashiyada, M. (2009b). 
Investigation of the methylation status around parent-of-origin detectable SNPs in 
imprinted genes. Forensic Science International: Genetics 3(4), 227-232. 
Nam, H., Whang, K., Lee, Y. (2007). Analysis of vaginal lactic acid producing 
bacteria in healthy women. Journal of Microbiology 45(6), 515-520. 
[352] 
 
National DNA Database Strategy Board (2012-2013). Annual Report (Home Office, 
Ed.), pp. 1-26. 
Neumann, L.C., Weinhausel, A., Thomas, S., Horsthemke, B., Lohmann, D.R., 
Zeschnigk, M. (2011). EFS shows biallelic methylation in uveal melanoma with poor 
prognosis as well as tissue-specific methylation. BMC Cancer 11, 380. 
Newell-Price, J., Clark, A.J., King, P. (2000). DNA methylation and silencing of gene 
expression. Trends in Endocrinology and Metabolism 11(4), 142-148. 
Nold, M.F., Nold-Petry, C.A., Zepp, J.A., Palmer, B.E., Bufler, P., Dinarello, C.A. 
(2010). IL-37 is a fundamental inhibitor of innate immunity. Nature Immunology 11, 
1014-1022. 
Nussbaumer, C., Gharehbaghi-Schnell, E., Korschineck, I. (2006). Messenger RNA 
profiling: a novel method for body fluid identification by real-time PCR. Forensic 
Science International 157(2-3), 181-186. 
Oakeley, E.J. (1999). DNA methylation analysis: A review of current methodologies. 
Pharmacology & Therapeutics 84(3), 389-400. 
Oehmichen, M., Zilles, K. (1984). Postmortem DNA and RNA synthesis. Preliminary 
studies in human cadavers. Zeitschrift für Rechtsmedizin 91(4), 287-294. 
Oh, J.J., Grosshans, D.R., Wong, S.G., Slamon, D.J. (1999). Identification of 
differentially expressed genes associated with HER-2/neu overexpression in human 
breast cancer cells. Nucleic Acids Research 27(20), 4008-4017. 
Ohtani, S., Yamamoto, T. (2010). Age estimation by amino acid racemization in 
human teeth. Journal of Forensic Sciences 55(6), 1630-1633. 
Ong, S.Y., Wain, A., Groombridge, L., Grimes, E. (2012). Forensic identification of 
urine using the DMAC test: a method validation study. Science & Justice 52(2), 90-95. 
Ou, X., Zhao, H., Sun, H., Yang, Z., Xie, B., Shi, Y., Wu, X. (2011). Detection and 
quantification of the age-related sjTREC decline in human peripheral blood. 
International Journal of Legal Medicine 125(4), 603-608. 
Pacheco, S.E., Houseman, E.A., Christensen, B.C., Marsit, C.J., Kelsey, K.T., 
Sigman, M., Boekelheide, K. (2011). Integrative DNA methylation and gene 
expression analyses identify DNA packaging and epigenetic regulatory genes 
associated with low motility sperm. PLoS One 6(6), e20280. 
Paliwal, A., Vaissiere, T., Herceg, Z. (2010). Quantitative detection of DNA 
methylation states in minute amounts of DNA from body fluids. Methods 52(3), 242-
247. 
Park, S.M., Park, S.Y., Kim, J.H., Kang, T.W., Park, J.L., Woo, K.M., Kim, J.S., Lee, 
H.C., Kim, S.Y., Lee, S.H. (2013). Genome-wide mRNA profiling and multiplex 
quantitative RT-PCR for forensic body fluid identification. Forensic Science 
International: Genetics 7(1), 143-150. 
[353] 
 
Parker, C., Hanson, E., Ballantyne, J. (2011). Optimization of dried stain co-
extraction methods for efficient recovery of high quality DNA and RNA for forensic 
analysis. Forensic Science International: Genetics Supplement Series 3(1), e309-e310. 
Parson, W., Strobl, C., Huber, G., Zimmermann, B., Gomes, S.M., Souto, L., Fendt, 
L., Delport, R., Langit, R., Wootton, S., Lagacé, R., Irwin, J. (2013). Evaluation of 
next generation mtGenome sequencing using the Ion Torrent Personal Genome 
Machine (PGM). Forensic Science International: Genetics  7(5), 543-549. 
Partemi, S., Berne, P.M., Batlle, M., Berruezo, A., Mont, L., Riuró, H., Ortiz, J.T., 
Roig, E., Pascali, V.L., Brugada, R., Brugada, J., Oliva, A. (2010). Analysis of mRNA 
from human heart tissue and putative applications in forensic molecular pathology. 
Forensic Science International 203(1-3), 99-105. 
Patel, G., Peel, C. (2008). Identifying the origin of cells. Forensic Science International: 
Genetics Supplement Series 1(1), 574-576. 
Patel, J.L., Goyal, R.K. (2007). Applications of artificial neural networks in medical 
science. Current Clinical Pharmacology 2(3), 217-226. 
Perez, C., Pascual, M., Martin-Subero, J.I., Bellosillo, B., Segura, V., Delabesse, E.,  
Álvarez, S., Larrayoz, M.J., Rifón, J., Cigudosa, J.C., Besses, C., Calasanz, M.J., 
Cross, N.C., Prósper, F., Agirre, X. (2013). Aberrant DNA methylation profile of 
chronic and transformed classic Philadelphia-negative myeloproliferative neoplasms. 
Haematologica 98(9), 1414-1420. 
Phang, T.W., Shi, C.Y., Chia, J.N., Ong, C.N. (1994). Amplification of cDNA via 
RT-PCR using RNA extracted from postmortem tissues. Journal of Forensic Sciences 
39(5), 1275-1279. 
Pilin, A., Pudil, F., Bencko, V. (2007). Changes in colour of different human tissues as 
a marker of age. International Journal of Legal Medicine 121(2), 158-162. 
Plachot, C., Lelievre, S.A. (2004). DNA methylation control of tissue polarity and 
cellular differentiation in the mammary epithelium. Experimental Cell Research 298(1), 
122-132. 
Pogribny, I., Raiche, J., Slovack, M., Kovalchuk, O. (2004). Dose-dependence, sex- 
and tissue-specificity, and persistence of radiation-induced genomic DNA methylation 
changes. Biochemical and Biophysica Research Communications 320(4), 1253-1261. 
Polisecki, E.Y., Schreier, L.E., Ravioli, J., Corach, D. (2004). Common mitochondrial 
DNA deletion associated with sudden natural death in adults. J ournal of Forensic 
Sciences 49(6), 1335-1338. 
Price, E.M., Cotton, A.M., Lam, L.L., Farre, P., Emberly, E., Brown, C.J., Robinson, 
W.P., Kobor, M.S. (2013). Additional annotation enhances potential for biologically-
relevant analysis of the Illumina Infinium HumanMethylation450 BeadChip array. 
Epigenetics & Chromatin 6(1), 4. 
[354] 
 
Prinz, M., Tang, Y., Siegel, D., Yang, H., Zhou, B., Deng, H. (2011). Establishment 
of a fast and accurate proteomic method for body fluid cell type identification (U.S. 
Department of Justice, Ed.), pp. 1-61. 
Promega (2013). MethylEdge Bisulfite Conversion System - Technical Manual. 
Promega (2014). PowerPlex ESI 16 System - Technical Manual. 
Psychogios, N., Hau, D.D., Peng, J., Guo, A.C., Mandal, R., Bouatra, S., Sinelnikov, 
I., Krishnamurthy, R., Eisner, R., Gautam, B., Young, N., Xia, J., Knox, C., Dong, E., 
Huang, P., Hollander, Z., Pedersen, T.L., Smith, S.R., Bamforth, F., Greiner, R., 
McManus, B., Newman, J.W., Goodfriend, T., Wishart, D.S. (2011). The human 
serum metabolome. PLoS One 6(2), e16957. 
Qiagen (2005). AllPrep DNARNA Mini Handbook. 
Qiagen (2008). MinElute PCR Purification kit. 
Qiagen (2009a). EpiTect Bisulfite Handbook. 
Qiagen (2009b). EZ1 DNA Investigator Handbook. 
Qiagen (2009c). PyroMark Gold Q96 Reagents Handbook. 
Qiagen (2009d). PyroMark PCR Handbook. 
Qiagen (2010a). Pyrosequencing - the synergy of sequencing and quantification. 
Qiagen (2010b). QIAamp DNA Investigator Handbook. 
Qiagen (2011). EZ1 DNA Blood Handbook. 
Quail, M.A., Smith, M., Coupland, P., Otto, T.D., Harris, S.R., Connor, T.R., 
Bertoni, A., Swerdlow, H.P., Gu, Y. (2012). A tale of three next generation 
sequencing platforms: comparison of Ion Torrent, Pacific Biosciences and Illumina 
MiSeq sequencers. BMC Genomics 13, 341. 
Raddatz, G., Hagemann, S., Aran, D., Sohle, J., Kulkarni, P.P., Kaderali, L., Hellman, 
A., Winnefeld, M., Lyko, F. (2013). Aging is associated with highly defined 
epigenetic changes in the human epidermis. Epigenetics & Chromatin 6(1), 36. 
Rakyan, V.K., Down, T.A., Maslau, S., Andrew, T., Yang, T.P., Beyan, H., 
Whittaker, P., McCann, O.T., Finer, S., Valdes, A.M., Leslie, R.D., Deloukas, P., 
Spector, T.D. (2010). Human aging-associated DNA hypermethylation occurs 
preferentially at bivalent chromatin domains. Genome Research 20(4), 434-439. 
Rakyan, V.K., Down, T.A., Thorne, N.P., Flicek, P., Kulesha, E., Gräf, S., Tomazou, 
E.M., Bäckdahl, L., Johnson, N., Herberth, M., Howe, K.L., Jackson, D.K., Miretti, 
M.M,, Fiegler, H., Marioni, J.C., Birney, E., Hubbard, T.J., Carter, N.P., Tavaré, S., 
Beck, S. (2008). An integrated resource for genome-wide identification and analysis of 




Ramchandani, S., Bhattacharya, S.K., Cervoni, N., Szyf, M. (1999). DNA 
methylation is a reversible biological signal. Proceedings of the National Academy of 
Sciences of the U.S.A. 96(11), 6107-6112. 
Rando, O.J., Verstrepen, K.J. (2007). Timescales of genetic and epigenetic 
inheritance. Cell 128(4), 655-668. 
Reed, K., Poulin, M.L., Yan, L., Parissenti, A.M. (2010). Comparison of bisulfite 
sequencing PCR with pyrosequencing for measuring differences in DNA methylation. 
Analytical Biochemistry 397(1), 96-106. 
Reik, W. (2007). Stability and flexibility of epigenetic gene regulation in mammalian 
development. Nature 447, 425-432. 
Reik, W., Walter, J. (2001). Genomic imprinting: parental influence on the genome. 
Nature Reviews Genetics 2(1), 21-32. 
Ribel-Madsen, R., Fraga, M.F., Jacobsen, S., Bork-Jensen, J., Lara, E., Calvanese, V., 
Fernandez, A.F., Friedrichsen, M., Vind, B.F., Højlund, K., Beck-Nielsen, H., 
Esteller, M., Vaag, A., Poulsen, P. (2012). Genome-wide analysis of DNA 
methylation differences in muscle and fat from monozygotic twins discordant for type 
2 diabetes. PLoS One 7(12), e51302. 
Richard, M.L., Harper, K.A., Craig, R.L., Onorato, A.J., Robertson, J.M., Donfack, J. 
(2012). Evaluation of mRNA marker specificity for the identification of five human 
body fluids by capillary electrophoresis. Forensic Science International: Genetics 6(4), 
452-460. 
Ritz-Timme, S., Laumeier, I., Collins, M. (2003). Age estimation based on aspartic 
acid racemization in elastin from the yellow ligaments. International Journal of Legal 
Medicine 117(2), 96-101. 
Rodwell, G.E.J., Sonu, R., Zahn, J.M., Lund, J., Wilhelmy, J., Wang, L., Xiao, W., 
Mindrinos, M., Crane, E., Segal, E., Myers, B.D., Brooks, J.D., Davis, R.W., Higgins, 
J., Owen, A.B., Kim, S.K. (2004). A transcriptional profile of aging in the human 
kidney. PloS Biology 2(12), e427. 
Roeder, A.D., Haas, C. (2013). mRNA profiling using a minimum of five mRNA 
markers per body fluid and a novel scoring method for body fluid identification. 
International Journal of Legal Medicine 127(4), 707-721. 
Ronaghi, M. (2000). Improved performance of pyrosequencing using single-stranded 
DNA-binding protein. Analytical Biochemistry 286(2), 282-288. 
Ronaghi, M. (2001). Pyrosequencing sheds light on DNA sequencing. Genome 
Research 11(1), 3-11. 
Rouge-Maillart, C., Jousset, N., Vielle, B., Gaudin, A., Telmon, N. (2007). 
Contribution of the study of acetabulum for the estimation of adult subjects. Forensic 
Science International  171(2-3), 103-110. 
[356] 
 
Sabatini, L.M., Ota, T., Azen, E.A. (1990). Structure and sequence determination of 
the gene encoding human salivary statherin. Gene 89(2), 245-251. 
Sabatini, L.M., Ota, T., Azen, E.A. (1993). Nucleotide sequence analysis of the 
human salivary protein genes HIS1 and HIS2 and evolution of the STATH/HIS gene 
family. Molecular Biology and Evolution 10(3), 497-511. 
Sahin, K., Yilmaz, S., Temel, A., Gozukirmizi, N. (2011). DNA methylation analyses 
of monozygotic twins. Abstracts/Current Opinion in Biotechnology 22S, S105. 
Sakurada, K., Akutsu, T., Watanabe, K., Fujinami, Y., Yoshino, M. (2011). 
Expression of statherin mRNA and protein in nasal and vaginal secretions. Legal 
Medicine (Tokyo) 13(6), 309-313. 
Sakurada, K., Ikegaya, H., Fukushima, H., Akutsu, T., Watanabe, K., Yoshino, M. 
(2009). Evaluation of mRNA-based approach for identification of saliva and semen. 
Legal Medicine (Tokyo) 11(3), 125-128. 
Schutte, B., El Hajj, N., Kuhtz, J., Nanda, I., Gromoll, J., Hahn, T., Dittrich, M., 
Schorsch, M., Müller, T., Haaf, T. (2013). Broad DNA methylation changes of 
spermatogenesis, inflammation and immune response-related genes in a subgroup of 
sperm samples for assisted reproduction. Andrology 1(6), 822-829. 
Setzer, M., Juusola, J., Ballantyne, J. (2008). Recovery and stability of RNA in vaginal 
swabs and blood, semen, and saliva stains. Journal of Forensic Sciences 53(2), 296-305. 
Shen, C.J., Maniatis, T. (1980). Tissue-specific DNA methylation in a cluster of rabbit 
b-like globin genes. Proceedings of the National Academy of Sciences of the U.S.A. 77(11), 
6634-6638. 
Shen, L., Kondo, Y., Guo, Y., Zhang, J., Zhang, L., Ahmed, S., Shu, J., Chen, X., 
Waterland, R.A., Issa, J.P. (2007). Genome-wide profiling of DNA methylation 
reveals a class of normally methylated CpG island promoters. PLoS Genetics 3(10), 
2023-2036. 
Sikirzhytskaya, A., Sikirzhytski, V., Lednev, I.K. (2012a). Raman spectroscopic 
signature of vaginal fluid and its potential application in forensic body fluid 
identification. Forensic Science International 216(1-3), 44-48. 
Sikirzhytskaya, A., Sikirzhytski, V., Lednev, I.K. (2012b). Raman spectroscopy 
coupled with advanced statistics for differentiating menstrual and peripheral blood. 
Journal of Biophotonics 7(1-2), 59-67. 
Singer-Sam, J., Tanguay, R.L., Rjggs, A.O. (1989). Use of Chelex to improve PCR 






Small, K.S., Hedman, A.K., Grundberg, E., Nica, A.C., Thorleifsson, G., Kong, A., 
Thorsteindottir, U., Shin, S.Y., Richards, H.B., GIANT Consortium, MAGIC 
Investigators, DIAGRAM Consortium, Soranzo, N., Ahmadi, K.R., Lindgren, C.M., 
Stefansson, K., Dermitzakis, E.T., Deloukas, P., Spector, T.D., McCarthy, M.I., 
MuTHER Consortium. (2011). Identification of an imprinted master trans regulator at 
the KLF14 locus related to multiple metabolic phenotypes. Nature Genetics 43(6), 
561-564. 
Song, F., Luo, H., Li, Y., Zhang, J., Hou, Y. (2013). Characteristics of the two 
microbial markers in vaginal secretions in Chinese Han population. Forensic Science 
International: Genetics Supplement Series 4(1), e312-e313. 
Song, F., Mahmood, S., Ghosh, S., Liang, P., Smiraglia, D.J., Nagase, H., Held, W.A. 
(2009). Tissue specific differentially methylated regions (TDMR): Changes in DNA 
methylation during development. Genomics 93(2), 130-139. 
Song, Y.L., Kato, N., Liu, C.X., Matsumiya, Y., Kato, H., Watanabe, K. (2000). 
Rapid identification of 11 human intestinal Lactobacillus species by multiplex PCR 
assays using group- and species-specific primers dericed from 16S-23S rRNA 
intergenic spacer region and its flanking 23S rRNA. FEMS Microbiology Letters 
187(2), 167-173. 
Spichenok, O., Budimlija, Z.M., Mitchell, A.A., Jenny, A., Kovacevic, L., 
Marjanovic, D., Caragine, T., Prinz, M., Wurmbach, E. (2011). Prediction of eye and 
skin color in diverse populations using seven SNPs. Forensic Science International: 
Genetics 5(5), 472-478. 
Steenhout, A., Pourtois, M. (1981). Lead accumulation in teeth as a function of age 
with different exposures. British Journal of Indrustrial Medicine 38(3), 297-303. 
Storm, T., Rath, S., Mohamed, S.A., Bruse, P., Kowald, A., Oehmichen, M., 
Meissner, C. (2002). Mitotic brain cells are just as prone to mitochondrial deletions as 
neurons: a large-scale single-cell PCR study of the human caudate nucleus. 
Experimental Gerontology 37(12), 1389-1400. 
Straussman, R., Nejman, D., Roberts, D., Steinfeld, I., Blum, B., Benvenisty, N., 
Simon, I., Yakhini, Z., Cedar, H. (2009). Developmental programming of CpG island 
methylation profiles in the human genome. Nature Structural and Molecular Biology 
16(5), 564-571. 
Sumi, H., Naito, E., Dewa, K., Fukuda, M., Xu, H.D., Yamanouchi, H. (2005). 
Applicability of the parentally imprinted allele (PIA) typing of a VNTR upstream the 
H19 gene to forensic samples of different tissues. Legal Medicine (Tokyo) 7(3), 179-
182. 
Suzuki, M.M., Bird, A. (2008). DNA methylation landscapes: provocative insights 
from epigenomics. Nature Reviews Genetics 9(6), 465-476. 
Suzuki, O., Oya, M., Katsumata, Y., Matsumoto, T., Yada, S. (1980). A new 
enzymatic method for the determination of spermine in human seminal stains. Journal 
of Forensic Sciences 25(1), 99-102. 
[358] 
 
Svingen, T., Tonissen, K.F. (2006). Hox transcription factors and their elusive 
mammalian gene targets. Heredity 97(2), 88-96. 
Szyf, M. (2010). DNA methylation and demethylation probed by small molecules. 
Biochimica et Biophysica Acta 1799(10-12), 750-759. 
Takada, F., Vander Woude, D.L., Tong, H.Q., Thompson, T.G., Watkins, S.C., 
Kunkel, L.M., Beggs, A.H. (2001). Myozenin: an alpha-actinin- and gamma-filamin-
binding protein of skeletal muscle Z lines. Proceedings of the National Academy of 
Sciences of the U.S.A. 98(4), 1595-1600. 
Tanaka, K., Okamoto, A. (2007). Degradation of DNA by bisulfite treatment. 
Bioorganic and Medicinal Chemistry Letters 17(7), 1912-1915. 
Teschendorff, A.E., Jones, A., Fiegl, H., Sargent, A., Zhuang, J.J., Kitchener, H.C., 
Widschwendter, M. (2012). Epigenetic variability in cells of normal cytology is 
associated with the risk of future morphological transformation. Genome Medicine 4(3), 
24. 
Teschendorff, A.E., Menon, U., Gentry-Maharaj, A., Ramus, S.J., Weisenberger, 
D.J., Shen, H., Campan, M., Noushmehr, H., Bell, C.G., Maxwell, A.P., Savage, 
D.A., Mueller-Holzner, E., Marth, C., Kocjan, G., Gayther, S.A., Jones, A., Beck, S., 
Wagner, W., Laird, P.W., Jacobs, I.J., Widschwendter, M. (2010). Age-dependent 
DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. 
Genome Research 20(4), 440-446. 
Teschendorff, A.E., West, J., Beck, S. (2013). Age-associated epigenetic drift: 
implications, and a case of epigenetic thrift? Human Molecular Genetics 22(R1), R7-
R15. 
Thompson, T.M., Sharfi, D., Lee, M., Yrigollen, C.M., Naumova, O.Y., Grigorenko, 
E.L. (2013). Comparison of whole-genome DNA methylation patterns in whole 
blood, saliva, and lymphoblastoid cell lines. Behavior Genetics 43(2), 168-176. 
Thorpe, S.R., Baynes, J.W. (1996). Role of the Maillard reaction in diabetes mellitus 
and diseases of aging. Drugs & Aging 9(2), 69-77. 
Tikhmyanova, N., Tulin, A.V., Roagiers, F., Golemis, E.A. (2010). Dcas supports cell 
polarization and cell-cell adhesion complexes in development. PLoS One 5(8), e12369. 
Trasler, J.M., Hake, L.E., Johnson, P.A., Alcivar, A.A., Millette, C.F., Hecht, N.B. 
(1990). DNA methylation and demethylation events during meiotic prophase in the 
mouse testis. Molecular and Cellular Biology 10(4), 1828-1834. 
Tsai, H.C., Baylin, S.B. (2011). Cancer epigenetics: linking basic biology to clinical 
medicine. Cell Research 21(3), 502-517. 
Tsuji, A., Ishiko, A., Takasaki, T., Ikeda, N. (2002). Estimating age of humans based 
on telomere shortening. Forensic Science International 126(3), 197-199. 
Tusnady, G.E., Simon, I., Varadi, A., Aranyi, T. (2005). BiSearch: primer-design and 
search tool for PCR on bisulfite-treated genomes. Nucleic Acids Research 33(1), e9. 
[359] 
 
Vallone, P.M., Butler, J.M. (2004). AutoDimer: a screening tool for primer-dimer and 
hairpin structures. BioTechniques 37(2), 226-231. 
Valore, E.V., Park, C.H., Quayle, A.J., Wiles, K.R., McCray Jr, P.B., Ganz, T. 
(1998). Human beta-defensin-1: an antimicrobial peptide of urogenital tissues. The 
Journal of Clinical Investigation 101(8), 1633-1642. 
van den Berge, M., Carracedo, A., Gomes, I., Graham, E.A., Haas, C., Hjort, B.,  
Hoff-Olsen, P., Maroñas, O., Mevåg, B., Morling, N., Niederstätter, H., Parson, W., 
Schneider, P.M., Syndercombe Court, D., Vidaki, A., Sijen, T. (2014). A 
collaborative European exercise on mRNA-based body fluid/skin typing and 
interpretation of DNA and RNA results. Forensic Science International: Genetics 10, 
40-48. 
Vennemann, M., Koppelkamm, A. (2010). mRNA profiling in forensic genetics I: 
Possibilities and limitations. Forensic Science International 203(1-3), 71-75. 
Vidaki, A., Daniel, B., Syndercombe Court, D. (2013). Forensic DNA methylation 
profiling - Potential opportunities and challenges. Forensic Science International: 
Genetics 7(5), 499-507. 
Virkler, K., Lednev, I.K. (2009). Analysis of body fluids for forensic purposes: from 
laboratory testing to non-destructive rapid confirmatory identification at a crime 
scene. Forensic Science International 188(1-3), 1-17. 
Visser, M., Zubakov, D., Ballantyne, K.N., Kayser, M. (2011). mRNA-based skin 
identification for forensic applications. International Journal of Legal Medicine 125(2), 
253-263. 
von Figura, G., Hartmann, D., Song, Z., Rudoplh, K.L. (2009). Role of telomere 
dysfunction in aging and its detection by biomarkers. Journal of Molecular Medicine 
(Berlin, Germany) 87(12), 1165-1171. 
von Zglinicki, T. (2000). Role of oxidative stress in telomere length regulation and 
replicative senescence. Annals of New York Academy of Sciences 908, 99-110. 
von Zglinicki, T., Martin-Ruiz, C.M. (2005). Telomeres as biomarkers for ageing and 
age-related diseases. Current Molecular Medicine 5(2), 197-203. 
Walsh, P.S., Metzger, D.A., Higuchi, R. (1991). Chelex 100 as a medium for simple 
extraction of DNA for PCR-based typing from forensic material. BioTechniques 10(4), 
506-513. 
Walsh, S., Liu, F., Wollstein, A., Kovatsi, L., Ralf, A., Kosiniak-Kamysz, A., 
Branicki, W., Kayser, M. (2013). The HIrisPlex system for simultaneous prediction of 
hair and eye colour from DNA. Forensic Science International: Genetics 7(1), 98-115. 
Warnecke, P.M., Stirzaker, C., Melki, J.R., Millar, D.S., Paul, C.L., Clark, S.J. 
(1997). Detection and measurement of PCR bias in quantitative methylation analysis 
of bisulphite-treated DNA. Nucleic Acids Research 25(21), 4442-4426. 
[360] 
 
Warshauer, D.H., Lin, D., Hari, K., Jain, R., Davis, C., Larue, B., King, J.L., 
Budowle, B. (2013). STRait Razor: a length-based forensic STR allele-calling tool for 
use with second generation sequencing data. Forensic Science International: Genetics  
7(4), 409-417. 
Wasserstrom, A., Frumkin, D., Davidson, A., Shpitzen, M., Herman, Y., Gafny, R. 
(2013). Demonstration of DSI-semen--A novel DNA methylation-based forensic 
semen identification assay. Forensic Science International: Genetics 7(1), 136-142. 
Webb, J.L., Creamer, J.I., Quickenden, T.I. (2006). A comparison of the presumptive 
luminol test for blood with four non-chemiluminescent forensic techniques. 
Luminescence 21(4), 214-220. 
Weber-Lehmann, J., Schilling, E., Gradl, G., Richter, D. C., Wiehler, J., Rolf, B. 
(2014). Finding the needle in the haystack: differentiating "identical" twins in paternity 
testing and forensics by ultra-deep next generation sequencing. Forensic Science 
International: Genetics 9, 42-46. 
Weidner, C.I., Lin, Q., Koch, C.M., Eisele, L., Beier, F., Ziegler, P., Bauerschlag, 
D.O., Jöckel, K.H., Erbel, R., Mühleisen, T.W., Zenke, M., Brümmendorf, T.H., 
Wagner, W. (2014). Aging of blood can be tracked by DNA methylation changes at 
just three CpG sites. Genome Biology 15(2), R24. 
Wild, L., Flanagan, J.M. (2010). Genome-wide hypomethylation in cancer may be a 
passive consequence of transformation. Biochimica et Biophysica Acta 1806(1), 50-57. 
Winnefeld, M., Brueckner, B., Gronniger, E., Stab, F., Wenck, H., Lyko, F. (2012). 
Stable ethnic variations in DNA methylation patterns of human skin. The Journal of 
Investigative Dermatology 132(2), 466-468. 
Wong, A.H., Gottesman, I., Petronis, A. (2005). Phenotypic differences in genetically 
identical organisms: the epigenetic perspective. Human Molecular Genetics 14 (Spec 
No 1), R11-R18. 
Wong, E.M., Dobrovic, A. (2011). Assessing gene-specific methylation using HRM-
based analysis. Methods in Molecular Biology 687, 207-217. 
Xiong, Z., Laird, P.W. (1997). COBRA: a sensitive and quantitative DNA 
methylation assay. Nucleic Acids Research 25(12), 2532-2534. 
Xu, H., Zhao, Y., Liu, Z., Zhu, W., Zhou, Y., Zhao, Z. (2012). Bisulfite genomic 
sequencing of DNA from dried blood spot microvolume samples. Forensic Science 
International: Genetics 6(3), 306-309. 
Xu, Y., Xie, J., Cao, Y., Zhou, H., Ping, Y., Chen, L., Gu, L., Hu, W., Bi, G., Ge, J., 
Chen, X., Zhao, Z. (2014). Development of highly sensitive and specific mRNA 
multiplex system (XCYR1) for forensic human body fluids and tissues identification. 




Xue, Y., Wang, Q., Long, Q., Ng, B.L., Swerdlow, H., Burton, J., Skuce, C., Taylor, 
R., Abdellah, Z., Zhao, Y., Asan MacArthur, D.G., Quail, M.A., Carter, N.P., Yang, 
H., Tyler-Smith, C. (2009). Human Y Chromosome base-substitution mutation rate 
measured by direct sequencing in a deep-rooting pedigree. Current Biology 19(17), 
1453-1457. 
Yacubova, E., Komuro, H. (2002). Stage-specific control of neuronal migration by 
somatostatin. Nature 415(6867), 77-81. 
Yamada, N., Nishida, Y., Tsutsumida, H., Goto, M., Higashi, M., Nomoto, M., 
Yonezawa, S. (2009). Promoter CpG methylation in cancer cells contributes to the 
regulation of MUC4. British Journal of Cancer 100(2), 344-351. 
Yang, Y., Xie, B., Yan, J. (2014). Application of Next-generation Sequencing 
Technology in Forensic Science. Genomics, Proteomics & Bioinformatics 12(5), 190-
197. 
Yarnell, A.T., Oh, S., Reinberg, D., Lippard, S.J. (2001). Interaction of FACT, 
SSRP1, and the high mobility group (HMG) domain of SSRP1 with DNA damaged 
by the anticancer drug cisplatin. The Journal of Biological Chemistry 276(28), 25736-
25741. 
Yasunaga, M., Matsumura, Y. (2014). Role of SLC6A6 in promoting the survival and 
multidrug resistance of colorectal cancer. Nature Scientific Reports 4, 4852. 
Yi, H., Fujimura, Y., Ouchida, M., Prasad, D.D., Rao, V.N., Reddy, E.S. (1997). 
Inhibition of apoptosis by normal and aberrant Fli-1 and erg proteins involved in 
human solid tumors and leukemias. Oncogene 14(11), 1259-1268. 
Yi, S.H., Xu, L.C., Mei, K., Yang, R.Z., Huang, D.X. (2014). Isolation and 
identification of age-related DNA methylation markers for forensic age-prediction. 
Forensic Science International: Genetics 11, 117-125. 
Yu, Z., Zhai, G., Singmann, P., He, Y., Xu, T., Prehn, C., Römisch-Margl, W., 
Lattka, E., Gieger, C., Soranzo, N., Heinrich, J., Standl, M., Thiering, E., Mittelstraß, 
K., Wichmann, H.E., Peters, A., Suhre, K., Li, Y., Adamski, J., Spector, T.D., Illig, 
T., Wang-Sattler, R. (2012). Human serum metabolic profiles are age dependent. 
Aging Cell 11(6), 960-967. 
Zapico, S.C., Ubelaker, D.H. (2013). Applications of physiological bases of ageing to 
forensic sciences. Estimation of age-at-death. Ageing Research Reviews 12(2), 605-
617. 
Zbieć-Piekarska, R., Spólnicka, M., Kupiec, T., Makowska, Ż., Spas, A., Parys-
Proszek, A., Kucharczyk, K., Płoski, R., Branicki, W. (2015). Examination of DNA 
methylation status of the ELOVL2 marker may be useful for human age prediction in 
forensic science. Forensic Science International: Genetics 14, 161-167. 
Zhang, Y., Wang, Z., Zhang, J., Farmer, B., Lim, S.H. (2008). Semenogelin I 




Zhao, D., Ishikawa, T., Quan, L., Michiue, T., Zhu, B.L., Maeda, H. (2009). 
Postmortem quantitative mRNA analyses of death investigation in forensic pathology: 
an overview and prospects. Legal Medicine (Tokyo) 11 (Suppl 1), S43-S45. 
Zhao, G., Yang, Q., Huang, D., Yu, C., Yang, R., Chen, H., Mei, K. (2005). Study on 
the application of parent-of-origin specific DNA methylation markers to forensic 
genetics. Forensic Science International 154(2-3), 122-127. 
Zhu, B.L., Tanaka, S., Ishikawa, T., Zhao, D., Li, D.R., Michiue, T., Quan, L., 
Maeda, H. (2008). Forensic pathological investigation of myocardial hypoxia-
inducible factor-1 alpha, erythropoietin and vascular endothelial growth factor in 
cardiac death. Legal Medicine (Tokyo) 10(1), 11-19. 
Zhuang, J., Jones, A., Lee, S.H., Ng, E., Fiegl, H., Zikan, M., Cibula, D., Sargent, A., 
Salvesen, H.B., Jacobs, I.J., Kitchener, H.C., Teschendorff, A.E., Widschwendter, M. 
(2012). The dynamics and prognostic potential of DNA methylation changes at stem 
cell gene loci in women's cancer. PLoS Genetics 8(2), e1002517. 
Zubakov, D., Hanekamp, E., Kokshoorn, M., van Ijcken, W., Kayser, M. (2008). 
Stable RNA markers for identification of blood and saliva stains revealed from whole 
genome expression analysis of time-wise degraded samples. International Journal of 
Legal Medicine 122(2), 135-142. 
Zubakov, D., Liu, F., van Zelm, M.C., Vermeulen, J., Oostra, B.A., van Duijin, C.M., 
Driessen, G.J., van Dongen, J.J., Kayser, M., Langerak, A.W. (2010). Estimating 
human age from T-cell DNA rearrangements. Current Biology 20(22), R970-R971. 
Zykovich, A., Hubbard, A., Flynn, J.M., Tarnopolsky, M., Fraga, M.F., Kerksick, C., 
Ogborn, D., MacNeil, L., Mooney, S.D., Melov, S. (2014). Genome-wide DNA 
methylation changes with age in disease-free human skeletal muscle. Aging Cell 13(2), 
360-366. 
ZymoResearch (2013a). EZ DNA Methylation Kit - Instruction Manual. 










Appendix I. Research Ethics documents 
Approval letter 
Miss Athina Vidaki 
Department of Forensic and Analytical Science  
Room 4.124 Franklin-Wilkins Building  








BDM/13/14-30 DNA methylation profiling for various forensic applications. 
 
Review Outcome: Full Approval 
 
Thank you for sending in the amendments/clarifications requested to the above project. I am pleased to inform you that these 
meet the requirements of the BDM RESC and therefore that full approval is now granted. 
 
Please ensure that you follow all relevant guidance as laid out in the King's College London Guidelines on Good Practice in 
Academic Research (http://www.kcl.ac.uk/college/policyzone/index.php?id=247). 
 
For your information ethical approval is granted until 27 January 2017. If you need approval beyond this point you will need to 
apply for an extension to approval at least two weeks prior to this explaining why the extension is needed, (please note however 
that a full re-application will not be necessary unless the protocol has changed). You should also note that if your approval is for 
one year, you will not be sent a reminder when it is due to lapse. 
 
Ethical approval is required to cover the duration of the research study, up to the conclusion of the research. The conclusion of the 
research is defined as the final date or event detailed in the study description section of your approved application form (usually 
the end of data collection when all work with human participants will have been completed), not the completion of data analysis or 
publication of the results. For projects that only involve the further analysis of pre-existing data, approval must cover any period 
during which the researcher will be accessing or evaluating individual sensitive and/or un-anonymised records. Note that after the 
point at which ethical approval for your study is no longer required due to the study being complete (as per the above definitions), 
you will still need to ensure all research data/records management and storage procedures agreed to as part of your application 
are adhered to and carried out accordingly. 
 
If you do not start the project within three months of this letter please contact the Research Ethics Office.  
 
Should you wish to make a modification to the project or request an extension to approval you will need approval for this and 
should follow the guidance relating to modifying approved applications:  
http://www.kcl.ac.uk/innovation/research/support/ethics/applications/modifications.aspx  
The circumstances where modification requests are required include the addition/removal of participant groups, 
additions/removal/changes to research methods, asking for additional data from participants, extensions to the ethical approval 
period. Any proposed modifications should only be carried out once full approval for the modification request has been granted. 
 
Any unforeseen ethical problems arising during the course of the project should be reported to the approving committee/panel. In 
the event of an untoward event or an adverse reaction a full report must be made to the Chair of the approving committee/review 
panel within one week of the incident. 
 
Please would you also note that we may, for the purposes of audit, contact you from time to time to ascertain the status of your 
research.  
 
If you have any query about any aspect of this ethical approval, please contact your panel/committee administrator in the first 
instance (http://www.kcl.ac.uk/innovation/research/support/ethics/contact.aspx). We wish you every success with this work. 
 
Yours sincerely, 
James Patterson – Senior Research Ethics Officer 
 





INFORMATION SHEET FOR PARTICIPANTS 
 
This study has been approved by King’s College London Biomedical Sciences, 
Dentistry, Medicine and Natural and Mathematical Sciences Research Ethics 
Subcommittee, BDM/13/14-30 
DNA methylation profiling for various forensic applications 
We would like to invite you to participate in postgraduate research.  You should only participate if you want 
to; choosing not to take part will not disadvantage you in any way. Before you decide whether you want to 
take part, it is important for you to understand why the research is being done and what your participation 
will involve.  Please take time to read the following information carefully and discuss it with others if you 
wish.  Ask us if there is anything that is not clear or if you would like more information. 
The Research 
I am a PhD student enrolled in the Department of Forensic and Analytical Science at King’s College 
London, completing the degree of PhD in Forensic Genetics. For completion, we are carrying out research 
projects sponsored by King’s College London, with funding from the European Forensic Genetics Network 
of Excellence (EuroForGen) or DNA Analysis at King’s. 
The research involves an investigation into the ability to use DNA in various forensic applications, such as 
identifying the tissue source of a stain or the biological age of an individual. Body fluid samples will 
undergo DNA methylation profiling as well as DNA profiling will be carried out. In more detail, possible 
DNA modifications of several locations within the genome will be investigated in order to identify any 
meaningful variations. 
These studies will develop methods to improve the way that evidence is analysed and interpreted in 
forensic and police investigations. You are invited to assist in this research by volunteering biological 
samples, and we would be very appreciative of your donation to our work. Volunteers will be asked to 
provide blood, saliva, sweat, semen, urine samples as well as vaginal fluid, menstrual fluid, cheek, skin  or 
nasal fluid swabs. (NOTE: you are able to donate all samples required if this is possible to do so, but you 
can donate as many or as few samples as you wish). 
You are invited to assist in this research by volunteering biological samples if you are over the age of 18, 
have no recent history of skin conditions or adverse reactions to blood donation, and we would be very 
appreciative of your donation to our work. For volunteers under the age of 18, the mother is asked to 
consent on behalf of the child. 
Should you wish to take part in this study, you will be asked to make any of the following small body fluid 
donations. It is up to you which samples you wish to donate for the research. 
x Blood: Blood samples will only need to be taken once. Please let us know if you have ever had 
an adverse reaction to donating blood. A 20 ml sample (less than 4 teaspoons) will be taken from 
your arm by a qualified and experienced medical professional. Blood collection will take place at 
a Study Suite, Room FWB 4.25.  
x Saliva, Sweat, Semen and Urine: You will be provided with receptacles for saliva, sweat, semen 
and urine donations, which you will be asked to collect in the privacy of your home. Please keep 
the samples refrigerated whilst at home.  
x Cheek, Skin, Vaginal Fluid, Menstrual Fluid and Nasal Fluid Swabs: You will be given a swab 
and asked to gently rub the inside of your cheek, forearm or vagina or nose.  
 
Volunteering for this study will involve sample donation only, and should not take longer than 30 minutes 
of your time. There will be a minor risk of bruising during collection of blood. To minimise this risk, an 
experienced phlebotomist will perform blood collection, which will also take place in the presence of a 
trained first aider. There will also be a minor risk of injury due to abrasion during mouth swab collection 
and fingerprint deposition.  
[365] 
 
DNA will be extracted from these samples for the purpose of DNA methylation profiling.  
DNA methylation profiling is a technique by which differences in peoples’ DNA modifications are used to 
identify the source of the biological fluid or estimate the age of an individual. 
If you would like more information on the process, please feel free to ask! 
No further genetic information will be assessed on your samples and you will receive no feedback on the 
analysis of your DNA. Your DNA samples will be stored until 31st December 2016, when the EuroForGen 
project comes to an end. All the data/records taken will be stored in a secure location in King's College 
London and stored for a period of up to 2 years after the end of the EuroForGen project to allow for 
publications, so until 31st December 2018. These data/records will only be accessed by me (Athina Vidaki) 
and my supervisor (Dr Denise Syndercombe Court) and will also be shared with our colleagues 
(EuroForGen, KCL). 
A DNA profile can, in theory, be used to provide personal information about an individual, including 
susceptibility to medical conditions and inheritable disease. However, we will not be carrying out any 
analysis that would show susceptibility to any medical conditions. To avoid concern over your privacy, the 
source of each donation will be anonymised and confidential. Each sample is given an individual code 
number so that DNA profiles will not be able to be traced back to their original donor. 
The DNA methylation profiling results will be published at the end of the research in the form of a PhD 
thesis and scientific publications, with the original donor being anonymised. You will be allowed to look 
through the report once it is complete, but no individual feedback on test results will be shared with you as 
the investigator will not know the identity of the original donor. 
At any time you may choose to withdraw your consent. Should you chose to do so, no explanation is 
needed and all your samples and any related data will be removed and destroyed. Please do so before 1st 
March 2014. 
It is up to you to decide whether or not to take part.  If you do decide to take part you will be given this 
information sheet to keep and be asked to sign a consent form. If you decide to take part you are still free 
to withdraw at any time before 1st March 2014 and without giving a reason.   
 
For further information on the study please contact: 
Miss Athina Vidaki, Department of Forensic and Analytical Science, Room 4.124, 4th Floor Franklin Wilkins 
Building, King’s College London, 150 Stamford Street, London, SE1 9NH.       
Email: athina.a.vidaki@kcl.ac.uk 
 
If this study has harmed you in any way you can contact King's College London using the contact details 
below for further advice and information. 
 
Dr Denise Syndercombe Court, Department of Forensic and Analytical Science, Room 4.109, 4th Floor 












CONSENT FORM FOR PARTICIPANTS IN RESEARCH STUDIES 
Please complete this form after you have read the Information Sheet and/or 
listened to an explanation about the research. 
 
Title of Study: DNA methylation profiling for various forensic applications 
King’s College Research Ethics Committee Ref: BDM/13/14-30 
 
Thank you for considering taking part in this research. The person organizing the research must 
explain the project to you before you agree to take part. If you have any questions arising from the 
Information Sheet or explanation already given to you, please ask the researcher before you decide 
whether to join in. You will be given a copy of this Consent Form to keep and refer to at any time. 
x I understand that if I decide at any other time during the research that I no longer wish to 
participate in this project, I can notify the researchers involved before 1st March 2014 and be 
withdrawn from it immediately (please tick if you agree)  
 
x I consent to donating the following samples for DNA methylation profiling (tick those that 
apply) 
Saliva                                            Sweat  
Blood                                            Vaginal Fluid Swab  
Cheek Swab                                 Skin Swab 
Semen                                          Menstrual Fluid Swab 
Urine                                             Nasal Fluid Swab 
 
x I understand that I will not receive any results about my own DNA profile (please tick if you 
agree) 
 
x I consent to the processing of my personal information for the purposes of this research 
study.  I understand that such information will be treated as strictly confidential and handled in 
accordance with the provisions of the Data Protection Act 1998 (please tick if you agree) 
 
x I agree that the research team may use my data for future research and understand that any 
such use of identifiable data would be reviewed and approved by a research committee. (In 





agree that the research project named above has been explained to me to my satisfaction and I agree to 
take part in the study. I have read both the notes written above and the Information Sheet about the 
project, and understand what the research study involves. 
Signed      Date 
Investigator’s Statement: 
I _____________________________________________________________________ 
confirm that I have carefully explained the nature, demands and any foreseeable risks (where 
applicable) of the proposed research to the volunteer. 
 




Appendix II. Bisulphite Pyrosequencing® assay 
design 
Example: BLood Methylated marker 1 – BLM1 
Gene: Solute Carrier Family 6, member 6 (SLC6A6) 
CpG Position: Chr3: 14,443,428 









DNA Sequence after bisulphite treatment: 
    1 TTCGGGGTTCTCACAGCGTTTCCCTCTCATGCTGCCAGGGCGGGGCAGTGGAAAATGGTC 
      ||++|||||:|:|:||++|||:::|:|:|||:||::||||++|||:|||||||||||||: 
    1 TTCGGGGTTTTTATAGCGTTTTTTTTTTATGTTGTTAGGGCGGGGTAGTGGAAAATGGTT 
 
   61 CCTGAGGGCCCGTTCATTCAAATAAGGACAAGAATAATGGCACACTCCCCATCTCCATTT 
      ::||||||::++||:|||:|||||||||:|||||||||||:|:|:|::::||:|::|||| 
   61 TTTGAGGGTTCGTTTATTTAAATAAGGATAAGAATAATGGTATATTTTTTATTTTTATTT 
 
  121 AAAAATAGTCACATTAGCTGACACTGGCTTGGCACTTCCTAGATGCCGGGTGCGTTCCGA 
      |||||||||:|:|||||:|||:|:|||:||||:|:||::||||||:++||||++||:++| 
  121 AAAAATAGTTATATTAGTTGATATTGGTTTGGTATTTTTTAGATGTCGGGTGCGTTTCGA 
 
  181 GTTCTCTACGCTGTTAACCTTGGATCTTCATAACAGCCGGAGGAGACAAGCGCTACTATT 
      |||:|:||++:||||||::||||||:||:||||:||:++|||||||:|||++:||:|||| 
  181 GTTTTTTACGTTGTTAATTTTGGATTTTTATAATAGTCGGAGGAGATAAGCGTTATTATT 
 
  241 TTCCTTTCCATTTTATAGATGAGGACACTGAGGCAGAGAAATTGAGTCACTTGCCCAGGG 
      ||::|||::||||||||||||||||:|:|||||:|||||||||||||:|:|||:::|||| 
  241 TTTTTTTTTATTTTATAGATGAGGATATTGAGGTAGAGAAATTGAGTTATTTGTTTAGGG 
 
  301 TCACACAGCCATGGCAAGGCCAGGATTCTGGAGCTCTGTACCTGGCTTCA 
      |:|:|:||::||||:||||::||||||:|||||:|:||||::|||:||:| 
  301 TTATATAGTTATGGTAAGGTTAGGATTTTGGAGTTTTGTATTTGGTTTTA 
 
 





Primer design parameters (screenshot from BiSearch software): 
Sequence 
 
Bisulphite         Max Tm difference = 2.5oC 
Set search region for Forward primer: -  Reverse primer: -
 
Max length of PCR  
 
Primer melting temperature 
 
Primer conc  mikromol Glycerol conc  % 
Potassium conc  milimol Ethylen glycol conc  % 
Magnesium conc  milimol Formamidconc  % 
 
Primer scoring values  
 
Description Weight Min Opt Max Description Weight Max 
Primer length     Self annealing   
GC content     Self end-annealing   
GC content (bis)     Pair annealing   
Melting temp     Pair end-annealing   
 
Primer design  
 
Results list size  Max Tm diff  Minimum of CpGs  
 
Database search and fast PCR  
 
Database  Mismatches  Max:  
PCR length  PCR product to show  
  Primer matches to show  
 
Primer design results: 
No Sc Primer sequences Pos Plen %GC Tm oTm CpG Sa Sea Pa Pea Len 
1. 11.11 TAGTTGATATTGGTTTGGTA 135 20 30.0 55.3 55.3 6 12 4 18 4 159 






0.5 18 23 30 0.1 20
1.0 40.0 50.0 60.0 0.2 10
1.0 0.0 30.0 60.0 0.1 20
1.0 45.0 55.0 65.0 0.2 10
10 3.0 1









Fpcr: Do Fast (electronic) PCR with the primer pairs 
Pseq: Primer sequence 
Pos: Position of the primer 
Plen: Primer length 
%GC: Content of G and C in percent 
Tm: Melting temperature 
oTm: Melting temperature of original primer (C are not translated to T) 
CpG: Number of CpG islands in the unmodified PCR product 
Sa: Self annealing 
Sea: Self end annealing 
Pa: Pair annealing 
Pea: Pair end-annealing 




Forward primer:  5’- TAGTTGATATTGGTTTGGTA – 3’ 
Reverse primer:  5’- CAAATAACTCAATTTCTCTAC -3’ 
(Converted cytosines in bold) 
 
Possible primer dimers: 
The best self annealing of the forward primer: 
    TAGTTGATATTGGTTTGGTA 
     |....||||....|  
ATGGTTTGGTTATAGTTGAT 
The best self end-annealing of the forward primer: 
TAGTTGATATTGGTTTGGTA 
       ||.........|| 
       ATGGTTTGGTTATAGTTGAT 
The best self annealing of the reverse primer: 
 CAAATAACTCAATTTCTCTAC 
  |.|.||.|..|.||.|.|  
CATCTCTTTAACTCAATAAAC 




The best pair annealing of these primers: 
TAGTTGATATTGGTTTGGTA 
  ||.||.|            
  CATCTCTTTAACTCAATAAAC 
The best pair end-annealing of these primers: 
TAGTTGATATTGGTTTGGTA 
                   | 
               CATCTCTTTAACTCAATAAAC 
Wrong annealing of the forward primer with the PCR product: 
5’- ATTATAAAAATCCAAAATTAACAACRTAAAAAACTCRAAACRCACCCRACATCTAAA -3’ 
         ||..|.....||.|| 
 3'-ATGGTTTGGTTATAGTTGAT-5' 
 
Possible hairpin formation: 
The best hairpin forming of the forward primer: 
 TGAT-5' 
T  || 
 GATATTGGTTTGGTA-3' 
The best hairpin forming of the reverse primer: 
 CAATAAAC-5' 
{   |||| 
 TCAATTTCTCTAC-3' 
The best self end-annealing of the PCR product: 
 ACTA-3' 





















PCR product(s) on the bisulphite transformed sense chain: 
      Forward primer: TAGTTGATATTGGTTTGGTA 
      Reverse primer: CAAATAACTCAATTTCTCTAC 
 
1. Chromosome 3 (len: 159) (Designed product) 
 
          14443389                      TAGTTGATATTGGTTTGGTATT 
          TTTTAGATGT TGGGTGTGTT TTGAGTTTTT TATGTTGTTA ATTTTGGATT 
          TTTATAATAG TTGGAGGAGA TAAGTGTTAT TATTTTTTTT TTTATTTTAT 
          AGATGAGGAT ATTGAGGTAGAGAAATTGAGTTATTTG      14443548 
 
Matches of forward primer: 854 matches based on the 3' 16mer oligo search. 
Matches of reverse primer: 601 matches based on the 3' 16mer oligo search. 
 
PCR product(s) on the bisulphite transformed antisense chain: 
      Forward primer: TAGTTGATATTGGTTTGGTA 
      Reverse primer: CAAATAACTCAATTTCTCTAC 
 
1. Chromosome 2 (len: 728) (Non-specific product) 
 
 185716536    ACAAAAACTCCATTTCTCTACATACTTA TCAACACTTA CTATCTTTTA 
            TATTTTACTA ACAAACATCC TAACAAATTT AAAATAATAT CTCATCATAA 
            TTTTACTTTA CATTTCTCTA ATAATTAATA ATACTAAACA TTTTATTTCA 
            TATATCTTTA AAACATTCAT ATATCTTCTT CTAAAAAATA TCTATTCAAA 
            TCCTTTACCC ATTTTTAATC AAATTATTTA TTTTCTTAAT CTTTAATCAT 
            TTAAATTTCT TATCAATTTT AATTATTAAA CCTTATCAAA TTTATAATTA 
            AAAATACAAT AATCACCTAC TTATCTATAA AAAATATTTT CCAAAATCTA 
            CAATAAATAC TTAAAATCAC AAATAATACT AATAATATAC TAAATATAAA 
            AATTATATAA ATACAATCTC TTTCTCTCTC TCTCTCTCTC TCTCTCTCTC 
            TCTCTATCTC TCAAAATATC CAATTATACT ACATTCACCT ATTTTTTAAA 
            TAATTAACCA TCAATAACTA AAACTACTAA AAACAAAACT ATAAATAAAA 
            AAAAACTACT ATATTTTTCC TATCCTATTA ATTATCTCTT CATCCTATTA 
            ATTATTTCCT TAACTATACA AAACTTTATA CTTTAAAATT ATCTCATTTA 
            ACTATACTTT TTTTTTTTTT TTTTTAACCT ATACTTTTAA AATCACTACC 
            AAAAATATAT TACCAAACTAATATCATAAA                185717264 
 
Matches of forward primer: 796 matches based on the 3' 16mer oligo search. 




PCR product DNA double-stranded sequence: 
                      Sequencing Primer 
                  Forward Primer 
5’- TAGTTG ATATTGGTTT GGTATTTTTT AGATGTYGGG TGYGTTTYGA GTTTTTTAYG 
3’- ATCAAC TATAACCAAA CCATAAAAAA TCTACARCCC ACRCAAARCT CAAAAAATRC 
 
TTGTTAATTT TGGATTTTTA TAATAGTYGG AGGAGATAAG YGTTATTATT TTTTTTTTTA  
AACAATTAAA ACCTAAAAAT ATTATCARCC TCCTCTATTC RCAATAATAA AAAAAAAAAT  
 
TTTTATAGAT GAGGATATTG AGGTAGAGAA ATTGAGTTAT TTG -3’ 
AAAATATCTA CTCCTATAAC TCCATCTCTT TAACTCAATA AAC -5’ 
                                                   Reverse Primer - Biotin 
Y: C or T 
R: G or A 
 
Amplicon Length: 159 bp 
Template Loop: No (Last 6 bp at 3’-end Æ GTTGAT) 
 
Sequencing Primer: 
5’- ATATTGGTTTGGTATTTTTTAGAT – 3’   (Converted cytosines in bold) 
Tm: 58.0 oC (BiSearch) 
 
Wrong annealing of the sequencing primer with the PCR-product: 
5'-CAAATAACTCAATTTCTCTACCTCAATATCCTCATCTATAAAATAAAAAAAAAAATAATAACRCTT 
                                    |||||x||||||xx|||xx||xxx 
                                 3'-TAGATTTTTTATGGTTTGGTTATA-5' 
 
DNA methylation assay: 
 
Sequence to analysed:  GCCGGGTGCGTTCCGAGTTCTCTACGCT 
Sequence to analysed bisulphite-treated:  GTYGGGTGYGTTTYGAGTTTTTTAYGTT 
Number of CpG sites: 4 
Dispensation order: AGTCGTGATCGTCGAGTCAGTCGT 
Chromosomal Location: Chr3: 14,443,420 – 14,443,469 
Sequenced strand: Sense 





Appendix III. MiSeq® auto-analysis command 
script for age markers 
for sample in *_L001_R1_001.fastq.gz  
# Get the name of the sample from the file names and designate $describer 2 as this 
name 
do  
echo $sample  
describer=$(echo ${sample} | sed 's/_L001_R1_001.fastq.gz//')  
echo $describer  
describer2=$(echo $describer | rev | cut -c 5- | rev) 
echo $describer2  
# Create sam files aligned to 16AgeMarkers ref  
/users/davidballard/bwa/bwa mem 
/users/davidballard/bwa/References/16AgeMarkers.fa 
${describer}_L001_R1_001.fastq.gz ${describer}_L001_R2_001.fastq.gz > 
$describer2.sam 
done 
# Convert file from SAM to BAM format  
/users/davidballard/samtools/samtools view -bt 
/users/davidballard/samtools/References/16AgeMarkers.fa.fai $describer2.sam > 
${describer2}.uns.bam  
# Sort BAM file  
/users/davidballard/samtools/samtools sort ${describer2}.uns.bam ${describer} 
# Index the bam file  
/users/davidballard/samtools/samtools index ${describer}.bam  
# Remove intermediate files  
rm ${describer2}.uns.bam    
# Remove sam files  
rm $describer2.sam 
# Create read groups  
java -jar /Users/davidballard/GATK/AddOrReplaceReadGroups.jar I= 
$describer.bam O= $describer2.bam SORT_ORDER=coordinate RGID=$describer2 
RGLB=bar RGPL=illumina RGPU=run RGSM=$describer2 
CREATE_INDEX=True 
# Remove intermediate files  
rm ${describer}.bam    
rm ${describer}.bam.bai    
# Create variant calls for all age SNPs  
java -jar /Users/davidballard/GATK/GenomeAnalysisTK.jar -T UnifiedGenotyper -
R /Users/davidballard/GATK/16AgeMarkers.fa -I $describer2.bam -glm SNP --
alleles /Users/davidballard/GATK/Age.vcf --genotyping_mode 
GENOTYPE_GIVEN_ALLELES -stand_emit_conf 10 -stand_call_conf 30 -o 






Appendix IV. Expected bisulphite-converted 
DNA sequences of designed PCR products (16 









































































































Appendix V. Expected vs. observed 
methylation of methylation controls for 
all 16 age-associated CpGs (MiSeq®) 
 
 
The graphs above represent the individual ‘normalised’ observed vs. expected 
methylation for all 16 age-associated CpG sites as quantified in predefined DNA 
methylation standards (0%-100%) on MiSeq® using 30 PCR cycles. Each CpG is 
identified by the last three numbers of its name (for example cg273 corresponds to 
cg19761273), while numbers in brackets correspond to average read numbers. As 
shown for most markers, graphs fit linear regression lines (e.g.cg567), while for some 
others significant amplification bias towards either the methylated (e.g. cg273) or the 
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